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ABSTRACT OF THE DISSERTATION 
Structural, Biophysical, and Functional Studies of TREM2 
In Neurodegenerative Disease 
by 
Daniel Luke Kober 
Doctor of Philosophy in Biology and Biomedical Sciences 
Molecular Microbiology and Microbial Pathogenesis 
Washington University in St. Louis, 2017 
Tom J. Brett, Thesis Advisor 
Alzheimer’s disease (AD) and other neurodegenerative diseases present a large 
and growing challenge to global health. The immune system, particularly the innate immune 
system, is increasingly recognized as having a major role in these pathologies. The innate 
immune system is responsible to contain disease and promote healing. However, immune 
misregulation exacerbates disease. The innate immunomodulatory receptor Triggering 
receptor expressed on myeloid cells-2 (TREM2) is expressed on myeloid cells such as 
dendritic cells, macrophages, and in the brain, on microglia. TREM2 is a single-pass 
transmembrane receptor with an extracellular Ig domain that mediates ligand binding. This 
protein regulates inflammation in vitro and is required in vivo to sustain the microglia 
response during neurodegenerative diseases. Additionally, genetic studies have identified rare 
coding variants that increase risk for AD and separate variants that cause the severe, early 
fatal dementia known as Nasu-Hakola Disease (NHD). Combined, these animal and genetic 
studies have described a crucial role for TREM2 
xi 
xii 
and identified variants that contribute disease risk. However, a full understanding of TREM2 
function has been lacking due to a dearth of information regarding its structure and ligands.  
The goal of this study was to determine the TREM2 structure and understand how the 
disease variants alter structure and function. The TREM2 Ig domain was expressed, purified, and 
crystallized using a novel mammalian expression system. The TREM2 crystal structure and 
subsequent biophysical and functional assays revealed that NHD variants reduce protein stability 
and cause protein misfolding while the AD variants have minimal structural changes and instead 
impact ligand binding. TREM2 bound cell-surface sulfated proteoglycans on mammalian cells. 
AD-risk variants decreased binding while another variant, which is possibly protective, increased 
binding. These variants mapped a functional ligand-binding surface on the TREM2 protein. 
Functionally, chemical inhibition of nascent proteoglycan sulfation impaired TREM2 signaling, 
suggesting a ligand that acts in cis to position TREM2 for signaling. Additionally, TREM2 
interacts with the soluble lipoprotein apolipoprotein E (ApoE) and with amyloid beta 
(Ab) peptides. Intriguingly, AD-risk variants impair both of these interactions, suggesting a 
physiological relevance during AD. These experiments offer the first structural and mechanistic 
studies of TREM2 function and will engender targeted molecular therapies to restore or enhance 
TREM2 function during neurodegenerative disease. 
1 
Chapter 1: TREM2 in health and disease 
This section is modified from a submitted manuscript titled 
“TREM2-ligand interactions in health and disease.” Submitted to J. Mol Biol. 
1.1 TREM2 is a poorly understood innate immune receptor 
Triggering receptor expression on myeloid cells-2 (TREM2) is an extracellular innate 
immune receptor expressed on myeloid cells such as dendritic cells and resident tissue 
macrophages including osteoclasts and microglia. The protein consists of an extracellular V-type 
immunoglobulin (Ig) domain followed by a short stalk leading to a single transmembrane pass 
which interacts with DNAX-activation protein 12 (DAP12, also known as TYROBP) to mediate 
downstream signaling. TREM2 terminates with a short cytosolic tail lacking known signaling 
motifs (1). In addition to the membrane-bound form, soluble TREM2 ectodomains (sTREM2) 
can be generated by proteolytic processing (2, 3) or by alternative splice sites (4). The 
importance of TREM2 is highlighted by genetic studies linking TREM2 variants to various 
neurodegenerative diseases, including Alzheimer’s disease (AD) (5, 6). TREM2 has been 
implicated in a wide array of functions including cell maturation, survival, proliferation, 
activation, phagocytosis, and the regulation of inflammation. Accompanying this diverse set of 
functions is an even longer list of potential TREM2 ligands (see Table 4). Indeed, since its 
discovery, the identification of bona fide endogenous TREM2 ligands has proven difficult, 
although there is an emerging pattern of ligands that are anionic and/or lipidic in nature. It 
unclear if the true TREM2 ligand is among the suggested ligands or whether TREM2 is simply a 
highly promiscuous receptor that can engage a wide array of ligands. A full understanding of 
2 
TREM2 function is not possible without complete information regarding its structure and 
ligands.  
1.2 The role of TREM2 in disease 
1.2.1  TREM2 variants are associated with neurodegenerative diseases 
The importance of TREM2 in neuronal health was first demonstrated by genetic studies 
that identified TREM2 variants in families with Nasu-Hakola disease (NHD, also known as 
Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy, or PLOSL) a 
fatal disease characterized by presenile dementia and bone cysts (7-9). NHD patients are 
homozygous for loss-of-function DAP12 or TREM2 variants. In some cases, TREM2 mutant 
carriers present a fronto-temporal lobar degenerative form of dementia lacking the bone 
phenotype. These TREM2 mutations include splice site (8, 10), early stop sites (8, 11-13), and 
ectodomain coding variants (7, 8, 14-16). These mutations are all believed to produce 
nonfunctional proteins. More recently, separate coding variants in the Ig domain of TREM2 were 
linked to an increase risk for AD (5, 6). The link between TREM2 variants, particularly the R47H 
and R62H variants and AD is now well-established (4, 17-19). TREM2 AD risk variants carry 
roughly the same risk as a copy of the apolipoprotein E ε4 (APOE4) allele and clearly link the 
innate immune system to neurodegenerative disease (20). Beyond AD, TREM2 variants have 
been linked to other neurodegenerative diseases, including Parkinson’s disease (21, 22), and 
sporadic amyotrophic lateral sclerosis (23), and fronto-temporal dementia (24, 25), though these 
non-AD associations have not been as widely reproduced (19). The association of distinct 
variants with different diseases is born out on the functional level. Initial cellular studies 
suggested the NHD coding mutants impair surface trafficking and glycan maturation, while the 
3 
AD variants are surface-expressed and have mature glycosylations (3, 26). However, a structural 
understanding for these phenotypes were lacking.  
1.2.2  Animal models of CNS disease highlight a role for TREM2 in microglia. 
Most studies of TREM2 in neurodegenerative diseases have used mouse models of AD. 
Here, I highlight key findings from those models and draw connections between the AD 
phenotypes and those observed in other neurodegenerative models such as stroke and MS to 
identify functions TREM2 may be carrying out during disease (Table 1).  
TREM2 is expressed on microglia during neurodegenerative disease 
Animal studies by several groups have consistently found Trem2 expression in the CNS 
restricted to microglia and increasing with age and disease progression (5, 27-30). Within the 
normal human brain, TREM2 is expressed most highly in white matter, with transcripts detected 
in all major areas (31). Pathway analysis identified the TREM2 co-receptor DAP12 as a key 
regulator of expression changes in late-onset AD (LOAD) disease (32). Although there have 
been reports of TREM2 detection on non-myeloid cells in the CNS (5, 33), these cases used 
immunostaining methods to identify neuronal expression of TREM2, which may identify soluble 
TREM2 (sTREM2) produced in microglia that is released and bound to neurons which express a 
TREM2 ligand (34-36). RNA expression analyses have confirmed Trem2 is expressed 
selectively in microglia in the brain (37, 38), and parabiosis experiments show these microglia 
are most likely resident microglia and not derived from infiltrating monocytes (39), although this 
is still controversial (40). Within the AD brain, laser microdissection (41) and high-resolution 
microscopy (42) showed Trem2 is highly expressed on plaque-associated microglia and localized 
on microglia processes that are in contact with Ab plaques. Thus, TREM2 is expressed on 
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microglia in the brain and its expression increases both with aging and in response to disease. 
Consistent with its expression on microglia, studies using Trem2-deficient animal models of AD 
have shown a role for TREM2 in microglial survival and activation (Table 1).   
TREM2 in models of Ab pathology 
The amyloid cascade hypothesis posits that Ab is cause of AD, whether directly by 
mediating neurotoxicity or indirectly by triggering other neurotoxic events, such as tau 
aggregation (43). It is based on the observation that autosomal dominant mutations causative for 
AD are found in proteins responsible for the production and maturation of the Ab peptide. 
Common animal models of AD are genetically engineered to carry these mutant proteins and/or 
overexpress Ab. To date, all AD studies involving Trem2 knockout mice have utilized such 
models. However, the Ab phenotypes have been inconsistent in these studies. Some studies using 
Trem2-/- mice found no change in the overall plaque load (39, 44), while other studies found 
increased (27, 40)  or even decreased burden (28, 40). Some of these differences are perhaps 
explained by the timing of data collection (40), although they could suggest Ab clearance is not 
the primary role for TREM2.   
While there have been mixed results on the accumulation of Ab, all Trem2-/- studies have 
found decreased clustering of myeloid or microglial cells around plaques, suggesting a defect in 
microgliosis, or microglia activation (27, 28, 39, 40, 42, 44). These studies have also found that 
Trem2-/- mice have fewer microglia and increased microglia apoptosis. Importantly, samples 
from human R47H carriers recapitulate the microglia-Ab plaque phenotype observed in Trem2 
haploinsufficient mice, with fewer microglia clustering around the plaques, and the plaques 
acquire a more toxic, diffuse morphology (42). Therefore, although TREM2 may not have a 
5 
dramatic effect on the overall Ab content of the diseased brain, it strongly affects the ability of 
microglia to respond to and contain the plaques.  
TREM2 in models of Tau pathology 
Besides Ab, intracellular tangles of hyperphosphorylated tau proteins are the other major 
pathological component of AD (45). While no studies using Trem2-/- mice have been published 
in tau models, studies altering Trem2 expression in vivo by lentiviral overexpression (under a 
Cd11b promoter) or shRNA knockdown  in the P301S tau transgenic model found that TREM2 
reduces inflammation, decreases tau kinase activity, and improves cognitive function (46, 47). 
Future studies should utilize Trem2 knockout and mutant Trem2 knock-in models on this 
background to understand the role of TREM2 in tau-mediate neuropathies.  
TREM2 in other neurodegenerative diseases 
Similar to what has been observed in AD models, mouse models of aging, prion 
pathogenesis and the cuprizone model of multiple sclerosis (MS) have fewer activated microglia 
in the course of the disease (48-50). In MS, there was less myelin clearance by Trem2-deficient 
microglia (48, 49) and although there was no obvious deficiency in myelin uptake in vitro, 
Trem2 deficiency was associated with decreased expression of lipid metabolism enzymes and a 
failure to degrade myelin debris and (48, 49). These findings suggest a more general defect in 
activation (48-50). Other studies examining the role of TREM2 in stroke have found increased 
expression following ischemic attack (36, 51, 52). As in the other cases, these studies have found 
that Trem2 deficiency decreased inflammation, impaired microglial activation, and resulted in a 
failure of microglia to cluster at scar tissue (36, 51).  
Summary TREM2 in of neurodegenerative disease 
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The consensus from the neurodegenerative disease studies is that TREM2 is important for 
enabling the response of myeloid cells (primarily microglia in the CNS) to disease. Mice lacking 
TREM2 have fewer microglia, and these microglia fail to activate and respond to damage during 
disease. These observations suggest a general deficit in microgliosis. Additionally, sTREM2 in 
the CSF seems to be a general feature of inflammatory neurodegenerative disease. Soluble 
TREM2 was first identified in the CSF of MS patients and neuroinflammatory patients (53), and 
has since been identified in a number of AD cohorts (54-57). 
1.2.3  Non-CNS diseases: TREM2 in COPD, gut injury, and infection 
Because of the genetic link between TREM2 and neurodegenerative disease, the majority 
of TREM2 research in the last few years has focused its role in the CNS. However, TREM2 has 
important roles outside the CNS, particularly in models where the activation and phenotype of 
myeloid/macrophage cells is important for disease outcome. In a model of viral-induced chronic 
obstructive pulmonary disease (COPD), TREM2 is required for survival and proliferation of 
alternatively activated (M2) macrophages (58). Unlike the healthy microglial response in AD, 
these macrophages foster a COPD-like disease. However, the role of TREM2 in preventing 
macrophage apoptosis and permitting macrophage proliferation bears a striking similarity to the 
TREM2 phenotype in CNS diseases. This study also identified a potential role for sTREM2 as a 
signaling molecule, as application of recombinant sTREM2 prevented macrophage apoptosis 
following M-CSF withdrawal.   
In a gut injury model, TREM2 also promoted an M2 macrophage phenotype, which was 
important for promoting for wound healing (59). TREM2-expressing macrophages infiltrated the 
wound area, inhibited the expression of inflammatory cytokines, and promoted the expression of 
7 
Th2 cytokines IL-4 and IL-13. However, in a chemical injury model of inflammatory bowel 
disorder (IBD), TREM2 promoted an inflammatory phenotype that was detrimental to healing 
(60). The differences in these studies may be due to the environment. In the biopsy injury model, 
the first step in healing was for epithelial cells to form a layer over the wound, which the authors 
hypothesized reduced exposure to bacteria and therefore reduced strong TLR signals that are 
known to down-regulate TREM2 (59). The healing response may be different in the chemical 
model, and the interaction between TREM2 and TLR pathways may result in the increased 
inflammation observed in that model (60). 
While the initial characterizations of NHD patients with DAP12 and TREM2 mutants did 
not report immune deficiencies (8, 61, 62), the role of TREM2 in infections has been studied in 
various models of bacterial infection. In general, these models are more acute than those 
discussed above, and therefore may highlight different roles for TREM2 in the rapid response to 
bacteria. These studies have mostly found TREM2 to be phagocytic and anti-inflammatory, 
although there are some exceptions (Table 1). Cell-level studies have shown that TREM2 
regulates the response to bacteria, in two examples by promoting the bacteria killing through 
production of reactive oxygen species (ROS) (63, 64) – even against bacteria that were not 
directly bound by TREM2 (63). The role of TREM2 may vary with different pathogens, as it did 
not promote killing of B. abortus, (65) a pathogen that specializes in invading and surviving in 
macrophages.  
Conclusions from disease models of TREM2. 
Recent years have seen substantial progress in identifying an important role for TREM2 
at the animal level. These studies using Trem2-deficient mice are highlighting its role in 
sustaining the microglial response to disease. However, important questions remain about what 
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precise functions TREM2 is performing, how different ligands may stimulate these functions, 
and how disease variants mutations affect function. Mechanistically, there are several 
possibilities for TREM2 functions, and the answers to these questions depend on understanding 
the interaction between TREM2, its signaling mechanisms, and its ligands.  
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Table 1 – Summary of TREM2 observations in disease models 
Disease Observation or model Phenotype Possible role of TREM2 Reference: 
Neurodegenerative disease 
Nasu-Hakola Disease Osteopenic mice Reduced proliferation of 
osteoclast precursors, 
accelerated osteoclast 
maturation and apoptosis. 
Myeloid proliferation and 
survival 
(66) 
Alzheimer’s disease 
Ab Models 
APPPS1 mice Decreased number and size of 
plaque-associated microglia in 
Trem2 heterozygotes. No 
change in total Ab. 
Microgliosis (44) 
5XFAD mice Trem2-/- mice have Increased 
Ab and impaired microglial 
response at  8mo. Decreased 
microglial survival. 
Microglia survival, 
microgliosis.  
Protective in Ab 
(27) 
5XFAD, APPPS1 
mice 
5XFAD Trem2-/- mice have 
fewer microglia (8mo) and less 
plaque clustering (4,8mo), 
producing diffuse plaque 
morphology and increased 
neuronal pathology. No change 
in total Ab.  
Microgliosis, microglial 
proliferaction.  
Protective in Ab 
(39) 
APPPS1 mice Trem2-/- mice have reduced Ab 
plaque burden at 4mo. 
Decreased plaque clustering of 
Iba1+ cells.  
Plaque response. Possible 
role in proliferation, 
survival, and/or 
trafficking 
Detrimental in Ab 
(28) 
5XFAD, CRND8, 
PS/APP  
Human R47H carrier 
samples 
TREM2 is required for 
microglial barrier function 
around Ab plaques. Human 
R47H carriers mirror Trem2 
haploinsufficient mice. 
Microgliosis and 
protective plaque 
response 
(42) 
APPPS1 mice TREM2 increases Ab burden 
early, but reduces Ab burden 
late in disease. 
Microglial/myeloid 
proliferation, 
inflammation, and plaque 
response 
(40) 
APPswe/PS1dE9 mice In vivo overexpression reduced 
plaque load and inflammation.  
Anti-inflammatory 
Phagocytosis of Ab 
(29) 
APPswe/PS1dE9 mice Overexpressing Trem2 in old 
mice (18mo) had no effect on 
AD pathology. 
Age-restricted protective 
role 
(67) 
Alzheimer’s disease 
Tau models 
P301S mice Trem2 overexpression 
ameliorated tau pathology. 
Protective, anti-
inflammatory 
(46) 
P301S mice Lentiviral knockdown 
increased tau pathology. 
Protective, anti-
inflammatory 
(47) 
Multiple Sclerosis Cuprizone TREM2 sustains microglia 
during aging and cuprizone 
challenge. Reduces myelin 
debris. 
Microglial survival and 
proliferation during aging 
myelin response 
(49) 
Cuprizone Trem2-/- mice have increased 
myelin debris, decreased 
microglial proliferation and 
activation.  
Microgliosis and 
proliferation  
(48) 
EAE Antibody blockade of TREM2 
signaling exacerbates 
symptoms. 
Beneficial in MS (68) 
EAE EAE symptoms were reduced 
by Trem2-transduced 
macrophages.   
Anti-inflammatory, 
protective 
(69) 
Prion Pathogenesis Prion infection No effect on prion Microgliosis and (50)
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pathogenesis, but reduced 
microlial activation. 
proliferation 
Cardiovascular disease 
Stroke Experimental Ischemia Trem2-/- mice had increased 
infarction, decreased microglia 
activation, and fewer 
phagocytic microglia. 
Microgliosis and 
phagocytosis 
Protective following stoke 
(36) 
Experimental Ischemia Trem2-/- mice have fewer 
microglia at glial scars and 
decreased microglial 
activation. No change in scar 
size.  
Microgliosis (51) 
Chronic pulmonary disease 
Viral-induced COPD SeV-induced chronic 
airway disease  
Trem2-/- mice have reduced 
macrophage expansion which 
reduced chronic disease. IL-13 
stimulation produces sTREM2 
which prevents macrophage 
apoptosis.  
Survival and proliferation. 
sTREM2 prevents 
macrophage apoptosis. 
(58) 
Wound Healing 
Colon injury Chemical colon injury Trem2-/- mice had reduced 
inflammation and wound 
damage.  
Inflammatory, bacterial 
killing. 
(60) 
Biopsy injury TREM2 required for wound 
healing and promotes M2 
phenotype 
Promote anti-
inflammatory M2 
phenotype 
(59) 
Infection 
Animal 
infection 
E. coli endotoximia. TREM2 was protective in 
sepsis infection.  
Phagocytic, anti-
inflammatory 
(70) 
LPS and E. coli 
endotoximia. 
Trem2-/- mice had increased 
early inflammation and faster 
resolution. 
Phagocytic. Anti-
inflammatory.  
(71) 
P. aeruginosa TREM2 activated PI3K/Akt 
pathway to control 
inflammation. 
Anti-inflammatory (72) 
S. pneumoniae TREM2 decreased C1q 
expression in alveolar 
macrophages and TREM2 was 
detrimental to survival in 
intranasal challenge. 
Anti-phagocytotic, pro-
inflammatory in AMs. 
Opposite results in 
BMDMs 
(73) 
In vitro cellular 
infection 
P. aeruginosa TREM2 increased ROS 
production through Akt/PI3K 
pathway. No change in 
phagocytosis. 
Bacterial killing (64) 
S. Typhimurium TREM2/DAP12 required for 
ROS response following 
Salmonella infection. 
Bacterial killing (63) 
B. abortus TREM2 inhibited NO 
production and increased 
bacterial load. 
Promotes bacterial growth (65) 
Table 1 is modified from Kober and Brett, 2017. J Mol Biol. Submitted 
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1.3 Mechanisms of TREM2 Signaling 
1.3.1  DAP12 mediates multiple intracellular responses 
DAP12 is the co-receptor for TREM2 and a number of other single-pass transmembrane 
receptors. DAP12 contains an Immuno-Tyrosine Activation Motif (ITAM, consensus sequence: 
YxxI/Lx(6–12)YxxI/L) Broadly, TREM2 signaling through DAP12 results in ITAM 
phosphorylation which leads to Ca2+ mobilization, ERK (MAPK) phosphorylation, and Actin 
remodeling (1). However, TREM2 also negatively regulates TLR signaling and has roles in 
signaling pathways for other receptors (74). Altogether, TREM2 is intimately involved with 
regulating cellular homeostasis, survival, and proliferation. Here I review the TREM2 signaling 
pathway and highlight areas where TREM2 signaling may have results outside canonical ITAM 
activation. This develops a framework for incorporating the results of this research into TREM2 
biology. 
DAP12 associates with receptors through transmembrane interactions 
Upon translation into the ER, DAP12 forms a disulfide-bonded homodimer with two 
intermolecular disulfide bonds forming in the ER lumen. Within the transmembrane domain, an 
electronegative Asp from each DAP12 monomer forms a 2:1 interaction with a Lys from the 
receptor. A Thr four residues below the Asp is also involved in the electrostatic network (75-77). 
The interaction with the receptor is important to shield the polar residues and allow trafficking to 
the cell surface. (Reviewed in (78)). While it is established that DAP12 requires complexing with 
a receptor for trafficking to the cell surface, there have been reports of TREM2 surface 
expression in Dap12 and Dap12/Dap10-deficient cells (58, 79, 80). Other DAP12-coupled 
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receptors do require DAP12 for surface expression (80), so it is possible that DAP12 could 
traffic to the surface with another receptor and there engage with TREM2. 
The DAP12 signaling pathway 
The standard DAP12-receptor signaling pathway was delineated using Ly49D as a model 
DAP12-coupled receptor on NK cells (81). First, the DAP12 ITAM is phosphorylated by Src 
kinases. The two phosphorylated Tyr residue in the ITAM create a binding site for the SH2 
domain of the kinase Syk. Activation of Syk lead to the phosphorylation of ERK1/2, PLCγ1, and 
Cbl. These same features are observed with TREM2: Stimulation with an anti-TREM2 antibody 
induced calcium flux and ERK phosphorylation, while monovalent stimulation by anti-TREM2 
Fab did not result in calcium flux (82). Functionally, TREM2 stimulation prolonged DC survival 
following withdrawal of GM-CSF and IL-4. TREM2 has also been implicated in actin 
mobilization (11, 83). Monocytes from TREM2-null NHD patients had defective actin 
rearrangement following RANKL/MCSF stimulation. These initial studies linked TREM2 to the 
hallmark ITAM signaling events: Ca2+ mobilization, ERK phosphorylation, and actin remodeling 
(Fig 1.1A). Subsequent studies have further elucidated the TREM2 signaling pathway, and 
began to identify nuances that are key to fully understanding TREM2 function.  
Although DAP12 is the primary adaptor for TREM2, DAP10 also interacts with DAP12-
TREM2 complex, possibly through the formation of DAP12-DAP10 heterodimers. DAP10 
contains a YINM motif that can recruit PI3K. Accordingly, DAP10 was required for effective 
activation of PI3K, Grb2, and therefore Akt and ERK signaling. However, calcium mobilization 
was surprisingly unchanged in DAP10-/- bone marrow derived macrophages (BMDMs) (84). 
Beyond DAP12, signaling cascades in hematopoietic cells that begin with ITAM 
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phosphorylation use scaffolding proteins to recruit downstream effector proteins such as Grb2, 
Cbl, PI3K, and Vav. Two such proteins are the Linkers for the Activation of T and B cells (LAT 
and LAB, LAB is also known as LAT2 and NTAL) (85). While they share most functions, a key 
difference is that LAT stimulates calcium mobilization more efficiently than LAB. DAP12 can 
signal using either LAT or LAB, however TREM2 signaling through DAP12 signaling utilizes 
LAB in osteoclasts and BMDMs (86).  
TREM2-DAP12 signaling is inhibited by phosphatases and ubiquitin ligases 
Once activated, how is TREM2 signaling terminated? Following TREM2 stimulation by 
anti-TREM2 antibodies, the phosphatidylinositol phosphatase SHIP-1 binds the phosphorylated 
membrane-proximal tyrosine, pY65, within the ITAM motif of DAP12 to inhibit DAP12 
signaling and TREM2-dependent osteoclast multinucleation (84). This tyrosine is part of a 
“closet ITIM” sequence which was previously hypothesized to mediate inhibitory signals 
(SPYQEL, canonical ITIM is S/I/V/LxYxxI/V/L) (87). Furthermore, as noted above, the E3 
ubiquitin ligase Cbl is recruited to LAB and forms a complex with LAB and PI3K (86) to target 
Src and Syk for ubiquitination and degradation (88). This activity requires LAB, as LAB-/- cells 
have increased Syk activation but decreased ERK activation (86). Finally, TREM-like transcript 
1, (TREML1, also TLT-1), an ITIM-containing member of the TREM family is expressed in 
bone tissue (89) and associates with the tyrosine phosphatase SHP-1 upon phosphorylation. An 
alternatively-spliced transcript lacking much of the ectodomain (TREML1s) is also expressed in 
osteoclast precursors and macrophages. TREML1s co-immunoprecipitates (co-IPs) with 
TREM2, SHP-1, and SHIP-1 and decreases ERK, Akt, and calcium signals following RANKL 
stimulation (90). Accordingly, TREML1 (or 1s) may inhibit TREM2 signaling (Fig 1.1B). 
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Therefore, DAP12 signaling directly leads to its own inhibition by recruiting inhibitory 
phosphatases and ubiquitin ligases. 
TREM2 regulates inflammation through tonic signaling and inhibitory adaptors. 
While TREM1 uses DAP12 to enhance inflammatory TLR signals (62), TREM2 
decreases TLR signals in cultured bone-marrow derived macrophages and dendritic cells (91-
93). TREM2-dependent modulation of cytokine production did not require exogenous 
stimulation of TREM2, suggesting TREM2 is recognizing endogenous ligands to produce an 
inhibitory signal. There is precedence for inhibitory ITAM signaling in a similar system (94). In 
this example, IgA binds its receptor FcαRI, which signals through the ITAM-containing co-
receptor FcRγ to produce either inhibitory (SHP-1 recruiting) or activating ITAM signals based 
on whether IgA is monomeric or aggregated by antigens. The transient monomeric interaction 
produces inefficient ITAM phosphorylation, leading the recruitment of the inhibitory tyrosine 
phosphatase SHP-1. This IgA-FcαRI-FcRγ system is analogous to ligand-TREM2-DAP12 and 
previous commentaries have suggested TREM2 could mediate tonic signals through such a 
mechanism (95-97) (Fig 1.1C).  However, the endogenous, inhibitory TREM2 ligand has not 
been identified. Along these lines, it was recently observed that expression of DAP12 with a C-
terminal fragment of TREM2 lacking the ectodomain but containing the DAP12-interacting 
transmembrane domain is sufficient to inhibit cytokine production following LPS stimulation 
(98). The C-terminal fragment may occupy DAP12 similarly to TREM2 with a monovalent 
ligand.  
TREM2 also uses adaptor proteins to influence the inflammatory environment. LAB-/- 
macrophages have increased ERK phosphorylation following TLR stimulation (86). It could be 
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that TREM2 signaling through LAB restricts ERK or other signaling molecules needed for TLR 
signaling, or that LAB-dependent Cbl-mediated ubiquitination reduces the level of kinases 
needed to activate TLR pathways (85). Another pathway for inhibiting TLR signals is the 
recruitment of the anti-inflammatory adaptor protein DOK3 to DAP12 following TLR 
stimulation with LPS. Following LPS stimulation, DOK3 becomes phosphorylated, associates 
with DAP12, and interacts with Grb2 and Sos1 to inhibit the TLR response. In this system, 
SHIP-1 was not required to inhibit TLR signals, demonstrating that the inhibition of ITAM 
signaling by SHIP-1 is separate from the inhibition of TLR signaling by DAP12 (99) (FIG 
1.2A). 
1.3.2 Soluble TREM2 as a signaling molecule 
TREM2 has been predominantly thought to signal through DAP12. However, the 
production of soluble TREM ectodomains appears to be a general feature of the TREM family as 
soluble forms of TREM1 (100) TREML1 (101) have been detected. While sTREM1 is thought 
to be a decoy receptor (102), application of sTREM2 (residues 19-136) to cultured BMDMs 
resulted in ERK and MAPK14 activation that persisted several hours and prevented apoptosis 
following M-CSF withdrawal (Fig 1.1D). A similar finding in primary mouse microglia was 
reported very recently (103). It is interesting that cell survival has been attributed to both soluble 
TREM2 and membrane-bound TREM2. These findings suggest that sTREM2 signals through a 
separate pathway to reinforce the results of membrane-bound TREM2 and highlights the 
importance of TREM2 in myeloid cell homeostasis. 
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Figure 1.1. TREM2 Signaling mechanisms. A) Canonical TREM2 signaling occurs 
following cross-linking of TREM2. Src phosphorylates the DAP12 ITAM. This recruits and 
activates Syk. Syk activity leads the phosphorylation and activation of downstream effectors 
including PI3K, PLCγ, LAB or LAT, Cbl, Grb2, and Vav. DAP10 also recruits PI3K. The end 
result of these pathways is Akt activation, calcium flux, ERK/MAPK activity, and actin 
mobilization. B) TREM2 signaling is inhibited through multiple mechanisms. TREML1 
associates with TREM2 signaling complexes and recruits SHP-1 through its ITIM. The 
scaffolding protein LAB recruits the E3 ubiquitin ligase Cbl, which downregulates Src and 
Syk. Incomplete DAP12 phosphorylation results in a “hidden ITIM” which can recruit SHIP-
1. C) The most prevalent model for multifaceted TREM2 signaling is activating vs tonic
receptor engagement by multivalent, high-affinity ligands vs low affinity, monovalent ligands.
D) Soluble TREM2 is produced by proteolytic cleavage and may have signaling functions
separate from transmembrane TREM2.
Figure 1.1 modified from Kober and Brett 2017, J Mol Biol. submitted. 
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1.3.3 TREM2 regulates signaling by other receptors 
Plexin-A1 is expressed in a number of tissues including DCs and osteoclasts and is a 
receptor for two separate Semaphorin proteins. When expressed on osteoclast precursors, Plexin-
A1 constitutively interacts with Neuropilin-1 (Nrp1) to mediate Semaphorin-3A (Sema3A) 
signaling, which prevents osteoclast maturation (104). However, when osteoclast precursors are 
stimulated with RANKL, Nrp1 is downregulated and Plexin-A1 can by bound by Sema6D to 
drive osteoclast maturation (105). Unexpectedly, this Sema6D signaling required TREM2 and 
DAP12 (106). Stimulation of BMDCs with a soluble form of Sema6D resulted in DAP12 
phosphorylation. An interaction between TREM2 and Plexin-A1 was identified using co-IP and 
intracellular FRET, suggesting TREM2 connects DAP12 to Plexin-A1 (106). This Plexin-
A1/TREM2 interaction is specific for Sema6D signaling, because the Nrp1-Plexin-A1 
interaction displaces TREM2 in co-IP experiments (104, 107) (Fig 1.2B). 
TREM2 is also involved in M-CSF-mediated survival and proliferation in macrophages 
and osteoclast precursors. M-CSF signaling through its receptor CSF-1R activates b-catenin and 
this requires phosphorylation of b-catenin by calmodulin-dependent kinases downstream of 
DAP12 (66, 108). In mice, the  b-catenin deficit in osteoclast precursors reduces proliferation 
and prematurely accelerates osteoclast maturation. The increase in osteoclasts produces an 
osteopenic phenotype in the Trem2-/- mice, similar to NHD patients (66). A separate study 
showed M-CSF stimulation resulted in DAP12 phosphorylation by Src kinases activated by CSF-
1R (109). This mechanism suggests these receptor pairs are in close physical proximity; 
however, a direct interaction between TREM2 and CSF-1R has not been reported (Fig 1.2C).  
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PDB references: 5ELI (110), 3FXI (111), 5L5K (112), 3OKY (113), and 4WRM (114) 
Figure 1.2. Role for TREM2 in regulating other signal pathways. A) TREM2 inhibits 
TLR responses through the recruitment of DOK3 to the DAP12 ITAM at the plasma 
membrane and potentially by sequestering signaling intermediates such as ERK or creating a 
less activating environment with scaffolding proteins such as LAB. (Structures PDBs: 
TREM2 5ELI and 3FXI - signaling complex of TLR4 (dark and light red), MD2 (cyans) 
complexed with LPS). B) TREM2 is required for the Plexin-A1 response to Sema6D. Two 
molecules of Plexin-A1 dimerize upon binding to a dimer of Sema6D. The Ig-like domains of 
Plexin-A1 colored in magenta were required for the interaction with TREM2. Structure PDBs: 
TREM2 5ELI, Plexin-A4 dimer 5L5K - (Blue and cyan with magenta highlights) 
superimposed on Sema6D (greens, 3OKY,). C) TREM2 signaling is required for b-catenin 
activation during M-CSF/CSF-1R signaling. (Structure PDB: 4WRM - CSF-1R orange and 
M-CSF cyan with signaling dimer shown in lighter shading).
Figure 1.2 modified from Kober and Brett 2017, J Mol Biol. Submitted.
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1.4 Summary of the literature and goals of this project 
Genetic studies have linked TREM2 to various neurodegenerative diseases. Within the Ig 
domain of TREM2, distinct coding variants are associated with either AD or NHD. Cellular 
studies suggested these variants may have discrete effects on the protein. However, at the start of 
this work, the structure of TREM2 was unknown. TREM2 is expressed on myeloid cells 
including microglia. Animal models published prior and throughout the course of this work 
revealed a role for TREM2 in myeloid cell homeostasis and survival. TREM2 signals through 
the DAP12 ITAM pathway to promote cell survival, maturation, and proliferation. These 
functions may include interactions other receptor pathways. TREM2 regulates inflammation, and 
is generally considered to facilitate an anti-inflammatory environment. Microglia lacking 
TREM2 are unable to mount a vigorous defense against disease features such as Ab plaques. 
There may also be a role for TREM2 as a soluble receptor signaling to inhibit apoptosis and 
reinforcing the effects of membrane-bound TREM2. 
The goal of this project was to determine the TREM2 structure and to understand how 
disease variants affect function by testing their role in expression, folding, stability, and ligand 
binding. In chapters 2 and 3, I developed methods to express, purify, crystallize, and characterize 
the hTREM2 Ig domain. The structure suggests different loss-of-function mechanisms for 
TREM2 variants through altered stability (NHD) or ligand binding (AD). NDH variants, but not 
AD variants, are grossly misfolded and unstable. In chapter 4, I sought to provide fresh insight 
about the TREM2 ligand by determining the biochemical requirements for the engagement of 
TREM2 with a cell-surface ligand and showed that AD variants disrupt binding to this ligand. In 
chapter 5, I provide the first quantitative characterization of the newly discovered TREM2-ApoE 
interaction and demonstrate for the first time that TREM2 directly interacts with Ab. Finally, in 
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chapter 6, I develop a model for TREM2 function through interaction with the various ligands 
examined in this work and in the literature. These findings are relevant for future studies of 
TREM2 in microglia, neurodegenerative disease, and other inflammatory disorders. 
Additionally, these findings will provide a structural framework for the rational design of 
molecular therapeutics directed at rescuing or enhancing TREM2 function. 
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Chapter 2: Expression, purification, and 
crystallization of TREM2 
2.1 Expression systems 
Structural studies require the ability to produce milligram (mg) amounts of properly folded 
protein that is stable and well-behaved. In the course of these studies, TREM2 was expressed 
from bother bacterial and mammalian systems. Mammalian expression and purification yielded 
protein in the range of 1-5 mg/L culture, while bacterial systems do not produce stable protein.  
2.1.1  Bioinformatic features of the TREM2 ectodomain 
The TREM2 gene encodes a 230 amino acid transcript. Domain boundaries are annotated in 
Figure 2.1a. Upon translation in the ER, the N-terminal signal peptide is removed. The TREM2 
ectodomain is residues 19-172, with 19-132 annotated as a V-type Ig domain. Following the 
protein stalk, TREM2 has a single-pass transmembrane helix and a short intracellular tail lacking 
any recognized signaling motifs (1). This study focused on characterizing the Ig domain, which 
is predicted to have two N-linked glycosylation sites at residues N20 and N79 (2). 
2.1.2  Expression of TREM2 in bacterial systems 
Cloning TREM2 Ig domains 
The human TREM2 Ig domain (19-134) was cloned from a pMX-3p lentiviral construct 
containing the full TREM2 gene kindly provided by Marco Colonna. Mouse Trem2 cDNA, a gift 
from Michael Holtzman, was similarly used as a template for PCR (Ig domain = 19-136). The 
predicted molecular weight (MW) of these domains were 14.387 kDa (human) and 14.440 kDa 
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(mouse). For bacterial expression, the Ig domains were amplified by PCR and ligated into 
pET23b as tagless constructs.  
Expressing and purification of TREM2 Ig domains from bacteria 
Tagless hTREM2 and mTREM2 Ig domains were expressed as inclusion bodies in 
Rosetta2 (DE3) cells. After transformation, single colonies were selected and starter cultures 
grown overnight under double antibiotic selection. The starter culture was used as inoculum for 
2-4L of Luria Broth (LB) media, and cultures were grown to an OD600 of ~ 1.0. Cultures were
induced with 500mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) at 37°C for 5 hours.  
After pelleting the cultures, insoluble inclusion bodies were harvested as follows (and as 
described in (2)) Cell pellets were resuspended in Lysis Buffer containing 50 mM Tris pH 8.0, 
12.5% sucrose, 50 mM NaCl, 0.5 mM ethylenediaminetetraacetic acid (EDTA), 0.5% Triton X-
100, freshly added 10 mM DTT, 0.5 mg/mL lysozyme and DNAse. Cells were lysed by 
sonication, centrifuged, and inclusion bodies were subjected to three washes in 50 mM Tris pH 
8.0, 100 mM NaCl, 1mM EDTA, and 0.5% Triton X-100 before a final wash in the 
aforementioned buffer lacking Triton X-100. Extensive sonication was used in each step to break 
up the inclusion body pellet in order to obtain pure TREM2 proteins (Fig 2.1b).  
Refolding TREM2 from inclusion bodies 
For refolding attempts, inclusion bodies were solubilized in 6 M guanidine hydrochloride 
(GuHCl), 20 mM b-mercaptoethanol (b-ME), and 50 mM Tris pH 8.0. Because several TREM 
and related Ig domain proteins had been successfully refolded and crystallized (3-7), TREM2 Ig 
domains were subjected to refolding trials. Initial attempts utilized conditions from a commercial 
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refolding screen (Athena Enzyme Systems) as well as a standard refolding condition: 100 mM 
Tris pH 8.5, 400 mM Arginine, 2 mM EDTA, 5 mM reduced glutathione and 0.5 mM oxidized 
glutathione. Inclusion bodies were added to filtered, pre-chilled buffer and allowed to refold 
overnight at 4°C. After refolding, insoluble aggregates were pelleted and soluble TREM2 
analyzed by sodium dodecyl sulfate – polyacrylamide gel electrophoresis (SDS-PAGE) (Fig 
2.1c, d). Although TREM2 proteins were detected, attempts to further purify protein by size-
exclusion chromatography (SEC) were unsuccessful. 
Figure 2.1 reprinted from Kober et al 2014 (2) with permission by Elsevier
Figure 2.1 Bacteria-expressed TREM2 a) Schematic for TREM2 protein domain and 
features. N-linked glycan sites shown with sticks. Domains: SS = signal sequence, Ig = 
immunoglobulin, ST = stalk, TM = transmembrane, and IC = intracellular. b) Human (1) 
and mouse (2) inclusion bodies analyzed by reducing SDS-PAGE. c) human and d) mouse 
TREM2 soluble after refolding screen.  
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In 2016, a report demonstrated the use of differential scanning fluorimetry (DSF) to 
screen refolding conditions (8).  This experiment uses a dye that is quenched in an aqueous 
environment. As the protein in the experiment unfolds, the dye binds the exposed hydrophobic 
residues and fluoresces. This progression can by monitored using a real-time PCR machine. 
Separately, in the process of purifying mammalian-expressed TREM2 (discussed below), it was 
discovered that TREM2 interacted with the matrix of the SEC columns. Additionally, NDSB 
molecules were found to improve crystal quality.  A DSF screen (created by Chris Nelson and 
Rick Stegemen) was used to screen refolding conditions. Four potential conditions were 
identified: 1) 0.5 M NDSB-201, 100 mM Tris pH 9.5, and 5/0.5 mM reduced/oxidized 
glutathione, 2) 0.5 M Arginine, 100 mM Bis-tris phosphate pH 9.0 with 5/0.5 mM 
reduced/oxidized glutathione, and 3) condition #2 with 10% Glycerol, and 4) 0.5 M Arginine, 
100 mM Tris pH 7.5, 0.2 M sucrose and 5/0.5 mM reduced/oxidized glutathione. These 
conditions were scaled up to 250 mL refoldings, concentrated, and the product protein analyzed 
with an analytical s200 column (GE) in 150 mM NaCl, 20 mM Tris pH 8.5, and 20 mM NDSB-
201. In these conditions, refolded TREM2 was observed, and the protein appeared at the
expected monomer size by non-reducing SDS-PAGE (Fig 2.2A, B). DSF was used to validate 
this finding, and a reduced Tm was observed when the protein was denatured in the presence 1 
mM DTT (Fig 2.2C), confirming the presence of disulfide bonds. In additional optimization, 
addition of 500 mM GuHCl to the NDSB condition reduced aggregation and further improved 
yields. However, the refolded protein behaved poorly when concentrated and has not yet been 
amenable to crystallization trials. 
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Figure 2.2 hTREM2 can be refolded. A) SEC profile of TREM2 refolded in 0.5 M NDSB-
201 and run in Tris pH 8 sizing buffer containing 20 mM NDSB-201. B) Concentrated SEC 
input shown ±b-ME confirms refolded TREM2 lacks intermolecular disulfide bonds. 
Fractions from SEC peak run without reducing agent confirm the eluted peak is properly 
folded protein. C) DSF profiles of refolded TREM2 analyzed ± 1 mM DTT. Tm = 46.7 and 
44.5 without and with DTT. Analyzed with Life Technologies Protein Thermal Shift software 
v1.1.  
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2.1.3  Expression and purification of TREM2 from a mammalian system 
Cloning TREM2 in pHLSEC 
To produce TREM2 from mammalian cells, TREM2 Ig domains were cloned into the 
pHLSEC vector using PCR amplification and AgeI-KpnI restriction enzyme digestion. PCR 
templates were as described above. TREM2 variants were produced as detailed in (9), generally 
through site-guided mutagenesis, although in later studies some variants were introduced by 
Gibson block assembly. The pHLSEC vector contains an optimized secretion signal and C-
terminal 6-His tag for facile purification (10). 
Expression in 293F cells 
TREM2 expression in mammalian cells was conducted as described in these publications (2, 9, 
11). Transient transfection of HEK 293F cells was accomplished by diluting DNA (1µg/ million 
cells) and either a chemically modified PEI (PEI-TMC-25, synthesized by Artie Romero, 2 µg/ 
µg DNA) or Hype-5 transfection reagent (OZ Biosciences, 1.5 µg/ µg DNA) separately into 
Opti-MEM media and then combining for 30 min to form complexes before addition to 293F 
cells. 293F cells were grown on shaking, baffled flasks in 8% CO2 in 293 freestyle media 
(Invitrogen) supplemented with Pen/Strep. After 72 hours, cells were pelleted and the 
supernatants filtered using 0.2 micron filters (Nalgene). The supernatants were passed over 
nickel chelated on nitrilotriacetic acid-agarose beads (NiNTA), which binds the 6-His 
purification tag. Supernatants were supplemented with 10% (v/v) of 1.5 M NaCl, 0.1 M Tris pH 
8.5, 0.5 M K2HPO4, and 50 mM imidazole, which adjusts the pH and reduces background 
binding and enhances binding. For optimal binding, supernatant was concentrated ten-fold using 
an Amicon concentration cell (76 mm, 10 MWKO membrane).  Proteins were bound to NiNTA 
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using a gravity column, washed in 300 mM NaCl, 20 mM imidazole, and 50 mM K2HPO4 pH 
8.0, and then eluted in 300 mM NaCl, 250 mM imidazole, and 50 mM K2HPO4, pH 8.0 (2, 11).  
Tools to control TREM2 glycosylation 
Mammalian glycosylations are both chemically and structurally heterogeneous and 
therefore detrimental to crystallization (12, 13). Because TREM2 has two N-linked 
glycosylations, TREM2 was expressed in the presence of 1 µg/mL kifunensine, an inhibitor of 
glycan maturation for structural studies. The immature glycans are specifically recognized and 
cleaved after the first N-acetylglucosamine (NAG) by EndoH. Following NiNTA purification of 
TREM2, an amylose-binding version of EndH, EndoHf, was added to the protein overnight at 
room temperature (RT) and then removed by incubation with amylose resin.  
Expression of TREM2 in HEK 293s GnTI-/- cells 
As an alternative to the kifunensine/EndoHf processing, HEK 293s GnTI-/- cells (14) 
were used to produce proteins with uniform, truncated glycosylations. These have been useful in 
small-angle X-ray scattering (SAXS) studies (15) and even crystallization (16). This protocol 
was developed because it was observed that the R47H variant protein was more prone to 
proteolytic degradation when deglycosylated compared to WT or glycosylated variant protein. It 
was envisioned that this system could facilitate crystallization of the R47H variant. HEK 293s 
GnTI-/- cells are typically grown in DMEM media with 10% FBS. To facilitate structural studies, 
I adapted them to serum-free growth conditions through lifting cells using trypsin and 
resuspending them in serum-free freestyle media. In some cases, I grew them in a 1:1 mix of 
freestyle and EX-CELL 293 serum-free media (Sigma). This protocol was suggested for 
adaption. However, EX-CELL media is reported to inhibit transfection, so on the day of 
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transfection, cells would be resuspended in 50% volume 293 freestyle media for transfection. 
Following transfection the 50% volume EX-CELL media was added. The cells would tolerate 
either adaption protocol for the short-term, but with time (~1 month or so) I would observe fully-
glycosylated protein by SEC and SDS-PAGE. This happened several times, even when grown 
and maintained completely separate from potentially contaminating 293F cells. The GnTI-/- cells 
seem to be capable of escape mutations in the glycosylation machinery, with may help them cope 
with the stress of serum-free adaption. Despite these setbacks, potential crystal hits of GnTI-/--
derived hTREM2 R47H, although they were not reproducible and unfortunately decayed before 
harvesting (Fig 2.3C).  
Purification of hTREM2 from mammalian cells 
TREM2 proteins were purified by SEC in 150 mM NaCl and 20 mM Tris pH 8.5 on an 
analytical s200 column (GE). Initial attempts using 150 mM NaCl and 20 mM HEPES pH 7.5 
(sizing buffer) were unsuccessful and the increased pH was necessary to obtain protein, probably 
through reducing interactions with the column matrix (TREM2 pIcalc = 8.5). Consistent with an 
interaction between TREM2 and the matrix, the glycosylation status of TREM2 greatly affected 
the elution volume (Fig 2.3A, B). Deglycosylated protein elutes well past one CV, suggesting an 
interaction with the column that is reduced by the glycosylation.  
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Figure 2.3. Chromatographic characterization of TREM2 in different states of 
glycosylation and preliminary R47H crystals. A) SEC profiles of R47H purified from 
native 293F, 293s GnTI-/-, or kifunensine-treated and EndoHf-deglycosylated 293F cells. 
B) SEC-purified WT (1,2) and R47H (3,4) proteins from native and GnTI cells. C) Initial
R47H crystals in 0.1 M Tris pH 7.0, 0.2 M NaCl, and 35% MPD.
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2.2 Crystallization of TREM2 
2.2.1  Obtaining and optimizing TREM2 crystals 
Tom Brett and David Randolf obtained initial crystal hits of TREM2 using mammalian-
expressed hTREM2 purified by NiNTA without subsequent purification by SEC. NiNTA-
purified proteins were deglycosylated with EndoHf, and concentrated to 10 mg/mL (Fig 2.4a,b). 
Crystallization screens (JCSG I-IV, Qiagen) were set by hanging drop using a TTP Mosquito 
robot. These crystals (condition 2.5 M NaCl, 0.2 M MgCl2, and 0.1 M Tris pH 8.0) diffracted 
poorly. Using the Hampton additive screen, 0.2 M of NDSB-201, NDSB-211, or BaCl2 were 
found to improve crystal size and diffraction (Fig 2.4c). Conditions were further refined so that 
optimal crystals grew in 2.0 to 2.5 M NaCl, 0.1 M HEPES pH 7.0-7.5, 0.2 M MgCl2, and 0.2 of 
the additive. Crystals were harvested in mother liquor with 25% ethylene glycol. Data was 
collected at APS, ID-19. The best-diffracting crystal was grown with NDSB-201 (2). 
Figure 2.4 modified from Kober et al 2014 (2), reprinted with permission from Elsevier. 
2.2.2  Determining the TREM2 structure 
Molecular replacement. 
Diffraction data was processed and scaled with HKL-2000 (17). The space group was 
found to be either P6222 or P6422. Distinguishing between these groups requires a phasing 
solution. Molecular replacement was conducted using PHASER (18). A number of probes were 
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Figure 2.4. Expression, purification, and crystallization of mammalian-expressed 
hTREM2. a) schematic for expression and purification of hTREM2 Ig domains. b) NiNTA-
purified TREM2 Ig domains from kifunensine-treated cells before (-) or after (+) 
deglycosylation by EndoHf. WT mouse and human proteins and human R47H shown. c) 
Immunoblot for 6-His tag confirms the major species as TREM2. d) TREM2 crystals grown 
as described with NDSB-201 additive.  
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tried, including mTREM1 (1U9K), hTREM1 (1SMO), hNKp44 (1HKF), hTREML1 (2FRG), 
mCLM1 (1ZOX). The CCP4 programs Chainsaw and Ensembler were used to create side-chain 
truncated and/or ensemble models. Ultimately, mTREM1 provided the best solution in the space 
group P6422 (TFZ = 13.8, Rigid body Rwork and Rfree of 0.3909 and 0.4602). Surprisingly, only 
two copies of the protein were found, which indicates a solvent content of 83% within the 
Asymmetric unit (ASU) (Fig 2.5A).  
Validating the molecular replacement solution 
The high solvent volume suggested the possibility that another protein had co-crystallized 
with TREM2. This was especially a concern given that purification was only done with NiNTA. 
However, the solution does have continuous lattice contacts (Fig 2.5B) (2), showing that TREM2 
could be forming crystal contacts without another protein. To address whether TREM2 was the 
only protein in the crystal, crystals were harvested, washed in mother liquor, separated by SDS-
PAGE and analyzed by silver stain (Fig 2.5C). These crystals only contained a single band, 
which was confirmed by immunoblot to have the 6-His purification tag. Furthermore, Patterson 
self-rotation analysis confirmed the expected peaks for the space group at kappa = 60°, 120°, and 
180°. An additional peak was observed at kappa = 90°, likely due to two-fold non-
crystallographic symmetry (NCS) created by the two copies of TREM2 in the ASU (Fig 2.5D). 
Patterson self-rotation analysis was performed with the program GLRF (19) with a 25 Å radius 
(2). 
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Panels C and D are reproduced from Kober et al 2014 (2) with permission from Elsevier
Figure 2.5. Initial analysis of the TREM2 molecular replacement solution. A) Matthews 
probability for protein copy number in the ASU. Generated at 
http://www.ruppweb.org/mattprob/default.html. B) TREM2 proteins form a continuous 
lattice. TREM2 structure with symmetry mates generated using the symexp command in 
Pymol. C) Silver stain of harvested TREM2 crystals shows TREM2 is the only protein 
present in the crystal.  D) Patterson self-rotation analysis at selected kappa angles.  
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2.2.3  Refining the TREM2 structure 
Determining the resolution cut-off 
Traditionally, the resolution for diffraction data analysis is determined by where the 
I/sigma of the diffraction spots is 2. However, Karplus and Diederichs demonstrated that data 
past this threshold can be useful and developed the CC* statistic to interpret where data quality 
decreases (20). This is partially enabled by the multiplicity of data collection, which can be high 
in crystallographic experiments, especially in certain crystal lattices. In practice, it can be 
demonstrated whether increasing resolution improves the model. This is done by scaling the data 
to a certain resolution, for example 3.3 Å and building a model. Similarly, data is scaled to 3.2 Å 
and a model built using that data. The model from the 3.2 Å data is then tested against the 3.3 Å 
data. If the 3.2 Å model gives a lower Rfree value at 3.3 Å than the 3.3 Å model, the 3.2 Å data, 
even if weak, is improving the model quality. In this manner, as shown in Table 2, the initial 
TREM2 solution was manually refined at 3.3 Å until the Rfree was around 31%. Then, this 
solution was tested on data reprocessed and scaled to further resolutions and the final TREM2 
dataset was extended to 3.1 Å. 
Table	 2.	 Determining	
Resolution	cut-off	
Refine	at:	
3.3	 3.2	 3.1	 3.0	
Calculate	at:	
3.3	 26.26/31.66	 25.30/31.47	
3.2	 26.75/31.88	 26.79/31.80	
3.1	 27.71/32.47	 27.64/32.87	
3.0	 28.30/32.52	
Table 2. is modified from Kober et al. 2016 (9) 
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Refinement strategies 
Once the resolution was determined, refinement proceeded through iteratively manual 
building in Coot (21) followed by refinement in PHENIX (22). Conservative strategies such as 
secondary structure restraints, group B factors, NCS restraints, and TLS refinements were 
employed. Final statistics are shown in Table 3. The model was of high-quality, with an overall 
Molprobity score of 1.66 (100th percentile), clash score of 9.62 (96th percentile), and the 
Ramachandran statistics were 97.7% favored, 0% outliers, and 2.3% allowed. The model and 
data were deposited in the protein data bank (PDB, accession code 5ELI). 
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Table 3.  Data collection and refinement statistics 
Human TREM2 Ectodomain 
Data collection 
Space group P 64 2 2 
Cell dimensions  
    a, b, c (Å) 125.76, 125.76, 183.70 
    a, b, g  (°)  90, 90, 120 
Resolution (Å) 50.00-3.10 (3.21-3.10) * 
Rsym  0.11 (1.00) 
Mean I / sI 21.0 (1.76) 
Completeness (%) 99.88 (99.75) 
Redundancy 12.9 (13.4) 
Refinement 
Resolution (Å) 50.00-3.10 
No. reflections 16285 
Rwork / Rfree 0.2605 / 0.2736 
No. atoms 1784 
    Protein 1756 
    Carbohydrate 28 
B-factors 93.48 
Protein 92.39 
Carbohydrate 162.1 
R.m.s. deviations
Bond lengths (Å) 0.006 
Bond angles (°) 1.18 
*Values in parentheses are for highest-resolution shell.
Table modified from Kober et al, 2016. (9) 
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2.3 Results of the TREM2 structure 
2.3.1  Interesting features of the TREM2 structure 
TREM2 has unexplained density on a hydrophobic surface 
The top surface of TREM2 is highly hydrophobic. When refining the structure, a blob of 
strong density above this surface was observed that was not explained by the protein chain (Fig 
2.6). Given the limited resolution, it was not possible to identify the ligand from the electron 
density. Attempts were made to model a ligand, using codes for NDSB-201 (1PS), HEPES 
(EPE), and phosphocholine (CH5). None were able to improve the Rfree, even with allowing 
partial occupancies. The blob seems to be on a special position with the molecule, with 
symmetry mates sitting above it. Modeling a ligand on one end of the blob places a ligand on the 
other end. For molecules like NDSB, which seem to fit best running through the blob, this meant 
the two molecules would be placed on top of each other in the same density. Because TREM2 
was expressed in mammalian cells and could have bound an endogenous ligand, attempts were 
made to determine if TREM2 had co-purified with a lipid cofactor. To do this, a number of lipid 
extraction techniques were performed and samples analyzed by HPLC with the help of Artie 
Romero. Three different extraction methods were attempted. All extractions were performed in 
new glass centrifuge tubes that were solvent-washed before exposure to samples. 
1. Bligh and Dyer (23). To a 200 µL sample, 0.750 mL of 1:2 chloroform:methanol
mixture is added in a glass tube and vortexed. Then another 0.250 mL of chloroform is
added and mixed. Finally, 0.250 mL of H2O is added. The sample is gently centrifuged to
separate the aqueous and organic layers. A glass capillary tip is used to remove the
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organic lower phase. The sample was dried under vacuum and resuspended in MeOH for 
HPLC analysis.  
2. MTBE extraction (24). To a 200 µL samples,1.5 mL of methyl tert-butyl ether (MTBE)
is added and placed on shaker for 1 hr with periodic vortexing. Then, 1.25 mL of H2O is
added for 10 min. The sample is spun and the upper organic phase is collected, dried, and
resuspended for analysis.
3. Acetonitrile-methanol (25). To the 200 µL samples, 1400 µL of 25:40:35 acetonitrile:
methanol: H2O were added on ice for 10 min. Then the sample was spun at 14,000 rpm in
the cold room for 20 min. Supernatant was removed, dried, and subjected to HPLC
analysis.
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Figure 2.6. Unexplained density – a co-crystallized ligand? Top - Fo-Fc density 
contoured at 2s in blue. TREM2 ASU colored by hydrophobicity using the color_h script 
was used to generate a protein surface colored by hydrophobicity. Bottom – alignment of 
TREM family Ig domains with conserved residues identified using the espript server. 
Invariant residues are yellow and conserved residues in magenta. Residues in the 
hydrophobic surface labeled with black boxes. AD-linked residues with magenta asterisks. 
Secondary structure from DSSP server.  
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Despite these efforts, there was no conclusive evidence for an organic particle enriched in 
the purified TREM2 samples over unrelated controls. In one experiment, harvested crystals were 
analyzed and NDSB was detected (a standard of NDSB was run for comparison), but the crystals 
were not extensively washed and therefore I could not exclude detecting NSDB from the 
crystallization liquid. Relatedly, one crystal dataset was collected where BaCl2 was used as an 
additive instead of NDSB, and lysophosphocholine was soaked into the crystal to see if it could 
be bound. This crystal diffracted to about 3.4 Å and the tubular density was not present. 
However, the PC could have partially displaced a bound ligand and disrupted the density in that 
manner. Altogether, it has not been possible to conclusively identify whether the density blob is 
due to NDSB-201, although that is the most conservative interpretation.   
Comparison of TREM2 monomers in the ASU 
There are two copies of TREM2 in the ASU. The only obvious difference is the shifting 
of a loop, which makes lattice contacts in the B molecule (Ca RMSD < 1Å between the two 
chains). Moreover, the AD residues are not impacted by this small alteration (Fig 2.7a, b). For 
clarity, chain A is shown whenever a single monomer is depicted. Could the two copies represent 
a biological dimer? While tempting, it should be noted that the N79-NAG glycan is participant in 
the dimer interface and presumably the full-length glycan would disrupt this interaction. The 
PISA server was used to examine symmetry-related molecules as possible interfaces. No 
interactions were predicted to be stable, and the largest surface buried between proteins is 
between the B chains related by the x,x-y+1,-z-1/3 symmetry operation (~680 Å2 buried surface). 
The complex significance score was 0.0 for all interfaces, showing they are unlikely to be stable 
in solution (Fig 2.7c). This is consistent with reports of human and mouse TREM1 behaving as 
51 
monomers in solution (3, 4). So, while this data does not rule out that TREM2 is oligomeric in 
solution, it is unlikely that the interfaces observed in the crystal structure represent biological 
interactions.  Therefore, all analyses will consider TREM2 as a monomer.   
Figure 2.7 reused from Kober et al, 2016 (9) 
2.3.2  The TREM2 structure suggests distinct loss-of-function mechanisms 
With the TREM2 structure determined, the next objective was to use the structure to 
generate hypotheses for the role of disease-linked variants. The structure lacks density only one 
Figure 2.7. TREM2 interactions in the crystal structure. a) the TREM2 ASU has two 
copies arranged in similar orientation. b) TREM2 monomers superposed on one another. 
Chain A in magenta and B in cyan. c) PISA analysis table, showing that the interfaces are not 
predicted to result in complex formation. 
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C-terminal and four N-terminal residues. Density for the N79-NAG, but not the N20-NAG is
present. All disease-associated residues within the Ig domain were present in the structure. The 
residues linked to disease were mapped on the TREM2 structure (Fig 2.8b). A pattern emerged 
where the NHD-causing residues all face inward, towards the protein core. In contrast, the AD-
associated variants are all on the protein surface. This qualitative observation was quantified with 
Naccess (26) (Fig 2.8c). Analysis of packing contacts further confirmed the NHD residues make 
extensive Van der Waals contacts within the protein core (9). This observation inspired the 
hypothesis that the NHD variants impact protein function by disrupting protein folding or 
stability while the AD variants likely do not impair protein folding or stability but may disrupt 
ligand binding. Strong density was observed for all the surface AD variants and the N79-NAG 
(Fig 2.8 d-g). Overall, the AD-linked residues have only minor interactions with other residues. 
Potential structural interactions with these residues are polar interactions between D87 and the 
bD-E loop, and those between the R47 side change and the carbonyl oxygen on the T66 
backbone. The other residues (R62, N68, T96) make no obvious polar contacts. Overall, these 
minimal interactions suggest the AD-linked variants would most likely impact function through 
altered ligand binding and not through destabilizing the protein.  
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Figure re-used from  Kober et al, 2016 (9) and genetic data in the table from (27). 
Figure 2.8. TREM2 structure and location of disease-linked residues. a) Schematic for 
TREM2 strucutre. The Ig domain portion of the ectodomain was crystallized. b) The TREM2 
structure in two different orientations. AD-associated residues are shown in magenta, NHD in 
cyan. N79-NAG shown in green sticks. c) Table of disease variants showing disease, odds 
ratio (OR), mean allelic frequency (MAF), p-value, and % solvent accessibility, calculated by 
Naccess. d-g, Density for N79-NAG (d, shown in stereo), R47 (e), R62 (f) and T96 (g). 
Density is 2mFo-DFc contoured at 2σ.  
54 
2.4 References: 
1. Colonna M. TREMs in the immune system and beyond. Nat Rev Immunol.
2003;3(6):445-53. doi: 10.1038/nri1106. PubMed PMID: 12776204.
2. Kober DL, Wanhainen KM, Johnson BM, Randolph DT, Holtzman MJ, Brett TJ.
Preparation, crystallization, and preliminary crystallographic analysis of wild-type and mutant
human TREM-2 ectodomains linked to neurodegenerative and inflammatory diseases. Protein
expression and purification. 2014;96:32-8. doi: 10.1016/j.pep.2014.01.015.
3. Kelker MS, Foss TR, Peti W, Teyton L, Kelly JW, Wüthrich K, Wilson Ia. Crystal
structure of human triggering receptor expressed on myeloid cells 1 (TREM-1) at 1.47 A. Journal
of molecular biology. 2004;342(4):1237-48. doi: 10.1016/j.jmb.2004.07.089.
4. Kelker MS, Debler EW, Wilson IA. Crystal Structure of Mouse Triggering Receptor
Expressed on Myeloid Cells 1 (TREM-1) at 1.76&#xa0;Å. Journal of molecular biology.
2004;344(5):1175-81. doi: http://dx.doi.org/10.1016/j.jmb.2004.10.009.
5. Márquez JA, Galfré E, Dupeux F, Flot D, Moran O, Dimasi N. The Crystal Structure of
the Extracellular Domain of the Inhibitor Receptor Expressed on Myeloid Cells IREM-1. Journal
of Molecular Biology. 2007;367(2):310-8. doi: http://dx.doi.org/10.1016/j.jmb.2007.01.011.
6. Gattis JL, Washington AV, Chisholm MM, Quigley L, Szyk A, McVicar DW,
Lubkowski J. The structure of the extracellular domain of triggering receptor expressed on
myeloid cells like transcript-1 and evidence for a naturally occurring soluble fragment. J Biol
Chem. 2006;281(19):13396-403. doi: 10.1074/jbc.M600489200. PubMed PMID: 16505478.
7. Cantoni C, Ponassi M, Biassoni R, Conte R, Spallarossa A, Moretta A, Moretta L,
Bolognesi M, Bordo D. The Three-Dimensional Structure of the Human NK Cell Receptor
NKp44, a Triggering Partner in Natural Cytotoxicity. Structure. 2003;11(6):725-34. doi:
http://dx.doi.org/10.1016/S0969-2126(03)00095-9.
8. Biter AB, de la Peña AH, Thapar R, Lin JZ, Phillips KJ. DSF Guided Refolding As A
Novel Method Of Protein Production. Scientific Reports. 2016;6:18906. doi: 10.1038/srep18906
http://www.nature.com/articles/srep18906 - supplementary-information. 
9. Kober DL, Alexander-Brett JM, Karch CM, Cruchaga C, Colonna M, Holtzman MJ,
Brett TJ. Neurodegenerative disease mutations in TREM2 reveal a functional surface and distinct
loss-of-function mechanisms. Elife. 2016;5:e20391. doi: 10.7554/eLife.20391. PubMed PMID:
27995897; PMCID: PMC5173322.
10. Aricescu aR, Lu W, Jones EY. A time- and cost-efficient system for high-level protein
production in mammalian cells. Acta crystallographica Section D, Biological crystallography.
2006;62(Pt 10):1243-50. doi: 10.1107/S0907444906029799.
11. Kober DL, Yurtsever Z, Brett TJ. Efficient mammalian cell expression and single-step
purification of extracellular glycoproteins for crystallization. J Vis Exp. 2015;106:53445.
12. Aricescu AR, Owens RJ. Expression of recombinant glycoproteins in mammalian cells:
towards an integrative approach to structural biology. Current Opinion in Structural Biology.
2013;23(3):345-56. doi: http://dx.doi.org/10.1016/j.sbi.2013.04.003.
13. Rich JR, Withers SG. Emerging methods for the production of homogeneous human
glycoproteins. Nat Chem Biol. 2009;5(4):206-15.
14. Reeves PJ, Callewaert N, Contreras R, Khorana HG. Structure and function in rhodopsin:
High-level expression of rhodopsin with restricted and homogeneous N-glycosylation by a
tetracycline-inducible N-acetylglucosaminyltransferase I-negative HEK293S stable mammalian
55 
cell line. Proceedings of the National Academy of Sciences. 2002;99(21):13419-24. doi: 
10.1073/pnas.212519299. 
15. Felix J, Elegheert J, Gutsche I, Shkumatov Alexander V, Wen Y, Bracke N, Pannecoucke
E, Vandenberghe I, Devreese B, Svergun Dmitri I, Pauwels E, Vergauwen B, Savvides
Savvas N. Human IL-34 and CSF-1 Establish Structurally Similar Extracellular Assemblies with
Their Common Hematopoietic Receptor. Structure. 2013;21(4):528-39. doi:
http://dx.doi.org/10.1016/j.str.2013.01.018.
16. Pronker MF, Lemstra S, Snijder J, Heck AJR, Thies-Weesie DME, Pasterkamp RJ,
Janssen BJC. Structural basis of myelin-associated glycoprotein adhesion and signalling. Nature
Communications. 2016;7:13584. doi: 10.1038/ncomms13584
http://www.nature.com/articles/ncomms13584 - supplementary-information. 
17. Otwinowski Z, Minor W. Processing of X-ray Diffraction Data Collected in Oscillation
Mode. 1st ed. C.W. Carter JRMS, editor. New York: Academic Press; 1997. 700 p.
18. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser
crystallographic software. Journal of Applied Crystallography. 2007;40(4):658-74. doi:
doi:10.1107/S0021889807021206.
19. Tong L, Rossmann MG. [34] Rotation function calculations with GLRF program.
Methods in Enzymology: Academic Press; 1997. p. 594-611.
20. Karplus PA, Diederichs K. Linking crystallographic model and data quality. Science
(New York, NY). 2012;336(6084):1030-3. doi: 10.1126/science.1218231.
21. Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta
Crystallographica Section D. 2010;66(4):486-501. doi: doi:10.1107/S0907444910007493.
22. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung L-
W, Kapral GJ, Grosse-Kunstleve RW, McCoy AJ, Moriarty NW, Oeffner R, Read RJ,
Richardson DC, Richardson JS, Terwilliger TC, Zwart PH. PHENIX: a comprehensive Python-
based system for macromolecular structure solution. Acta Crystallographica Section D.
2010;66(2):213-21. doi: doi:10.1107/S0907444909052925.
23. Bligh EG, Dyer EG. A rapid method of total lipid extraction and purification. Can J
Biochem Physiol. 1959;37(8):911-7.
24. Matyash V, Liebisch G, Kurzchalia TV, Shevchenko A, Schwudke D. Lipid extraction by
methyl-tert-butyl ether for high-throughput lipidomics. Journal of lipid research.
2008;49(5):1137-46. doi: 10.1194/jlr.D700041-JLR200.
25. Mapstone M, Cheema AK, Fiandaca MS, Zhong X, Mhyre TR, MacArthur LH, Hall WJ,
Fisher SG, Peterson DR, Haley JM, Nazar MD, Rich SA, Berlau DJ, Peltz CB, Tan MT, Kawas
CH, Federoff HJ. Plasma phospholipids identify antecedent memory impairment in older adults.
Nat Med. 2014;20(4):415-8. doi: 10.1038/nm.3466. PubMed PMID: 24608097.
26. Hubbard S, Thornton J. NACCESS, Computer Program. 1993.
27. Jin SC, Benitez BA, Karch CM, Cooper B, Skorupa T, Carrell D, Norton JB, Hsu S,
Harari O, Cai Y, Bertelsen S, Goate AM, Cruchaga C. Coding variants in TREM2 increase risk
for Alzheimer's disease. Hum Mol Genet. 2014;23(21):5838-46. doi: 10.1093/hmg/ddu277.
PubMed PMID: 24899047; PMCID: PMC4189899.
56 
Chapter 3: Biophysical impact of 
neurodegenerative variants on TREM2 
3.1 Solution behavior of WT and variant TREM2 proteins 
The TREM2 structure suggested that AD-linked variants would be properly folded and 
stable while the NHD variants would be misfolded. These misfolded variants might be expected 
to be cleared by ERAD quality control machinery in the ER and not secreted (if expressed as 
soluble Ig domain) or reach the cell surface (if expressed in full-length proteins). To test the 
former possibility, disease variants were introduced into the hTREM2 Ig domain within the 
pHLSEC vector. Large-scale expressions of WT and mutants would be purified by NiNTA and 
then purified by SEC using a superdex 200 10/300 GL analytical column in 150 mM NaCl with 
20 mM Tris pH 8.5 with a flow rate of 0.5 mL/min. If the proteins eluted as WT, they would then 
be concentrated and re-run on the column to establish that they remained monodisperse.  
3.1.1  Expression and solution behavior of NHD variants. 
Although it was hypothesized that the NHD variants would not be secreted, immunoblot 
analysis of supernatant from transfected 293F cells surprisingly showed significant amounts of 
these proteins. However, analysis by reducing/non-reducing SDS-PAGE followed by 
immunoblot for the 6-His tag demonstrated these proteins have aberrant intermolecular disulfide 
bonds. In fact, no properly-migrating monomeric species were observed in these experiments 
(Fig 3.1a). Because these proteins were secreted, they were purified by NiNTA and analyzed by 
SEC. In contrast to WT, which elutes at a volume corresponding to the predicted MW (Fig 3.1b, 
c). the NHD variants elute early, in fractions that correspond to aggregated or oligomeric 
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proteins (Fig 3.d-i). NHD proteins were not efficiently recovered after concentrating the 
fractions, and were therefore not tested in further biophysical assays (such as DSF). 
Figure 3.1 modified from Kober et al, 2016 (1) 
Figure 3.1 Solution behavior of NDH TREM2 Ig domains. a) anti-6-His immunoblot 
analysis of supernatant from 293F cells transfected with WT or NHD variant proteins. + or – 
indicates presence of b-ME in the loading buffer. NHD domains run as higher molecular 
weights, indicated intermolecular disulfide bonding. b) SEC purification of WT TREM2. WT 
protein elutes in fraction 3, which corresponds to about 14kDa. Elution volumes of MW 
standards shown with *. c) Immunoblot of pooled fractions from WT TREM2 SEC run. d-f) 
SEC profiles of NHD variants. g-i) Anti-6 his immunoblot of pooled fractions from SEC runs. 
NHD proteins elute as aggregates, with minimal monomeric protein detected.  
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3.1.2  Expression and solution behavior of surface variants. 
The crystal structure suggests the surface variants should behave like WT. As with the 
NHD variants, these were expressed in 293F cells and analyzed by SEC. As an additional check, 
the purified fractions were again run on the column to see if they remained monodisperse. In 
these experiments, all surface variants (R47H, R62H, N68K, D87N, T96K) all elute at the same 
volume as WT and with similar profiles. All proteins could be re-run on the column with 
minimal aggregation or shouldering (Fig 3.2). Upon purification, WT and mutant Ig domains 
were analyzed by reducing/non-reducing SDS-PAGE to see if they had aberrant disulfide 
bonding. No improper oligomers were detected.  
Concerning the glycosylation status of the surface variants 
In these studies, differential glycosylations have not been observed. One group expressed 
full-length WT or R47H in HeLa cells, analyzed glycosylations using immunoblots and mass 
spectroscopy, and reported that the R47H has slightly altered glycosylation patterns (2, 3). 
Importantly, these reports do not show that R47H is under-glycosylated or lacks mature glycans, 
rather, they report that the mature glycans have slightly altered modifications compared to WT. 
My studies used HEK293 cells and predominantly expressed just the Ig domain. It is possible 
that the different cell lines or different domains could produce different glycosylation. However, 
over the course of this work the AD disease variants were expressed numerous times and there 
was not obviously detectible impairment of glycan maturation or changes in the appearance by 
SDS-PAGE (Fig 3.2 m,n).  
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Figure 3.2 modified from Kober et al, 2016 (1) 
Figure 3.2. Purification and SEC analysis of WT and surface AD variants. a-f) 
Preparative SEC of WT or surface variant proteins. Fractions were collected as depicted in 
panel a and analyzed by SDS PAGE (m). g-l) Fraction 3, which is the purified protein, was 
concentrated and run again. All proteins re-run as monodisperse peaks, with minimal 
aggregation. m) Protein fractions were pooled and concentrated. TREM2 proteins elute in the 
third peak, which corresponds to a monomeric MW. n) purified proteins were run ± b-ME to 
test for improper disulfides.  
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3.2 Cell surface expression of WT and variant TREM2 
3.2.1  Rationale and experimental design for cell surface expression 
That the NHD variants could be secreted and detected was surprising, as it was 
hypothesized they would be retained in the ER. Indeed, two separate studies had reported the 
Y38C and T66M variant were not expressed on the cell surface (2, 4). To see if the buried and 
surface variants could achieve cell surface expression, full-length TREM2 constructs with an N-
terminal FLAG tag were introduced into the pHLSEC vector. These constructs express the full 
transmembrane TREM2 gene with an extracellular N-terminal FLAG tag. The FLAG peptide, 
DYKDDDDK, is a linear motif recognized by anti-FLAG antibodies (Sigma, M2 clone) 
independently of conformation. This antibody would detect surface-expressed TREM2 even if 
misfolded. Separately, through the Hydriboma center at Washington University, two hamsters 
were immunized with mammalian expressed hTREM2 Ig domain and the full mTREM2 
ectodomain. Immune reactivity was confirmed by ELISA to biotinylated human and mouse 
proteins. These antibodies were raised against folded epitopes and should recognize TREM2 in 
its native state. Polyclonal sera from these animals were produced as part of an effort to produce 
monoclonal anti-TREM2 antibodies (Antibody characterization is detailed in section 5.5). 
Finally, a commercial mTREM2 antibody (R&D, provided by the Michael Holtzman lab) was 
used to confirm the observations made with the hamster sera. In these experiments, 293F cells 
were co-transfected with full-length FLAG-TREM2 and mDAP12 in a pcDNA3.1 vector (cDNA 
provided by M. Holtzman). Transfection was accomplished with by mixing equal amounts of 
TREM2 and DAP12 DNA with 293fectin. Cells were collected after 24 hours, placed on ice, 
washed in chilled FACS buffer (PBS with 1% FBS), and stained with anti-FLAG-FITC (1:50) or 
anti-TREM2 sera (1:1000, followed by anti-hamster secondary-PE, 1:200, eBioscience). Cells 
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were not permeabilized, and were on ice for the entire process. Flow cytometry data was 
collected on a BD FACscan and data was analyzed using FlowJo (Treestar). Background in 
staining experiments was very minimal, and was defined by the staining to 293F cells transfected 
with DAP12-only.  
In addition to the flow cytometry experiments, confocal experiments were conducted to 
evaluate surface expression in an independent system. 293T cells were plated on glass coverslips 
and co-transfected with FLAG-TREM2 and DAP12 as described above. Cells were washed in 
cold PBS, fixed in 4% paraformaldehyde (PFA) in PBS, and then were either left 
unpermeabilized or were permeabilized with 0.1% triton X-100. Cells were blocked in animal-
free blocker (Vector laboratories) and then stained with mouse anti-FLAG overnight at 4° C 
(1:1000). In the morning, cells were washed, stained with Alexa Fluor 555-conjugated secondary 
(1:200) for one hour before being washed and mounted with VECTASHEILD mounting medium 
containing DAPI, which stain nuclei. Finally, total TREM2 was evaluated by anti-FLAG 
immunoblot of cell lysates. Cells were collected, washed into PBS with 0.1% triton X-100, and 
left rotating at 4° C for 15 min to lyse cells. Insoluble debris (nuclei, membranous organelles) 
were pelleted by centrifugation and the supernatant added to 2x SDS buffer with b-ME, boiled 
for 10 min, and analyzed by SDS-PAGE. 
3.2.2  AD and NHD TREM2 variants are surface-expressed 
TREM2 surface expression was measured by flow cytometry in two different formats – 
by detecting the linear FLAG epitope or the folded TREM2 protein. Expression was evaluated 
by quantifying the percentage of cells that were TREM2+ by FLAG or hamster sera after 
subtracting the percent positive in DAP12-only cells, and then normalizing this value to WT. 
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Contrary to the initial hypothesis, but consistent with their secretion by 293F cells, all the 
variants were detectable using anti-FLAG immunostaining (Fig 3.3a). In contrast, there was a 
significant reduction in the number of TREM2+ cells using the polyclonal sera (Fig 3.3b). This 
difference was even more pronounced using the commercial monoclonal (Fig 3.3c). The 
decreased detection with the polyclonal sera is especially significant because the polyclonal 
should not be sensitive to a single epitope, whereas the monoclonal might be impacted by certain 
variant sequences.  
In the confocal experiments, the FLAG antibody confirmed surface expression of WT, 
Y38C, and R47H – representative members of the buried and surface disease-risk variants (Fig 
3.3d). If anything, expression was higher in the NHD variant. This increased intensity could be 
due to decreased proteolytic processing of this variant. Anti-FLAG immunoblot of the whole cell 
lysate also confirmed equivalent or even increased expression for the NHD variants (Fig 3.3e).  
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Figure 3.3 modified from Kober et al, 2016. (1) 
Taken together, data using both the Ig and full-length variant TREM2 support the 
prediction from the crystal structure that the NHD residues cause protein misfolding, as they 
have intermolecular disulfide bonds and have decreased detection by conformation-sensitive 
antibodies. Despite being misfolded, these variants are surface expressed. It is possible that this 
Figure 3.3 Surface expression studies of WT and variant TREM2. a) Normalized TREM2 
surface expression by anti-FLAG measured by flow cytometry. b) Normalized TREM2 
surface expression by anti-TREM2 polyclonal sera measured by flow cytometry c) 
Normalized TREM2 surface expression by a commercial monoclonal measured by flow 
cytometry. d) Confocal microscopy of FLAG-TREM2 expressed in permeabilized on non-
permeabilized 293T cells confirms surface expression of AD and NHD variants. e) Anti-
FLAG immunoblot of full-length TREM2 proteins expressed in 293T cells. 
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is be an artifact of protein construction or overexpression. However, given that secretion was 
observed with a C-terminal 6-His tag and surface expression was observed with an N-terminal 
FLAG tag, it is unlikely that the secretion or expression is an artifact of the protein construct. 
This finding will need to be confirmed with in vivo animal knock-ins or human samples. If these 
variants are surface-expressed, they may present a therapeutic target. In contrast to the NHD 
variants, the AD-risk and other surface variants do not cause folding defects on a gross scale. 
They behave comparably to WT by SEC and are recognized both by a commercial monoclonal 
and novel polyclonal that are sensitive to TREM2 misfolding.  
3.3 Using CD spectroscopy to evaluate TREM2 folding 
The secretion and expression studies showed that the AD variants and other possible AD 
variants which are on the protein surface probably do not cause disease by loss of structural 
integrity. However, detailed studies of solution structure and stability might reveal nuances 
associated with risk variants. In these experiments, the NHD variants were not used because they 
resisted SEC purification. The surface variants R47H, R62H and T96K were used for all 
experiments because the R to H variants have the strongest genetic link to disease while the 
T96K variant showed increased binding in cell-binding assays and may be protective (discussed 
later). The N68K and D87N variants were only used in initial circular dichroism spectroscopy 
(CD) analysis to confirm folding as predicted by structural and solution studies.
3.3.1  CD spectroscopy reveals a subtle change in the R47H variant 
CD spectroscopy is a spectroscopic technique that measures the difference between the 
left and right circularly polarized light absorbed by a sample. This value is reported as the mean 
residue molar ellipticity. CD experiments were conducted in a JASCO J-815 machine in the 
laboratory of Daved Fremont. Because chloride absorbs strongly in the far-UV range, proteins 
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were exchanged into sterile-filtered 150 mM NaF and 10 mM phosphate pH 7.0. This buffer was 
also used as the dilution agent. An equal volume of concentrator flow-through was used for 
buffer subtraction. Experiments were either conducted at 3 µM in a 10 mm cuvette or at 30 µM 
in a 1 mm cuvette. All thermal denaturations were conducted in the 10 mm cuvette placed in a 
Peltier temperature controller with a small stir bar to ensure mixing. In all CD experiments, 
proteins were expressed in mammalian cells and purified by SEC as described above. 
Experiments were always conducted within one week of purification, and generally on the same 
day as purification. With melting experiments, the data was smoothed using the JASCO 
software. All CD curves, except for N68K and D87N were replicated on at least three individual 
expressions. WT and R47H were analyzed on at least five individual expressions.  
Ig domains have a typical b-sheet minima around 218 nm, but also have a characteristic 
secondary minima around 233 nm, which is thought to be due to canonical tryptophan residues 
within the Ig fold (5). These features were observed with WT and all surface variants (Fig 3.4a). 
This analysis showed that the surface variants do not grossly alter the fold. In initial experiments, 
it was noted that the R47H variant has a slightly altered CD profile. To quantify this, the ratio of 
the two minima were evaluated. R47H was the only variant with an altered profile by this 
analysis, and this was statistically significant (Fig 3.4b) (1). Therefore, this analysis shows that 
the surface variants retain a characteristic Ig fold, although the R47H variant has a slight, but 
measurable conformational change.  
66 
Figure 3.4 modified from Kober et al, 2016  (1) 
Figure 3.4 CD characterization of WT and surface variant TREM2 proteins. a) CD 
profiles of WT, R47H, R62H, and T96K. b) Ratio of minima at 214 to 233 nm in WT and all 
surface variant proteins. *** = p<0.001 by ANOVA with Bonferroni post-test correction. 
Note: D87N and N68K were not included in statistical test as their N = 1. All others N ≥ 3. 
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3.4 Thermal and chemical stability of WT and variant 
TREM2 Ig domains 
To assess whether TREM2 variants impact protein stability of the surface variants, a 
number of assays were performed. In all cases, SEC-purified protein was used. The SEC 
experiments where purified protein was re-run on the column confirmed that protein remains 
monodisperse, free from aggregates, and is therefore suitable for denaturation experiments. 
3.4.1  Thermal stability by CD spectroscopy 
To determine suitable wavelengths to monitor TREM2 unfolded by CD, an interval scan 
experiment was conducted where WT TREM2 was heated from 20° C to 90° C and full CD 
scans taken every 5° C. This experiment revealed a transition at 225 nm that was suitable for 
monitoring (Fig 3.5a). (The larger transition around 205 is noisier and usually beyond the 
voltage limit when DTT is in the buffer).  While this transition is different than the classical 
flattening loss of CD signal, it is typical of Ig domains (5). TREM2 thermal denaturation in CD 
experiments was reversible (Fig 3.5b) with the native CD spectra restored after returning to 20° 
C. All surface variants were capable of refolding, while refolding was ablated for WT and all 
variants in the presence of 1 mM DTT (not shown). Therefore, WT and variant TREM2 proteins 
were melted from 20° C to 90° C with continuous monitoring at 225 nm (Fig 3.5c). In these 
experiments, R47H and R62H were indistinguishable from WT, while the T96K variant had a 
slightly lower transition. All proteins had reduced transitions in the presence of 1 mM DTT, 
confirming the presence of disulfide bonds that were enhancing protein stability. 
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3.4.2  Thermal stability by differential scanning fluorimetry 
Thermal stability was also assessed by DSF. These assays were performed using an ABI 
Fast7500 qPCR machine according to the manufacturer’s protocol. Data were analyzed using the 
Protein Thermal Shift software (ABI). Melting temperatures were calculated by Boltzman curve 
fitting. Protein was exchanged into PBS, the concentration was adjusted to 0.5 mg/mL and 12.5 
µL of this was added to the reaction mix with a total volume of 20 µL. In early experiments, it 
was noted that there is a small concentration-dependence to the Tm, so all experiments were 
done at this same concentration. Samples were run with or without 1 mM DTT. All proteins had 
reduced Tm with DTT. There was a statistically significant pattern where WT melted later than 
R47H and R62H, which melted after T96K. With DTT, all proteins again had a reduced melting 
point. While these measurements were statistically significant, within the DSF literature and 
previous experiments in our lab, a melting point change of ≤ 5° C is very modest and unlikely to 
be biologically significant (Fig 3.5d).   
3.4.3  Chemical stability by CD spectroscopy 
In addition to thermal melting experiments, chemical stability was tested through CD 
experiments conducted where TREM2 WT or variants were incubated in increasing 
concentrations of GuHCl. In these experiments, proteins were incubated with GuHCl for at least 
an hour before measuring and at least one partially denatured sample was measured a second 
time an hour later to confirm equilibrium had been reached. It was hoped that these 
measurements could assess the ∆G of protein folding (6). However, this method requires a linear 
transition. For TREM2, the curve would shift as in the thermal melting conditions, and then 
reverse and slowly flatten. For this analysis, the melting concentration was recorded as the 
GuHCl concentration of the transition point. Consistent with the DSF and CD data, WT TREM2 
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denatured slightly later than R47H and R62H, which were slightly more stable than T96K (Fig 
3.5e).  
Taken together, these analyses (expression, SEC, surface expression by flow cytometry 
and confocal microscopy, CD scans, thermal and chemical denaturation by CD and DSF) support 
the primary interpretation of the crystal structure – that the NHD variants are misfolded and 
suffer reduced stability, while the surface variants, which include the primary AD-risk variants, 
are largely intact. These proteins are folded and behave like WT by course solution methods. 
Finer analysis detailed subtle but measurable alterations; however, these are unlikely to be 
pathological.  
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Figure 3.5 panels a, c, d, and e are modified from Kober et al, 2016 (1). 
Figure 3.5. Thermal and chemical denaturation experiments. a) Interval scan of WT 
TREM2 at 5° C increments from 20-90° C. TREM2 has a transition at 225 nm that was 
monitored in subsequent melting experiments b) WT TREM2 CD scans before thermal 
denaturation, at 90° C, and after returning to 20° C for 30 min. TREM2 largely regains 
folding, and this was observed for all surface variants. Refolding was ablated in the presence 
of 1 mM DTT. c) Thermal denaturation of WT or variant TREM2 measured at 225 nm in the 
absence or presence of 1 mM DTT. DTT results in a reduced melting for all variants. d) 
Melting temperatures from DSF experiments in the presence or absence of DTT. Mean and 
SEM of at least three independent experiments. e) Table of thermal and chemical denaturation 
values. 
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Chapter 4: Impact of neurodegenerative 
variants on TREM2-ligand binding 
4.1 TREM2 ligands in the literature 
Because the AD variants did not grossly affect TREM2 structure or stability, it was 
hypothesized that they might alter ligand binding. Although the endogenous TREM2 ligand is 
unresolved, a long list of potential TREM2 ligands or interacting partners has been proposed in 
the literature. These are summarized in Table 4, which lists the ligands, techniques used to 
demonstrate an interaction, the KD if reported, and the role of disease-risk variants if tested. 
Briefly, prior to this work, TREM2 had been shown to bind a variety of mammalian cells, 
including myeloid cells (1, 2) and non-myeloid CNS cells such as astrocytes (3-5) and neurons 
(4, 6-8). These data suggested potential ligands for TREM2 that could exist in cis or in trans 
relative to the TREM2-expressing myeloid cell. Additionally, TREM2 was shown to recognize a 
wide range of anionic bacterial ligands (5) and directly binds bacteria (5, 9, 10). TREM2 had also 
been shown to bind the chaperone protein HSP60, which may be surface-expressed on apoptotic 
neurons (4) and TREM2 co-IPs with potential co-receptor proteins, most notably Plexin-A1 (11) 
and TREML1s, a short transcript of TREML1, which contains an inhibitory ITIM motif (12). In 
2012, TREM2 was shown to bind a wide range of phospholipids (13). This phospholipid 
interaction gained considerable interest during the course of this work and is discussed at length 
below. Finally, during the course of this work, multiple groups reported an interaction with 
soluble lipoproteins, including ApoE, one of the major risk factors for AD (14-17).  
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Table 4. Reported TREM2 ligands 
Ligand Techniques KD Variants 
Ref 
Bacteria/bacterial 
components 
Whole Bacteria CS, P, FC, RC, CB, E (5, 9, 10) 
C. jejuni lysate E, RC (18) 
N. gonococcus
lipooligosaccharides E, SPR, RC 350nM (19) 
Anionic Bacterial 
Carbohydrates  CB (5) 
Cholera toxin B E, RC (20) 
Mammalian Cells 
THP-1 monocytes 
FC (7) 
BMDMs 
FC (1) 
BMDCs 
FC (2) 
Astrocytes 
RC, CS (3-5) 
Neuronal Cells 
CS, RC, FC (4, 6-8) 
Apoptotic cells 
FC, RC, P (6, 21) 
Anionic molecules 
Phospholipids & 
Sulfolipids E, DB, RC, LB 
R47H, R62H ↓ D87N, 
T96K ↑ 
(7, 13, 15, 17, 
21-23)
DNA 
IP, RC (8) 
Sulfated proteoglycans 
FC (7) 
Mammalian proteins 
HSP60 E, CS. 3.8µM (4) 
Plexin-A1 FRET, IP (11) 
TREML1 (short transcript) IP 
  
(12) 
Apolipoproteins (A,B,E,J) 
DB, P, IP, E, BLI, PM 
6.7nM 
(14) 
R47H ↓(14, 15) 
R47H, R62H, D87N↓(16) (14-16) 
Lipoparticles 
BLI, RC, PM 
R47H, R62H ↓ D87N↑↓, 
T96K ↑ (16, 17) 
Negative results 
Certain Mammalian Cells CS (5) 
Apoptotic Jurkat cells FC (15) 
Key: E = ELISA, RC = reporter cell, FC = flow cytometry, P = phagocytosis/cellular uptake, IP = Co-immunoprecipitation, CB 
= competitive binding, CS = cell staining, LB = liposome binding, BLI = Biolayer Interferometry, PM = protein microarray, 
SPR = surface plasmon resonance, DB = dot blot. 
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4.2 TREM2 variants minimally impact phospholipid 
binding 
4.2.1  TREM2 and Ig domain-phospholipid binding in the literature 
Cannon et al first reported that TREM2 (produced as a Fc-fusion protein) bound to 
phospholipids (13). They used a solid-state ELISA system and found that TREM2 and CD300 
family members bound plated phospholipids. Similar findings were reported by Bailey et al (15), 
who used a dot blotting system.  More recently, the Colonna lab reported that both mouse (22) 
and human (21) TREM2 signaled when incubated overnight on plated phospholipids. This was 
measured by GFP expression under the control of a NFAT reporter, which is activated by 
calcium flux as a result of TREM2 signaling. Interestingly, the pattern is different for these 
systems (Fig 4.1). The signaling assays respond to lower concentrations of plated 
phosphatidylcholine (PC).  In contrast, PC binding was barely detected in the solid-state assays. 
Wang et al also showed that the R47H variant has decreased signaling to phospholipids (21). 
This was the first time a TREM2 variant had been shown to alter signaling. Therefore, this study 
sought to answer whether the TREM2 variants altered direct binding to phospholipids.  
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4.2.2  TREM2 binds phospholipids differently than other Ig domains 
There is precedent for similar Ig domains selectively binding phospholipids. Members of 
the CD300 and TIM family proteins selectively bind PS and sometimes PE and the binding 
determinants are well-understood (24-30). (The CD300 proteins are also known as CMRF35-like 
(CLM), IREM, or LMIR). Lipid binding by this family of proteins is highly dependent on a 
divalent metal (usually Ca2+) coordinated within the lipid-binding pocket. The acyl chains of the 
lipid are coordinated by hydrophobic residues on the C-C’ and FG loops. The FG loop in 
particular contain a canonical “WFND” motif that is thought to insert into the plasma membrane 
to help the protein search for a binding lipid (30). Importantly, these lipid binding mechanisms 
have been shown to require divalent cations, are sensitive to EDTA and EGTA, and are highly 
specific for PS (sometimes PS and PE) (24-30). As noted above, TREM2 differed from these 
Figure 4.1 Heat map of phospholipid 
interactions from the literature and this 
study. Binding to or signaling from 
selective lipids in each study was 
qualitatively scaled from 0-3 for none, 
weak, moderate, and strong binding or 
signaling. The lipid species is listed on the 
Y-axis and the study is listed on the lower
X-axis with the type of assay listed on the
top X-axis. Empty boxes indicate the lipid
was not evaluated in that study. Black box
highlights PC as an example where binding
and signaling studies produce different
results,
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other proteins with the reports of binding fairly non-selectively to phospholipids. Additionally, 
Cannon et al showed that Ca2+ or Mg2+ did not enhance TREM2 lipid binding (13).  
To test whether purified TREM2 directly bound phospholipids with selectivity or in a 
cation-dependent manner, a number of experiments were conducted. For solid-state ELISAs, 
lipids were solubilized in methanol or methanol chloroform as needed. Solubilized lipids were 
diluted in methanol and 100 µL of lipids at 5 µg/mL were plated on ELISA plates and allowed to 
air dry. Wells were blocked in 3% BSA in PBS and then 100 µL of biotinylated protein (usually 
diluted 1:1000) was added at overnight at 4°C and then washed in BSA/PBS with 0.05% Tween-
20. Biotinylated protein was detected by streptavidin-HRP and a colorimetric peroxidase
substrate (TMB microwell peroxidate substrate, KPL) (Biotinylation protocol is described in 
section 4.3). Fig 4.2a shows the binding of mTREM2 to plated phospholipids in the presence of 
5 mM EDTA, Ca2+, or Mg2+. Binding was not affected by any of the treatments. Similar results 
were obtained with hTREM2. Additionally, the binding to phosphatidic acid (PA) shows that the 
head group is not required, arguing against selective binding. In contrast to the signaling assays, 
but consistent with the initial report by Cannon et al, PC was bound only at background level.  
The TREM2 sequence and structure provide clues as to why the binding mechanism is 
different. Most notably, the hydrophobic residues of the “WFND” motif in the FG loop are 
absent in TREM2 (Fig 4.2b). The residues in this loop from the TREM2 and TIM4-PS crystal 
structures are shown in Fig 4.2c. In addition to the absent hydrophobic residues, the Asp which 
coordinates the Ca2+ in the TIM4 structure is facing away from the canonical lipid binding 
pocket in TREM2. It is possible that this residue could be rotated towards the groove during lipid 
binding, but the lack of sensitivity to divalent metals or chelators suggests that this mechanism is 
not how TREM2 binds phospholipids.  
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Figure 4.2 is modified from Kober et al, 2016 (7) 
Figure 4.2 TREM2 binds phospholipids differently than other Ig domains with selective 
binding. a) TREM2 binding does not require divalent metals to bind phospholipids. TREM2 
prefers anionic species, but does not require a headgroup to coordinate binding. Solid-state 
ELISAs were conducted in the presence of 5 mM EDTA, calcium, or magnesium. 
Representative of two independent experiments with both human and mouse TREM2. b) 
Sequence alignment of the Ig domains of TREM2, CD300a, TIM1 and TIM4 shows TREM2 
does not have canonical lipid-binding motifs. c) hTREM2 and TIM4 (3BIB) aligned showing 
the hydrophobic residues that interact with PS are not present in TREM2 and the D required 
to coordinate Ca2+ in 3BIB. 
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4.2.3  TREM2 AD variants do not lose phospholipid binding 
Having established that TREM2 binds phospholipids, the role of TREM2 variants in 
phospholipid binding was examined. Phospholipid binding was tested using solid-state ELISA, 
liposome sedimentation, and direct binding by BLI. ELISAs were performed as described above. 
TREM2-avitag proteins were purified by NiNTA, concentrated, biotinylated, and used to probe 
plated lipids. To control for differences in biotinylation efficiency, the signal for each protein 
was normalized to its background signal on MeOH coated plates. All overall protein signals were 
comparable, especially compared to TREML2 or TREML4, which had extremely minor binding 
to phospholipids and required much lower dilutions for appreciable signal (not shown). The 
ELISA assays showed that the overall level of binding between the mutants was comparable and 
that the discrimination between different phospholipids was unchanged (Fig 4.3a, b). This is 
completely different from the signaling assays, where R47H loses almost all signal to most 
phospholipids but retains signaling to PC and Sphingomyelin (21).  
Liposome sedimentation was also performed to assess binding to a more physiological 
form of lipid presentation. Crude liposomes were made as previously described (31). Liposomes 
were made by reconstituting PC, PE, and cholesterol in PBS (35:35:10 w/w/w) after vacuum-
drying to remove organic solvent, and then subjecting them to three freeze-thaw cycles at 37° C 
and in liquid N2 followed by vortexing to achieve a uniform liposome suspension. To measure 
specific binding to individual lipids, 20% w/w of the indicated phospholipids were added to the 
base liposome. Liposomes were mixed with SEC-purified TREM2 and the concentration 
quantified by BCA. 100 µg liposomes were mixed with 10 µg TREM2 proteins for one hour at 
RT and then pelleted by centrifugation (16,800xg). The supernatant was removed, SDS-PAGE 
loading buffer was added to the pellet, which was then analyzed by anti-6-His immunoblot. 
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Similar to the ELISA assays, preferential binding to anionic lipids (PA, PG, PI, PS) but not more 
neutral lipids (PC, PE) was observed. Most notably, the R47H and other variants had similar 
levels of overall binding and there was no change in the lipid preference (Fig 4.3c). 
Finally, to assess direct binding and kinetics, liposomes were immobilized using 
aminopropylsaline (APS) pins in the BLI system and used to measure binding to SEC-purified 
WT or R47H proteins. Minimal binding was observed to base liposomes (not shown), while both 
WT and R47H bound PS liposomes comparably (Steady-state response KD’s of 1.4 and 2.5*10-5 
M, with R2 of 0.997 and 0991, respectively) (Fig 4.3d). Nearly identical values were also 
determined by kinetic fits, but not reported here because of the need to optimize dissociation 
conditions.   
In three different assays, the R47H and R62H variants do not appear to have a large 
effect on binding to phospholipids. It remains possible that subtle change in affinity is missed in 
these assays. Another important consideration is the manner of phospholipid presentation. 
Towards that end, a recent report demonstrated TREM2 binding to phospholipids on a strip dot 
blot assay but failed to detect TREM2 binding to apoptotic Jurkat cells, which expressed PS on 
the cell surface as assessed by TIM1 and Annexin V binding (15). This suggests phospholipid 
exposure is not sufficient for TREM2 cell binding. While phospholipids stimulate TREM2 
signaling, they are unlikely to be the full TREM2 ligand.  
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Figure 4.3 a-c are modified from Kober et al, 2016 (7) 
Figure 4.3 TREM2 variants do not grossly impact phospholipid binding. a) Mouse 
TREM2 and b) Human TREM2 phospholipid ELISAs. c) hTREM2 liposome sedimentation 
assays. d) BLI analysis of WT or R47H hTREM2 binding to PS-enriched liposomes from (c) 
immobilized onto aminopropylsilane (APS) pins and dipped into purified TREM2 proteins. 
Background binding to uncoated pins was subtracted. Minimal binding was observed to base 
liposomes in the same experiment. 
81 
4.3 TREM2 binds a cell-surface ligand 
4.3.1  TREM2 binds a GAG-dependent cell-surface ligand 
TREM2 had been previously shown to bind various mammalian cells (Table 4). 
However, with the exception of increased staining when apoptosis was induced (6), no 
demonstration of specific or selective binding had been made. In contrast, the only report 
examining TREM2 binding to viable cells stimulated with different conditions found no change 
in TREM2 binding to DCs pretreated with LPS, CpG DNA, or Zymosan (2). 
To investigate whether TREM2 could bind a specific cell-surface ligand, a staining 
reagent was produced by expressing TREM2 in the pHL-Avitag construct which encodes a C-
terminal BirA biotinylation tag. The protein is purified by NiNTA chromatography and then 
exchanged into biotinylation buffer (100 mM Tris pH 7.5, 5 mM MgCl2, and 200 mM NaCl*), 
*In some experiments, NaCl was replaced with 200 mM K-Glutamate for 4°C biotinylation.
biotinylated in vitro by addition of 10 µL BirA enzyme at 1 mg/mL, 1/10 vol buffer A (0.5 M 
bicine pH 8.3), 1/10 buffer B (100mM ATP, 100uM MgOAc) and 50 µM final concentration of 
free biotin. Excess biotin was removed using a desalting column and biotinylation verified by 
immunoblot with streptavidin-HRP. For cell staining, biotinylated TREM2 proteins were diluted 
in FACS buffer (PBS with 1% FBS) and then complexed with phycoerythrin-conjugated 
streptavidin (SAPE) for at least 30 min on ice. 100 µL aliquots of staining solution would be 
added to cells that were harvested and washed into FACS buffer. Culturing conditions for cells in 
this study are listed in Table 5.  
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Table 5. Cell culture conditions in this study 
Cell Media Base Serum Additives %CO2 ATCC # 
THP-1 RPMI 10% P/S, 10 mM HEPES, 50 
µM b-ME, L-glut 
5% TIB-202 
N2A MEM 10% P/S, L-glut, MEM NEAA 5% CCL-131
CHO (K1 or 745) F12 10% P/S, L-glut 5% CCL-61
293T DMEM 10% P/S, L-glut 5% CRL-3216 
293F Freestyle None P/S 8% 
Expi293 Expi293 
Medium 
None Anti-Anti 8% 
RAW 264.7 DMEM 10% P/S, L-glut 5% TIB-71 
BV2 DMEM 5% P/S, L-glut 5% 
Several cell lines were screened for TREM2 binding, and cells were treated with various 
stimuli to test whether binding was to a specific ligand. TREM2 bound THP-1 cells, and staining 
could be ablated by treating the cells overnight with 20 ng/µL PMA and 500 µg/mL ionomycin. 
Staining was not decreased by treatment with LPS (1 µg/mL), polyIC (1 µg/mL), M-CSF (20 
ng/µL) or IL-13 (50 ng/mL) (Fig 4.4a, b). This was the first time a treatment had been shown to 
decrease TREM2 staining and showed that TREM2 stained a specific ligand on these cells.  
Next, proteases were used to see whether the cell-surface ligand had a proteinaceous 
component. 50 µg/mL of the indicated proteases were added to cells on ice for 30 min. Protease-
treated cells were washed four times with FACS buffer supplemented with PMSF before staining 
with SAPE-TREM2 complexes, also in the presence of PMSF and HALT protease inhibitor 
cocktail. Proteinase K completely abolished staining to THP-1, and N2A and 293F cells (Fig 4.4 
c,d,e). Other proteases (chymotrypsin, trypsin, elastase) had intermittent effects (Fig 4.4 c,e). 
These experiments demonstrated a protein-component to the cell-surface ligand. They also 
confirmed that membrane phospholipids are not sufficient for cellular binding by TREM2.  
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Because TREM2 has a high pI and binding was observed to a number of different cells, 
both myeloid and non-myeloid, proteoglycans were considered as possible ligand. To test 
whether TREM2 bound cells in a glycosaminoglycan (GAG)-dependent manner, CHO cells that 
do (CHO-K1) or do not (CHO-745) express heparan sulfates (HS) or chondroitin sulfates (CS) 
(32) were tested for TREM2 binding. TREM2 bound CHO-K1 robustly, but not CHO-745 cells
(Fig 4.4f). To answer whether TREM2 selectively bound either HS or CS, cells were pre-treated 
with enzymes that selectively cleave HS or CS. Heparinases and chondroitinase ABC were 
purchased from Sigma and reconstituted according to the manufacturer’s protocol. Heparinases I, 
II, and III (which also cleave HS) were combined into a cocktail to remove HS, and 
chrondroitinase ABC was used to cleave CS. Final enzyme concentrations were 0.1 U/mL. Cells 
in PBS supplemented with 0.1% BSA were treated for 1 hr at 37° C while shaking and then 
washed three times in cold FACs buffer. TREM2 staining of CHO cells, THP-1 cells, and N2A 
cells was greatly diminished following treatment with heparinases, but not with chrondroitinase, 
although N2A did show some reduction with chrondrotinase (Fig 4.4 f, g, h). These experiments 
demonstrated that TREM2 bound a cell-surface ligand in a protein and GAG-dependent manner, 
and suggest that HS is the dominant ligand on these cells. Importantly, this is observed on 
myeloid cells (THP-1 are human monocytic), suggesting that HS may interact with TREM2 in 
cis to mediate function.   
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Figure 4.4 a-h are modified from Kober et al, 2016 (7) 
Figure 4.4 TREM2 binds a specific cell-surface ligand. a) mTREM2 binding THP-1 cells 
stimulated as with the indicated conditions. b) hTREM2 binding THP-1 ± PMA/ionomycin c) 
hTREM2 binding THP-1 cells pre-treated with indicated proteases d) mTREM2 binding N2A 
cells and e) 293F cells pre-treated with indicated proteases. f-h) mTREM2 binding f) CHO-
K1 or CHO-745 cells g) THP-1 cells, or h) N2A cells pre-treated with heparinases or 
chondroitinase  i) mTREM2 binding to mouse whole-lung digest cells co-stained with CD45 
shows that TREM2 stains CD45 + and - subsets.  
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4.3.2  Other TREM proteins with high pIs do not bind the same ligand 
Because TREM2 has a pI, it was possible that binding sulfated proteoglycans is an 
artifact of surface charge, not a specifically recognized ligand. To address this, the Ig domains of 
human and mouse TREML2 and TREML4 were cloned into pHLSEC vectors using Gibson 
block assembly and then introduced into the pHL-Avitag vector through EcoI-KpnI restriction 
enzyme digests. These proteins have similarly high pIs, Figure 4.5a shows the pIcalc for these Ig 
domains. Unlike TREM2, these proteins did not robustly bind N2A cells (Fig 4.5b) or THP-1 
cells (not shown) as assessed by flow cytometry. This finding argues that the cell-surface ligand 
recognition by TREM2 is not an artifact of charge but has at least some level of specificity. This 
is also consistent with the observation TREM2 is selective for HS over CS.  
Figure 4.5 is modified from Kober et al, 2016 (7) 
Figure 4.5 TREM-like proteins with 
similar basic pI do not bind the same 
cells as TREM2. a) Schematic and 
pIcalc for human and mouse TREML2 
and TREML4 Ig domains. b) 
Biotinylated Ig domains were 
complexed with streptavidin-PE and 
used in binding experiments. TREML2 
and TREML4 had very little binding to 
N2A cells (similar results with THP-1 
cells).  
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4.4 TREM2 variants alter ligand binding 
Satisfied that TREM2 binds a selective ligand, the next question was whether the surface 
variants altered binding to this ligand. This was tested in a variety of assays, monomer binding, 
tetramer binding, and competition assays.  
4.4.1  TREM2 variants have altered cell binding 
Figure 4.6 is modified from Kober et al, 2016 (7) 
Figure 4.6. TREM2 surface variants alter ligand binding. a) Schematic for detection of 
SEC-purified 6-His TREM2 proteins by flow cytometry b) SEC-purified 6-His hTREM2 
proteins binding THP-1 cells. c) Dose-dependent binding of 6-His proteins to THP-1 cells. d) 
mTREM2-SAPE tetramer staining N2A and e) THP-1 cells f) hTREM2 competitive binding 
where purified Ig domains compete with SAPE-WT tetramers for binding THP-1 cells.   
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Monomeric variant TREM2 proteins have altered binding 
To test whether the purified, monomeric mutants would alter binding to THP-1 cells, 
hTREM2 WT, R47H, R62H, and T96K were purified by NiNTA using their 6-His tag and then 
purified by SEC to obtain monomeric proteins. Proteins concentrations were carefully matched 
by UV280 and BCA analysis. Washed THP-1 cells were incubated with increasing concentrations 
of TREM2 proteins for 1 hour before being washed and incubated with a PE-conjugated anti-6-
His antibody for 30 min. Cells were analyzed by flow cytometry (Fig 4.6a). In each data point, 
20,000 cells were counted. This assay was repeated three times with two independent protein 
expressions. The disease-risk variants R47H and R62H had reduced binding that never matched 
WT MFI at any concentration. In contrast, the T96K variant had more staining at all 
concentrations (representative plot shown in Fig 4.6b and MFI plotted against concentration in 
Fig 4.6c).  
Tetramer staining shows altered binding 
Similar results were observed in staining experiments with mTREM2 tetramers. R47H 
had decreased binding while T96K has increased binding. The effect of R62H was less 
pronounced and not as reproducible. Staining is shown to N2A (Fig 4.6d) and THP-1 (Fig 4.6e).  
Competition assays show altered binding 
Finally, binding was evaluated in a competition format. In these experiments, the amount 
of WT tetramers needed for binding was first titrated so that there would be as little excess 
tetramer as possible. Separately, WT or variant hTREM2 proteins were incubated with THP-1 
cells for one hour. Then, TREM2-SAPE was added for 20-30 min. Cells were then washed and 
analyzed by flow cytometry. The T96K competed more effectively than WT, as shown by 
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reduced MFI at the same concentrations. The R47H variant was less effective, and had higher 
MFIs. The R62H variant had a modest effect.  
Collectively, these experiments show that the R47H variant, and perhaps the R62H 
variant to a lesser extent, lose binding compared to WT. This trend was observed in multiple 
formats and on multiple cells lines. In contrast, the T96K variant robustly increased binding in 
all formats. Notably, in some genetic analyses, this variant has been associated with decreased 
risk for AD (Fig 2.9). Complicating the genetic analysis is the observation that this variant is also 
commonly found in linkage disequilibrium with another variant, L211P (33). L211P is in the 
cytosolic tail and it is unclear whether it impacts TREM2 function. In a preliminary experiments 
this variant did not decrease surface expression (not shown).  
4.5 TREM2 variants identify a functional binding surface 
4.5.1  TREM2 has a basic surface not conserved on other TREM proteins 
To interpret the results of the gain and loss of function variants, the protein electrostatic 
solvent-accessible surface was examined. A prominent basic patch was found on the protein (Fig 
4.7a, b) that includes the R47 and R62 residues. The T96 residue is on the other side of this 
patch. The R to H mutations would decrease the basic potential, while the T to K change would 
increase the basic surface. This surface is absent on the other TREM family proteins that have 
been crystallized (Fig 4.7 d-f) d)mTREM1 pdb 1U9K (34), e) hTREM1 pdb 1SMO (35), and f) 
hTREML1 pdb 2FRG (36). Additionally, alignment of the Ig domains of the TREM family 
proteins shows that the residues in the basic surface, while conserved in TREM2, are not 
conserved within the larger TREM family (Fig 4.7c). In contrast, the NHD residues are more 
conserved, which attests to their structural role.  
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4.5.2  Structure-guided mutations alter binding 
To test whether this surface is a functional ligand binding site, mutations to two 
prominent arginine residues within this surface were introduced and tested in binding 
experiments. As predicted, these mutations resulted in loss of binding to THP-1 cells (Fig 4.7g). 
These findings support the hypothesis that the AD-disease risk residues impair binding to a cell-
surface ligand that is primarily HS proteoglycans.  
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Figure 4.7 is re-used from Kober et al, 2016 (7) 
Figure 4.7. Disease variants reveal a functional ligand-binding surface. a) hTREM2 
solvent-accessible surface electrostatics generated by APBS, scaled from 6.0 kT/e (blue) to +6 
kT/e (red). Dotted line outlines the basic patch. b) TREM2 rotated to show the patch 
extending to T96 residue. The lysine variant adds to this surface. c) sequence alignment of 
human and mouse TREM family members. TREM2 structure assigned by DSSP server shown 
on top. Disulfide bonds labeled in green. NHD residues highlighted with black boxes, AD 
residues with blue boxes. Residues contributing to the basic patch marked with blue asterisks. 
Conserved residues in yellow and invariant residues in magenta. d) mTREM1, e) hTREM1, 
and f) hTREML1 aligned to TREM2 in (a) and solvent-accessible electrostatics colored on 
the same scale. g) TREM2 basic-patch mutants R76D and R77D have reduced binding to 
THP-1 cells.  
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4.6 TREM2 directly binds heparin 
To test whether TREM2 could directly bind heparan sulfate, a BLI experiment was 
devised where biotinylated heparin was immobilized on a streptavidin pin and dipped into wells 
containing purified hTREM2. The BLI assay buffer was PBS with 0.1% BSA and 0.005% 
Tween-20. Heparin was placed on the pin because it is polymeric would complicate the 
interpretation of binding if it was the analyte (By BLI convention, the ligand is immobilized on 
the pin and the analyte is in the well). Heparin is a commonly used surrogate for HS in binding 
studies. Both heparin and HS are polymers of a disaccharide unit and differ in the degree of 
sulfation. Heparin is readily available commercially and is has been used in many structural 
studies for HS-binding proteins (i.e. (37)). 
To load heparin, 10 µL of 1 mg/mL heparin was diluted into 500 mM NaCl in a 
phosphate buffer. This was to reduce the charge-repulsion in order to get more heparin loaded on 
the pin. This process still needs optimization, as heparin loading has been variable pin-to-pin and 
in different experiments. Additionally, in the course of these experiments, it was noticed that 
TREM2 has a high amount of non-specific binding to the streptavidin pins. Therefore, it is 
necessary to do a double-reference experiment where a blank pin is run through the same wells 
as the heparin-loaded pin. Missing this control confounded early experiments. However, I was 
able to get one experiment where biotinylated heparin was loaded and bound to WT-TREM2 in a 
double-reference format (Fig 4.8). This experiment needs to be optimized and performed with 
the variants, but it does show that TREM2 can directly bind heparin, and presumably HS. This is 
consistent with the cell-staining and suggests that TREM2 is directly binding HS on the cell 
surface. 
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Figure 4.8. Human TREM2 binding to immobilized heparin by BLI. WT TREM2 was 
titrated in the range of 0.035 – 35.0 µM. Data is double reference-subtracted.  
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4.7 Impact of variants and GAGs on TREM2 signaling 
4.7.1  Disease variants have altered signaling 
Because surface expression of the misfolded proteins was observed, I wanted to test 
whether these variants could produce intracellular signals. In these experiments, phosphor-ERK 
immunoblotting was used to assess TREM2 signaling. ERK phosphorylation and activation is 
one of the hallmarks of ITAM signaling, and was one of the first features described for TREM2 
signaling (38).  
In these experiments, RAW 264.7 (mouse macrophage) cells were seeded in a 24-well 
plate (300 µL media/well) and transfected with full-length FLAG-TREM2 (0.25 µg/well) 
complexed 1:2 with Lipofectamine 2000. Cells expressed TREM2 for 24 hours and before being 
stimulated with anti-FLAG at 1:100 dilution from a 1 mg/mL stock (Sigma, M2 clone). Cells 
were returned to the 37° C incubator for the indicated amount of time and then placed on ice to 
quench signaling. The media was immediately aspirated and replaced with ice-cold PBS with 
EDTA to lift the cells. Cells were lifted, centrifuged at 1000 x g for 5 min, and then 50 µL of ice-
cold PBS with 0.1% triton X-100 was added. Cells were rotated for 15 min at 4° C to undergo 
lysis and then insoluble debris was pelleted by centrifugation for 5 min at 16,800 x g. 30 µL of 
supernatant was removed and mixed with 30 µL 2x SDS loading dye, boiled 5 min, and analyzed 
by SDS-PAGE and immunoblot for the indicated proteins. Immunoblots were performed with 
anti-ERK and anti-p-ERK from Cell Signaling and were used at 1:2000 dilutions. Anti-ERK was 
diluted in PBS with 0.1% Tween-20 supplemented with 0.5% milk while anti-p-ERK was diluted 
in PBS with 0.1% Tween-20 supplemented with 1% BSA. These diluents were suggested by the 
manufacturer. The primary antibodies were incubated for 30-60 min in trays while shaking at 
RT. Secondary antibodies (mouse for ERK and rabbit for p-ERK) were from Santa-Cruz and 
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were used 1:2000 in the same buffer as the primaries. Secondary antibodies were incubated for 
20 min.  
In addition to RAW 264.7, Cos-7 cells (a gift from Colin Nichols) were also used in 
stimulation experiments. HEK293T cells were also attempted, but in these cells ERK was not 
reliably detected. Cos-7 cells were treated in the same way as RAW 264.7 cells, except that 
DAP12 was co-transfected with TREM2.   
Consistent with the surface expression experiments, p-ERK levels above background 
could be detected for the proteins. Using time courses, WT proteins appeared to have signaling 
that persisted for longer than Y38C (NHD) or R47H (AD) (Fig 4.9). This effect was perhaps 
subtle, but it was reproducible in two different cell lines. One possibility is that, whether by 
misfolding or reduced recognition of a signaling co-factor, the disease variants result in reduced 
signaling. Another possibility is altered trafficking, and it was recently reported that the R47H 
protein has reduced interactions with trafficking complexes (39). These possibilities still need to 
be tested further, perhaps using a more robust system of measurement.  
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Figure 4.9 is modified from Kober et al, 2016 (7) 
4.7.2  Inhibiting GAG sulfation impairs TREM2 signaling 
Because TREM2 interacts with HS proteoglycans on the cell surface of myeloid, I 
wanted to test whether these have a functional role in TREM2 signaling. Sodium chlorate is an 
inhibitor of sulfation on nascent GAG chains, and has been used with RAW 264.7 cells (40) and 
does not appear to inhibit ERK phosphorylation (41, 42). RAW264.7 cells were grown in 20 mM 
sodium chlorate for 24 hours before transfection with FLAG-TREM2 constructs. WT TREM2 
was then expressed for 24 hours and stimulation experiments were conducted as described 
above. In these experiments, TREM2 signaling was inhibited in chlorate-treated cells, suggesting 
that the TREM2-HS interaction could be important for TREM2 signaling (Fig 4.10). 
Figure 4.9. Disease variants alter TREM2 signaling. a) Full-length FLAG-tagged 
TREM2 was transfected in RAW264.7 cells and stimulated with anti-FLAG antibody.  Left: 
Signaling was assessed by phosphor-ERK immunoblot. Right: loading control (ERK). b) 
Signaling assay performed in Cos-7 cells. Cos-7 cells were co-transfected with DAP12 for 
signaling experiments.   
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4.7.3  Inhibiting GAG sulfation does not impair TREM2 surface expression 
One possibility for impaired signaling during GAG inhibition is that HS is necessary for 
cell-surface expression or that chlorate inhibits TREM2 trafficking as an off-target effect. To test 
this possibility, immunostaining experiments were conducted on RAW 264.7 plated on glass 
coverslips that were pre-treated with poly-lysine and then treated and transfected in parallel with 
the cells used in signaling experiments. Immunostaining was done as described above, with the 
modification that anti-FLAG antibodies were incubated for at 1:1000 for 2 hours at RT and then 
secondary antibodies for 1 hr at RT. Cells were not permeabilized, so that surface expression 
could be determined. In this initial experiment, comparable levels of surface expression were 
detected on both treated and untreated cells. Interestingly, chlorate treatment resulted in more 
diffuse TREM2 staining, whereas untreated cells were more clustered and punctate (Fig 4.11). 
Figure 4.10. Inhibiting GAG sulfation impairs TREM2 signaling. RAW 264.7 cells were 
untreated or treated with 20 mM chlorate before being transfected with TREM2. Cells were 
stimulated with anti-FLAG and TREM2 signaling assessed by pERK immunoblot. Chlorate-
treated cells have an impaired signaling response. Representative of two independent 
experiments.  
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These experiments need to be reproduced and a scoring system developed. Experiments should 
also be conducted with the TREM2 variants. However, one possibility from these results is that 
HS chains cluster or orient TREM2 on the cell surface to receive stimulating signals from 
external ligands. 
Figure 4.11. Inhibiting GAG sulfation alters TREM2 surface expression 
patterns. RAW cells transfected with FLAG-TREM2 in presence (upper) or 
absence (lower) of 20 mM chlorate. Fixed, non-permeabilized and stained with anti-
FLAG.  
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Chapter 5: TREM2 interacts with 
extracellular proteins involved in 
Alzheimer’s disease 
The work described above detailed for the first time how TREM2 interacts with a GAG-
dependent cell-surface ligand. However, the full set of TREM2 ligands remains to be elucidated. 
This section details progress towards identifying and characterizing the interactions between 
TREM2 and proteins involved in AD that may represent disease-relevant TREM2 interaction 
partners. 
5.1 The role of Apolipoprotein E and amyloid beta in 
Alzheimer’s disease 
Apolipoprotein E (ApoE) is a soluble protein that associates with lipoparticles in serum 
and CSF. The APOE4 variant is the strongest risk for non-familial AD, providing about 4-8 fold 
increased risk with a single copy and a 12-fold increased risk with homozygosity. This allele is 
relatively common, with a mean allelic frequency of about 14% (1). ApoE has a number of roles, 
and like TREM2, it has been linked to microglia functions including phagocytosis, inflammation, 
and cell health (2, 3). ApoE is also involved in the formation of and response to Ab plaques, and 
has isoform-dependent effects on Ab aggregation, uptake, and clearance (1).  
During the course of this work, two groups first reported that TREM2 binds ApoE, both 
lipid-loaded and unloaded, ApoE3 and E4, and that the R47H variant decreases binding (4, 5). 
Both use studies used relied on indirect, non-quantitative methods such as co-IPs, dot blots, and 
ELISA. However, they obtained similar results. After these initial reports, another group used a 
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high-throughput binding screen and BLI follow-up experiments to show an interaction between 
TREM2, ApoE, and other lipoproteins (6). They found the R47H, R62H, and D87N variants 
decreased binding, but this was determined by the response signal, not by calculating kinetics or 
determining a dose-dependent response. In contrast to the first reports, this group did not observe 
binding to non-lipidated ApoE. However, they made this determination by the response signal, 
which may not be similar for unloaded ApoE and lipoparticles. Functionally, TREM2 facilitated 
uptake of ApoE when expressed in 293T cells. Therefore, I wanted to determine whether 
TREM2 directly bound ApoE, whether TREM2 variants or ApoE isoforms affected binding, and 
what is the minimal binding domain between these proteins.  
In addition to ApoE, the primary driver of AD is believed to be Ab peptides. This model 
is known as the amyloid cascade hypothesis (7). Indeed, most animal models of AD overexpress 
mutant proteins that contribute to the production and maturation of Ab. Whether TREM2 
directly interacts with Ab is an open question. A large number of Ab receptors have already been 
identified, some thought to be protective and others harmful (8).  
5.2 TREM2 directly binds ApoE and disease variants alter 
binding  
5.2.1  TREM2 directly binds ApoE3 and ApoE4 
Expression and purification of ApoE 
Mammalian ApoE is expressed and secreted in lipoparticles from the liver into serum and 
from in the CNS, primarily from astrocytes, although microglia do produce some ApoE. Some 
evidence suggests neurons can be induced to secrete ApoE, but astrocytes are considered the 
primary expressers within the brain  (9). In addition to its lipidation, secreted ApoE contains an 
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O-linked glycosylation on T194 (10). This glycan can be matured to contain sialic acid moieties
which are subject to further post-translational modifications dependent on the environment: 
ApoE proteins in the CNS are more highly sialylated than ApoE from serum (11).  
ApoE has three major isoforms: ApoE2, E3, and E4. ApoE3 (roughly 7%, 78% and 14% 
allelic frequency). ApoE3 is considered the wild-type, while ApoE4 is associated with increased 
risk for AD and atherosclerosis. ApoE2 is actually protective against AD, although it produces 
other metabolic deficits. ApoE2 homozygosity is necessary, but not entirely sufficient, for 
developing type III hyperlipoproteinemia. These diverse effects are considerable, especially 
since each isoforms differs from E3 at only a single residue. ApoE3 is C112 and R158. ApoE4 is 
C112R, and ApoE2 is R158C. The ApoE2 isoform nearly completely abolishes binding to the 
LDL receptor, which decreases lipoprotein clearance (Reviewed in (2)). The R158C mutation 
results in changes to the LDLR-binding surface. This mechanism was elucidated from the crystal 
structure of the N-terminal domain of Apoe2 (12). In contrast, ApoE4 retains receptor binding, 
but has altered preference for VLDL over HDL lipoparticles, altered Ab binding. The C112R 
variant alters the interactions between the N-terminal region and the C-terminal tail, which 
mediates oligomerization and lipid binding. The structural mechanisms of are still unclear. In 
addition to ApoE2, the N-terminal domains of ApoE3 and ApoE4 have also been determined 
(13-17), however the crystal structure of any full-length ApoE isoform has been elusive. An 
NMR structure of ApoE3 was determined, but this required making five mutations to the C-
terminal tail to reduce oligomerization and aggregation during NMR experiments (18). This 
model showed unexpected salt-bridges, and did not agree with data collected by other methods 
(19), raising concerns about the effect of the introduced mutations. Despite these many 
considerations, E. coli-derived ApoE has been the primary tool for structural studies.   
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I obtained ApoE constructs which encode ApoE following a thioredoxin protein 
containing a 6-His tag and PreScission protease site (20). This protein is expressed in E. coli 
cells, purified by NiNTA, and then cleaved by PreScission protease to release ApoE. The ApoE 
retains a two-residue GS tail, but the thioredoxin contains the 6-His tag. This strategy is a 
modification of the previous standard method, which used a thrombin cut site to cleave the 
fusion. The challenge to that method is that ApoE is highly sensitive to thrombin cutting within 
its hinge region. In that approach, ApoE would be purified by NiNTA and lipidated by mixing 
with 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) lipoparticles, which protect it from 
cleavage. Thrombin would be added to release thioredoxin, following which ApoE was 
delipidated and denatured with methanol, solubilized in 6 M GuHCl, and purified by SEC in 4M 
GuHCl before being dialyzed into ammonium bicarbonate where it would refold as a tetramer 
(21). The method used here produces unlipidated ApoE in its tetrameric form without the need 
for an intermediate lipidation or refolding. The oligomeric state was verified during preliminary 
HDX experiments with the Michael Gross lab. PreScission protease was purified as a GST-
fusion protein using a construct provided by N. Tolia. GST-protease was eluted from glutathione 
resin in 50 mM Tris pH 8.0, 10 mM reduced glutathione, and 1 mM DTT. The yield was over 10 
mg/L. PreScission protease was aliquoted and stored at -80° C. To purify ApoE, I initially used 
MonoQ and SEC chromatography (Fig 5.1) but in later experiments found that SEC alone 
readily purifies the ApoE proteins. 
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Figure 5.1 Expression and purification of ApoE3 and E4. A) Schematic for expression and 
purification of ApoE. B) ApoE3-Thioredoxin fusion from NiNTA affinity column. Box 
highlights uncleaved fusion protein. C) Purified ApoE3 from SEC chromatogram, with 
fractions labeled corresponding to curves in (E). Box labels cleaved, purified ApoE. ApoE 
presence was also verified by peptide-fragment MS and immunoblot (not shown) D) monoQ 
chromatography profile of the NiNTA elution. Box indicated fractions collected for SEC. E) 
SEC profile of ApoE3 at final purification.   
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TREM2 binds ApoE3 and ApoE4 
To test whether TREM2 directly bound ApoE, BLI experiments were conducted where 
biotinylated TREM2 was immobilized on the pin and dipped into wells containing purified 
ApoE. The running buffer was 20 mM HEPES, 150 mM NaCl, 0.05% Tween-20, and 0.1% 
BSA. Both human and mouse TREM2 bound ApoE3, and human TREM2 bound both ApoE3 
and ApoE4 with similar affinity (Fig 5.2 and Table 6). The apparent KD of these interactions 
were typically in the high nanomolar range. This is considerably reduced from the single-digit 
nanomolar affinity reported by quantifying dot blots in the study by Atagi et al (4) (Table 4), but 
has been consistent across many experiments and these represent direct biophysical 
measurements. These data confirm that TREM2 can bind ApoE in the non-lipidated format and 
that this binding occurs with a high-nanomolar affinity. There is also no dramatic change in the 
affinity for ApoE3 or ApoE4, which is consistent with the previous reports.   
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Figure 5.2 TREM2 binds full-length ApoE. Double reference-subtrated BLI data (left) and 
steady-state response (right) for hTREM2 binding ApoE3 (top), ApoE4 (middle) and 
mTREM2 binding ApoE3 (bottom). Signal is shown in black trace and fits shown in red lines 
or dashes.  
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Table 6. Affinity values from experiments in Figure 5.2 
Kinetic	fits	 Steady-state	fits	
	
KD	(M)	 Error	 R2	 KD	(M)	 R2	
hTREM2	ApoE3	 7.36E-07	 9.55E-09	 0.9748	 8.30E-07	 0.9926	
hTREM2	ApoE4	 8.89E-07	 2.33E-08	 0.9352	 1.50E-06	 0.9906	
mTREM2	ApoE3	 4.51E-07	 5.92E-09	 0.9685	 6.90E-07	 0.9984	
5.2.2  Determining the minimal domain of ApoE required to bind TREM2 
Expression and purification of ApoE truncation constructs 
To determine the minimal domain binding site, a series of C-terminal truncations were produced 
and used in BLI experiments. The initial constructs were a gift from Carl Freiden and were 
encoded in a pet30a vector. This vector contained the full-length ApoE gene preceded by an N-
terminal 8-His tag. The truncations were designed by introducing stop codons at targeted 
residues. These constructs were ApoE4 1-238 (stop codon inserted at 239) and ApoE3 1-169 
(stop codon inserted at 170). (By convention, ApoE residues are numbered starting after the 18 
residue secretion peptide). While working with these proteins, I observed the 1-238 protein 
suffered considerable proteolytic degradation. Immunoblotting revealed an intact N-terminal His 
tag. With the help of Hanliu Wang in the lab of Michael Gross, this proteolytic fragment was 
determined to be residues 1-192 (by peptide mapping and native mass). This cleavage affected 
about 50% of the protein within days and would be detrimental towards crystallization. 
Therefore, I cloned ApoE4 1-192, as well as 1-191 (PDB 1NFN) (12) and 1-183 (PDB 2KC3) 
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based on crystal structure and NMR PDB boundaries. PCR primers are listed in Table 7. 
Expression of some of these constructs was problematic. As part of the troubleshooting process I 
used restriction digests to place these constructs in pet23b vectors in addition to the pet30a 
vectors. Figure 5.3 shows representative SEC traces and SDS-PAGE analyses of these proteins. 
Several of the proteins required overnight expression at 20° C to generate appreciable yields. All 
proteins were purified by NiNTA chromatography and aggregates removed by SEC in sizing 
buffer. All ApoE3 proteins were in buffers containing either 5 mM b-ME during NiNTA steps 
or 1 mM DTT during SEC. In general, the larger ApoE4 constructs and the shorter ApoE3 
constructs were better behaved as assessed by their expression and SEC profiles. ApoE4 1-169 
was only weakly detected by immunoblot of NiNTA eluate. All the other truncations can be 
expressed and readily purified.  
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Figure 5.3 Expression and purification of ApoE truncation products. First row: ApoE3 
truncation proteins. SEC profiles of a) ApoE3 1-238, b) ApoE3 1-192, c) ApoE3 1-191, d) 
ApoE3 1-183, e) ApoE3 1-169. Second Row: ApoE4 truncation protiens. SEC profiles of f) 
ApoE4 1-238, g) ApoE4 1-192, h) ApoE4 1-191, j) ApoE4 1-183. Black arrows mark peak 
containing desired protein. Third row: j) SDS-PAGE analysis of ApoE4 1-238 cleavage 
produce. #1 = 238 monoQ input after ~1 week following initial purification where the protein 
was a single band. 2-6 fractions in increasing NaCl concentration shows the two species 
cleanly separate. Immunoblot analysis was used to determine the C-terminus was intact. 
Peptide MS/MS and native MS was used to identify the mass and peptide content in the two 
species and identify the cleavage site. k) SDS-PAGE of ApoE3 truncation proteins used in the 
experiment below. l) purified ApoE4 proteins.   
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Table 7. Primers used to generate ApoE constructs 
Sequence (5'-3') 
R112C TGGA GGACGTGTGC GGCCGCCTG 
ACCT CCTGCACACG CCGGCGGAC 
A193* AGCCCACAGTGGCCTACCGCACGCGGCCC 
GGGCCGCGTGCGGTAGGCCACTGTGGGCT 
A192* GGGAGCCCACAGTCTAGGCCCGCACGCGG 
CCGCGTGCGGGCCTAGACTGTGGGCTCCC 
L184* GCCCTGTTCCACCTAGGGCCCCAGGCGC 
GCGCCTGGGGCCCTAGGTGGAACAGGGC 
NdeI-start-
6H 
GGGAATTCCATATGCACCATCATCACCACCATAAGGTGGAGCAAGCG
GTGGAGACAGAGCCG 
238-*-XhoI CTCGAGCTACTCCGCCACCTGCTCCTTCACCTCGTCCAGGCGG 
169-*-XHO CTCGAGCTAGCCCTCGCGGGCCCCGGCCTGGTACACTGCCAG 
The C-terminal domain is not required for full binding 
Having cloned truncation constructs, I have begun to analyze the minimal binding 
domain for TREM2. In initial experiments, full-length ApoE3, a C-terminal deletion (1-238, 
Nterm-Hinge), or the N-terminal domain alone (1-169) were tested for binding to immobilized 
TREM2. Full-length and the Nterm-hinge protein bound equally, but the N-term alone had 
greatly reduced affinity (Fig 5.4). This loss of binding to the ApoE3 N-term was observed in two 
separate experiments. Beyond narrowing the interaction domain, these assays establish that 
ApoE does not have to be lipidated to interact with TREM2, as C-terminal domain is required for 
lipid binding (22). In future experiments, the truncations within the hinge domain (1-192, 191, 
and 183) will be tested to further narrow down the binding site. In initial experiments, the ApoE4 
versions of these proteins seemed to be competent to bind TREM2, but the failure to produce the 
1-169 construct and, until recently, not having the ApoE3 truncations cloned and expressed has
prevented a final conclusion on the minimal binding interface. This determination will be 
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important for crystallization attempts, as the 1-238 construct of both ApoE3 and ApoE4 is very 
prone to proteolytic degradation. The other constructs may be more resistant and would be more 
suitable for co-crystal screens. 
Figure 5.4. The hinge region of ApoE is required for full binding to TREM2. TREM2 
was immobilized on streptavidin pins and dipped into wells containing full-length or 
truncated ApoE3. Steady-state response is plotted, with curve fit analysis and affinities 
calculated using Prism.  Inset depicts domain boundaries. 
114 
5.2.3 TREM2 binds lipid-loaded ApoE 
ApoE naturally occurs as a lipoprotein, so to test binding in a more physiologically 
relevant state, I obtained a mouse anti-ApoE antibody from the David Holtzman lab (clone HJ 
15.7) for using in BLI experiments as a reagent to capture lipidated ApoE. Anti-murine-Fc BLI 
pins were loaded with this antibody and then dipped into lipidated supplied by Jason Ulrich of 
the Holtzan lab (Schematized in Fig 5.5A). The immobilized ApoE was then dipped into wells 
containing SEC-purified TREM2 in PBS buffer with 0.1% BSA (No Tween-20). Dose-
dependent binding of lipidated ApoE3 by TREM2 was observed, although the kinetics of binding 
were appreciably different than the unlipidated experiments described above (Fig 5.5B). The KD 
calculated in the experiment shown was about 14 µM. In the experiments with lipidated ApoE 
from the Holtzman lab, none of the affinities have been as high as determined by the unlipidated 
ApoE made in our lab.   
Figure 5.5. TREM2 binds lipidated ApoE3. A) Schematic for binding experiments. B) 
Double-reference subtracted curves of hTREM2 binding to immobilized ApoE3. TREM2 was 
titrated in a range of 44 to 0.7 µM.  
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5.2.4 TREM2 variants alter ApoE binding 
To determine whether the basic patch is involved in binding to ApoE, I expressed and 
biotinylated WT, R47H, and a R47H-R76D-R77D triple mutant (HDD) which severely disrupts 
the basic surface. These proteins were captured on streptavidin pins and used to test binding to 
SEC-purified ApoE3 as described above in a double-referenced experiment. While the R47H did 
not completely lose binding, the both variants had reduced binding as assessed by kinetic and 
steady-state affinity determinations (Table 8). This is consistent with the initial reports of R47H 
losing some binding to ApoE (4-6). These differences will likely be more profound when done 
with ApoE immobilized on the pin to prevent complications from avidity from the tetrameric 
ApoE.  
Table 8. Mutant TREM2 binding ApoE3. 
Kinetic fits Steady-state fits 
KD (M) KD Error Full R^2 SSG KD SSG R^2 
WT 4.11E-07 1.77E-08 0.7931 8.50E-07 0.8159 
R47H 3.03E-06 1.27E-07 0.8228 6.10E-06 0.8561 
HDD 6.42E-06 1.77E-07 0.968 2.20E-05 0.9917 
I have also attempted to determine whether the disease variants alter binding to lipidated 
ApoE. These experiments used lipidated ApoE provided by Jason Ulrich. Figure 5.6 shows the 
results of these experiments. In most cases, R47H appears to have reduced binding. However, in 
one experiment with ApoE4, there did appear to be some binding. ApoE3 was also attempted in 
that experiment, but there was a machine error during that part of the run. In a separate 
experiment not shown, I tried to reproduce the differential binding of R47H to ApoE3 and E4, 
but observed weak binding for both. Another concern is that I did observed quality binding in the 
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capture format by non-lipidated ApoE provided by Jason as a control for lipidation (not shown). 
Because of these inconsistencies, and because this protein was not prepared in a way where the 
quality can be readily assessed, I have recently begun attempting to lipidate and validate ApoE 
proteins made in my system (See section 5.4.4). Experiments with these samples will be 
necessary to finalize conclusion about TREM2-ApoE binding. However, in most experiments, I 
have observed decreased binding to the R47H variant, suggesting this surface is involved in 
ApoE binding.  
Figure 5.6. TREM2 variants alter binding to 
lipidated ApoE3. Lipidated ApoE3 (provided 
from the Holtzman lab) was immobilized on a 
BLI pin using a capture antibody and dipped 
into wells containing WT or variant TREM2 at 
the indicated concentrations. Curves were 
double-reference subtracted using a capture 
antibody-only loaded pin dipped into the same 
wells and a buffer-only control pin. 
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5.3 TREM2 directly binds Ab and disease variants alter 
binding 
There have been mixed reports on the role of TREM2 potentially interacting with (Ab). 
In one report, synthetic or extracted Ab did not induce TREM2 signaling in reporter cells (23), 
(This experiment is mentioned in the text but data was not shown). However, in another report, 
TREM2-dependent tyrosine phosphorylation was observed on microglia processes in contact 
with Ab plaques, suggesting plaques, or a plaque-deposited ligand could induce TREM2 
signaling (24). However, direct binding to of Ab to TREM2 had never been demonstrated. This 
section details the first characterization of a TREM2-Ab interaction. 
5.3.1  Expression of a GST-Ab fusion protein 
Amyloid beta 1-42, (Ab1-42) is a peptide produced by the proteolytic processing of 
amyloid precursor protein (APP) by b-secretases and is thought to be the primary driver of AD 
(25). This peptide is aggregation-prone and also bactericidal (26, 27),  making recombinant 
expression of this peptide difficult. Most studies utilize synthetic peptides; however, it is difficult 
to control the oligomeric state of these peptides and this complicates binding studies. One report 
showed that Ab1-42 could be expressed from E. coli using a GST-fusion system (28). Because 
FortéBio manufactures anti-GST pins for the BLI system, I cloned the Ab1-42 peptide onto the C-
terminal end of GST expressed in the pGEX-4T1 vector through BamHI-XhoI restriction 
digestion using a Gibson block insert. The Ab1-42 sequence was optimized for expression in E. 
coli. As a control, pGEX-4T1 (which encodes GST-only) was expressed alongside the fusion 
protein. In the first expression, cells were induced at 30° C, but fusion protein was undetectable. 
To reduce potential toxicity, expression was induced at overnight at 20° C. In this case, 
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expression was detectable following purification with glutathione resin. To purify the protein, 
cells were resuspended in 30 mL PBS with 1 mM DTT /L of cells. Cells were lysed by 
sonication and centrifuged at 16,000 x g for 30 min to pellet debris. The supernatant was 
collected and incubated with 0.5 mL of glutathione resin for 1 hour at 4° C. The mixture was 
transferred to a gravity column. Beads were washed in 10 mL of PBS + DTT and then eluted 
with 50 mM Tris pH 8.0, 10 mM reduced glutathione, and 1 mM DTT in a total volume of 2 mL. 
Samples were analyzed by SDS-PAGE (Fig 5.7). Robust loading of both GST and GST-Ab on 
the anti-GST pins confirmed the presence of GST.   
Figure 5.7. Expression and purification of GST-Ab. 
GST and GST-Ab(1-42) were expressed in E. coli. Protein 
purified by glutathione resin are from 1L cell pellet. Note 
shift in MW for GST-Abeta, and markedly reduced yield of 
this protein.  
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5.3.2  TREM2 binds Ab 
To test whether TREM2 bound the Ab, anti-GST pins were used to capture bound GST-
Ab, and were then dipped into wells containing SEC-purified TREM2. The running buffer was 
PBS with 0.01% BSA and 0.005% Tween-20. To control for non-specific binding, a GST-only 
loaded pin was run through the same wells. To control for sensor drift, GST-only dipped into 
buffer was subtracted from GST-Ab into buffer. Binding was measured to WT, R47H, and T96K 
TREM2 proteins. GST-Ab bound TREM2 with an affinity in the low micromolar range (Fig 
5.8). In one experiment, some weak binding was observed to R47H, however, the affinities were 
greatly reduced both as measured by kinetic fits and steady-state analysis. This assay seems to be 
especially sensitive to the buffer conditions. In two other experiments, one with no BSA but 
0.05% Tween 20 and another with 0.1% BSA and 0.005% Tween-20, I observed no signal from 
R47H but similar WT signal. This micromolar affinity binding could be relevant in the context of 
the Ab plaques, which are highly aggregated and fibrillated and would therefore present a high-
avidity ligand. Future experiments will need to be designed to investigate binding of TREM2 to 
different forms of the Ab peptides.  
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5.4 Towards the structure of TREM2-ApoE complex 
5.4.1  Attempts to crystallize the minimal TREM2-binding domain of ApoE 
My preliminary experiments suggest the hinge domain of ApoE is important for TREM2 
binding. This region is not observed in any of the ApoE crystal structures. In attempt to gain 
structural insight about this region (such as for use in docking experiments), I expressed and 
purified ApoE4 1-238 and attempted to crystallize this protein. Protein was purified in sizing 
buffer by SEC, concentrated to 8 mg/mL and crystals grew in 10% PEG3350 and 0.2 M KCl 
(Fig 5.9 a,b). Crystals were harvested by preservation in mother liquor with 20% ethylene 
Figure 5.8. Human TREM2 Ig domain binds Ab. BLI analysis of immobilized 
GST-Ab(1-42) binding TREM2 Ig domain. Data are shown for WT TREM2 (left), AD 
risk variant TREM2 R47H (middle), and AD protective variant TREM2 T96K (right). 
Affinities shown (KD) are derived either from kinetic analysis (upper panels) or 
steady state fits (lower panels). 
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glycol, frozen under a nitrogen stream, and stored in liquid N2 until data collection. Data was 
collected at APS beamline 19-ID. One crystal diffracted very well, and strong data was collected 
out to the detector edge at 1.58 Å (Table 9). The phase problem was solved by molecular 
replacement using PHASER and ApoE4 PDB 1B68 (29). The TFZ was 36.7, and the spacegroup 
was P212121. All but one of the ApoE truncation crystal structures deposited in the PDB are in 
this space group (13 total at this writing). Unfortunately, my structure is missing the first 22 and 
last 73 amino acids of the ApoE4 1-238 protein. I was able to build in one of the loops not 
present in the search probe and to add a couple residues to the C-terminus, but was not able to 
observe density for the rest of the protein (Fig 5.9c). The crystal packing has a tight arrangement 
and it is difficult to see where another 70 or so residues could fit. The decent Rfree suggests that 
the model could be probably be improved, but is not likely to be missing one third of the protein. 
It is more likely that the missing residues were cleaved to leave only the N-terminal helical 
bundle. Silver staining would typically be used to confirm cleavage, but these crystals were only 
produced in one well and were used for diffraction experiments. 
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Table 9. ApoE4 1-238 Data collection and refinement statistics. 
ApoE4 1-238 
Data collection 
Space group P 21 21 21 
Cell dimensions  
    a, b, c (Å) 45.38, 52.69, 72.39 
    a, b, g  (°)  90, 90, 90 
Resolution (Å) 50.00-1.58 (1.61-1.58) * 
Rsym  0.053 (0.494) 
Mean I / sI 35.69 (2.97) 
Completeness (%) 95.8 (60.4) 
Redundancy 6.0 (5.6) 
Refinement 
Resolution (Å) 50.00-1.58 
Total reflections 148308 
Unique reflections 24499 (2329) 
Rwork / Rfree 0.1807 / 0.2102 
No. atoms 1396 
    Protein 1172 
    Waters 224 
B-factors 33.29 
Protein 32.24 
Solvent 38.81 
Protein Residues 143 
R.m.s. deviations
Bond lengths (Å) 0.005 
Bond angles (°) 0.75 
Ramachandran statistics 
    Favored 99.29% 
    Allowed 0.71% 
Rotamer Outliers 0 
Clashscore 5.08 
Overall MolProbity 1.27 
* Parenthesis indicate data for the highest resolution shell
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Figure 5.9. Crystal structure of N-terminal ApoE4. a) ApoE4 1-238 crystal grown in 10% 
EPG 3350 and 0.2M KCl. b) ApoE4 1-238 crystals grown in 0.1 M HEPES 7.0 and 10% PEG 
6000. c) Crystal structure from crystal in a) in yellow aligned with 1B68 in cyan. N and C 
termini are labeled. 
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5.4.2  Initial attempts to crystallize the TREM2-ApoE complex 
In attempt to gain a structural standing of the ApoE-TREM2 interaction, hTREM2 was 
expressed in mammalian cells and deglycosylated using EndoHf as before. TREM2 and ApoE4-
183 were purified separately by SEC and then mixed in equimolar amounts (Fig 5.10 a). Small 
preliminary crystals were obtained after three weeks in one condition (Fig 5.10b,c). 
Unfortunately, these crystals have not been reproduced and their condition is similar to 
conditions for ApoE alone, so they may very well be the ApoE4 N-terminal bundle  
Figure 5.10. Potential crystal hit of TREM2 with ApoE4 1-183. a) SDS-PAGE gel of 1) 
ApoE4 1-183, 2) hTREM2, and 3) the two protein mixed at equimolar amounts (crystal 
input). b-c) preliminary crystals grown in: 10% PEG 6000 and 0.1 M MES pH 6.0 
125 
5.4.3  TREM2 SAXS Experiments 
SAXS background 
Small angle X-ray scattering (SAXS) is a solution technique which can be used to 
determine the overall shape and size of a protein. In SAXS experiments, the proteins are 
randomly tumbling in solution, unlike the uniform array of proteins in a crystal. Therefore, the 
electron scattering is a rotational average of the protein and buffer scattering. Following buffer 
subtraction, the scattering from the protein can be transformed and interpreted to understand the 
protein’s behavior (30).   
Sample purity and behavior is the ultimate concern with SAXS experiments. Scattering is 
proportional to the square of the molecular weight of a sample, so higher molecular weight 
contaminants will disparately affect the scattering. Likewise, protein oligomerization, whether 
real or artefactual, will contribute disproportionately to the scattering curve. To interpret SAXS 
data with confidence, one must verify that there are no concentration-dependent changes in the 
scattering profile. Any interpretation of oligomerization must be verified by an orthogonal 
method (30).  Protein glycosylation is another concern. The TREM2 Ig domain contains two N-
linked glycosylation sites. Carbohydrates have higher mean electron density and different 
hydration than protein (31), so these must be accounted for when modelling an ab initio structure 
and determining the quality of fit to the data.  
Sample preparation 
TREM2 proteins were purified by NiNTA and SEC. The final purity was assessed by 
SDS-PAGE and proteins were above 99% purity, with no visible higher molecular weight bands. 
Samples were concentrated to about 150 µL and buffer matching was accomplished by dialysis 
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using Hampton microdialysis buttons with a 50 µL sample dialyzed against 50 mL of buffer 
overnight at 4°C using a 3 kDa MWCO membrane. After recovery, sample concentration was 
measured by UV280. 30 µL of sample was placed in a 96-well plate and sealed with a silicone 
sealing mat (both from AXYGEN) for shipment. A dilution series was done using the dialysis 
buffer.  The dialysis buffer was 20 mM HEPES pH 7.5 with 150 mM NaCl and 2% glycerol with 
200 mM NDSB-201. Glycerol is used as a scavenger to decrease radiation damage. In our trials, 
this was found to increase the amount of usable data. NDSB was used in the final sample to try 
to reduce concentration-dependent aggregation observed in preliminary experiments.   
Data collection and processing 
Data was collected at the SYBILS beamline at ALS. Samples were exposed at for 10.2 
seconds to collect data over 33 frames of 0.3 sec/frame. In this way, the data can be monitored 
for damage. The wavelength was 11keV/ 1.27 Å. Data was collected at 10° C. Buffer-subtracted 
data files were provided by the SYBILS staff with a recommendation on frames and which 
buffer match to use. Data were manually inspected for radiation damage using PRIMUS, part of 
the ATSAS package. Curves were inspected for consistency and curves that were deemed 
outliers by the data comparison wizard were rejected for further analysis. After initial analysis, 
curves were scaled and merged to create a single file for that concentration data set. This was 
done for each concentration of data collected. Initial data statistics (e.g. Radius of gyration (Rg), 
and zero-angle scattering I(0)) were determined in PRIMUS and the interatomic distance 
distribution function P(r), an indirect Fourier transform of the scattering data, was done using 
autognom. Initial modelling was done using DAMMIF for 10 cycles and this result used as a 
starting model for further refinement with DAMMIN. Envelopes were visualized in Pymol.  
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Data interpretation and challenges 
Preliminary analysis for WT and R47H proteins was performed by examining the raw 
data (Fig 5.11 a,e), comparing the data scaled by dilution factor (Fig 5.11 b,f), scaled Kratky 
plot (I*q2 vs q) (Fig 5.11 c,g), and Guinier regions (Fig 5.11 d,h) and by plotting the Rg 
determined by Guinier fitting against protein concentration (Fig 5.11i and Table 10) The Kratky 
plot confirms that both WT and R47H are folded. However, both have some change in Rg with 
increasing concentrations, and this is most pronounced in with WT TREM2. These changes are 
most visible in the low q region of the scaled data sets (Fig 5.11 b,f) and the Guinier region (Fig 
5.11 d,h). Interestingly, at all concentrations, the R47H has a lower Rg than WT. This has been 
observed in every SAXS experiment conducted. This could be consistent with a conformational 
change or a more compact protein. Interestingly, WT shows the most pronounced concentration-
dependent changes. Whether this is indicative of a native ability to oligomerize or is just a SAXS 
artifact remains to be determined.  
Table 10. Rg statistics determined from Guinier fitting in PRIMUS 
 Table 10 
Rg Error Start End 
sRg 
limits Fidelity 
WT Low 30.88 2.34 10 44 1.21 0.93 
Medium 32.56 0.56 3 36 1.10 0.98 
High 33.45 1.09 21 38 1.19 0.79 
R47H Low 26.31 6.5 36 58 1.26 0.76 
Medium 26.9 0.29 16 48 1.12 0.9 
High 28.4 0.26 17 43 1.10 0.87 
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Figure 5.11 Initial SAXS analysis of WT and R47H TREM2 Ig domains. a, e) WT and 
R47H data at high (black) medium (dark grey) and lowest (light grey) concentrations. b, f) 
Data scaled by dilution factor. c,g) Kratky plot from scaled data. d,h) Guinier regions (first 50 
data points) scaled by dilution factor. i) Rg’s determined by Guinier fitting plotted against 
concentration show that both WT and R47H have concentration-dependent changes, although 
WT is much more pronounced and has a higher Rg at all concentrations. 
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5.4.4  Producing lipid-loaded ApoE3 
For structural studies, it is important to produce protein that is well-characterized, 
especially with regards to being aggregate-free. I attempted to reproduce and adapt the protocols 
described here: (32, 33) to produce ApoE lipidated with 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC). DPPC at 25 mg/mL in chloroform was purchased from Avanti. Cholate 
was purchased as a powder from Sigma. DPPC was dried under vacuum and cholate was 
reconstituted at 30 mg/mL in sizing buffer with 1 mM DTT. I calculated the volume of cholate to 
be used to resuspend the dried DPPC for a molar ratio of 1.4:1 cholate:DPPC. The mixture was 
incubated at 42° C to form a clear solution. This was cooled to RT, SEC-purified and 
concentrated ApoE3 was added so that the final ratio was 46:1 DPPC:ApoE3. This mixture was 
then placed at 42° C for 1 hr, with gentle mixing every 10 min. In the reference protocols, this is 
sufficient to get thorough lipidation. The protocols state that the unbound ApoE precipitates. In 
my hands, I did not observe much precipitation. Following incubation, two rounds of dialysis 
against sizing buffer with 1mM DTT were performed to remove excess cholate. The samples 
were then filtered and analyzed on a superpose 6 column (GE) at RT. As a control, ApoE that 
was not lipidated was run on the same column (Fig 5.12 a).  
There is a slight shift towards a later retention time. In the references, it is suggested that 
the lipidated ApoE has two ApoE molecules per lipoparticle. The dimer plus phospholipids 
likely runs similarly to the tetramer created by the unlipidated protein. Therefore, SEC does not 
seem to be very efficient at separating lipidated and unlipidated particles. A PC detection kit 
(Sigma, MAK049) was used to confirm the presence of phosphotidylcholine. This assay works 
by hydrolizing the choline from the lipid and detecting the choline fluorometrically. The assay 
was conducted according to the manufacturer’s specifications. Background was determined with 
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a no-enzyme negative control for each sample. The lipidated ApoE3 gave a strong signal, while 
unlipidated ApoE3 was at background level (Fig. 5.12c). This suggests the protein was indeed 
lipidated and could be used in SAXS or other structural studies. Another important experiment 
will be to complex ApoE3 with DPPC and DPPS to see how the lipid species influences TREM2 
binding. Finally, limited proteolysis was performed to see if lipidation induced differential 
protection. Unlipidated ApoE3 had a slightly altered cleavage pattern with chymotrypsin (Fig 
5.12b). This experiment should be repeated with Thrombin, as ApoE is supposed to be protected 
from thrombin cleavage when lipidated.   
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Figure 5.12. Producing lipidated ApoE3. a) SEC profiles of unloaded, tetrameric ApoE3 
and DPPC-complexed ApoE3 analyzed by SEC on a superpose 6 column. b) Limited 
proteolysis on ApoE samples shows differential cleavage with chymotrypsin, suggesting a 
conformational change. c) Results of colormetric PC detection assay. ApoE3 complexed with 
DPPC had a strong signal above background that correlated with UV signature, while ApoE3 
alone had no signal above background.  
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5.5 Generation and characterization of anti-TREM2 mAbs 
To generate monoclonal anti-TREM2 antibodies, I worked with the Hybridoma center at 
Washington University to immunize hamsters and screen antibody clones. Two animals were 
immunized with human and mouse TREM2 protein expressed from 293F cells. The proteins 
were exchanged into PBS for immunizations. To verify an antibody response, an ELISA assay 
was developed. The plate was coated overnight with 100 µL of 1 µg/mL Neutravidin. In the 
morning, the plate was washed twice with 250 µL of PBS with 0.05% Tween-20. Wells were 
blocked with 100 µL of 1% BSA in PBS for 1 hr at RT. Then, 100 µL of biotinylated TREM2 
was added at a 1:1000 dilution. TREM2 was captured for 30 min at RT, then washed. Wells were 
then exposed to 100 µL of diluted serum overnight at 4° C. The next day, unbound antibodies 
were washed 2x with wash buffer, and an anti-hamster-HRP secondary (Santa Cruz) was added 
at 1:2000 for two hours at RT. Finally, the secondary was washed and the plate developed with a 
chromogenic substrate (TMB peroxidase) and read on a plate reader. Immunization was 
considered successful when it produced a response at a serum dilution of 105. After validating 
the antibody response, the animal was sacrificed, and the splenic B cells were fused with mouse 
lymphoma cells to create hybridoma fusions. The cells were serially plated to isolate clonal 
populations to be expanded and screened for antibody responses.  
With the first animal, I tried to screen antibodies by flow cytometry for cell-surface 
expression. This ultimately was not useful, perhaps due to the somewhat weak surface 
expression on 293F cells. I was able to get some clones identified and subcloned, but the final 
products had no reactivity. The early pooled samples of this process are saved with the 
hybridoma center and could be restarted if desired. For the second animal, I screened the clones 
by ELISA. This was very robust and strongly reactive monoclonals were generated by three 
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rounds of serial dilution. The final clones were amplified and stocks frozen down. Conditioned 
media from these clones was used in validation assays shown in Figure 5.13.   
5.5.1  Validating monoclonal antibodies by ELISA 
Human and mouse TREM2 were immobilized as described above and exposed to 
conditioned media from the hamster monoclonals. The signal is shown in Fig 5.13a. All clones 
were reactive against hTREM2, which is the format in which they were screened. All but two of 
the clones were reactive against mTREM2. These experiments were done on separate days, so 
the level of reactivity of human vs mouse should not be directly compared. This assay shows that 
most of the clones detect both human and mouse TREM2, and that two are selective for human 
over mouse protein.  
5.5.2  Validating monoclonal antibodies by BLI 
The media supernatants were also evaluated for binding to hTREM2 in BLI format. This 
was done at multiple dilutions of serum, and the value for 1:4 is shown. TREM2 on pins was 
dipped into conditioned or unconditioned media for 5 min. The response signal is shown in Fig 
5.13b. All the antibodies tested had reactivity to hTREM2 above the unconditioned background. 
Note that in these assays, the antibodies are not purified, so the differences in signal could reflect 
different affinity, but most likely reflect different antibody concentrations. All antibody 
interactions had very little dissociation, indicating a high-affinity, stable interaction.   
5.5.3  Validating monoclonal antibodies by cell staining 
Finally, antibodies were screened for binding to hTREM2-transfected 293F cells. As a 
control, binding was compared to BST-2 transfected cells (unrelated protein). Four antibodies 
had binding in this format (Fig 5.13c).  
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Figure 5.13 Validation of mAb TREM2 binding in different assays. a) Monoclonals 
binding to plated mTREM2 or hTREM2 by ELISA – note, values for hTREM2 and mTREM2 
are from separate experiments. All monoclonals bound TREM2, two did not bind mTREM2. 
b) BLI response with immobilized hTREM2 dipped into wells with hybridoma-conditioned
media diluted 1:4. All cultures had binding to hTREM2. c) MFI values for cell binding by
flow cytometry. 293F cells transfected with TREM2 or BST2 (negative control). Binding
observed for four monoclonals. Full clone name given in b, parent line names in a and c.
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5.5.4  Novel antibodies block TREM2-ApoE interaction 
To assess whether antibodies blocked TREM2-ApoE binding, an initial BLI experiment 
was performed where TREM2 was immobilized on a streptavidin pin and dipped into wells 
containing unconditioned hybridoma media or media conditioned with anti-TREM2 
monoclonals. These were allowed to bind TREM2, which was then washed and dipped into wells 
containing ApoE4 1-183 (this protein had been purified for crystal trays at the time). Figure 5.14 
shows the antibody loading normalized to the highest value and the steady-state response for 
TREM2 into ApoE4 1-183 averaged over the last five seconds of the association stage. This 
experiment needs to be optimized by measuring binding to full-length ApoE, and also by 
increasing the antibody loading (either longer times, lower dilution of supernatant, or purified 
and concentration-matched monoclonals). With these caveats, the initial data suggests certain 
antibodies do block ApoE binding (Fig 5.14). Notably, the antibody with the highest loading also 
allowed the most ApoE binding, while other antibodies with less loading more effectively 
blocked ApoE binding. These tools may be useful in epitope-mapping by co-crystallization or 
HDX experiments with Fab fragments if an ApoE-TREM2 complex is not readily attained.  
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Figure 5.14 Novel anti-TREM2 antibodies block ApoE binding. a) Schematic for 
experiment and b) Antibody response normalized to the highest binder and ApoE response 
normalized to TREM2 dipped into unconditioned media instead of antibodies. Note that 7A1 
and 11A9 block ApoE binding while having less loading than 12A5, which no reduction in 
ApoE binding.  
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Chapter 6: Implications for TREM2 in health 
and disease 
6.1 TREM2 functions in health and disease 
This section is modified from a submitted manuscript titled 
“TREM2-ligand interactions in health and disease.” Submitted to J. Mol Biol. 
TREM2 is an immunomodulatory protein expressed on myeloid cells including microglia 
in the brain. Genetic studies have conclusively linked TREM2 to neurodegenerative disease and 
animal and cellular studies have revealed a role for TREM2 in a broad array of functions 
including cell survival, proliferation, activation, inflammation, and phagocytosis (1). Exactly 
how TREM2 functions is still not fully known, and this depends on understanding the TREM2 
structure how TREM2 interacts with its ligands. The goal of this study was to help fill the gap 
between genetic studies that identified specific, important residues on TREM2 and the 
animal/cellular studies that identified the roles for TREM2. By understanding the TREM2 
structure and how the different variants alter structure and function, this work further elucidates 
the mechanisms underpinning TREM2 in health and disease. In the first section of this chapter, I 
describe the different reported TREM2 functions and discuss how they could be associated with 
different ligands or modes of signaling. In the subsequent sections, I highlight the contributions 
from this study and propose a model for TREM2 function before finally suggesting future and 
translational directions for this work.  
The reported ligands for TREM2 are broad and include ligands that could be thought to 
represent steady-state tonic stimuli or disease-specific stimuli. Therefore, the functions of 
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TREM2 signaling could range from specific responses such as phagocytosis, cell activation, or 
collaboration with other signaling pathways to maintain cell survival and proliferation (Fig 6.1). 
These possibilities are not mutually exclusive; on the contrary, it may be useful to conceptualize 
the different ligands as either tonic, homeostatic signals or damage-associated signals which 
produce different kinds or strengths of stimuli in order to accomplish the wide variety of 
functions reported for TREM2. Here, I propose where different ligands could contribute to 
TREM2 function. This model provides a framework to interpret the results of this study.  
TREM2 functions from endogenous signals maintain myeloid cell homeostasis, regulate 
inflammation, and enable phagocytosis.  
During development and homeostatic conditions, TREM2 is important for myeloid cell survival, 
proliferation, and maturation. TREM2 signals ensure myeloid cells remain ready and competent 
to respond to damage and disease.  
1. TREM2 responds to tonic stimuli as a receptor and/or co-receptor for myeloid
survival and maturation so that myeloid cells can respond to disease stimuli.
This is an attractive, but still unknown mechanism where TREM2 signaling sustains myeloid cell 
survival and proliferation in order that the myeloid cells can respond to other stimuli in a 
condition-specific manner. One possible mechanism is a role for TREM2 in b-catenin activation 
(2), which probably involves interactions with M-CSF signals (3). Another possibility is TREM2 
is not engaging an activating ligand, but is preferentially associating with DAP12 to localize it at 
the cell surface where it can phosphorylated by Src or other kinases activated by CSF-1R or 
other survival pathways (4) (Fig 6.1A). 
2. TREM2 signals are important for myeloid cell maturation
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Studies using human monocytes from NHD patients with mutations in TREM2 observed  
decreased capacity to mature into osteoclasts and DCs (5, 6). Similar to collaboration with M-
CSF, TREM2 connects Plexin-A1 to DAP12 for osteoclastogenesis. Plexin-A1-/- mice have 
defects in DC antigen presentation and OC maturation (7), similar to what had been reported for 
DAP12-/- mice (8). Therefore, TREM2 plays a role in the ability of myeloid cells to mature 
following stimulation by cytokines (Fig 6.1B). 
3. TREM2 responds to tonic stimuli to regulate inflammation.
TREM2 and DAP12 reduce inflammatory TLR signals (9, 10) in cultured BMDMs. This role did 
not require stimulation with an exogenous ligand, suggesting it is mediated by a ligand on the 
BMDMs or perhaps from the culture media. This function likely also involves co-regulation of 
adaptor proteins that dampen TLR signaling such as LAB and DOK3 (Fig 6.1C).  
Which ligands could be important for these functions? Many of these in vitro results did 
not require antibody stimulation of TREM2, suggesting a ligand present on the myeloid cells or 
readily available in culture. Phospholipids, proteoglycans, or lipoproteins make attractive 
candidates as these ligands would be ubiquitous. For example, APOE is highly abundant in 
serum and CSF, with concentrations in the µg/mL range (11). However, because these ligands 
are so ubiquitous, understanding how signaling could be regulated is a challenge.  
TREM2 functions during disease 
In addition to its role as a tonic receptor, TREM2 recognizes a variety of ligands associated with 
damage, disease, and infection. These ligands may mimic tonic stimuli or instead may produce 
an activating signal above the tonic threshold.  
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1. TREM2 responds to damage stimuli to drive survival and activation of myeloid
cells.
During disease, TREM2 responds to DAMPs such as ligands exposed on apoptotic membranes 
(12), myelin lipids (13), DNA exposed by necrotic cells (14), ligands presented by Ab plaques, 
or perhaps lipoparticles enriched in apoptotic phospholipids (15). TREM2 stimulation by these 
ligands could be important for TREM2 function under the additional stress from damage. In this 
scenario, TREM2 signaling licenses the response to pathogens and other damage. This cellular 
activation program can take a number of forms including sustaining cell survival, regulating 
cytokine production, and/or permitting phagocytosis by other receptor pathways. For example, 
TREM2 was required for full phagocytic capacity of antibody-Ab beta complexes (which are 
recognized by FcR for phagocytosis), showing TREM2 enables the phagocytic functions of other 
receptors (16). TREM2 inhibits inflammatory cytokine production in cultured microglia 
following exposure to apoptotic neurons (17), and Trem2-deficient and haploinsufficient 
microglia have impaired microgliosis and don’t properly respond to plaques (15, 18-21) (Fig 
6.1D). 
2. TREM2 directly binds DAMPs/PAMPs for phagocytosis
While the primary role of TREM2 may not be phagocytosis, there have been reports of TREM2-
mediated phagocytosis of a direct ligand, including phagocytosis of apoptotic neurons that 
express a TREM2 ligand (12, 17, 22), and bacteria (23) likely through recognition of anionic 
bacterial components (24). These examples did not require TREM2 stimulation by antibodies or 
separate ligands. Instead, cross-linking by bacterial carbohydrates or apoptotic membrane-
exposed ligands activate TREM2 signaling, resulting in microtubule mobilization and 
phagocytosis (Fig 6.1 E).   
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Figure 6.1. Possible roles for TREM2 resulting from different ligands. A-C) During 
normal conditions, TREM2 signaling from endogenous ligands permits a number of 
functions. A) TREM2 is a co-receptor or co-stimulatory molecule for signaling pathways 
involved in myeloid maturation, proliferation, and survival. B) TREM2 signals (perhaps 
independently of co-receptors) are important for maturation. C) TREM2 regulates 
inflammatory responses by influencing TLR and other activating networks to maintain 
homeostasis.  D-E) TREM2 recognizes additional ligands associated with disease. D) These 
signals may increase activation and survival so that myeloid cells can respond in a context-
dependent manner. E) TREM2 can induce phagocytosis of certain ligands, such as bacteria. 
Figure 6.1 is modified from Kober and Brett 2017, submitted. 
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6.2 Contributions from this study 
The goal of this study was to determine the structure of TREM2, elucidate how disease-
linked residues altered its structure and function, and to understand how TREM2 might engage 
with ligands. Genetic studies had identified key residues, and in vitro and in vivo studies 
identified a role for TREM2 signaling in cell survival and various activities. However, a 
structure-based model for TREM2 that connected TREM2-ligand interactions with the different 
observed functions was missing. This study addressed that knowledge gap and contributed to the 
understanding of TREM2 in five main areas: 
1. Determined the WT TREM2 structure
The structure of WT hTREM2 was determined using protein expressed natively in
mammalian cells. This protein was purified and crystallized using methods developed during this 
study. TREM2 is the only TREM family protein so far that has required mammalian expression 
to crystallize, suggesting post-translational modifications such as glycosylations are important 
for stability and should be carefully considered in future studies.  
2. Showed the NHD variants are misfolded, while the AD-risk variants are intact
The structure revealed the location of residues linked to disease. The NHD-causative
variants are buried in the protein core. These mutations cause protein misfolding and impair the 
expression of folded protein. However, these proteins may still reach the cell-surface in an 
unfolded state. In contrast, the AD-linked variants do not grossly alter structure or stability and 
are robustly detected by conformation-sensitive antibodies. However, there are subtle, 
measurable effects, particularly for the R47H variant. This variant uniquely has an altered CD 
signature, which could indicate a conformational change.  
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3. Showed TREM2 binds a cell-surface proteoglycan-dependent ligand
Despite reports that the R47H variant has impaired signaling in response to phospholipids
(13, 15), I was not able to convincingly identify loss of phospholipid binding by disease variants. 
Indeed, direct binding to liposomes confirmed that R47H can bind phospholipids with similar 
kinetics as WT. Additionally, a separate study found TREM2 did not stain apoptotic Jurkat cells 
presenting PS on their outer membrane (25). Together, these findings show that while 
phospholipids may be part of a stimulatory complex recognized by TREM2, they are insufficient 
to be the complete TREM2 ligand and do not explain the effect of AD variants. Instead, the 
surface variants were found to alter binding to a cell surface ligand that was ablated with 
proteases or heparinases. WT TREM2 can directly bind heparin, and preliminary experiments 
showed that depleting GAG sulfates impaired signaling and altered surface localization, 
suggesting this ligand acts with TREM2 in cis, perhaps as a tonic ligand or to mediate signaling.  
4. Disease variants map a functional ligand-binding surface
R47 and R62 are part of a basic patch that is involved in the recognition of anionic
proteoglycans and other ligands such as ApoE and Ab. T96K, another surface variant with 
unclear disease risk extends this basic surface. This surface is not observed on the other TREM 
family proteins and is unique to TREM2. Structure-guided mutations to this surface also resulted 
in loss of binding, confirming that it is a functional surface used to recognize ligands.  
5. TREM2 binds ApoE and Ab
TREM2 binds to ApoE and this interaction does not require ApoE lipidation. Full-affinity
binding does require the hinge region of ApoE, and this is the first time this region has been 
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shown to be involved in a protein-protein interaction. The AD-risk residue R47H and basic patch 
mutations disrupt binding. TREM2 also binds Ab and binding is impaired by the R47H variant. 
These findings suggest a physiological role for TREM2 in interacting with these important AD 
proteins.  
These results explain how mutations within the same domain produce different diseases. 
The proposed effect of disease variants on TREM2 function is shown in Figure 6.2. AD variants 
have reduced function through decreased ligand binding, but are folded and likely retain some 
basal level function. These variants are typically heterozygotes. The NHD variants result in 
complete loss of function and produce a fatal disease when homozygous. These variants are 
extremely rare, however, it would be consistent with this model that heterozygote NHD variants 
increase AD risk. 
148 
Figure 6.2 is modified from Kober et al, 2016 (26) 
Figure 6.2 Proposed model for impact of disease mutations on TREM2 function. WT 
protein is surface expressed and engages with its ligand for signaling. AD variants, which 
are typically heterozygous, result in decreased signaling through impaired ligand 
recognition. NHD variants have been identified in homozygous cases and result in complete 
loss of function.  
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6.3 Proposed model for TREM2 function 
The data produced in this study suggest that TREM2 interacts with heparan sulfate 
proteoglycans on the surface of myeloid cells. During resting conditions, these may represent a 
tonic ligand to control inflammation or maintain homeostasis. Additionally, GAGs may be 
required to orient, position, or cluster TREM2 on the surface to engage with activating ligands. 
These ligands may be phospholipids, ApoE, Ab, or some as-of-yet unknown ligand. These 
ligands could interact with TREM2 separately from GAGs (as may be the case with 
phospholipids) or could compete with GAGs through a hand-off mechanism. In this scenario, the 
AD-disease mutations would result in loss of function because they would have decreased 
interactions with GAGs and perhaps additionally decreased interactions with stimulating ligands. 
Indeed, it may not be necessary for the variants to have complete loss of binding. A partial 
deficiency in binding to GAGs, phospholipids, or ApoE ect… would be compounded at each 
stage so that the end result is loss of signaling, as was observed for the R47H variant responding 
to plated phospholipids (15). This putative mechanism is depicted in Fig 6.3. Such a pathway 
would not be without precedent. GAG-protein interactions have been implicated in signaling 
with TLR (27), chemokine (28), and acetylcholine receptors (29). It is also possible that HS 
proteoglycans mediate attachment of sTREM2 to interact with a proteinaceous receptor on the 
cell surface or after HS-mediated internalization. 
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Figure 6.3. Model for TREM2 signal by WT and variant proteins. A) TREM2 has a 
pronounced basic patch, and the disease variants R47 and R62 are part of this surface. 
TREM2 also has separate surfaces that are potentially involved in ligand binding, such as a 
hydrophobic surface above the basic patch. Note that residues involved in recognition and 
binding of specific phospholipids in other Ig domain proteins are not present in TREM2. B) 
Role of GAGs in TREM2 signaling. Heparan sulfate proteoglycans interact with TREM2, 
likely in cis on TREM2-expressing cells. These may function to orient and cluster TREM2 to 
receive activating signals such as phospholipids or APOE. C) The R47H and R62H variant 
have reduced binding to cell-surface proteoglycans and have reduced signaling to 
phospholipids and lipoparticles. The decreased affinity for GAG may impair the ability of 
these variants to recognize and/or signal in response to these ligands.  
Figure 6.3 taken from Kober and Brett 2017, manuscript in prep. 
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6.4 Future directions 
1. How do TREM2 and ApoE interact?
I cloned, expressed, and purified a number of ApoE truncation constructs (Fig 5.3).
These constructs will be tested in BLI experiments to determine which portions are essential for 
ApoE3 and ApoE4 to bind TREM2. Co-purification and co-crystallization trials will be 
attempted to obtain a high-resolution picture of the interaction. In lieu of a crystal structure, a 
SAXS envelope may be attainable. I have performed preliminary SAXS analysis of TREM2, and 
SAXS studies of lipidated ApoE have been reported previously (30), so this complex should be 
amenable to this type of analysis. BLI analysis will be done to verify residues implicated in 
binding by crystallography or SAXS. Additionally, I have developed and characterized novel 
anti-TREM2 mAbs that may be useful in co-crystallization and epitope mapping. The data here 
show that lipidation is not necessary for the ApoE-TREM2 interaction, but it will be important to 
conduct signaling assays to test whether lipidation is required to stimulate TREM2 signaling.  
2. How does TREM2 interact with phospholipids?
In these experiments, TREM2 basic patch mutations did not appear to alter phospholipid
binding. However, phospholipids are a potent stimulator of TREM2 signaling (13, 15).  
Determining how TREM2 interacts with phospholipids will be vital towards understanding 
TREM2 function. As discussed in Chapter 2, TREM2 has a hydrophobic surface that harbored 
unexplained density in the crystal structure. This density is likely NDSB-201, which may be 
acting as a surrogate for an endogenous lipid. Fig 6.4 shows the hydrophobic patch with the 
contributing residues labeled. These residues have been individually mutated to Asp in the full-
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length protein for signaling studies, and the Ig domains are being subcloned into pHLSEC 
vectors for lipid binding studies.  
3. How do GAGs contribute to TREM2 signaling?
GAGs appear to be necessary for ERK activation, but this finding needs to be reproduced
in CHO cells that don’t express GAGs to control for off-target chemical effects. Additionally, 
signaling studies with phospholipids, ApoE, and Ab should be conducted in the presence or 
absence of GAGs to see whether these ligands induce TREM signaling and whether GAGs are 
involved in these pathways.  
Figure 6.4 is modified from Kober et al, 2016 (26) 
Figure 6.4. TREM2 hydrophobic patch. TREM2 hydrophobic surface plotted using color_h 
pymol script where red = hydrophobic. a) TREM2 side view as in Figure 4.7 with R47 and 
R62 marked for orientation. b) top view, showing hydrophobic patch with contributing 
residues labeled.  
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4. What is the sTREM2 receptor?
Soluble TREM2 has been shown to inhibit apoptosis in microglia (31) and macrophages
(32). The intracellular pathways were different, as survival was associated with PI3K/Akt 
signaling in microglia (31) and ERK signaling in macrophages (32). Whether there are two 
different receptors or the differences are due to cell origin or experimental conditions remains to 
be determined. Interestingly, the work in macrophages showed that sTREM2 was internalized 
and detectable on permeabilized but not intact macrophages, suggesting sTREM2 may interact 
with an intracellular receptor. Therefore, GAG interactions could mediate internalization for 
interaction with the unknown receptor. What is clear is that phospholipids or GAGs alone are not 
the complete signaling receptor for sTREM2, and future work will need to identify this receptor.  
In an initial experiment, I used SEC-purified mTREM2 to stimulate RAW264.7 and BV2 
cells (mouse macrophage and microglia). BV2 cells were a kind gift from Celeste Karch. I 
exposed the cells to 0.5 µM sTREM2 for 30 or 5 minutes and then collected the cells and 
immunoblotted for activated ERK and AKT as described above (pAKT and AKT antibodies 
were from Cell Signaling). Phosphor-ERK activation was observed in both RAW and BV2 cells 
at 30 minutes, but not 5 minutes (Fig 6.5). Boiling the TREM2 protein before application greatly 
reduced signaling (not shown). This was a control for LPS contamination. A small amount of 
signaling was detected with the boiled protein; this could indicate contamination or that some of 
the protein refolded after cooling, as was observed in CD experiments. In both sTREM2 reports, 
which used lower concentrations, boiling the protein abrogated the survival effect (31, 32). In 
contrast to the microglia report, I did not detect AKT activation in either cell line, although 
overall AKT detection was low. This suggests that ERK may be a proximal response to sTREM2 
and AKT is more distal. This initial observation needs to be extended, but it confirms that the 
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TREM2 Ig domain is a potent signaling factor in addition to the role of TREM2 as a signaling 
receptor.  
Figure 6.5. Soluble mTREM2 stimulates ERK signaling. Raw264.7 (left) and BV2 (right) 
cells were stimulated with 0.5 µM mTREM2 purified by SEC. Cells were harvested and lysed 
in PBS with 1% Triton X-100. Immunoblots were run for the indicated antigens. Phosphor-
ERK, but not p-AKT was readily detected after 30 min exposure to mTREM2.  
155 
6.5 Translational implications of this work 
This work is the first structural characterization of TREM2 and disease-associated 
variants, and there are several areas where these findings are of value in the pursuit of molecular 
therapies targeting or restoring TREM2 function. 
1. The structure could be used as a basis for in situ small-molecule docking.
Small molecules could be screened in situ for potential interactions. Alternatively, high-
throughput libraries could be screened for TREM2 activity (i.e. reporter cell signaling) and then 
the structure could be used to predict binding sites and suggest rational approaches to optimizing 
binding and selectivity. Candidate molecules could be further studied by co-crystallization with 
TREM2 to confirm binding modes. Currently, there are no well-validated TREM2 agonists or 
antagonist, so molecules performing either function would be useful as a research tool as well as 
therapeutically.  
2. Cell-surface expression data suggests the NHD variants are not cleared by ERAD
and could be targeted molecular chaperones.
In contrast to previous reports (33, 34), my expression system showed cell-surface
expression of NHD variants by flow cytometry and confocal microscopy. Additionally, these Ig 
domains, while misfolded, were still secreted and detectable in solution. While this may be an 
artifact of overexpression, these findings should be investigated with human NHD samples by 
using antibodies that recognize the misfolded proteins. The detection of cell-surface protein 
shows that these proteins may survive clearance by ERAD and be amenable to folding 
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chaperones that restore function. This approach has been successfully used to target other 
misfolded proteins (e.g. Lumacaftor in cystic fibrosis) 
3. Basic patch variants could be targeted to restore binding.
In contrast to the NHD variants, R47H and R62H do not grossly impair protein folding or
stability. Instead, these variants negatively impact binding to ligands such as ApoE and cell-
surface GAGs. Therapeutics could be designed either to rescue binding to these ligands or to 
directly stimulate the variant protein. 
4. Enhancing the TREM2-GAG-Ligand interactions.
The disease-risk basic patch variants - R47H in particular - disrupt binding to cell-surface
proteoglycans and soluble ligands such as ApoE. This suggests these interactions are important 
during disease and therefore molecules that enhance these interactions may be broadly 
therapeutic, and could potentially be used to increase microglia survival and activity during AD 
or other neurodegenerative disease in TREM2-WT patients. 
5. Soluble TREM2 as a therapeutic protein.
With the Holtzman lab, we showed that soluble TREM2 inhibits macrophage apoptosis
through ERK signaling and is a survival signal (32). These general findings were recently 
reproduced in primary microglia, although in that report the phenotype depended on AKT 
signaling (31). In this paradigm, sTREM2 may have therapeutic potential. Indeed, the T96K 
gain-of-binding variant should be tested to see if it has enhanced protective effects. 
Understanding this TREM2-receptor interaction could also suggest ways to enhance binding.  
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a b s t r a c t
TREM-2 (triggering receptor expressed on myeloid cells-2) is an innate immune receptor expressed on
dendritic cells, macrophages, osteoclasts, and microglia. Recent genetic studies have reported the occur-
rence of point mutations in TREM-2 that correlate with a dramatically increased risk for the development
of neurodegenerative diseases, including Alzheimer’s disease, frontotemporal dementia, and Parkinson’s
disease. Structural and biophysical studies of wild-type and mutant TREM-2 ectodomains are required to
understand the functional consequences of these mutations. In order to facilitate these studies, we under-
took the production and crystallization of these proteins. Here we demonstrate that, unlike many single
Ig domain proteins, TREM-2 could not be readily refolded from bacterially-expressed inclusion bodies.
Instead, we developed a mammalian-cell based expression system for the successful production of
wild-type and mutant TREM-2 proteins in milligram quantities and a single-chromatography-step puri-
fication scheme that produced diffraction-quality crystals. These crystals diffract to a resolution of 3.3 Å
and produce data sufficient for structure determination. We describe herein the procedures to produce
wild-type and mutant human TREM-2 Ig domains in sufficient quantities for structural and biophysical
studies. Such studies are crucial to understand the functional consequences of TREM-2 point mutations
linked to the development of neurodegenerative diseases and, ultimately, to develop patient-specific
molecular therapies to treat them.
! 2014 Elsevier Inc. All rights reserved.
Introduction
The molecular mechanisms contributing to age-related neuro-
degenerative disease pathogenesis are not well understood. Genet-
ic studies released within the last year have identified specific
mutations in TREM2 that are linked to a significantly increased risk
for the development of late-onset Alzheimer’s Disease (1AD) [1,2].
The greatest risk is associated with the point mutant R47H, and is
roughly equivalent to that associated with mutations in APOE4, cur-
rently the strongest known risk factor for late-onset AD [3]. This
mutation has now been found in cohorts from Iceland [2], USA, Ger-
many, Netherlands, Norway [1], Spain [4], and France [5]. Further,
this mutation has recently been identified as a determinant in Par-
kinson’s disease (PD) patients [6,7]. Additional variants including
D87N and T96K have been linked to AD development [1] and two
other point mutations in TREM-2 (Y38C and T66M) have been linked
to the development of frontotemporal dementia (FTD) [8–11]. These
findings highlight a crucial homeostatic role for TREM2 in maintain-
ing neuronal health and represent the first molecular link between
innate inflammatory signaling and neurodegenerative diseases
[12]. However, it is currently unknown how these mutations affect
TREM-2 function and thereby contribute to neurodegenerative dis-
ease pathogenesis.
http://dx.doi.org/10.1016/j.pep.2014.01.015
1046-5928/! 2014 Elsevier Inc. All rights reserved.
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The TREM2 gene encodes the protein triggering receptor ex-
pressed on myeloid cells 2 (TREM-2). TREM-2 is an innate immune
receptor expressed on dendritic cells, macrophages, osteoclasts,
and microglia [13]. The protein has a minimal intracellular se-
quence and therefore traffics and signals through association with
the adaptor protein DAP12 [14]. The ectodomain consists of a sin-
gle Ig fold anchored to a transmembrane domain via a short stalk.
The major role of the Ig domain is presumed to be ligand engage-
ment, though the endogenous signaling ligand(s) of TREM-2 are
uncertain. Several different types of ligands have been suggested,
including various anionic bacterial carbohydrates [15], apoptotic
cell membrane components [16], the immune receptor Plexin-A1
[17], and the chaperone Hsp60 [18]. A proper understanding of
the function of TREM-2 has been constrained by a lack of structural
information and the elusive nature of TREM-2 ligands.
A crucial role for TREM-2 in neuronal health was first suggested
through association with neurodegenerative Nasu-Hakola disease
(NHD) [19]. The major mutations associated with NHD produce
premature termination of TREM-2 protein and are also phenocop-
ied by deletion of DAP12. In contrast, all of the point mutations
associated with AD, PD, and FTD are located within the Ig domain,
suggesting these mutations alter function of full-length TREM-2.
Proper understanding of how the newly identified point muta-
tions of TREM-2 could modulate function and contribute to disease
requires not only functional studies but also structural and
biophysical comparisons of wild-type (WT) and mutant TREM-2
ectodomains. In order to facilitate this approach, we developed a
mammalian cell-based expression and purification system to ad-
dress the difficulties with generating TREM-2 protein suitable for
structural and biophysical studies. Indeed, we were able to identify
experimental conditions that produce crystals of human TREM-2
that diffract to 3.3 Å resolution and can be phased by molecular
replacement. The studies outlined here provide a methodological
framework for understanding the molecular basis of TREM-2
mutations and their contribution to the development of neurode-
generative diseases.
Materials and methods
Expression constructs
For expression in Escherichia coli, the Ig domains of human
TREM-2 (NBCI ref NP_061838; amino acids 19–134; MWcalc[with
tag] = 14387 Da; pIcalc = 8.5) and mouse TREM-2 (NCBI ref
NP_112544; amino acids 19–136; MWcalc[with tag] = 14440 Da;
pIcalc = 8.4) were amplified using PCR and cloned into pET23b as
tagless constructs using standard molecular biology techniques.
Full-length human TREM-2 in pMX-3p plasmid (a gift from Marco
Colonna) and mouse Trem-2 cDNA were used as PCR templates,
respectively. Mammalian cell expression constructs of human
TREM-2 wild-type, R47H mutant, and mouse TREM-2 Ig domains
were produced similarly by cloning into the pHLSEC vector [20],
which contains an optimized signal sequence and C-terminal 6-
histidine tag for purification. All constructs were confirmed by
sequencing.
Expression and purification of TREM-2 inclusion bodies in E. coli
Human and mouse TREM-2 Ig domains in pET23b were trans-
formed into Rosetta2 (DE3) cells (Novagen) for expression. Cul-
tures were grown to O.D.600 = 1.0, induced with 0.5 mM IPTG,
and expressed with shaking at 37 "C for 4 h. Cells were then har-
vested by centrifugation and lysed in buffer containing 50 mM Tris
pH 8.0, 12.5% sucrose, 50 mM NaCl, 0.5 mM EDTA, 0.5% Trition X-
100, and 10 mM DTT supplemented with lysozyme (0.5 mg/mL)
and DNAse. The inclusion bodies were harvested by centrifugation
and washed 3 times in buffer containing 50 mM Tris pH 8.0,
100 mM NaCl, 1 mM EDTA, 1 mM DTT and 0.5% Triton X-100. A fi-
nal wash without Triton X-100 was performed and the purified
inclusion bodies were solubilized in 6 M guanidine hydrochloride
containing 20 mM b-ME and 50 mM Tris pH 8.0.
Refolding trials for human and mouse TREM-2 Ig domains
Initial refoldings were attempted by rapid dilution of the solu-
bilized inclusion bodies into a buffer containing 100 mM Tris pH
8.5, 400 mM arginine, 2 mM EDTA, 5 mM reduced glutathione,
and 0.5 mM oxidized glutathione, as similar conditions had previ-
ously been used to refold human and mouse TREM-1 [21–23], hu-
man TREM-like transcript 1 (TLT-1) [24], human immune receptor
expressed on myeloid cells (IREM-1) [25], and human NK cell
receptor NKp44 [26]. Solutions were initially clear upon addition
of protein, but after about 1 h the protein would precipitate. Sub-
sequent workup revealed no properly folded soluble protein.
Therefore we performed screening of refolding conditions. A
refolding screen was developed based on the QuickFold Protein
Table 1
Refolding screen conditions.
Buffer Salt Cation/Chelator Guanidine Stabilizing
agent(s)
Additives Detergent 1 mM
DTT
1 mM GSH/
0.1 mM GSSH
1 MES pH 6.0 9.6 mM NaCl, 0.4 mM KCl 2 mM MgCl2, 2 mM CaCl2 0.75 M 0.5% Triton X-100 !
2 MES pH 6.0 9.6 mM NaCl, 0.4 mM KCl 2 mM MgCl2, 2 mM CaCl2 0.5 M L-Arginine 0.05% PEG 3,350 !
3 MES pH 6.0 9.6 mM NaCl, 0.4 mM KCl 1 mM EDTA 0.75 M 0.4 M Sucrose 0.05% PEG 3,350 0.5% Triton X-100 !
4 MES pH 6.0 240 mM NaCl, 10 mM KCl 2 mM MgCl2, 2 mM CaCl2 0.5 M L-Arginine 0.5% Triton X-100 !
5 MES pH 6.0 240 mM NaCl, 10 mM KCl 1 mM EDTA 0.75 M 0.4 M Sucrose !
6 MES pH 6.0 240 mM NaCl, 10 mM KCl 1 mM EDTA 0.4 M Sucrose
0.5 M L-Arginine
0.05% PEG 3,350 0.5% Triton X-100 !
7 MES pH 6.0 240 mM NaCl, 10 mM KCl 2 mM MgCl2, 2 mM CaCl2 0.75 M 0.05% PEG 3,350 !
8 Tris pH 8.5 9.6 mM NaCl, 0.4 mM KCl 2 mM MgCl2, 2 mM CaCl2 0.4 M Sucrose 0.05% PEG 3,350 0.5% Triton X-100 !
9 Tris pH 8.5 9.6 mM NaCl, 0.4 mM KCl 1 mM EDTA 0.75 M 0.5 M L-Arginine 0.05% PEG 3,350 !
10 Tris pH 8.5 9.6 mM NaCl, 0.4 mM KCl 2 mM MgCl2, 2 mM CaCl2 0.75 M 0.4 M Sucrose
0.5 M L-Arginine
!
11 Tris pH 8.5 9.6 mM NaCl, 0.4 mM KCl 1 mM EDTA 0.5% Triton X-100 !
12 Tris pH 8.5 240 mM NaCl, 10 mM KCl 1 mM EDTA 0.05% PEG 3,350 !
13 Tris pH 8.5 240 mM NaCl, 10 mM KCl 1 mM EDTA 0.75 M 0.5 M L-Arginine 0.5% Triton X-100 !
14 Tris pH 8.5 240 mM NaCl, 10 mM KCl 2 mM MgCl2, 2 mM CaCl2 0.75 M 0.4 M Sucrose
0.5 M L-Arginine
0.05% PEG 3,350 0.5% Triton X-100 !
15 Tris pH 8.5 240 mM NaCl, 10 mM KCl 2 mM MgCl2, 2 mM CaCl2 0.4 M Sucrose !
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Refolding Kit (Athena Enzyme Systems) (Table 1). For this screen,
50 lL of each solubilized TREM-2 inclusion body (at 2 mg/mL)
was added to 950 lL of each refolding condition, rocked overnight
at 4 "C, and then centrifuged at high speed to pellet insoluble
protein. The presence of soluble protein in the supernatant was
assessed by SDS–PAGE.
Expression and purification of TREM-2 Ig domains from mammalian
cells
Wild-type human and mouse TREM-2 Ig domain and human
R47H mutant were expressed in mammalian cells by large-scale
transient transfection. Briefly, plasmid DNA (1 lg/mL final concen-
tration) was diluted in Opti-MEM (Gibco) and mixed 1:2 with
25 kDa branched polyethyleneamine chemically modified with tri-
methylene carbonate (termed PEI-TMC25) [27] (2 lg/mL final con-
centration) and allowed to form micellar complexes for 30 min.
Transfection was achieved by adding these mixtures to FreeStyle
293F cells (Invitrogen) at a ratio of 1 lg DNA: 1 " 106 cells. Cells
were allowed to grow in serum-free 293 FreeStyle media (Invitro-
gen) with shaking in vented flasks at 37 "C and 8% CO2. The TREM-2
Ig domain has two conserved N-glycosylation sites (Fig. 1a). To
facilitate removal of N-linked glycans, kifunensine (Sigma; 1 lg/
mL), an inhibitor of a-mannosidase I, was added to the culture to
inhibit maturation of N-linked glycans and leave them as high-
mannose glycans that can be removed with EndoH [28]. Culture
supernatants were collected at 72 and 144 h post-transfection,
modified by addition of 50 mM phosphate, 10 mM Tris pH 8.5,
300 mM NaCl, and 10 mM imidazole, and then purified using NiN-
TA-affinity chromatography. Proteins were washed on column
using the same buffer containing 20 mM imidazole and eluted in
250 mM imidazole. After elution, EndoHf (NEB), a fusion protein
of EndoH and maltose binding protein, was used to deglycosylate
TREM2 to homogeneity. This reaction cleaves the high-mannose
glycan leaving a single glucose attached to the asparagine and
was carried out by addition of 50 mM sodium citrate pH 5.5 and
approximately 2000 units of EndoHf per mg of TREM-2 Ig domain.
Reactions were incubated overnight at 25 "C. EndoHf was then re-
moved by incubation with amylose resin for 1 h at 4 "C, followed
by pelleting of the resin by centrifugation and harvesting of the
supernatant. The deglycosylated TREM-2 Ig domains were then ex-
changed into buffer containing 20 mM Hepes pH 7.5 and 150 mM
NaCl with a concentrator (Vivaspin, Sartorius) for use in experi-
ments. The resulting proteins were >90% pure as assessed by
SDS–PAGE.
Crystallization, data collection, and initial crystallographic analysis
Human and mouse TREM-2 Ig domains at 10 mg/mL were
screened for crystallization by hanging drop vapor diffusion. Initial
hits were only obtained for human TREM-2 Ig domain. Optimal
crystals were obtained when protein solution was mixed 1:1 with
well solution containing 100 mM Tris pH 7.1, 2.1 M NaCl, 200 mM
MgCl2, 200 mM NDSB-201. Crystals appeared over the course of
2–5 days and had approximate dimensions of 300 " 300 " 50 lm.
For data collection, crystals were cryopreserved in reservoir
solution containing 25% ethylene glycol and flash-frozen in a nitro-
gen stream at 100 K. A native data set was collected at a wave-
length of 1.0007 Å with 5 s exposure times and 1" oscillations
per image at beamline ID19 (Advanced Photon Source, Argonne).
Data were processed with HKL-2000 [29]. Scaling and analysis of
systematic absences revealed the space group to be either P6222
of P6422. Molecular replacement was carried out in PHASER [30]
using various similar single Ig domain probes including human
TREM-1 (PDB ID: 1SMO) [22], mouse TREM-1 (1U9K) [21], human
NKp44 (1HKF) [26], human TLT-1 (2FRG) [24], human IREM-1
(2NMS) [25], mouse CNRF35-like molecule 1 (CLM-1) (1ZOX),
and ensembles of these structures. The best rotational and transla-
tional Z scores were obtained with mouse TREM-1 (1U9K). The
translational search revealed the correct space group to be P6422.
Two copies of the probe were placed in the asymmetric unit
(ASU). Data collection and molecular replacement statistics are
provided in Table 2. Patterson and self-rotation function were cal-
culated with GLRF [31] using a 25 Å radius of integration.
Western blot analysis
Recombinant human TREM-2 Ig domain proteins were analyzed
on Western blot using an antibody directed against the C-terminal
6-histidine tag (HRP conjugated rabbit a-6-His antibody, Bethyl
Labs, A190–114A). The antibody was used at a 1:5000 dilution in
binding buffer (PBS containing 0.1% TWEEN-20 and 0.5%
powered milk). Blocking, binding, and washing steps were carried
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Fig. 1. Production of human and mouse TREM-2 ectodomain inclusion bodies in
E. coli and refolding screening. (a) Schematic representation of human TREM-2
protein. Conserved N-linked glycosylation sites are shown as branched trees.
Structural features are labeled as follows: SS = signal sequence; Ig = immunoglob-
ulin domain; ST = stalk; TM = transmembrane; IC = intracellular region. (b) SDS–
PAGE analysis of human (lane 1) and mouse (lane 2) TREM-2 solubilized inclusion
bodies (M = molecular weight marker). Proteins in 6 M guanidine were diluted at a
ratio of 1:50 into SDS–PAGE loading buffer (to prevent precipitation of guanidine by
SDS). Final protein concentration in the loading buffer was 1 mg/ml and approx-
imately 15 lg of protein were loaded on each lane of the gel. (c) SDS–PAGE analysis
of refolding screen outcome for human TREM-2 and (d) mouse TREM-2 Ig domains.
The lane numbers correlate to the refolding screen conditions in Table 1.
Table 2
Crystallographic data and initial molecular replacement statistics.
Space group P6422
X-ray data collection statistics
Unit Cell (Å) a = 125.76
b = 125.76
c = 183.66
X-ray source APS, ID-19
Wavelength (Å) 0.979180
Resolution (Å) 50.00–3.30
(3.42–3.30)a
Rsym (%) 0.133 (0.920)
Completeness (%) 99.9 (100)
Redundancy 13.6 (14.1)
I/r (I) 21.8 (3.0)
Molecular replacement statistics
Probe PDB ID 1U9K
No. molecules/ASU 2
Program PHASER
TFZ 13.8
Rigid body Rwork 0.3909
Rigid body Rfree 0.4602
a Values in parenthesis are for the highest-resolution shell.
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out in a SNAP i.d. system (Millipore) according to product
recommendations.
Results and discussion
TREM-2 Ig domain refolding screen
Initial experiments were directed at obtaining the large
amounts of purified protein that are required for structural and
biophysical studies. Structure predictions estimate that the
TREM-2 ectodomain consists of a single immunoglobulin (Ig) do-
main followed by an approximately 40 amino acid unstructured
stalk (Fig 1a). Most of the mutations linked to increased risk of
neurodegenerative diseases lie in the Ig domain [12], which is most
likely to be involved in ligand engagement for signaling. A number
of Ig domains from TREM family receptors have previously been
crystallized, including human TREM-1 [22,23], mouse TREM-1
[21], human TLT-1 [24], human IREM-1 [25], mouse CLM-1, and
human NKp44 [26]. Each of the proteins for these studies was pro-
duced by bacterial expression of insoluble inclusion bodies and
refolding. Thus, we initiated our structural studies of the TREM-2
Ig domain by attempting to refold both the human and mouse
TREM-2 Ig domains from bacterially expressed inclusion bodies.
Although the inclusion body preparations were very homogeneous
(Fig 1b), we were unable to refold these proteins by rapid dilution
into a buffer similar to that used for other family members
(100 mM Tris pH 8.5, 400 mM arginine, 2 mM EDTA, 5 mM reduced
glutathione, and 0.5 mM oxidized glutathione). The protein would
initially be soluble, but after about one hour, heavy precipitation
was observed in the refolding buffer. We then attempted to screen
numerous potential refolding conditions (Table 1). This screening
produced a number of potential conditions (Fig 1c). A number of
potential hits, including conditions #4 and #14, were expanded
to large-scale refoldings in 500 mL of refolding buffer. However,
these conditions produced similar results (heavy precipitation
after 1 h) when scaled-up. In addition, given that NDSB-201 in-
creased solubility and crystal size for the mammalian cell-pro-
duced protein, we attempted large-scale refolding in buffers
incorporating that reagent as the solubilizer (50 mM Hepes pH
7.5, 0.4 –1.0 M NDSB-201, 150 mM NaCl, 5 mM EDTA, 5 mM re-
duced glutathione, and 0.5 mM oxidized glutathione). This attempt
gave similar unsuccessful results. Some possible interpretations of
these observations could be a requirement for post-translational
modification that is unable to occur in E. coli, the need of chaper-
ones for proper folding, or instability due to absence of a ligand.
Production and purification of TREM-2 from mammalian cells
To circumvent the protein production problems found in the
bacterial system, we next pursued expression and purification of
natively folded and secreted protein from mammalian cells. We
previously incorporated a large-scale transient transfection system
using mammalian cells in suspension to produce secreted proteins
[32]. The advantages of this transient transfection system are:
expression constructs can be quickly optimized as there is no
requirement to produce expression viruses or stably expressing
cell lines; the 293 Freestyle cells are readily transfected and can
be grown to high densities (up to around 4 " 106/ml); and the cells
can be cultured in serum-free media, simplifying purification from
media supernatants (Fig 2a). Using this system, we transfected 293
Freestyle cells at a density of 1 " 106/ml with expression plasmids
encoding mouse TREM-2 Ig domain, humanWT TREM-2 Ig domain,
and human TREM-2 Ig domain R47H variant. To inhibit glycan
maturation, kifunensine was added to the culture medium at the
time of transfection. This treatment allows for removal of the
resulting high-mannose glycans by post-purification addition of
Endo Hf, which is advantageous for crystallization. Media superna-
tants were harvested 72-h post-transfection and adjusted to pH 8.5
with phosphate/Tris, 300 mM NaCl, and 10 mM imidazole for effi-
cient retrieval of the 6-histidine-tagged proteins using Ni–NTA
superflow resin. Bound proteins were eluted from the column in
a buffer consisting of 50 mM phosphate pH 8.0, 300 NaCl, and
250 mM imidazole. The eluted proteins ran at approximately
28 kDa on SDS–PAGE and displayed laddering due to inhomoge-
neous glycosylation (calculated monomeric weight is approxi-
mately 14 kDa) (Fig. 2b). The eluted proteins were then adjusted
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Fig. 2. Expression, purification, and crystallization of mammalian expressed TREM-2 Ig domains. (a) Schematic of protein production and purification from mammalian cells.
(b) SDS–PAGE analysis of purified TREM-2 Ig domains before (#) and after (+) endoHf treatment. Proteins were diluted in SDS–PAGE loading buffer to a concentration of 1 mg/
ml, and 15 lg of protein were loaded on each lane of the gel. (c) a-6-His Western blot of WT TREM-2 Ig domain before (#) and after (+) endoHf treatment. Bands
corresponding to TREM-2 Ig domain modified with 2, 1, of 0 glycans are highlighted. (d) Hexagonal crystals of human TREM-2 WT Ig domain grown in 100 mM Tris pH 7.0–
7.2, 2.0 M NaCl, 200 mM MgCl2, 200 mM NDSB-201.
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to acidic pH (50 mM sodium citrate pH 5.5) and treated with Endo
Hf overnight at 25 "C. The deglycosylated proteins collapsed to a
single band of about 15 kDa on SDS–PAGE (Fig 2b) and this was
confirmed by Western blot for the C-terminal 6-histidine tag (Fig
2c). Typical yield was 5–10 mg of pure TREM-2 Ig domains per liter
of culture medium.
Crystallization of the human TREM-2 Ig domain
Both human and mouse WT TREM-2 Ig domains were
exchanged into a buffer consisting of 20 mM Hepes pH 7.5 and
150 mM NaCl and concentrated to 10 mg/mL prior to crystalliza-
tion screening. Crystallization screening was carried using a Mos-
quito crystallization robot (TTP Labtech, UK). Screening was
carried out by hanging drop vapor diffusion with crystallization
drops containing 150 nL protein solution plus 150 nL precipitant
solution. The most promising hits were obtained with the human
TREM-2 Ig domain. The best initial condition produced multiple
small hexagonal crystals per drop and consisted of 100 mM Bis-
Tris pH 7.0, 2.0 M NaCl, 200 mM MgCl2. Crystallization conditions
were optimized by fine varying of buffer pH and NaCl concentra-
tion, and the addition of additives (96 condition Additive Screen,
Hampton Research, CA, USA). The best additives produced only a
few large crystals per drop and consisted of sulfobetaines
(NDSB-201 and NDSB-211) and divalent cations (CsCl2 and BaCl2).
The final optimized conditions for the best crystals consisted of
100 mM Tris pH 7.0–7.2, 2.0–2.2 M NaCl, 200 mM MgCl2, and
200 mM NDSB-201 with crystallizations drops setup in a 1:1
protein:precipitant ratio. Large hexagonal crystals appeared after
2–3 days, reaching maximum dimensions of around 300 "
300 " 50 lM after 3–5 days (Fig. 2d).
Preliminary crystallographic data
Initial diffraction data was collected at the Advanced Photon
Source, Argonne National Lab, beamline ID-19. Crystals of most
of the previously analyzed TREM family members produced dif-
fraction beyond 2.0 Å resolution. In contrast, the best crystals of
human TREM-2 purified from mammalian cells diffracted to a
resolution of 3.3 Å (Fig 3a). This decreased resolution is partially
because the protein crystallizes in a large unit cell (Table 2). Even
given the high symmetry space group (P6422), six to seven TREM-2
Ig domains would be required per ASU for the crystals to have a
solvent content near the commonly observed average of about
50%. However, molecular replacement using numerous suitable
probes was only able to locate two molecules in the ASU, for a
solvent content of 83%. This result suggested that a co-purified
protein enriched in the crystallization process might have
co-crystallized with the human TREM-2 Ig domain. In order to
determine if this was the case, we extracted single crystals from
crystallization drops, washed the crystals, dissolved them in SDS
loading buffer, and finally analyzed the crystal contents by silver-
stained SDS PAGE. This analysis revealed that the only protein in
the crystals was human TREM-2 Ig domain and was confirmed
by Western blot for the C-terminal 6-histidine tag (Fig 3b).
Furthermore, analysis of the Patterson self-rotation function
revealed only peaks consistent with the crystallographic symmetry
on the j = 60", 120", and 180" sections [33], and a unique peak on
the j = 90" section (Fig 3c), indicative of twofold non-crystallo-
graphic symmetry, and thus consistent with the observation of
two TREM-2 Ig domains in the ASU. Thus, the limited resolution
observed from this crystal form of human TREM-2 Ig domain is
mainly due to the large unit cell (limiting the number of unit cells
per diffracting volume) and high solvent content. However, the
data are sufficient to solve the structure to 3.3 Å resolution using
molecular replacement.
Conclusions
TREM-2 is an innate immune receptor that is implicated in reg-
ulating inflammatory responses as well as acute and chronic
inflammatory diseases [34]. In this capacity it has been suggested
to contribute to and/or represent a biomarker for a number of dis-
eases including multiple sclerosis [35,36], stroke [37], inflamma-
tory bowel disease [38], and chronic inflammatory lung disease
[39]. Recent genetics studies have uncovered point mutations in
the TREM-2 Ig domain that correlate with a significantly increased
risk for the development of neurodegenerative diseases such as AD,
FTD, and PD. To begin to understand the influence of TREM-2 poly-
morphisms on TREM-2 function will require structural and bio-
physical studies of TREM-2 protein. These types of studies
require generous amounts of purified protein and production of
protein crystals that diffract to a resolution reasonable for struc-
ture determination. Single Ig domains often readily refold from
bacterial inclusion bodies, however, we were unable to identify
conditions under which the TREM-2 Ig domain would refold. There
may be a functional basis for this observation, such as the lack of a
stabilizing binding partner, post-translational modification, or
folding chaperone. Nonetheless, we abandoned this strategy in fa-
vor of developing a mammalian cell-based expression system.
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Fig. 3. Preliminary diffraction data from human TREM-2 WT Ig domain crystals (a)
representative oscillation diffraction image from human TREM-2 WT Ig domain
crystals (b) left: Silver-stained SDS–PAGE of human TREM-2 Ig WT crystals; Right:
a-6-His Western blot of the TREM-2 Ig WT crystals (c) Patterson self-rotation
function kappa sections from the 3.3 Å resolution data set.
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Using this system, we were able to produce both WT and mutant
TREM-2 Ig domains in sufficient quantities for structural and bio-
physical studies. This protein readily crystallizes and these crystals
produce diffraction data sufficient for structure determination at
3.3 Å. It is worth noting that we were able to perform a one-step
purification to obtain these crystals, which are homogeneous by
gel analysis and by preliminary LC/MS analysis of solvent extrac-
tions from the purified protein (data not shown). This is significant
as further purification steps can often lead to losses in protein yield
that then prohibit or limit the number of crystallization trials that
can be attempted in order to identify crystallization conditions.
Thus, this study is hallmark example of minimal purification that
produces crystals sufficient for structure determination. In our fu-
ture efforts, we will attempt to manipulate these crystals to diffract
to higher resolution. High solvent content crystals such as the ones
reported here usually respond well to dehydration [40,41], desicca-
tion [42], or annealing [43–45]. The current results provide a basis
for structural and biophysical studies of the TREM-2 variants asso-
ciated with neurodegenerative diseases, which will be required to
understand the functional consequences of these point mutations.
Ultimately, these studies of TREM-2 structure and function have
the potential to lead to the development of patient-specific treat-
ments for neurodegenerative and related inflammatory diseases.
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Abstract
Production of secreted mammalian proteins for structural and biophysical studies can be challenging, time intensive, and costly. Here
described is a time and cost efficient protocol for secreted protein expression in mammalian cells and one step purification using nickel affinity
chromatography. The system is based on large scale transient transfection of mammalian cells in suspension, which greatly decreases the time
to produce protein, as it eliminates steps, such as developing expression viruses or generating stable expressing cell lines. This protocol utilizes
cheap transfection agents, which can be easily made by simple chemical modification, or moderately priced transfection agents, which increase
yield through increased transfection efficiency and decreased cytotoxicity. Careful monitoring and maintaining of media glucose levels increases
protein yield. Controlling the maturation of native glycans at the expression step increases the final yield of properly folded and functional
mammalian proteins, which are ideal properties to pursue X-ray crystallography. In some cases, single step purification produces protein of
sufficient purity for crystallization, which is demonstrated here as an example case.
Video Link
The video component of this article can be found at http://www.jove.com/video/53445/
Introduction
Understanding protein structure at an atomic level is key to uncovering the molecular basis of biological pathways and diseases. X-ray protein
crystallography is the most widely used/applicable method for determining macromolecular structures. The main challenge of this method
is obtaining sufficient amounts of properly folded, pure protein. This becomes an issue particularly when working with secreted mammalian
proteins, which undergo specific post-translational modifications.
Bacterially-expressed proteins are the primary source of crystallized proteins deposited in the Protein Data Bank1. Bacterial expression
systems are largely preferred because they are fast, inexpensive and typically produce high yields of protein. However, extracellular domains
of mammalian proteins expressed in bacteria are often not properly folded, in which case refolding and extensive purification steps are required
for obtaining homogeneously folded protein. Additionally, many mammalian proteins require post-translational glycosylation to achieve proper
folding2. Although expression and glycosylation in yeast or insect cells can overcome the folding problem, post-translational modifications,
including glycosylation, differ significantly from those of mammalian cells3, yielding proteins with incorrect or non-homogeneous modifications.
Mammalian cells express all the required molecular machinery to ensure proper post-translational modifications and folding; however,
these expression systems are not typically preferred by most labs, due to limited yields and high costs of reagents and consumables.
Polyethyleneimine (PEI), a standard transfection reagent is relatively cheap but imposes considerable cytotoxicity and low transfection efficiency,
resulting in increased costs in cell media, DNA, and culturing equipment. Many alternatives to PEI are prohibitively expensive. We address these
issues by describing a combination of improved cell culture tools and chemically modified PEI for the quick and relatively inexpensive method for
the expression of secreted mammalian proteins, followed by single-step purification. This robust method gives sufficient yields for functional and
biochemical studies4, and in some cases, results in protein amenable to crystallization without further purification.
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This protocol describes several techniques to maximize expression and yield for secreted mammalian proteins in human embryonic kidney
(HEK) 293F cells grown in suspension. Transfection efficiency (and cost), protein production and purification are all greatly enhanced by
following this protocol. PEI modified by the addition of carbamates through a single-step ring-opening reaction (PEI-TMC-25, synthesis and
properties described in detail in ref 5) greatly improves transfection efficiency, reduces the cytotoxicity from cationic membrane disruption
and accordingly reduces experiment costs. Furthermore, cell viability and protein expression are greatly improved with the addition of culture
supplements to supply glucose and vitamins. Importantly for the production of glycosylated proteins, treatment with kifunensine, a non-toxic
chemical inhibitor of Mannosidase I, produces proteins with defined, immature glycans, which can be removed by the endoglycosidase EndoHf
to yield proteins with a single N-acetylglucosamine in place of a full-length N-linked glycan6. Finally, the secretion of proteins into a serum-free,
chemically defined medium allows rapid and facile purification for structural and biochemical studies. Single-step nickel-nitrilotriacetic acid (Ni-
NTA) resin purification removes the majority of contaminating species in the supernatant and, in some cases, can yield protein of sufficient purity
for crystallization.
Protocol
1. Production of Milligram Quantities of Plasmid DNA for Large-scale Transient
Transfection
1. Clone the protein of interest into a high copy number mammalian expression vector using restriction site cloning, or other appropriate
technique.
1. For optimal results, use pHLsec 7 vector, which has a built-in C-terminal 6His-tag, a strong promoter Kozak sequence and an optimized
secretion signal.
2. Transform the plasmid onto competent cells.
1. Add 20 µl of competent E. coli cells onto 1 µg of plasmid DNA and incubate on ice for 30 min.
2. Heat shock cells at 42 °C for 35 sec, then incubate on ice for 2 min.
3. Add 300 µl of microbial growth medium (SOC) and incubate at 37 °C for 45 mins, shaking at 220 rpm.
4. Plate cells on agar plate with appropriate antibiotic selection.
1. Use 100 µg/ml carbenicillin if the plasmid is in the pHLsec vector.
3. Culture colonies in 250 ml of Luria Broth (LB) Media supplemented with 100 µg/ml antibiotic (carbenicillin) O/N at 37 °C, shaking at 220 rpm.
4. Purify DNA from culture using Hi-Speed Plasmid Maxi Kit according to manufacturer's protocol.
1. Elute DNA in buffer EB (10 mM Tris-Cl, pH 8.5), instead of buffer TE.
2. Aliquot the purified plasmid at amount needed for transfection and store at -20 °C.
2. Large-scale Culture and Transient Transfection of 293F Cells
1. Supplement 1 L 293F media with 10 ml of glutamine and 5 ml Pen/Strep (both 100x). Store at 4 °C. 5 ml Pen/Strep is a sufficient strength in
serum-free conditions and the reduced antibiotic concentration improves cell viability during transfection, which improves protein yields.
2. Culture 293F cells in 300 ml media in 1 L polycarbonate baffled Erlenmeyer flasks with vented caps at 37 °C with 8% CO2, while shaking in a
standard tissue culture incubator.
3. Dilute cells to 5 x 105/ml density one day before transfection.
4. On the day of transfection, supplement culture medium by adding 10% volume of 2% w/v Cell Boost in 293F media.
1. Measure glucose concentration using a glucose monitor according to the manufacturer's instructions and use supplements as needed
to achieve a glucose concentration of 500 mg/dL.
5. Add kifunensine (1 µg/ml final concentration) at this step to control protein glycosylation.
6. Calculate volume of DNA required for 1 µg plasmid per 1 x 106 cells. Under sterile conditions, dilute DNA in 5 ml serum-free medium.
7. Calculate volume of transfection reagent required for 1 µg plasmid per 2 µl transfection reagent. Under sterile conditions, dilute transfection
reagent (PEI-TMC-25) in 5 ml serum-free medium.
8. Add transfection reagent into DNA solution in 1 ml increments, mixing gently. Incubate for 30 min at RT for reagent-DNA complexes to form.
Then add the solution onto the cells in a drop-wise fashion.
9. Allow transfected cells to express protein for 72-96 hr. Supplement with ~10% volume Cell Boost Media daily, or as necessary to keep
glucose reading 400-600 mg/dl.
3. Purification
1. Decant culture into a centrifuge flask, centrifuge for 20 min at 1,300 x g to pellet cells and then collect the supernatant. If necessary, spin a
second time and/or use 0.22 µm filter to clarify supernatant.
2. Add 10% volume 10x Ni-NTA binding buffer (1.5 M NaCl, 0.5 M K2HPO4, 0.1 M Tris pH 8.5, 50 mM imidazole).
3. Prepare a gravity column by adding 2 ml of Ni-NTA slurry in a column and equilibrating with 10 column volumes (CV) of 1x binding buffer.
If possible, do all column steps in a 4 °C room. Alternatively, chill protein and all buffers on ice before column step, and keep protein and
collected flow-through on ice.
Note: Ni-NTA slurry is 50% resin by volume and the manufacture's stated binding capacity is 50 mg/ml. Ni-NTA beads can be re-charged for
multiple uses
4. Flow the supernatant over the resin and collect flow-through. Repeat this step.
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5. Wash with 10 CV of wash buffer (300 mM NaCl, 50 mM K2HPO4, 20 mM imidazole pH 8).
6. Elute the protein in 5 CV of elution buffer (300 mM NaCl, 50 mM K2HPO4, 250 mM imidazole pH 8).
7. If deglycosylation is required:
1. For a final volume of 0.5 ml, concentrate eluate to 0.43 ml using a centrifugation concentrator. If precipitates form, pellet any debris by
centrifugation at 16,000 x g and 4 °C.
2. Add 50 µl of 500 mM Na-Citrate pH 5.5.
3. Add 20 µl of EndoHf (1 x 106 U/ml). Incubate at RT for 2 hr.
Note: The enzyme works optimally at 37 °C, which may cause the concentrated protein to aggregate. Extend the RT incubation, if
deglycosylation, assessed by SDS-PAGE or immunoblotting, is incomplete. The enzyme does not have activity at 4 °C.
4. To remove EndoHf: Wash Amylose Resin 3x in phosphate buffered saline (PBS) or final storage buffer. Incubate protein with resin for 1
hr at 4 °C. Spin 5 min at 1,000 x g to pellet beads and collect the supernatant.
5. Concentrate protein using appropriate molecular weight cutoff centrifugation filter and buffer exchange into storage buffer (150 mM
NaCl and 20 mM HEPES pH 7.5).
Representative Results
Herein follows the results of this expression system applied to a secreted 13 kDa immunoglobin (Ig) domain from the human protein triggering
receptor expressed on myeloid cells 2 (hTREM2, residues 19-132). TREM2 is a type I transmembrane protein containing a single extracellular
Ig domain that has two disulfide bonds and two N-linked glycosylation sites. Unlike many other Ig domain proteins8, TREM2 was not amenable
to refolding from bacterial inclusion bodies9. Subsequent mutagenesis confirmed N-linked glycans are required for proper expression and
folding. To facilitate structural and functional studies, TREM2 was introduced into the pHLsec vector with a C-terminal 6His-tag7 using standard
molecular biology techniques. Transient expression in HEK293F cells treated with kifunensine yielded protein that was purified by Ni-NTA
chromatography (Figure 1B, lane 2) and the sample was then deglycosylated to produce natively folded, homogenous protein (Figure 1B, lane
3). 293F expression of TREM2 produced 5-10 mg/L (5-10µg/million transfected cells). After buffer exchanging into the storage buffer, this protein
was crystallized (Figure 1C). Despite the final purity of about 80%, these crystals reliably reproduced, diffracted, and were shown by silver-
stain to only contain TREM2 protein (Figure 1D). This observation suggests the biochemical homogeneity of the protein (i.e., folding and post-
translational modifications) can, in some cases, be more critical than overall purity for crystallization success.
In addition to crystallization, this system offers a robust tool for structural and functional studies. It is exploited to produce natively glycosylated
protein and achieve >95% purity by size-exclusion chromatography (Figure 1E, F). This additional purification step, which shows the solution
behavior of the protein, is also an ideal way to monitor protein quality. The purified protein should elute at a volume corresponding to its
molecular weight and should be the most abundant species in the sample. Abnormally large amounts of aggregated protein may indicate
unstable protein and provide clues to optimize protein production and purification. Furthermore, this final purified protein is superior for use in
quantitative biophysical experiments such as circular dichroism spectroscopy, thermal stability, and investigating protein-ligand interactions.
Lastly, controlling the extent of glycosylation provides a robust tool to study glycan-dependent functions.
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Figure 1. Mammalian Expression System: (A) Scheme for mammalian expression of proteins with controlled or native glycosylation in HEK
293F cells. (B) SDS-PAGE of NiNTA-purified hTREM2 expressed under kifunensine shown before (lane 2) and after (lane 3) deglycosylation
with EndoHf. (C) Crystals produced from NiNTA-purified and deglycosylated protein. (D) Silver stain of crystallization input (lane 1) and
harvested crystals (lanes 2 and 3) reveals crystals only contain TREM2. (E) Further purification of TREM2 was achieved using size-exclusion
chromatography of NiNTA-purified TREM2 produced in 293F cells without Kifunensine. Asterisks (*) indicate elution volumes of molecular weight
standards. Proteins eluted in TBS using an analytical S200 column (GE). (F) SDS-PAGE analysis of size exclusion-purified TREM2: input protein
(lane 2) and folded peak (lane 3). Note how full, heterogeneous glycans run at a higher apparent molecular weight with a broad smear by SDS-
PAGE. Please click here to view a larger version of this figure.
Discussion
HEK 293F cells offer robust production of proteins requiring post-translational modifications. This system allows rapid and scalable expression of
natively folded proteins containing disulfides, glycosylation, and phosphorylation that would otherwise be absent using more routine expression
tools. In addition, this system can be used for the expression and purification of multi-protein complexes simply by co-transfection of multiple
plasmids. Besides TREM2, this system has been extensively used for functional studies with other proteins of interest in the lab10,11. Mammalian
cells also offer endotoxin-free protein expression optimal for in vivo experiments or for production of natively folded antigens to generate
conformation-dependent antibodies.
Optimal cell viability and transfection conditions are the most crucial for efficient protein production. For better cell viability, low-passage
cell cultures are boosted with cell culture supplements and the antibiotic concentration in the growth media is reduced. The modified PEI-
TMC-25 has suitable transection efficiency with most proteins; however, there are other options available at moderate price that offer increased
transfection efficiency and reduced cytotoxicity. Hype 5 (Oz Bioscience) increases yields compared to PEI or other reagents, at a considerably
reduced cost compared to more expensive transfection reagents, such as 293fectin. The reagent type and DNA: reagent ratios can be optimized
for individual expressions and the needs of the desired experiment.
The method described here has several advantages over other methods of protein production. Mammalian cells offer native chaperone folding
and post-translational modifications unavailable to bacteria and yeast. The reduced time for plasmid construction and preparation, along the use
of media, the pH of which can be directly modified, make it superior to baculovirus-based production in insect cells; and finally, the serum-free
media offers facile scaling (higher cell density) and purification not attainable to adherent 293T cells. The chief limitation of this system is only the
time and scale the individual researcher is able to commit to protein expression.
Included below are troubleshooting options for the most common issues encountered.
Troubleshooting
If there is low protein expression, avoid passaging 293F cells longer than 2-3 months. Prolonged passaging results in decreased cell health
reflected in slower doubling times and significantly reduced protein expression. Cell growth should be monitored daily and cultures no longer
doubling daily should be discarded. Cell viability can be improved by using culture supplements while passaging cells. Monitor glucose to ensure
a culture concentration of 400-600 mg/dl Cell density should not exceed 2 million/ml and cell viability should be ≥98% by trypan blue exclusion.
Dilute dense cells to 0.5 million/ml and allow to double O/N before transfection. Optimize transfection using different ratios of transfection
reagent: DNA (within the range of 1 µg DNA: 1.5-6 µl reagent). This can be done using 2 ml cultures in a 6-well plate and the output measured
by immunoblotting. Doing 12 hr time points can indicate if the protein is being expressed and degraded rapidly; check the cell lysate if protein is
not observed in the supernatant fraction. Misfolded proteins, which fail to be secreted, will still be apparent in the cell lysate by immunoblotting.
If Ni-NTA retention is low, i.e., protein remains in flow-through after column binding, use fresh resin. Increasing pH of sample to 8.5 will result
in stronger binding to the resin, although this will also increase non-specific binding. Concentrating the sample and batch binding to resin O/N
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at 4 °C before Ni-NTA purification may result in ~5x increase in recovered protein. If the 6His-tag is inaccessible due to tertiary structure of the
protein, try cloning it on the other terminus. Alternatively, use Cobalt resin, which has a higher affinity for His residues.
If the protein aggregates and/or precipitates during purification, increase solubility by adding 10% glycerol into the Ni-NTA wash and elution
buffers. Run the nickel affinity columns at RT instead of 4 °C. Use differential scanning fluorimetry12 to screen for pH and salt/additives that
increase stability of the protein in solution.
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Abstract Genetic variations in the myeloid immune receptor TREM2 are linked to several
neurodegenerative diseases. To determine how TREM2 variants contribute to these diseases, we
performed structural and functional studies of wild-type and variant proteins. Our 3.1 A˚ TREM2
crystal structure revealed that mutations found in Nasu-Hakola disease are buried whereas
Alzheimer’s disease risk variants are found on the surface, suggesting that these mutations have
distinct effects on TREM2 function. Biophysical and cellular methods indicate that Nasu-Hakola
mutations impact protein stability and decrease folded TREM2 surface expression, whereas
Alzheimer’s risk variants impact binding to a TREM2 ligand. Additionally, the Alzheimer’s risk
variants appear to epitope map a functional surface on TREM2 that is unique within the larger
TREM family. These findings provide a guide to structural and functional differences among genetic
variants of TREM2, indicating that therapies targeting the TREM2 pathway should be tailored to
these genetic and functional differences with patient-specific medicine approaches for
neurodegenerative disorders.
DOI: 10.7554/eLife.20391.001
Introduction
The precise molecular determinants and mechanisms underlying neurodegenerative diseases remain
uncertain, but recent large-scale genetic sequencing projects have uncovered new candidates asso-
ciated with these diseases. For example, whole genome and whole exome sequencing has identified
point mutations in the gene encoding the protein TREM2 (triggering receptor expressed on myeloid
cells 2) that correlate with a significantly increased risk of developing Alzheimer’s disease (AD)
(Guerreiro et al., 2013b; Jonsson et al., 2013). In particular, the TREM2 R47H variant is associated
with a risk that is similar to that associated with APOE4, previously the only well-established risk fac-
tor for late-onset AD. This mutation correlates with increased cerebrospinal fluid (CSF) tau levels, a
well-established risk factor for AD (Cruchaga et al., 2013), and subsequent studies have identified
this mutation in patients who have frontal temporal dementia (FTD), Parkinson’s disease (PD)
(Rayaprolu et al., 2013), and sporadic amyotrophic lateral sclerosis (ALS) (Cady et al., 2014). A
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recent study of more than 1,600 late-onset AD (LOAD) and cognitively normal brains revealed that
microglia-specific networks, including those containing TREM2, are those most significantly dysregu-
lated in LOAD (Zhang et al., 2013). Thus, even in the absence of rare variants in TREM2 that
increase AD risk, TREM2-containing pathways play a significant role in disease. Recent studies in AD
mouse models that are deficient in TREM2 confirm that loss of TREM2 function contributes to classic
AD pathology and demonstrates a crucial role for TREM2 in central nervous system (CNS) biology
(Jay et al., 2015; Wang et al., 2015; Ulrich et al., 2014). TREM2-deficient AD mice display fewer
activated microglia, and the absence of TREM2 prevents microglia proliferation and promotes micro-
glia apoptosis, which was correlated with increased accumulation of Ab plaques (Wang et al., 2015;
Jay et al., 2015). Microglia in TREM2-deficient AD mice displayed less activation and did not engulf
Ab plaques. This impacts the density of Ab plaques and promotes diffuse Ab structures, which in
turn are more neurotoxic, and contributes to the accumulation of classic AD pathology (Wang et al.,
2016; Yuan et al., 2016). These findings highlight a crucial role for TREM2 in maintaining CNS
homeostasis. Therefore,understanding how these risk variants affect TREM2 function and contribute
to the pathogenesis of neurodegenerative diseases is vital to the development of therapies target-
ing these devastating conditions.
TREM2 is an innate immune receptor expressed on dendritic cells (DCs), resident macrophages
such as osteoclasts and microglia, infiltrating (Jay et al., 2015) and inflammatory (Wu et al., 2015)
macrophages, and CSF monocytes (Colonna and Wang, 2016). It is a type one receptor protein
consisting of an extracellular V-type Ig domain, a short stalk, a transmembrane domain that associ-
ates with the adaptor protein DAP12 for signaling, and a cytoplasmic tail (Figure 1a)
(Colonna, 2003). TREM2 has historically been shown to play an anti-inflammatory role in vitro by
antagonizing the production of inflammatory cytokines from bone-marrow-derived macrophages
eLife digest Alzheimer’s disease is a neurodegenerative disease and the most common cause of
dementia – characterized by memory loss and difficulties with thinking, problem solving and
language – in the elderly. Individuals with rare mutations in the gene that encodes a protein called
TREM2 have a substantial risk of developing Alzheimer’s disease in their mid-60s. A different set of
mutations in the gene for TREM2cancause a more severe degenerative brain disease known as
Nasu-Hakola disease in much younger people.
Proteins are made up of chains of building blocks called amino acids that need to fold into
specific three-dimensional shapes to allow the protein to work properly. TREM2 is a signaling
protein that is found on the surface of immune cells in the brain. Mutations causing Alzheimer’s and
Nasu-Hakola disease result in the production of mutant TREM2 proteins that differ from the normal
protein by only a single amino acid. It is not clear how different mutations affecting the same protein
can give rise to two distinct neurodegenerative diseases.
To address this question, Kober et al. used a range of techniques to study normal and mutant
TREM2 proteins. First, a technique called X-ray crystallography – which makes it possible to
construct three-dimensional models of proteins – revealed that the mutations responsible for Nasu-
Hakola disease are buried deep within the core of the folded TREM2 protein. On the other hand,
mutations associated with Alzheimer’s disease lie on the surface of the protein.
Further experiments examined how these mutations alter the properties of TREM2, revealing that
mutations linked to Nasu-Hakola disease affect the ability of TREM2 to fold correctly and how stable
its final shape is. This results in fewer TREM2 proteins being present on the surface of immune cells.
In contrast, mutations associated with Alzheimer’s disease make it harder for TREM2 to bind to
molecules known as glycosaminoglycans. The Alzheimer’s mutations affect a specific part of TREM2
that is not found in other closely related proteins.
The findings of Kober et al. suggest that TREM2 binding to glycosaminoglycans is likely to be
important in preventing Alzheimer’s disease. The next step following on from this work is to find out
exactly how these interactions affect immune cells, which may aid the development of new therapies
for this disease.
DOI: 10.7554/eLife.20391.002
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(BMDMs) and dendritic cells (BMDDCs) in response to FcR (Hamerman et al., 2006) and Tlr signal-
ing (Turnbull et al., 2006; Ito and Hamerman, 2012). Likewise, TREM2 participates in phagocytosis
of apoptotic cells in cultured microglia and reduces the production of inflammatory cytokines
(Takahashi et al., 2005). However, TREM2-expressing macrophages can also promote inflammatory
disease in the brain (Jay et al., 2015) and lung (Wu et al., 2015). The identity of a physiologic
TREM2 ligand (TREM2-L) remains uncertain, although several classes of molecules have been
Figure 1. Crystal structure of the human TREM2 ectodomain. (a) Schematic of TREM2 cell-surface association with adapter protein DAP12,
which contains an Immuno Tyrosine Activation Motif (ITAM). Engagement of TREM2-L by the ectodomain of TREM2 induces signaling. Domain
boundaries are indicated. (b) TREM2 ectodomain in two orientations with disease-linked residues shown as sticks. The positions of AD risk variants are
shown in magenta, whereas Nasu-Hakola disease (NHD) mutations are shown in cyan. The N-acetylglucosamine (NAG) is shown as green sticks. (c)
Table of TREM2 disease-linked mutations, associated disease, and calculated solvent accessible surface exposure for the side-chain (calculated using
Naccess), along with statistical correlations to AD (OR = odds ratio; MAF = mean allele frequency) (from Jin et al., 2014). Table is highlighted with
same color scheme as Figure 1b. Validated AD risk variants (R47H and R62H) are not marked. Potential AD risk variants are denoted with an asterisk.
(d) Side-by-side stereo view of difference electron density (2mFo-DFc contoured at 2s) for the N79-NAG. (e–g) Difference electron density (2mFo-DFc
contoured at 2s) for the surface-exposed AD-associated mutation positions (e) R47, (f) R62 and (g) T96.
DOI: 10.7554/eLife.20391.003
The following figure supplements are available for figure 1:
Figure supplement 1. Analysis of TREM2 glycosylation, comparison of TREM2 monomers in the crystal structure, and SA-omit maps of AD-linked
residues.
DOI: 10.7554/eLife.20391.004
Figure supplement 2. Packing neighbors for the TREM2 AD risk variant R47 and the TREM2 NHD mutants Y38, T66, and V126.
DOI: 10.7554/eLife.20391.005
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proposed, including bacterial carbohydrates (Daws et al., 2003; Quan et al., 2008), sulfoglycolipids
(Phongsisay et al., 2015), nucleic acids (Kawabori et al., 2015), phospholipids (Cannon et al.,
2012; Wang et al., 2015) and proteins (Stefano et al., 2009; Takegahara et al., 2006; Yoon et al.,
2012; Atagi et al., 2015; Bailey et al., 2015). Additionally, previous studies have identified cells
that express a TREM2-L, including astrocytes (Daws et al., 2003), DCs (Ito and Hamerman, 2012),
BMDMs (Hamerman et al., 2006), neurons and apoptotic cells (Hsieh et al., 2009). This growing
body of literature underscores the case for immune deregulation, specifically involving TREM2-asso-
ciated pathways in neurodegenerative and inflammatory diseases (Golde et al., 2013).
Intriguingly, genetic variations in TREM2 are associated with two distinct groups of neurodegen-
erative diseases. Homozygous mutations including early-stop codons (Paloneva et al., 2003;
Soragna et al., 2003), splice site mutations (Numasawa et al., 2011; Chouery et al., 2008),
the coding stalk mutations D134G and K186N (Paloneva et al., 2002), and the coding ectodomain
mutations Y38C, T66M, and V126G (Guerreiro et al., 2013a, 2013c; Le Ber et al., 2014) cause
either NHD, characterized by early-onset dementia, demyelination, and bone cyst lipoma
(Paloneva et al., 2002; Colonna, 2003), or a frontotemporal dementia variant with severe loss of
brain matter but lacking the bone manifestations. By contrast, TREM2 mutations associated with AD
contribute to disease risk as heterozygous variants. In addition to R47H, the coding mutation R62H
is associated with increased risk of AD in independent studies (Jin et al., 2014; Ridge et al., 2016).
These two variants have the strongest risk link to AD. N68K and D87N have also been identified in
AD patients, but because these mutations are very rare, their risk remains uncertain
(Guerreiro et al., 2013b; Jonsson et al., 2013). In addition, the mutation T96K has been linked to a
decreased risk of AD, but this mutation is also too rare to allow verification of this observation
(Jin et al., 2014). This curious segregation of disease phenotypes by distinct mutations occurring
within the same protein suggest that these mutations should have divergent effects on the structure
and function of TREM2.
In order to understand the molecular basis of how different mutations within TREM2 can lead to
distinct neurodegenerative diseases, we performed structural, biophysical, and functional studies of
wild-type (WT) and mutant TREM2 proteins. To facilitate these studies, we developed a novel mam-
malian expression system to produce the natively folded and glycosylated TREM2 ectodomains in
milligram quantities (Kober et al., 2014, 2015). We determined the crystal structure of the TREM2
ectodomain at 3.1 A˚ resolution and found that the disease-linked mutations exhibit distinct structural
patterns, suggesting that they would impact TREM2 function through alternate mechanisms. To
investigate this hypothesis, we carried out extensive biophysical, cellular, and functional assays. We
found that NHD-causing mutations impact TREM2 protein folding and stability, whereas AD risk var-
iants decrease binding to the cellular TREM2-ligand (TREM2-L). Furthermore, these AD-linked muta-
tions appear to epitope map a disease-relevant functional surface on TREM2 that facilitates binding
to cell-surface TREM2-L. These findings demonstrate two distinct loss-of-function mechanisms for
TREM2, illuminate a disease-relevant functional surface on TREM2, and pave the way for the devel-
opment of patient-specific molecular therapies for the treatment of distinct neurodegenerative
diseases.
Results
Structure of the hTREM2 ectodomain
We previously reported the crystallization of the WT human TREM2 ectodomain (amino acids 19–
134) purified from a mammalian cell expression system (Kober et al., 2014). These crystals dif-
fracted to 3.1 A˚ (Table 1 and Table 2). The TREM2 ectodomain is a V-type Ig domain containing
two disulfide bonds, the canonical Ig disulfide between residues C36 and C110 (bB–bF) and an addi-
tional linkage between C51 and C60 (bC-bC’) (Figure 1b). A single N-acetylglucosamine (NAG) gly-
can that remains after Endo Hf treatment (Figure 1—figure supplement 1a) is clearly visible in the
electron density at residue N79 (Figure 1d and Figure 1—figure supplement 1g). The nine b-
strands characteristic of proteins within this Ig domain class are present, and two short a-helix pas-
sages are observed spanning b-sheets B–C and E–F. The asymmetric unit (ASU) contains two mono-
mers of hTREM2 in a parallel arrangement, but the limited buried surface area (~400 A˚2) and
chemical nature of the interface suggest that this dimer would not exist in solution (Figure 1—figure
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supplement 1b). Furthermore, these two monomers are quite similar (Ca RMSD of 0.65 A˚, Fig-
ure 1—figure supplement 1c), therefore, our analysis of hTREM2 described henceforth will refer to
chain A.
Table 1. Determination of resolution cut-off by evaluation of meaningful data.
To evaluate the functional resolution of data past 3.3 A˚, data were scaled to 3.0 A˚ resolution. Data were successively truncated at 0.1
A˚ intervals from 3.4 A˚ to 3.0 A˚ and the initial 3.3 A˚ solution was used to initiate molecular replacement, rigid body refinement and XYZ
refinement in PHENIX without manual refinements. After refinement at the higher resolution, the resulting model was used to calculate
R and Rfree values at the immediate lower resolution. If this resulted in a better model, as judged by Rfree, the higher resolution data
are useful for improving the model. Data at resolutions that improved the model are highlighted in green while data at resolutions
that worsened the model are highlighted in red.
Refine at:
3.3 3.2 3.1 3.0
Calculate at: 3.3 26.26/31.66 25.30/31.47
3.2 26.75/31.88 26.79/31.80
3.1 27.71/32.47 27.64/32.87
3.0 28.30/32.52
DOI: 10.7554/eLife.20391.006
Table 2. Data collection and refinement statistics.
Human TREM2 ectodomain
Data collection
Space group P 64 2 2
Cell dimensions
a, b, c (A˚) 125.76, 125.76, 183.70
a, b, g (˚) 90, 90, 120
Resolution (A˚) 50.00–3.10 (3.21–3.10)*
Rsym 0.11 (1.00)
Mean I / sI 21.0 (1.76)
Completeness (%) 99.88 (99.75)
Redundancy 12.9 (13.4)
Refinement
Resolution (A˚) 50.00–3.10
No. reflections 16,285
Rwork / Rfree 0.2605/0.2736
No. atoms 1,784
Protein 1,756
Carbohydrate 28
B-factors 93.48
Protein 92.39
Carbohydrate 162.1
R.m.s. deviations
Bond lengths (A˚) 0.006
Bond angles (˚) 1.18
*Values in parentheses are for highest-resolution shell.
DOI: 10.7554/eLife.20391.007
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We analyzed the structure to map the location of disease-linked point mutations and noticed an
intriguing pattern. The side chains of mutations causing NHD (Y38, T66 and V126) are all buried
within the core of the Ig fold, whereas the side chains of verified AD risk variants (R47H and R62H)
and possible AD risk variants (N68K, D87N and T96K) all lie on the protein surface (Figure 1b).
Quantification using solvent-accessible surface calculations verified this qualitative observation
(Figure 1c). Using structural analysis, we can hypothesize how the buried NHD mutations could neg-
atively impact protein folding. Y38 is adjacent to C36, which forms an intramolecular disulfide with
C110, so the Y38C mutation most likely disrupts correct disulfide formation (Figure 1—figure sup-
plement 2b). T66 immediately follows the C’ b-sheet and is tightly packed inside the core of the pro-
tein, with the side chain hydroxyl engaging the backbone amide of K48 (Figure 1—figure
supplement 2c). The T66M mutation would sterically disrupt this packing and probably destabilize
the protein. V126 is located on b-sheet G; it is entirely buried and contributes to a hydrophobic core
of the buried residues F24, D104, A105, and Y108. Removal of the side chain by the V126G mutation
would disrupt this packing and probably destabilize this hydrophobic core (Figure 1—figure supple-
ment 2d). In addition, sequence analysis reveals that Y38 and V126 are conserved within the TREM
family, implying that they are probably required to preserve the common fold within this family of
receptors (Figure 5c). The T66 residue is less conserved in the TREM family, but is highly conserved
in TREM2 proteins across species.
In stark contrast to the NHD mutants, all of the residues implicated in the development of AD are
surface exposed (Figure 1b,c,e–g) and engage in very few structure-stabilizing contacts. R47, the
residue with the strongest link to AD as the R47H variant, is at the end of the loop preceding b-sheet
C. It is well-ordered in the structure with the side chain lying parallel along the surface of the protein,
and the side-chain amines engage the carbonyl oxygen of T66 (Figure 1e, Figure 1—figure supple-
ment 2d, and Figure 1—figure supplement 2a). R62, another strong AD risk factor as the R62H var-
iant, comes after the loop marked by the C51-C60 disulfide bond (Figure 1f and Figure 1—figure
supplement 2e). Its side chain faces outward and makes no polar contacts. N68 is also surface
exposed and its side chain makes no obvious polar contacts within the molecule. D87 is at the end
of b-strand D; its side chain extends from the protein surface and the side-chain carboxyl engages
the backbone amide of G90. This interaction probably stabilizes the bD-E loop. T96 is on the end of
b-strand E and its side chain points away from the surface and engages the side chain of Q33
(Figure 1g and Figure 1—figure supplement 2f). On the basis of this structural analysis of neurode-
generative disease mutations in TREM2, we hypothesized that NHD mutants (which are buried)
would affect protein folding and stability and thus decrease their surface expression, whereas AD
risk variants (which lie on the protein surface) would not affect surface expression and instead proba-
bly impact ligand binding.
Impact of TREM2 variants on folding and surface expression
To begin to test tour hypothesis, we expressed each TREM2 ectodomain variant and analyzed their
secretion and solution properties using size exclusion chromatography. WT hTREM2 ectodomain
consistently eluted as a monomer (Figure 2a and b), in accordance with our crystallographic analysis.
The verified (R47H and R62H) and possible (N68K, D87N and T96K) AD-risk variants all elute at the
same volume as WT TREM2 (Figure 2—figure supplement 1g–l), suggesting that these mutations
do not drastically alter the folding or oligomerization of TREM2 in solution. Furthermore, all of the
TREM2 AD risk variant ectodomains migrated as monomers in the absence of reducing agent
(Figure 2b). By contrast, although the buried NHD mutants Y38C, T66M, and V126G were secreted,
they elute much earlier, consistent with aggregation and misfolding of these proteins (Figure 2—fig-
ure supplement 1m–o). Consistent with this observation, SDS-PAGE analysis of TREM2 NHD
mutants in the absence of reducing agent showed that these ectodomains were largely produced as
covalent dimers or trimers, indicating that misfolding of these mutants promoted the formation of
aberrant intermolecular disulfide bonds (Figure 2c).
Given that our structural analysis suggested that the TREM2 NHD mutants should be misfolded,
we were surprised to observe that these ectodomains bypassed cellular quality control and were
secreted. We therefore devised an assay using flow cytometry to investigate whether these point
mutants in full-length TREM2 impair cell surface expression. DAP12 was co-expressed with FLAG-
tagged WT or mutant TREM2 full-length proteins and surface expression was measured either by an
anti-FLAG antibody or by anti-TREM2 sera raised against our secreted, folded protein. Whole-cell
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Figure 2. Chromatographic and surface expression analysis of WT and variant TREM2. The schematic depicts the domain of TREM2 used in the
experiments shown in (a–c). (a) Gel filtration chromatography profile (Superdex 200 10/300 GL) of purified WT human TREM2 ectodomain showing
a single monomeric peak. (b) SDS-PAGE analysis of purified TREM2 AD risk variants prepared with (+) and without (-) reducing agent (b-
mercaptoethanol). (c) Western blot analysis of TREM2 NHD mutants secreted from transfected 293F cells prepared with (+) and without (-) reducing
agent (b-mercaptoethanol). The NHD mutants Y38C, T66M, and V126G all migrate as higher MW oligomers under non-reduced conditions, indicating
that they are misfolded and linked by aberrant intermolecular disulfide bonds. Purified WT TREM2 is shown for comparison. Representative of more
than three independent expressions. The second schematic depicts FLAG TREM2 used in the experiments shown in (d–h). (d–e) Surface expression of
WT and variant TREM2 in 293F cells assayed by flow cytometry. Full-length FLAG-WT or mutant TREM2 were co-transfected with mDAP12 into 293F
cells. Surface expression was measured by either (d) a polyclonal serum or (e) an anti-FLAG antibody. Normalized TREM2 indicates the normalized
Figure 2 continued on next page
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expression levels of the TREM2 NHD mutants were slightly higher than those of WT or AD risk vari-
ant TREM2 (Figure 2f). However, as predicted by our structural analysis, anti-TREM2 staining was
decreased for the NHD mutants Y38C, T66M, and V126G, but not for the AD risk variants R47H,
R62H, N68K, D87N, and T96K (Figure 2d). Similar observations were made using a commercial anti-
TREM2 antibody (R&D, Figure 2—figure supplement 2). By contrast, the anti-FLAG antibody
showed surface expression for all TREM2 mutants (Figure 2e). We next examined cells expressing
TREM2 WT, NHD mutant Y38C, and AD risk variant R47H by immuofluorescence confocal micros-
copy in the presence or absence of permeabilization. We found that the surface expression pattern
in non-permeabilized cells was similar for all cell types, whereas in permeabilized cells, the NHD
mutant Y38C displayed diffuse intracellular accumulation, in comparison to WT and R47H which dis-
played a distinct punctate staining pattern (Figure 2g). Taken together, these results suggest that
NHD mutant proteins do retain some level of surface expression; but the protein is misfolded or
aggregated and thus is not recognized by conformation-specific TREM2 antibodies. Consistent with
these observations, we found significant amounts of SDS-resistant aggregates by anti-FLAG immu-
noblotting when expressing the full-length TREM2 NHD mutants in 293T cells (Figure 2h). Finally,
we evaluated how these different classes of mutations impact TREM2 signaling by crosslinking the
different versions of FLAG-TREM2 using anti-FLAG antibody. Consistent with our observation of
FLAG-TREM2 on the cell surface for all the variant proteins, we found that while both the Y38C and
R47H variants have some signaling potential, as assessed by phosphorylated-ERK blotting in
RAW264.7 and Cos-7 cells, neither of these variants sustains signaling as efficiently as WT TREM2
(Figure 2i,j). The loss of sustained signaling by the disease variants may suggest that these
mutant proteins have aberrant folding kinetics (and thus are replenished more slowly at the surface
than WT proteins) or cannot bind co-factors that may be required to sustain signaling. Altogether,
these experiments demonstrate that the buried residue changes linked to NHD cause misfolding
and aggregation, with variable impact on surface expression, as would be suggested by our struc-
tural analysis.
AD variants slightly impact TREM2 stability and structure
We next sought to evaluate whether the AD-linked surface mutations affect protein structure or sta-
bility using sensitive solution techniques. First, we used circular dichroism (CD) spectroscopy to ana-
lyze whether AD-linked variants induced large conformational changes in the TREM2 ectodomain.
For these experiments, we chose to analyze the R47H and R62H mutations, as they represent the
Figure 2 continued
fraction of cells staining positive over DAP12-only background. Data are from four (d) or five (e) independent experiments. Bars are color-coded in the
same way as the residues in Figure 1b (cyan = NHD mutant; magenta = AD risk variant). Error bars are SEM. Significance was determined by ANOVA
with Bonferroni post-test correction. (*p<0.05, **p<0.01, and ***p<0.001). (f) Western blot analysis of whole-cell lysates of 293F cells used in (d) and (e)
showing expression levels of WT, NHD mutant (Y38C, T66M and V126G), and AD risk variant (R47H, R62H, N68K, D87N and T96K) TREM2. Note that
the NHD mutants are more highly expressed than the AD risk variants. (g) Confocal microscopy of 293F cells co-transfected with DAP12 and FLAG-
TREM2. Cells were fixed and either permeabilized (left) or non-permeabilized (right) and stained with anti-FLAG antibody (red). (h) FLAG-TREM2 full-
length constructs were co-transfected with DAP12 into 293T cells and expression analyzed by anti-FLAG immunoblot. Samples were prepared by
suspending cells in reducing SDS loading buffer and boiling for no more than 5 min. We observe SDS-resistant aggregate bands for the NHD variants,
which were largely absent in WT and AD risk variants. The T96K variant shows some light aggregation, consistent with the slight shift (~5˚C) in
denaturation temperature for that variant (Figure 3). Schematic depicts FLAG TREM2 signaling assay employed in the experiments shown in (i–j). (i)
TREM2 signaling analyzed by phosphor-ERK1/2 and ERK1/2 immunoblot in RAW264.7 macrophage cells transfected with WT or variant FLAG-TREM2.
(RAW264.7 cells express endogenous DAP12.) 24 hr post-transfection, cells were stimulated with anti-FLAG antibody (1:100) for the indicated length of
time. ERK/pERK content was assessed by immunoblot. In these cells, we observe pERK at 10 min post-stimulation. However, only WT sustained
signaling 30 min post-stimulation. (j) TREM2 signaling analyzed in Cos-7 cells as in (c). Cos-7 cells were co-transfected with DAP12 and TREM2. In these
cells, there is a non-specific antibody response at 10 min. However, as in the RAW264.7 cells, we observe sustained WT signaling at the later time point
which is diminished in R47H and Y38C variants.
DOI: 10.7554/eLife.20391.008
The following figure supplements are available for figure 2:
Figure supplement 1. Analysis of WT and variant TREM2 ectodomains by size exclusion chromatography.
DOI: 10.7554/eLife.20391.009
Figure supplement 2. hTREM2 surface expression probed using a commercial antibody.
DOI: 10.7554/eLife.20391.010
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most significant TREM2 risk factors identified to date, as well as the T96K mutation, which is a spo-
radically occurring mutation that is not significantly associated with AD. In order to evaluate whether
the point mutations induced conformational changes, we collected CD spectra on the proteins, ana-
lyzed for large changes, and compared the ratio in minima at 214 nm (due to b sheets) to minima at
233 nm (due to tryptophans), which are characteristic features of the CD spectra for Ig folds
(Sikkink and Ramirez-Alvarado, 2008). We found that R62H and T96K displayed CD spectra similar
to WT proteins while, surprisingly, R47H showed a subtle, yet statistically significant difference in the
214 nm/233 nm ratio (Figure 3a and b). Thus the R47H mutation in TREM2 seems to induce a small,
but measurable, conformational change, whereas the R62H and T96K mutations do not induce any
structural changes detectable by CD.
We next investigated the impact of these mutations on thermal stability using differential scan-
ning fluorimetry (DSF) (Niesen et al., 2007). Each surface variant produced slightly lower denatur-
ation temperatures, with R47H and R62H marginally reduced when compared to WT proteins and
T96K having the lowest denaturation temperatures (Figure 3c). As a control, the same experiments
were carried out in the presence of 1 mM DTT, which induced the expected shift to lower denatur-
ation temperatures by disrupting the disulfide bonds. We also used thermal denaturation CD to
assess the thermal stability of these proteins. By obtaining full CD scans at 5˚C increments, we
observed that TREM2 has a denaturation transition at 225 nm, consistent with other Ig domains
(Sikkink and Ramirez-Alvarado, 2008), and this wavelength was monitored in subsequent denatur-
ation experiments (Figure 3—figure supplement 1a). WT TREM2 and all the TREM2 variants tested
Figure 3. Structure and stability analysis by CD and DSF of human WT and AD-linked surface variant TREM2 ectodomains. (a) CD spectra of human WT
TREM2 (blue) and R47H (red), R62H (brown), and T96K (green) variants. (b) Ratio of CD minima at 214 nm and 233 nm reveals that R47H has an altered
CD spectrum. Minima ratios were measured on five (WT and R47H) or three (R62H and T96K) independent protein preparations, respectively. (c)
Thermal melt temperatures measured by DSF. (d) WT and variant TREM2 thermal denaturation measured by CD at 225 nm while increasing the
temperature from 20˚C to 90˚C with or without 1 mM DTT.
DOI: 10.7554/eLife.20391.011
The following figure supplement is available for figure 3:
Figure supplement 1. Structure and stability analysis by CD and DSF of human WT and AD-linked surface variant TREM2 ectodomains.
DOI: 10.7554/eLife.20391.012
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showed reversible thermal denaturation as they reacquired their native spectra rapidly after cooling
from 90˚C to 20˚C, but their ability to refold was ablated in the presence of DTT (not shown). In con-
trast to DSF measurements, thermal denaturation by CD did not show a difference between WT,
R47H, and R62H proteins; however, the T96K variant has a pronounced shift towards lower denatur-
ation temperature (Figure 3d). In the presence of DTT, all proteins had lower denaturation tempera-
tures (Figure 3d). We further assayed stability using chemical denaturation by titration of guanidine-
HCl (GuHCl) in CD experiments. The R47H and R62H proteins melt at slightly lower GuHCl concen-
trations than the WT protein, while the T96K variant unfolds at lower GuHCl concentrations than
R47H and R62H, consistent with the thermal melt experiments (Figure 3—figure supplement 1b).
Thus, as predicted by our structural analysis, the AD-risk surface variants do not induce large confor-
mational changes in TREM2, nor do they dramatically impact protein stability, but they can induce
subtle changes in both parameters.
TREM2 AD risk variants impact binding to TREM2-L
Our structural analysis suggested that AD risk variants might impact function by altering ligand bind-
ing due to the surface presentation of the mutated residues. Recently, TREM2 was shown to signal
following stimulation of reporter cells by plated phospholipids, and the R47H mutation resulted in
loss of signaling (Wang et al., 2015). To test the direct binding of TREM2 to phospholipids in a cell-
free system, we used purified protein in solid-state ELISA and liposome sedimentation assays. Con-
sistent with the results of previous work (Cannon et al., 2012), we detected TREM2 binding to phos-
pholipids by both ELISA and liposome sedimentation. However, we did not observe differences in
phospholipid discrimination or in direct lipid binding between WT and AD variant TREM2 ectodo-
mains (Figure 4—figure supplement 1a–c). We therefore investigated binding to a cell surface
ligand (TREM2-L). Although no endogenous protein ligand for TREM2 has yet been identified, sev-
eral cell types have been reported to express a ligand on the basis of staining with a TREM2-Fc
fusion construct (Ito and Hamerman, 2012; Hamerman et al., 2006; Daws et al., 2003;
Hsieh et al., 2009; Stefano et al., 2009). In order to evaluate the effect of AD-linked mutations on
TREM2 binding to TREM2-L, we constructed a novel TREM2 protein cell-binding reagent containing
a site-specific BirA-biotinylation sequence on the C-terminus of TREM2, which could then be com-
plexed with PE-labeled streptavidin to create a tetrameric cell-staining reagent (Figure 4a). In initial
experiments, we found that both human and mouse TREM2/SA-PE tetramers were able to bind Neu-
ro2A (N2A) and THP-1 cells (Figure 4b–d,f,g and Figure 4—figure supplement 2a,c). To validate
the specificity of our reagent, we cultured THP-1 cells with various immune stimuli and found that
overnight treatment with PMA/ionomycin dramatically decreased binding of TREM2/SA-PE tet-
ramers to THP-1 cells (Figure 4b and c), while the myeloid cell marker CD45 remained unchanged
(not shown). Other stimuli tested (overnight exposure to IL-13, Poly I:C, LPS, or M-CSF) did not alter
staining (Figure 4—figure supplement 2a). PMA/ionomycin treatment is the first identified stimulus
that ablates TREM2 staining, and this confirms that TREM2 recognizes a specific cell-surface ligand.
We next sought to interrogate the endogenous target recognized by TREM2 on the cell surface,
and found that TREM2 binding is sensitive to proteinase treatment of cells prior to incubation with
our staining reagent (Figure 4d and Figure 4—figure supplement 2b). Treatment with proteinase K
abolished binding while the more specific proteases chymotrypsin and elastase had an intermediate
effect. Proteinase K treatment did not affect cell viability, which was >99% by 7-aminoactinomycin D
(7-AAD) staining (Figure 4—figure supplement 2f). This demonstrates that TREM2-L contains a pro-
tein component. In addition, given the high pI of TREM2, and the frequent reports of anionic poten-
tial ligands for TREM2, we reasoned that proteoglycans containing highly sulfated
glycosaminoglycans (GAGs) may facilitate cell-surface binding. We tested binding to wild-type CHO-
K1 cells, which express heparan and chondroitin sulfates, and to CHO-745 cells, which are deficient
in GAG maturation and surface expression (Esko et al., 1985). In this experiment, GAG-dependent
cell binding of the TREM2 tetramer was observed (Figure 4e). Next, we used heparinases (which
also cleave heparan sulfates) and chondroitinase ABC to ask whether TREM2 selectively binds either
type of GAG. In CHO (Figure 4e), THP-1 (Figure 4f) and N2A (Figure 4g) cells, treatment with hep-
arinases had a pronounced effect on cell surface binding while chondroitinase only slightly dimin-
ished binding, together implicating GAGs, specifically heparin sulfate, as a major component of the
cell surface TREM2-L.
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Figure 4. AD risk variants in TREM2 alter binding to cell surface TREM2-L. (a) Schematic outlining the flow cytometry experiments in (b–g). TREM2
ectodomains were specifically biotinylated at the C-terminus and probed for binding to TREM2-L on the surface cells, which was reduced by pre-
treating cells with proteinases or heparinases. (b–c) Flow cytometry analysis of either (b) mTREM2/SA-PE tetramer or (c) hTREM2/SA-PE tetramer
staining of THP-1 cells ± PMA/ionomycin treatment. (d) Flow cytometry analysis of hTREM2/SA-PE tetramer staining of THP-1 cells pretreated by various
proteases. (e) mTREM2 staining of CHO-745 (GAGless) and CHO-K1 cells. CHO-K1 cells were treated with a cocktail of heparinases, chondroitinase
ABC, or both. (f–g) mTREM2 staining of (f) THP-1 and (g) N2A cells treated with heparinases, chondroitinases, or both. (h) Schematic outline of control
cell-binding experiments with the TREM-like proteins TREML2 and TREML4. On the left is a schematic of receptor versions of TREM2, TREML2, and
TREML4, along with calculated pI values for the respective ectodomains. (i) Tetramer staining of TREM family ectodomains to N2A cells. (j) Schematic
outlining monomeric TREM2-6His cell-staining experiments. Cells were stained with monomeric TREM2-6H and detected using PE-labeled anti-6H
antibody. (k) Representative plot of THP-1 staining by hTREM2-6H analyzed by flow cytometry. (l) MFI of anti-6His staining of SEC-purified hTREM2 WT
and variant ectodomains pre-incubated with THP-1 cells at the indicated concentrations. All data are representative of at least two independent
experiments.
DOI: 10.7554/eLife.20391.013
The following figure supplements are available for figure 4:
Figure supplement 1. TREM2 lipid binding as assessed by phospholipid ELISA and liposome sedimentation.
DOI: 10.7554/eLife.20391.014
Figure supplement 2. TREM2 binding to mammalian cells.
DOI: 10.7554/eLife.20391.015
Kober et al. eLife 2016;5:e20391. DOI: 10.7554/eLife.20391 11 of 24
Research article Biophysics and Structural Biology Neuroscience
Next, we tested the impact of TREM2 AD risk variants on TREM2-L binding in three different for-
mats. For these experiments, we chose to compare WT TREM2, the validated TREM2 AD risk var-
iants (R47H and R62H), and the possibly protective AD risk variant (T96K). We utilized anti-6H
detection of purified monomeric hTREM2 ectodomains bound to THP-1 cells (Figure 4j,k, and l), tet-
ramer staining of WT and variant mTREM2 binding to N2A and THP-1 cells (Figure 4—figure sup-
plement 2c,d), and competition assays in which SEC-purified monomers competed with SA-PE-
labeled WT tetramers (Figure 4—figure supplement 2e). Consistent with our hypothesis, the AD-
linked variant R47H displayed markedly diminished binding to N2A and THP-1 cells. In stark con-
trast, the potentially AD-protective T96K variant significantly increased binding. The R62H variant
reduced binding as measured in the anti-6H format, but the reduction in binding was less
dramatic when measured by competition or tetramer staining, suggesting an intermediate decrease
in affinity. Thus, as suggested by our structural analysis, the AD risk variant R47H TREM2 negatively
impacts binding to cell surface TREM2-L, whereas the variant T96K results in increased cellular bind-
ing. These data, together with our direct phospholipid binding experiments, suggest that TREM2
AD-risk variants retain phospholipid binding, and instead impact binding to cell surface GAGs. As
the R47H risk variant is able to bind phospholipids directly, but does not signal in cellular assays of
TREM2 signaling triggered by plated phospholipids (Wang et al., 2015), we suggest that TREM2
interaction with GAGs in cis is likely required to orient or cluster TREM2 to mediate signaling upon
stimulation by phospholipids. Alternatively, phospholipids may function to orient TREM2 on the cell
surface for proper presentation to GAGs and/or additional as of yet undefined protein surface
receptors.
AD risk variants map a unique functional surface on TREM2
Our cell surface TREM2-L binding experiments categorized the naturally occurring TREM2 mutations
as loss-of-binding (R47H and R62H) and enhancement-of-binding (T96K) compared to WT, and
showed that these mutations influence TREM2 interactions with cell surface GAGs. We returned to
analysis of our crystal structure in order to interpret these observations. Upon mapping the electro-
static surface of hTREM2, we noticed a large basic surface that was not present on the surface of
other TREM family receptors for which coordinates are available (mTREM1, PDB 1 U9K,
[Kelker et al., 2004a]; hTREM1, PDB 1SMO, [Kelker et al., 2004b]; and TLT-1, PDB 2FRG
[Gattis et al., 2006]) (Figure 5a,b and d–f). Furthermore, sequence analysis shows that the residues
constituting this basic patch are highly conserved within TREM2, but not within the rest of the TREM
family, suggesting that this interface has evolved specifically toward a role in TREM2 function
(Figure 5c). To demonstrate this, we prepared staining tetramers for other TREM-like family mem-
bers with similar overall high pI values calculated for the ectodomain (Figure 4h). Consistent with
our hypothesis, TREM2 ectodomain tetramers bound to N2A cells, while tetramers of ectodomains
from TREM-like 2 (TREML2) and TREM-like 4 (TREML4) did not (Figure 4i). This cluster of residues
contains most of the AD-linked surface mutations (including R47H and R62H). Additionally, the T96K
mutation is located adjacent to this basic patch and would therefore extend it, providing a structural
explanation for the gain of function observed with this variant (Figure 5b). To test whether addi-
tional basic residues located within this surface influence TREM2-L binding, we selected two other
basic residues that are conserved only in TREM2 (R76 and R77), and assayed the ability of these var-
iants to bind TREM2-L using our flow cytometry assay. We found that both a R76D and a R77D
mutation decreased binding to TREM2-L on THP-1 cells in a manner similar to the validated AD risk
variants (R47H and R62H) (Figure 5g). Together, the data indicate that this surface represents a con-
served functional interface on TREM2 that participates in cell-surface ligand binding and that this
surface is unique to TREM2 within the TREM family.
Discussion
Here we elucidate how distinct point mutations in TREM2 give rise to different neurodegenerative
diseases via two separate loss-of-function mechanisms. Our studies indicate, as presaged by our
crystal structure, that NHD-linked mutant residues are buried and impact protein folding and stabil-
ity, while AD-linked variant residues are on the protein surface and do not diminish the stability or
surface expression of the molecule but instead impact ligand engagement (Figure 6a). Several var-
iants have been reported for TREM2, but some are very rare, so it is not clear whether they associate
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with AD risk. The structure-based studies presented here provide a framework with which one could
make predictions as to the variant’s impact on function. Our observation of detectable misfolded
cell-surface TREM2 NHD mutant proteins was surprising, given that one would expect that the cellu-
lar quality-control machinery should degrade misfolded proteins and prevent their surface expres-
sion. In addition, previous reports noted decreased surface expression for these mutants
(Park et al., 2015; Kleinberger et al., 2014). Here, we used an approach that probes surface
expression using both non-conformational (anti-FLAG) and conformational (anti-hTREM2) antibodies.
We found that both the NHD-associated and AD-linked mutant proteins reach the cell surface, how-
ever the NHD-associated TREM2 mutants are probably not functional as they are either misfolded or
aggregated, and thus are not recognized by the conformational-dependent antibodies. These results
are supported by our analysis of the solution behavior of theTREM2 ectodomains of these mutant
proteins. An alternative explanation could be that the FLAG tag or overexpression drives the surface
expression of these mutated proteins; but we do not think that is the case since we found that the
TREM2 ectodomains carrying these mutations (which contain a different tag that is on the opposite
terminus) were also secreted. These findings are of potential therapeutic value, as the discovery of
molecular chaperones that rescue the folding of and restore function to these mutants could be pur-
sued for patient-specific NHD treatments.
Figure 5. AD risk variants reveal a functional surface on TREM2. (a) Electrostatic surface of hTREM2 and (b) hTREM2 rotated 90˚. The extended basic
patch on hTREM2 is outlined with a dashed line. (c) Structure-based sequence alignment of human (h) and mouse (m) TREM family members.
Secondary structure assigned using the DSSP server. Invariant residues are shown in magenta and conserved residues are shown in yellow. Disulfide
bonds are numbered in green. NHD residues are highlighted with black boxes and AD residues in blue boxes. Basic patch residues are labeled with
blue asterisks. (d) mTREM-1 (1 U9K), (e) hTREM-1 (1SMO), and (f) hTLT-1 (2FRG) aligned with hTREM2 as in (a). Electrostatic potential was plotted on
the solvent-accessible surface using the AMBER force field and the PDB2PQR server within the APBS Pymol plugin. Scale is !6.0 kT/e (blue) to +6 kT/e
(red). (g) Flow cytometry analysis of WT, R76D, and R77D hTREM2/SA-PE binding to TREM2-L on THP-1 cells. Representative of two independent
experiments.
DOI: 10.7554/eLife.20391.016
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In contrast to the buried NHD mutant proteins, the AD risk variants lie on the surface of the pro-
tein and do not severely impact the protein folding or stability of TREM2. However, it should be
noted that the R47H mutation does induce a subtle change in secondary structure detectable by
CD. The AD mutations probably alter TREM2 function by impairing ligand binding. Recent studies in
AD mouse models that are deficient in TREM2 confirm that loss of TREM2 function contributes to
classic AD pathology and suggest a crucial role for TREM2 in microglia function (Jay et al., 2015;
Wang et al., 2015; Ulrich et al., 2014). TREM2-deficient AD mice display fewer activated microglia,
and the absence of TREM2 prevents microglia proliferation and promotes microglia apoptosis, which
is correlated with increased accumulation of Ab plaques (Wang et al., 2015; Jay et al., 2015).
Microglia in TREM2-deficient AD mice display less activation and do not engulf Ab plaques, which
reduces the density of Ab plaques and promotes diffuse Ab structures, which, in turn, are more
neurotoxic and contribute to the accumulation of classic AD pathology (Wang et al., 2016;
Yuan et al., 2016). These models suggest a crucial role for TREM2 in microglia biology and in the
turnover of Ab. On the basis of the conserved nature of AD-linked basic surface residues and our
analysis of cell-surface ligand binding for multiple cell lines, we favor the concept that AD risk var-
iants lead to impaired binding of TREM2-L, which in turn perturbs microglia function.
With this in mind, we investigated how AD risk variants in TREM2 affect binding to
previously identified and newly hypothesized ligands based on the analysis of ourcrystal structure.
The many diverse ligands reported for TREM2 may in fact suggest that TREM2 is capable of recog-
nizing multiple ligands and that under different conditions, their respective affinities might tune sig-
naling accordingly. For example, low-affinity ligands may induce a tonic inhibitory signal while
ligation of a high-affinity ligand could result in an activating response. Indeed, anionic bacterial car-
bohydrates (Daws et al., 2003), phospholipids (Wang et al., 2015), myelin lipids (Poliani et al.,
2015), and even purified DNA (Kawabori et al., 2015) all activate TREM2 reporter cell lines. This is
not surprising in light of our crystal structure, which reveals an extended basic patch on the surface
of TREM2 that would be capable of forming electrostatic interactions with these anionic ligands. In
contrast to highly selective phospholipid binding by other Ig domains (Kobayashi et al., 2007;
Miyanishi et al., 2007; Santiago et al., 2007; Simhadri et al., 2012), purified TREM2 shows only
Figure 6. Models developed from the current data. (a) Current model for the role of TREM2 ectodomain point mutations in neurodegenerative
diseases. WT TREM2 is surface expressed in complex with DAP12 and engages TREM2-L normally. AD risk variants do not impair surface expression,
but do impair ligand binding. They occur heterozygously, so this would lead to overall reduced TREM2 function in individuals carrying these risk
variants. NHD mutations cause misfolding, which leads to aggregation and impaired surface expression. These mutations occur homozygously, leading
to no TREM2 function in individuals carrying these mutations. (b) Current model for the engagement of possible TREM2 ligands investigated here.
Membrane-bound or soluble TREM2 (sTREM2) produced by proteolytic cleavage likely engages GAGs via the basic patch and engages phospholipids
(PL) via the hydrophobic patch. In addition, there is a protein component of TREM2-L.
DOI: 10.7554/eLife.20391.017
The following figure supplement is available for figure 6:
Figure supplement 1. hTREM2 has an extended hydrophobic surface.
DOI: 10.7554/eLife.20391.018
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broad discrimination for anionic (PA, PG, PI, PS) over more neutral (PC, PE) lipids (Figure 4—figure
supplement 1a,b and c). Structurally, Ig domains with selective lipid binding feature a canonical FG
loop motif that contains large hydrophobic residues, absent in TREM2, which mediate membrane
insertion and acyl chain binding (Tietjen et al., 2014) (Figure 4—figure supplement 1d,e). More-
over, while TREM2 does share a conserved aspartic acid residue from this motif, which chelates a
required Ca2+ ion for the TIM and CD300a proteins, TREM2-lipid binding is not sensitive to EDTA,
unlike TIM and CD300 (Figure 4—figure supplement 1e and f). Thus, while we do observe direct
binding of TREM2 to phospholipids, it does not appear that TREM2 binds phospholipids with high
selectivity or using the same binding mode as other phospholipid-binding Ig domains. By contrast, it
should be noted that there is a long and narrow hydrophobic patch on the end of TREM2 most distal
from the plasma membrane (Figure 6—figure supplement 1) that is the most likely lipid-binding
surface. Interestingly this patch is adjacent to the basic patch, which could mediate interaction with
anionic phospholipid head groups (Figure 6b). These hypotheses will need to be tested in future
studies using sensitive binding assays (such as surface plasmon resonance) and crystallographic stud-
ies of TREM2-phospholipid recognition. In contrast to recent studies employing reporter cells
expressing TREM2 R47H (Wang et al., 2015), we did not observe any large differences in binding to
phospholipids for any of the validated TREM2 AD risk variants. In light of our experimental observa-
tions, we believe this is best explained by the hypothesis that another interaction (such as TREM2
binding to GAGs, which we show here is impacted by these AD risk variants) is required to mediate
phospholipid signaling; thus in the context of cellular experiments, TREM2 R47H shows diminished
signaling, while in direct lipid-binding assays it performs in the same way as WT TREM2. This is
potentially supported by a recent report that TREM2 binds to isolated PS, but does not bind apo-
ptotic Jurkat T cells, which present PS on their cell surface but may also be deficient in GAGs
(Bailey et al., 2015). The results presented here suggest that the point mutations in TREM2 partici-
pate in neurodegenerative disease pathogenesis through distinct molecular mechanisms.
We found that the validated AD risk variants in TREM2 impact binding to a cell-surface ligand
(TREM2-L). This ligand does appear to contain a protein component, as pre-treatment of cells with
proteases decreases or prevents the binding of TREM2 to these cells. This interaction also appears
to be highly GAG-mediated, as TREM2 cell-staining tetramers do not bind CHO 745 cells, which do
not express GAGs. This interaction seems most dependent on heparan sulfate, as treatment with
heparin sulfatases remove much of the observed binding. As the AD risk variants most notably
impact binding to TREM2-L, we reason that this interaction is involved in the pathogenesis of AD. In
support of this, we find that the mutations R47H and perhaps R62H deleteriously impact TREM2-L
recognition. By contrast, T96K appears to be a potential gain-of-function mutation in our binding
experiments. Interestingly, this mutation appears at a much higher frequency than R47H and R62H,
and in some studies it has been reported to be enriched in European-American AD cases compared
to controls; overall it is associated with a decreased odds ratio for the development of late-onset AD
(Figure 1c), again suggesting the TREM2-L binding function is coupled to AD risk. Altogether, the
structural and functional analysis of these variants illuminates a surface epitope that is specific to
TREM2, that is not conserved among the other members of the TREM family, and that mediates
binding to a cell-surface ligand. Additional point mutations localized to that surface also resulted in
loss of binding, supporting this functional role. Our results suggest that this ligand may have a spe-
cific protein component in addition to GAGs. On that note, while this manuscript was in preparation,
it was reported that TREM2 binds lipid-loaded ApoE and that this interaction facilitates uptake of
Ab loaded into lipoparticles by microglia (Yeh et al., 2016). This report also suggests that TREM2
AD risk variants decrease binding to ApoE, but binding affinities were not quantitated. However, we
do not suspect that ApoE is the protein component of cell surface TREM2-L because it is a soluble
rather than a surface-bound protein. Our study demonstrates that TREM2 can specifically bind
GAGs, utilizing the basic patch; other TREM-like proteins with the same overall calculated pI, but
lacking the basic patch residues, do not bind GAGs. We also demonstrate that TREM2 AD risk var-
iants affect binding to GAGs. Future studies will need to focus on how TREM2 binding to GAGs and
ApoE are coordinated and how they impact TREM2 function in microglia.
Our results illustrate two distinct paths to loss-of-function in TREM2, so how might these different
mechanisms result in either AD or NHD? In attempting to explain this, it is important to take into
account genetics-based dosage affects (Figure 6a). In NHD, the mutations are homozygous and the
TREM2 is either deleted or misfolded, leading to a complete loss of function, and more serious and
Kober et al. eLife 2016;5:e20391. DOI: 10.7554/eLife.20391 15 of 24
Research article Biophysics and Structural Biology Neuroscience
early-onset neurodegenerative disease. In AD, the mutations are heterozygous and impair function
(but do not completely abolish it), leading to less severe and late onset neurodegenerative disease.
Under this hypothesis, it should be possible that a heterozygous NHD mutant would give increased
risk for AD. Consistent with this, there have been reports of rare AD cases containing heterozygous
NHD variants, including Q33X, Y38C, and T66M (Guerreiro et al., 2013b). In addition, TREM2 may
function not only as a receptor but also as a signaling molecule as it can be cleaved. We have
recently shown that the soluble TREM2 may be a survival signal in bone-marrow macrophages
(Wu et al., 2015). Interestingly, we have observed that the absence of TREM2 in an AD mouse
model prevents microglia proliferation and promotes microglia apoptosis, suggesting that soluble
TREM2 could play a similar role in the CNS (Wang et al., 2015). Accordingly, soluble TREM2 can be
detected in the CNS, and we have shown that some AD risk variants, but not the NHD
mutant proteins are readily detected in the CSF of patients (Piccio et al., 2016). Because the AD
risk variant proteins are expressed and stable enough to be soluble factors, they may retain some
signaling ability and prevent more serious diseases. These hypotheses will require animal knock-in
studies for full evaluation. Therefore, a comprehensive analysis of all TREM2 variants will be essential
to understanding TREM2 function in both neurodegenerative diseases and other inflammatory dis-
eases, and to design targeted therapies accordingly.
Materials and methods
Expression constructs
Full-length wild-type (WT) human TREM2 as well as R47H, N68K, D87N, and T96K mutants in pMX-
3p plasmid and mouse Trem2 cDNA were used as PCR templates. Mammalian cell expression con-
structs of human TREM2 wild-type, R47H, D87N, T96K and mouse TREM2 ectodomains were pro-
duced as previously described (Kober et al., 2014, 2015) by subcloning from these templates into
the pHLsec vector, which contains an optimized signal sequence and a C-terminal 6-histidine tag for
purification. Similarly, primers were designed to amplify the full-length human TREM2 gene with an
N-terminal FLAG peptide. Additional mutants (human Y38C, R62H, T66M, R76D, R77D; mouse
R47H, R62H, and T96K) were generated in the pHsec constructs using either the QuikChange Light-
ning Site-Direct Mutagenesis Kit (Agilent. Santa Clara, CA) or the Q5 Mutagenesis Kit (NEB) (primer
sequences in Table 3). WT and mutant human and mouse TREM2 constructs containing site-specific
biotinylation sites were generated by EcoRI-KpnI restriction digest of the pHLsec inserts followed by
ligation into the pHLAvitag3 vector, which encodes a C-terminal BirA biotin ligase biotinylation
sequence followed by a 6-histidine tag. All constructs were verified by sequencing.
Crystallization, structure determination, and analysis
The WT human TREM2 ectodomain was expressed in Freestyle 293F cells in the presence of 1 mg
mL!1 kifunensine, deglycosylated with EndoHf, and purified for crystallization in a single-step using
Ni-NTA resin as previously described (Kober et al., 2014). Protein was concentrated to 10 mg ml!1
in buffer containing 20 mM HEPES pH 7.4 and 150 mM NaCl. Crystals were grown by hanging drop
vapor diffusion by mixing 1:1 with well solution containing 100 mM HEPES 7.0, 2.1 M NaCl, 0.2 M
MgCl2 and 0.2 M NDSB-201. Crystals were cryoprotected in mother liquor containing 20% ethylene
glycol and flash frozen under a nitrogen stream at !160˚C.
Data were collected at the Advanced Photon Source, beamline 19-ID (Argonne National Lab, Chi-
cago). A molecular replacement solution was found with PHASER using mouse TREM-1 ectodomain
(1 U9K) (Kelker et al., 2004a) as the probe, locating two molecules in the asymmetric unit (ASU).
Data were initially scaled and processed at 3.3 A˚ using HKL2000 (Otwinowski and Minor, 1997).
The initial model was substantially improved by iterative rounds of manual rebuilding in COOT
(Emsley et al., 2010) and refinement using Phenix (Adams et al., 2010). Next, resolution was
extended using the method described by Karplus and Diederichs (Karplus and Diederichs, 2012)
(Table 1). The 3.3 A˚ model was used as a molecular replacement probe on data scaled to 3.4 A˚ and
3.3 A˚, and subsequently subjected to automated refinement in Phenix without manual intervention.
The 3.3 A˚ solution was then used to calculate Rfree and Rwork at 3.4 A˚. Rfree was lower at 3.4 A˚
using the model refined at 3.3 A˚ compared to the model refined at 3.4 A˚, providing evidence that
3.3 A˚ data improved the model. Similarly, data were again extended to 3.2 A˚ and finally 3.1 A˚. Data
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past 3.1 A˚ did not improve the model as determined by an increased Rfree calculated at 3.1 A˚ using
the model refined on 3.0 A˚ data. Final model refinement occurred by iterative building and refine-
ment in Phenix. NCS and secondary structure restraints were used during refinement, and TLS
refinement of B-factors was applied in later rounds. The structure is complete with only one N-termi-
nal residue and four C-terminal residues not visible in the electron density (Figure 1b). Ramachan-
dran statistics are 97.7% favored, 0% outliers, 2.3% allowed. Molprobity score was 1.66 (100th
percentile) and clashscore was 9.62 (96th percentile) for the final model.
Calculations on the final model were performed using Naccess (Hubbard and Thornton, 1993) to
measure the solvent accessibility of side chains and HBPLUS (McDonald and Thornton, 1994) to
identify hydrogen bonds. LigPlot+ (Laskowski and Swindells, 2011) was used to analyze side-chain
contacts. For structure-based alignment, amino acid sequences were aligned using Clustal Omega
(Sievers et al., 2011) and residue conservation scored by ESPript (Robert and Gouet, 2014). All
crystallographic and analysis software used were compiled and distributed by the SBGrid resource
(Morin et al., 2013) and diffraction images were archived with the SB Data Grid (Meyer et al.,
2016).
Cell culture
For protein expression, Freestyle 293F cells were cultured at 8% CO2 in serum-free 293Freestyle
media supplemented with Glutamax and penicillin/streptomycin (Pen/Strep, Gibco by ThermoFisher,
Waltham, MA). Human monocyte THP-1 cells were cultured at 5% CO2 in RPMI media supplemented
with 10% Fetal Bovine Serum (FBS), 10 mM HEPES, 50 mM b-mercaptoethanol, L-glutamine and pen-
icillin/streptomycin (Pen/Strep). Mouse neuroblast N2A cells were cultured at 5% CO2 in MEM
Table 3. Primers used in this study.
hTREM2
ectodomain
GAAACCGGTCACAACACCACAGTGTTCCAGGGC
CGGGGTACCCAGGGGGTCTGCCAGCACCTCCAC
hTREM2
Y38C*
CTGCAGGTGTCTTGCCCCTGTGACTCCATGAAGCACT
AGTGCTTCATGGAGTCACAGGGGCAAGACACTTGCAG
hTREM2
T66M*
TGCCAGCGTGTGGTCAGCATGCACAACTTGTGGCTGC
GCAGCCACAAGTTGTGCATGCTGACCACACGCTGGCA
hTREM2
V126G*
TCAGGAAGGTCCTGGGGGAGGTGCTGGCAGA
TCTGCCAGCACCTCCCCCAGGACCTTCCTGA
hTREM2
R62H+
CCCAGTCCAGCATGTGGTCAGCA
CCCTTCTCTCCCAGCTGGC
hTREM2
R76D+
GTCCTTCCTGGACAGGTGGAATGGG
AGCAGCCACAAGTTGTGC
hTREM2
R77D+
CTTCCTGAGGGACTGGAATGGGAGCACAG
GACAGCAGCCACAAGTTG
FLAG-hTREM2 GAAACCGGTGATTATAAAGATGATGATGATAAACACAACACCACAGTGTTCCAGGGC
CGGGGTACCTCACGTGTCTCTCAGCCCTGGCAG
mTREM2 ectodomain GAAACCGGTCTCAACACCACGGTGCT
CGGGGTACCTTGGTCATCTAGAGGGT
mTREM2
R62H+
CCCATGCCAGCATGTGGTGAGCA
CCCTCCTCACCCAGCTGC
mTREM2
R47H*
AAGCACTGGGGGAGACACAAGGCCTGGTGTCGG
CCGACACCAGGCCTTGTGTCTCCCCCAGTGCTT
mTREM2
T96K*
CTTGCTGGAACCGTCACCATCAAGCTGAAGAACCTCCAAGCCGGT
ACCGGCTTGGAGGTTCTTCAGCTTGATGGTGACGGTTCCAGCAAG
mDAP12 CCGGAATTCGCCACCATGGGGGCTCTGGAGCCCTCCTGG
CGGGGTACCTCATCTGTAATATTGCCTCTGTGT
All primers 5’!3’ with the coding direction primer listed first
*Designed for Quikchange Lightning Mutagenesis
+Designed for NEB Q5 mutagenesis
DOI: 10.7554/eLife.20391.019
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supplemented with 10% FBS, L-glutamine and Pen/Strep. CHO cells were cultured at 5% CO2 in
Ham’s F12 supplemented with 10% FBS, L-glutamine and Pen/Strep.
Protein expression and purification
Protein expression for biophysical and functional studies was performed as described previously
(Kober et al., 2014). In brief, plasmid DNA was complexed at a ratio of 1:2 (mg/mg) with PEI-TMC25
to transfect Freestyle 293F suspension cells cultured in serum-free 293 Freestyle Media. One mg of
plasmid DNA was used per 1 " 106 cells. Transfected cells were allowed to express protein for 72–
96 hr. Supernatants were collected and protein was purified using Ni-NTA chromatography. The
eluted protein was then further purified by gel filtration chromatography using an analytical s200
size-exclusion column (GE) run in a buffer containing 20 mM Tris pH 8.5 and 150 mM NaCl.
Surface expression studies
Full-length FLAG-tagged hTREM2 WT or mutant genes in pHL vectors were co-transfected with
mDAP12 in pcDNA3.1 vector into 293F cells using 293fectin. After 24 hr, cells were harvested and
washed into FACs buffer (1% BSA in PBS). FLAG epitope expression was detected using a FITC-con-
jugated M2 anti-FLAG antibody (1:50, Sigma-Aldrich. St. Louis, MO), and folded TREM2 surface
expression was detected by staining with anti-TREM2 primary polysera (1:1000, hamster) followed
by PE-anti-hamster secondary (1:200 eBioscience). Background was defined by cells transfected with
mouse DAP12 only.
WT and mutant TREM2 cell-surface ligand binding studies
Production of fluorescently labeled TREM2 tetramers
For analysis of cell binding by flow cytometry, pHLAvitag3 constructs of WT and mutant human and
mouse TREM2 ectodomains were transfected into Freestyle 293F cells and proteins were purified by
Ni-NTA chromatography. The eluted proteins were exchanged into buffer containing 100 mM Tris-
HCl pH 7.5, 200 mM K-glutamate, and 5 mM MgCl2, concentrated to 400 mL, and then enzymatic
biotinylation was carried out by addition of 40 mM bicine pH 8.3, 8 mM Mg(OAc)2, 8 mM ATP, 0.1
mM biotin and 20 mL Escherichia coli BirA biotin ligase (1 mg/mL). Biotinylation proceeded for 12 hr
at 4˚C. Excess biotin was removed using Zeba desalting spin columns (Thermo Scientific) and biotiny-
lation was confirmed by western blot with Extravidin-HRP (Sigma). The biotinylated TREM2 was pre-
incubated with SA-PE at a 4:1 molar ratio for 15 min at 25˚C to produce fluorescently labeled tet-
ramers (TREM2/SA-PE). Biotinylated TREM2 was complexed with phycoerythrin-conjugated strepta-
vidin (SA-PE) at a 4:1 molar ratio on ice for 1 hr in 1% FBS prior to staining cells.
Cell staining
Prior to staining, N2A and CHO cells were lifted following brief exposure to trypsin/EDTA (other
cells grow in suspension). Cells (4 " 105 cells/ sample) were stained using tetramers at 1:100 dilution
in PBS containing 1% FCS (FACS buffer) at 4˚C. Cells were either stained with SA-PE alone (1:100) or
with TREM2/SA-PE (1:100). Cells were incubated for 1 hr on ice then washed three times with FACS
buffer, and then analyzed for binding by flow cytometry using a BD FACScan. Analysis was per-
formed using FlowJo (Tree Star).
Chemical stimulation
For each condition, 1 x 106 THP-1 cells were stimulated overnight at the indicated concentration.
Poly IC (1 mg mL!1), LPS (1 mg mL!1), PMA+ionomycin (20 ng mL!1 and 500 ng mL!1, respectively),
M-CSF (20 ng mL!1), and IL-13 (50 ng mL!1). Cells were collected and washed in FACs buffer before
staining.
Protease treatment
Cells were washed in ice-cold PBS and then incubated with indicated proteases (50 mg mL!1) on ice
for 30 min. Proteolysis was quenched by washing cells four times in FACs buffer containing PMSF.
Cells were stained with SAPE-TREM2 in FACs buffer containing PMSF and HALT protease inhibitors.
Cell viability was verified by 7-AAD staining (BD Biosciences. San Jose, CA ) according to the manu-
facturer’s directions.
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6-His staining of THP-1 cells
WT and mutant human TREM2 ectodomains were purified by SEC as in Figure 2—figure supple-
ment 1. The monomeric peak was collected, concentrated and buffer-exchanged into PBS by centri-
fugation. Protein concentration was quantitated in triplicate using the Micro BCA kit (Thermo
Scientific) according to the manufacturer’s instructions. THP-1 cells were washed into FACS buffer
and incubated with purified proteins for 1 hr, washed twice, and then incubated in FACS media with
Fc-block followed by anti-6His-PE (Miltenyi Biotec. Germany) for 30 min before a final wash and flow
cytometry analysis. 20,000 cells were counted for each measurement.
Proteoglycan digestion assay
Chondroitinase ABC and Heparinases I, II, and III were purchased from Sigma-Aldrich. Digestion of
cell-surface sulfated glycans was carried out as follows: cells were washed into PBS with 0.1% BSA
and incubated with enzymes at 0.1 U mL!1 for 1 hr at 37˚C while shaking before being washed three
times with cold FACS buffer.
Thermostability of TREM2 variants by DSF
Thermal stability was assessed by differential scanning fluorimetry (DSF) on protein purified by SEC.
The Protein Thermal Shift kit (Applied Biosystems) was used according to the manufacturer’s instruc-
tions. Briefly, protein was concentrated to 0.5 mg mL!1 after buffer exchange into PBS. 5 ml of reac-
tion buffer and 2.5 ml 8x fluorescent dye were added to 12.5 mL protein on ice. Melt-curve
experiments were performed using Fast7500 qPCR machine (ABI) starting at 25˚C and
with continuous 1% ramp to 95˚C (roughly 1˚C min!1). The data were analyzed using Protein Thermal
Shift software.
Thermal and chemical stability of TREM2 variants by CD
Circular dichroism spectroscopy (CD) measurements were performed using a JASCO J-815 spectro-
polarimeter equipped with a Peltier temperature controller. Thermal denaturation experiments were
carried out in 10 mM phosphate (pH 7.0) and 150 mM NaF. For native and GuHCl-denaturation
scans, a 1 mm path length cuvette was used and the protein concentration was 30 mM. For denatur-
ation experiments, a 1 cm path length cuvette was used and the protein concentration was 3 mM.
For reducing conditions, the buffer contained 1 mM DTT. Ellipticity was measured at 225 nm in 1˚C
steps from 20˚C to 90˚C at a rate of 1˚C min!1 and melt-curve data were smoothed using JASCO
software. For chemical stability experiments, purified human ectodomains were incubated with
GuHCl (Fluka 50933) at room temperature for at least 1 hr before measuring CD. Repeat measure-
ments at later time points confirmed that equilibrium had been achieved.
Solid-Phase lipid ELISA
Lipid ELISA experiments were carried out essentially as described by Kobayashi et al., (2007). In
brief, phospholipids were dissolved in methanol or methanol:chloroform as needed and diluted to 5
mg mL!1 in methanol. 100 mL was added to ELISA plates and allowed to air-dry. Wells were blocked
with 3% BSA in PBS. Biotinylated WT or mutant TREM2 in 3% BSA-PBS were incubated overnight at
4˚C. Plates were washed three times in PBS + 0.05% Tween 20. Biotinylated TREM2 was detected
by streptavidin-HRP (R and D) in 1% BSA-PBS for 2 hr at RT before final wash and developing with
TMB Microwell Peroxidase Substrate (KPL. Gaithersburg, MD). Absorbance was measured at 450 nm
on a Gemini Plus plate reader (Molecular Devices. Sunnyvale, CA).
Immunoflourescent confocal microscopy
HEK293T cells were co-transfected with full-length FLAG-TREM2 and DAP12 for 24 hr before replat-
ing on glass slides. Cells were washed 2x with PBS, then fixed with 4% paraformaldehyde (PFA) in
PBS for 5 min. Cells were then washed and blocked with animal-free blocker (Vector
Laboratories. Burlingame, CA) for 1 hr at RT. For permeabilized cells, 0.1% triton x-100 was added
to the blocking buffer and subsequent steps. Anti-FLAG antibody (M2, Sigma) was added at 1:1000
overnight at 4˚C. Cells were then washed twice, and anti-mouse secondary Alexa Fluor 555 conju-
gate (Life Technologies) was added at 1:200 for 1 hr. Cells were washed a final time and then
mounted in VECTASHIELD H-1200 Mounting Medium with DAPI (Vector Laboratories). Confocal
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microscopy was carried out using a Zeiss LSM 510 META Confocal Laser Scanning Microscope (Carl
Zeiss Microscopy, Thornwood, NY) at 400x magnification. The images were acquired with LSM 4.2
software.
Liposome sedimentation assays
Liposomes consisted of a base of 35:35:10 PtdCholine, PtdEthanolamine, and cholesterol with an
additional 20% wt/wt of candidate phospholipids. Phospholipids were purchased from Sigma or
Avanti dissolved in chloroform. Lipids were mixed in solvent-washed glass vials and solvent was
evaporated under nitrogen stream. Lipids were resuspended in PBS, warmed at 37˚C for 15 min fol-
lowed by three freeze-thaw cycles on liquid N2 and 37˚C H2O. For the sedimentation assay, 10 mg
TREM2 proteins quantified by BCA were mixed with 100 mg liposomes and incubated for 1 hr at
room temperature. Liposomes were sedimented by centrifugation at 16,800 x g at 4˚C. The superna-
tant was removed and the pellet resuspended in SDS buffer for 6His immunoblot analysis.
Statistics
All statistics were calculated using GraphPad Prism5.
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Abstract 
The protein Triggering receptor expressed on myeloid cells-2 (TREM2) is an immunomodulatory 
receptor with a central role in myeloid cell activation and survival. In recent years, the 
importance of TREM2 has been highlighted by the identification of coding variants that increase 
risk for Alzheimer’s disease and other neurodegenerative diseases. Animal studies have further 
shown the importance of TREM2 in neurodegenerative and other inflammatory disease models 
including chronic obstructive pulmonary disease, multiple sclerosis, and stroke. A mechanistic 
understanding of TREM2 function remains elusive, however, due in part to the absence of 
conclusive information regarding the identity of endogenous TREM2 ligands. While many 
TREM2 ligands have been proposed, their physiological role and mechanism of engagement 
remains to be determined. In this review, we highlight the suggested roles of TREM2 in these 
diseases, recent advances in our understanding of TREM2, and discuss potential TREM2-
ligand interactions and their potential roles in signaling during health and disease. We develop a 
model based on the TREM2 structure to explain how different TREM2 ligands might interact 
with the receptor and how disease-risk variants may alter ligand interactions. Finally, we 
propose future experimental directions to establish the role and importance of these different 
interactions on TREM2 function. 
Introduction 
Triggering receptor expression on myeloid cells-2 (TREM2) is an extracellular innate immune 
receptor expressed on myeloid lineage cells such as dendritic cells (DC) and resident tissue 
macrophages (including osteoclasts and microglia). The receptor consists of an extracellular V-
type immunoglobulin (Ig) domain followed by a short stalk (ectodomain = 19-172 a.a.) leading to 
a single transmembrane helix which interacts with DNAX-activation protein 12 (DAP12, also 
known as TYROBP) to mediate downstream signaling. TREM2 terminates with a short cytosolic 
tail (195-230 a.a.) lacking known signaling or trafficking motifs [1]. In addition to the membrane-
bound form, soluble TREM2 ectodomains (sTREM2) can be generated by proteolytic 
processing [2] or by alternative splicing [3].  The importance of TREM2 is highlighted by genetic 
studies linking TREM2 variants to various neurodegenerative diseases, including Alzheimer’s 
disease (AD) [4, 5]. TREM2 has been implicated in a wide array of functions including cell 
maturation, survival, proliferation, activation, phagocytosis, and the regulation of inflammation 
[1]. Accompanying this diverse set of functions is an even longer list of potential TREM2 ligands. 
Indeed, since its discovery, the identification of bona fide endogenous TREM2 ligands has 
proven elusive, although there is an emerging pattern of ligands that are anionic and/or lipidic in 
nature. It is unclear if the TREM2 ligand is among the suggested ligands or whether TREM2 is 
simply a highly promiscuous receptor that can engage a wide array of ligands. The goals of this 
review are to: 1) highlight functions for TREM2 evident from animal studies of homeostasis and 
disease; 2) identify facets of TREM2 signaling that may be influenced by different ligands; 3) 
discuss the evidence for the various TREM2 ligands; and 4) suggest where and how different 
ligands may be involved in TREM2 function. We develop the model that distinct ligands may 
mediate different components of TREM2 signaling and that a complex of ligands interacting with 
various portions of TREM2 may be required to assemble a productive signaling complex. 
1. TREM2 in disease
TREM2 variants are risk factors for neurodegenerative diseases 
The importance of TREM2 in neuronal health was first demonstrated by genetic studies 
that identified TREM2 variants in families with Nasu-Hakola disease (NHD, also known as 
Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy, or PLOSL) a 
fatal disease characterized by presenile dementia and bone cysts [6-8]. NHD patients are 
homozygous for loss-of-function DAP12 or TREM2 variants. In some cases, TREM2 mutant 
carriers present a fronto-temporal lobar form of dementia lacking the bone phenotype. The 
TREM2 variants include splice site [7,	 9] early stop sites [7,	 10-12], and coding ectodomain 
mutations [7,	 8,	 13-15]. These mutations are all believed to produce nonfunctional proteins. 
More recently, separate coding variants in the Ig domain of TREM2 were linked to an increase 
risk for late onset AD (LOAD) [4, 5]. The link between TREM2 variants and LOAD, particularly 
the R47H and R62H variants, is now well-established [3,	16-18]. TREM2 AD risk variants are 
rare, but carry roughly the same risk as a copy of the apolipoprotein E4 (APOE4) allele and 
clearly link the innate immune system to neurodegenerative disease [19]. Beyond AD, TREM2 
variants have been linked to other neurodegenerative diseases, including Parkinson’s disease 
[20,	 21] and sporadic amyotrophic lateral sclerosis (ALS) [22], and fronto-temporal dementia 
[23,	 24], though these non-AD associations have not been as widely reproduced [16]. The 
association of distinct variants with different diseases is born out on the protein level. Structural, 
biophysical, and cellular studies have shown the NHD coding mutants are misfolded with 
immature glycosylation patterns while the AD variants are properly folded and have mature 
glycosylation patterns but likely impact ligand binding [25,	 26]. Slightly altered glycosylation 
patterns have been observed for the R47H variant [27,	 28], but it is unclear if these have 
functional ramifications. Finally, a study examined the levels of sTREM2 in human variant 
	carriers and found reduced levels of protein with NHD variants but normal or perhaps even 
elevated detection of AD variants, showing a functional divergence in protein stability with the 
different variants [29]. 
Animal models and human studies of CNS disease indicate a crucial role for TREM2 in 
microglia function 
Most studies of TREM2 in neurodegenerative diseases have used mouse models of AD. 
We will highlight key findings from those models and draw connections between the AD 
phenotypes and those observed in other neurodegenerative models such as stroke and MS to 
identify functions TREM2 may be contributing to during disease (Table 1). 
Animal model studies by several groups have consistently found Trem2 expression in 
the CNS restricted to microglia and increasing with age and disease progression [4,	 30-33]. 
Within the normal human brain, TREM2 is expressed most highly in white matter, with 
transcripts detected in all major areas [34]. Pathway analysis identified the TREM2 co-receptor 
DAP12 as a key regulator of expression changes in LOAD [35]. Although there have been 
reports of TREM2 detection on non-myeloid/microglial cells in the CNS [4,	 36], these cases 
have largely used immunostaining methods to identify neuronal expression of TREM2, which 
may identify sTREM2 produced by microglia that is released and bound to neurons which 
express a TREM2 ligand [26,	 37-39]. RNA expression analyses have confirmed Trem2 is 
expressed selectively on microglia in the brain [40,	41], and parabiosis experiments show these 
microglia are most likely resident microglia and not infiltrating monocytes [42], although this is 
still controversial [43]. Within human AD brain, laser microdissection showed Trem2 is highly 
expressed on plaque-associated microglia [44], and high resolution microscopy techniques 
showed that TREM2 protein is concentrated on microglia processes that are in contact with 
amyloid beta (Ab) plaques [45]. Thus, TREM2 is expressed in the brain and its expression 
increases both with aging and in response to disease. Moreover, during AD, TREM2 is present 
on microglia at sites of Ab deposition. Consistent with its expression on microglia, studies using 
Trem2-deficient mouse models of AD have shown a role for TREM2 in microglial survival and 
activation (Table 1). 
Impacts of TREM2 function on Amyloid beta pathology 
The amyloid cascade hypothesis posits that Ab is the cause of AD, whether directly by 
mediating neurotoxicity or indirectly by triggering other neurotoxic events, such as tau 
aggregation [46]. It is based on the observation that autosomal dominant mutations causative 
for AD are found in proteins responsible for the production and maturation of the Ab peptide. 
Common animal models of AD are genetically engineered to carry these mutant proteins and/or 
overexpress Ab. To date, all AD studies involving Trem2 knockout mice have utilized such 
models. However, the Ab phenotypes have been inconsistent in these studies. Some studies 
using Trem2-/- mice found no change in the overall plaque load [42,	47], while further studies 
found increased [30,	 43] or even decreased burden [31,	 43]. Some of these differences are 
perhaps explained by the timing of data collection [43], although they could suggest Ab 
clearance is not the only role for TREM2. 
While there have been mixed results on the accumulation of Ab, all Trem2-/- studies have 
shown decreased clustering of myeloid or microglial cells around plaques, suggesting a defect 
in microgliosis, or microglia activation [30,	31,	42,	43,	45,	47]. These studies have also found 
that Trem2-/- mice have fewer microglia and increased microglia apoptosis. Importantly, samples 
from human R47H carriers recapitulate the microglia- Ab plaque phenotype observed in Trem2 
haploinsufficient mice, with fewer microglia clustering around the plaques, and the plaques 
displaying a diffuse morphology, which is more toxic to neurons [45]. Therefore, although 
TREM2 may not have a dramatic effect on the overall Ab content of the diseased brain, it 
strongly affects the ability of microglia to respond to and contain the plaques. In support of a role 
for TREM2 in microgliosis, a recent study found that production of sTREM2 is increased prior to 
the onset of symptoms but after initial markers of Ab accumulation and neuronal injury [48]. This 
sTREM2 continues to increase until after the onset of symptoms and highlights the role for 
TREM2 in microgliosis at a critical point for the response to accumulating damage from disease. 
TREM2 in models of Tau pathology 
Besides Ab, intracellular tangles of hyperphosphorylated tau proteins are the other major 
pathological component of AD [49]. While no studies using Trem2-/- mice have been published 
in tau models, Jiang and colleagues have conducted studies altering TREM2 expression in vivo 
by lentiviral overexpression (under a Cd11b promoter) or shRNA knockdown [50,	 51] in the 
P301S tau transgenic model. These studies found that TREM2 reduces inflammation, 
decreases tau kinase activity, and improves cognitive function. Future studies should utilize 
Trem2 knockout and mutant Trem2 knock-in models on this background to confirm the role of 
TREM2 in tau-mediated neuropathies (if any). 
TREM2 in other neurodegenerative diseases 
Similar to what has been observed in AD models, Trem2-deficient mouse models of 
aging, prion pathogenesis and the cuprizone model of multiple sclerosis (MS) demonstrated 
fewer activated microglia in the course of the disease [52-54]. In MS models, there was less 
myelin clearance by microglia [52,	 53] although there was no obvious deficiency in myelin 
uptake in vitro. Instead, Trem2 deficiency was associated with decreased expression of lipid 
metabolism enzymes and a failure to degrade myelin debris [52,	53]. These findings suggest a 
more general defect in activation [52-54]. Other studies examining the role of TREM2 in stroke 
have found increased expression following ischemic attack [39,	55,	56]. As in the other cases, 
these studies found that Trem2 deficiency decreased inflammation, impaired microglial 
activation, and resulted in a failure of microglia to cluster at scar tissue [39,	55]. 
Summary TREM2 in neurodegenerative diseases 
The consensus from the neurodegenerative disease studies is that TREM2 is important 
for enabling the response of myeloid cells (primarily microglia in the CNS) to disease. Mice 
lacking TREM2 have fewer microglia, and these microglia fail to activate and respond to 
damage during disease. These observations suggest a general deficit in microgliosis. 
Additionally, sTREM2 in CSF seems to be a general feature of inflammatory neurodegenerative 
disease. Soluble TREM2 was first identified in the CSF of MS patients and neuroinflammatory 
patients [57], and has since been identified in a number of AD cohorts [58-61]. 
Non-CNS diseases – the role of TREM2 in COPD, gut injury, and infection 
Because of the genetic link between TREM2 and neurodegenerative diseases, the 
majority of TREM2 research in recent years has focused on its role in the CNS. However, 
TREM2 has important roles outside the CNS, particularly in models where the activation and 
phenotype of myeloid/macrophage cells is pivotal to disease development. In a model of virus-
induced chronic obstructive pulmonary disease (COPD), TREM2 is required for survival and 
proliferation of alternatively activated (M2) macrophages [62]. Unlike the healthy microglial 
response in AD, these macrophages promote a COPD-like disease. However, the role of 
TREM2 in preventing macrophage apoptosis and permitting macrophage proliferation bears a 
striking similarity to the TREM2 phenotype in CNS diseases (where TREM2 contributes to 
microglia survival and proliferation). This study also identified a potential role for sTREM2 as a 
signaling molecule, as application of recombinant sTREM2 prevented macrophage apoptosis 
following M-CSF withdrawal. 
In a gut injury model, TREM2 also promoted an M2 macrophage phenotype, which was 
important for promoting wound healing [63]. TREM2-expressing macrophages infiltrated the 
		
wound area, inhibited the expression of inflammatory cytokines, and promoted the expression of 
Th2 cytokines IL-4 and IL-13. However, in a chemical injury model of inflammatory bowel 
disorder (IBD), TREM2 promoted an inflammatory phenotype that was detrimental to healing 
[64]. The differences in these studies may be due to the environment. In the biopsy injury 
model, the first step in healing was for epithelial cells to form a layer over the wound, which the 
authors hypothesized would reduce exposure to bacteria and therefore reduce strong TLR 
signals that are known to down-regulate TREM2 [63]. The healing response may be different in 
the chemical model, and the interaction between TREM2 and TLR pathways may result in the 
increased inflammation observed in that model [64]. 
While the initial characterizations of NHD patients with DAP12 and TREM2 mutants did 
not report immune deficiencies [7,	 65], the role of TREM2 in infections has been studied in 
various models of bacterial infection. In general, these models are more acute than those 
discussed above, and therefore may highlight different roles for TREM2 in the innate response 
to bacteria. These studies have mostly found TREM2 to be phagocytic and anti-inflammatory, 
although there are some exceptions (Table 1). Cellular studies have shown that TREM2 
regulates the response to bacteria, in two examples by promoting killing of bacteria through 
production of reactive oxygen species (ROS) [66,	 67] – even against bacteria that were not 
directly detected by TREM2 [66]. The role of TREM2 may vary with different pathogens, as it 
did not promote killing of B. abortus, [68] a pathogen that specializes in invading and surviving 
in macrophages. 
Conclusions from disease models of TREM2 
Recent years have seen substantial progress in identifying an important role for TREM2 
in animal models of disease. Studies using Trem2-deficient mice highlight its role in sustaining 
the microglial response to disease. However, important questions remain about what precise 
function TREM2 is performing, how different ligands may stimulate these functions, and how 
disease variants or mutations affect function. Mechanistically, there are several possibilities for 
TREM2 functions, and the answers to these questions depend upon understanding the 
interaction between TREM2, its signaling mechanisms, and its ligands. 
2. TREM2 Signaling
DAP12 mediates intracellular signaling of TREM2 and other receptors 
DAP12 is the co-receptor for TREM2 and a number of other single-pass transmembrane 
receptors. DAP12 contains an Immuno-Tyrosine Activation Motif (ITAM, consensus sequence: 
YxxI/Lx(6–12)YxxI/L). Broadly, TREM2 signaling through DAP12 results in ITAM 
phosphorylation which leads to Ca2+ mobilization, ERK (MAPK) phosphorylation, and actin 
remodeling. However, TREM2 also negatively regulates TLR signaling and has roles in 
signaling pathways for other receptors [69]. Here we review the TREM2 signaling pathway and 
highlight areas where TREM2 signaling may have influence outside of the canonical “activation” 
pathway. 
DAP12 associates with receptors through transmembrane interactions 
DAP12 forms a disulfide-bonded homodimer with two intermolecular disulfide bonds 
contained within in a short ectodomain (14 residues in human aa 28-41 [70], 16 in mouse aa 
28-43 [71]). Within the transmembrane domain, an electronegative Asp from each DAP12
monomer forms a 2:1 interaction with a Lys from the receptor. A Thr four residues below the 
Asp is also involved in the electrostatic network [72-74]. The interaction with the receptor is 
important to shield the polar residues from the lipophilic membrane environment and to allow 
trafficking to the cell surface (reviewed in [75]). While it is established that DAP12 requires 
complexing with a receptor for trafficking to the cell surface, there have been multiple reports of 
TREM2 surface expression in Dap12 and Dap12/Dap10-deficient cells [62, 76, 77]. Other 
DAP12-coupled receptors require DAP12 for surface expression [77], so it is possible that 
DAP12 could traffic to the surface with another receptor and engage TREM2 there. 
The DAP12 signaling pathway 
The standard DAP12-receptor signaling pathway was delineated using Ly49D as a 
model DAP12-coupled receptor on NK cells [78]. Ly49D ligation results in ITAM phosphorylation 
by Src kinases. The two phosphorylated Tyr residues in the ITAM create a binding site for the 
SH2 domain of the kinase Syk. Activation of Syk leads to the phosphorylation of ERK1/2, 
PLCγ1, and Cbl. These same features were observed with TREM2. Stimulation with an anti-
TREM2 antibody produced calcium flux and ERK phosphorylation while monovalent stimulation 
by anti-TREM2 Fab did not result in calcium flux [79]. Functionally, TREM2 stimulation 
prolonged DC survival following withdrawal of GM-CSF and IL-4. TREM2 has also been 
implicated in actin mobilization [10,	 80]. Monocytes from TREM2-null NHD patients had 
defective actin rearrangement following RANKL/MCSF stimulation. These initial studies linked 
TREM2 to the hallmark ITAM signaling events: Ca2+ mobilization, ERK phosphorylation, and 
actin remodeling (Fig. 1A). Further studies extended the TREM2 signaling pathway, and began 
to identify nuances that are key to fully understanding TREM2 function. 
Although DAP12 is the primary adaptor for TREM2, DAP10 can also interact with 
DAP12-TREM2 complex, possibly through the formation of DAP12-DAP10 heterodimers	 [81]. 
DAP10 contains a “YINM” motif that can recruit PI3K. Accordingly, DAP10 was required for 
effective activation of PI3K, Grb2, and therefore Akt and ERK signaling. However, calcium 
mobilization was surprisingly unchanged in DAP10-/- bone marrow-derived macrophages 
(BMDMs) [81]. Beyond DAP12, signaling cascades in hematopoietic cells that begin with ITAM 
phosphorylation use scaffolding proteins to recruit downstream effector proteins such as Grb2, 
Cbl, PI3K, and Vav. Two such proteins are the Linkers for the Activation of T and B cells (LAT 
and LAB; LAB is also known as LAT2 and NTAL) [82]. While they share most functions, a key 
difference is that LAT stimulates calcium mobilization more efficiently than LAB. DAP12 can 
signal using either LAT or LAB, however TREM2 signaling through DAP12 utilizes LAB in 
osteoclasts and BMDMs [83]. 
TREM2-DAP12 signaling is inhibited by phosphatases and ubiquitin ligases 
Once activated, how is TREM2 signaling terminated? Following TREM2 stimulation by 
anti-TREM2 antibodies, the phosphatidylinositol phosphatase SHIP-1 binds the phosphorylated 
membrane-proximal tyrosine, pY65, within the ITAM motif of DAP12 to inhibit DAP12 signaling 
and TREM2-dependent osteoclast multinucleation [81]. This tyrosine is part of a “closet ITIM” 
sequence which was previously hypothesized to mediate inhibitory signals (SPYQEL, canonical 
ITIM is S/I/V/LxYxxI/V/L) [84]. Furthermore, as noted above, the E3 ubiquitin ligase Cbl is 
recruited to LAB and forms a complex with LAB and PI3K [83] to target Src and Syk for 
ubiquitination and degradation [85]. This activity requires LAB, as LAB-/- cells have increased 
Syk activation but decreased ERK activation [83]. Therefore, DAP12 signaling directly leads to 
its own inhibition by the recruitment of these two molecules. Finally, TREM-like transcript 1, 
(TREML1, also TLT-1), an ITIM-containing member of the TREM family is expressed in bone 
tissue [86] and associates with the tyrosine phosphatase SHP-1 upon phosphorylation. A short 
alternatively-spliced transcript lacking much of the ectodomain (TREML1s) is also expressed in 
osteoclast precursors and macrophages. TREML1s co-IPs with TREM2, SHP-1, and SHIP-1 
and decreases ERK, Akt, and calcium signals following RANKL stimulation [87]. Therefore, 
TREML1 (or TREML1s) may inhibit TREM2 signaling (Fig. 1B). 
TREM2 regulates inflammation through tonic signaling 
In contrast with TREM1, which signals through DAP12 to amplify TLR responses [88], 
TREM2 inhibits inflammatory cytokine production following TLR stimulation in cultured BMDMs 
and DCs [89-91]. TREM2-dependent modulation of cytokine production did not require 
exogenous stimulation of TREM2, suggesting TREM2 could be recognizing endogenous ligands 
to produce an inhibitory signal. There is precedence for inhibitory ITAM signaling in a similar 
system [92]. In this example, IgA binds its receptor FcαRI, which signals through the ITAM-
containing co-receptor FcRγ to produce either inhibitory (SHP-1 recruiting) or activating ITAM 
signals based on whether IgA is monomeric or aggregated by antigens. The transient 
monomeric interaction produces inefficient ITAM phosphorylation, leading the recruitment of the 
inhibitory tyrosine phosphatase SHP-1. This IgA-FcαRI-FcRγ system is analogous to ligand-
TREM2-DAP12 and previous commentaries have suggested monovalent or low-affinity TREM2 
ligands induce tonic  signals that are less activating and anti-inflammatory through such a 
mechanism [93-95] (Fig. 1C). However, the endogenous, inhibitory TREM2 ligand has not been 
identified. Along these lines, it was recently observed that expression of DAP12 with a C-
terminal fragment of TREM2, which lacks the ectodomain but contains the DAP12-interacting 
transmembrane domain, is sufficient to inhibit cytokine production following LPS stimulation 
[96]. The C-terminal fragment may occupy DAP12 similarly to TREM2 with a monovalent ligand. 
Soluble TREM2 (sTREM2) as a signaling molecule 
The TREM2 receptor signals through DAP12. However, release of the soluble TREM2 
ectodomain (sTREM2) via proteolysis is well-documented [2, 25]. The production of soluble 
TREM ectodomains appears to be a general feature of the family as soluble forms of TREM1 
[97] and TREML1 [98] have also been reported. While sTREM1 is thought to be a decoy
receptor [99], current evidence suggests sTREM2 is a signaling molecule. In the first study of 
sTREM2 function, application of sTREM2 (residues 19-136) to cultured BMDMs resulted in ERK 
and MAPK14 activation that persisted several hours and prevented apoptosis following M-CSF 
withdrawal [62]. A similar phenotype was recently observed using microglia [100], although the 
signaling mechanism differed (Fig. 1D). In the macrophage study, sTREM2 did not detectably 
increase pAKT, while in microglia, the anti-apoptotic effect was blocked with PI3K inhibitors and 
was mediated by AKT inhibition of GSK3-b to increase b-catenin. Soluble TREM2 also 
increased transcription of inflammatory cytokines in microglia through NF-kB activation [100], a 
pathway that was not previously reported to be activated by cellular TREM2 signaling [79]. It is 
interesting that only some functions associated with receptor TREM2, such as survival but not 
proliferation have been recapitulated with sTREM2, which suggests discrete roles for TREM2 
both as a cellular receptor and soluble signaling molecule. 
TREM2 regulates TLR signaling using inhibitory adaptors 
TREM2 also uses adaptor proteins to influence the inflammatory environment. LAB-/- 
macrophages display increased ERK phosphorylation following TLR stimulation [83]. It could be 
that TREM2 signaling through LAB restricts ERK or other signaling molecules needed for TLR 
signaling, or that LAB-dependent Cbl-mediated ubiquitination reduces the level of kinases 
needed to activate TLR pathways [82]. Another pathway for inhibiting TLR signals is the 
recruitment of the anti-inflammatory adaptor protein DOK3 to DAP12 following TLR stimulation 
with LPS. Following LPS stimulation, DOK3 becomes phosphorylated, associates with DAP12, 
and interacts with Grb2 and Sos1 to inhibit the TLR response. In this system, SHIP-1 was not 
required to inhibit TLR signals, demonstrating that the inhibition of ITAM signaling by SHIP-1 is 
separate from the inhibition of TLR signaling by DAP12 [101] (Fig. 2A). 
The role of TREM2 and DAP12 in co-stimulatory signaling 
Plexin-A1 is expressed in a number of tissues including DCs and osteoclasts and is a 
receptor for two separate Semaphorin proteins. When expressed on osteoclast precursors, 
Plexin-A1 constitutively interacts with Neuropilin-1 (Nrp1) to mediate Semaphorin-3A (Sema3A) 
signaling, which prevents osteoclast maturation [102]. However, when osteoclast precursors are 
stimulated with RANKL, Nrp1 is downregulated and Plexin-A1 can be bound by Sema6D to 
drive osteoclast maturation [103]. Unexpectedly, this Sema6D signaling required TREM2 and 
DAP12 [104]. When Plexin-A1-/- mice were first characterized, they were discovered to have an 
osteopetrotic phenotype with decreased osteoclast counts as well as deficits in activation of T 
cells by DCs, similar to what had been reported for DAP12-/- mice [105,	106]. Takegahara et al. 
found that stimulation of BMDCs with a soluble form of Sema6D resulted in DAP12 
phosphorylation and also found an interaction between TREM2 and Plexin-A1 using co-IP and 
intracellular FRET. DAP12 and Plexin-A1 did not co-IP without TREM2, suggesting TREM2 
connects DAP12 to Plexin-A1 signaling [104]. This Plexin-A1/TREM2 interaction is specific for 
Sema6D signaling, because the Nrp1-Plexin-A1 interaction displaces TREM2 in co-IP 
experiments [102,	107] (Fig. 2B). 
TREM2 is also involved in M-CSF-mediated survival and proliferation in macrophages 
and osteoclast precursors. M-CSF signals through its receptor CSF-1R to activate b-catenin 
through phosphorylation of b-catenin by calmodulin-dependent kinases downstream of DAP12 
in a TREM2-dependent mechanism [108,	 109]. In Trem2-/-  mice, the b-catenin deficit in 
osteoclast precursors reduces proliferation and prematurely accelerates osteoclast maturation. 
The increase in osteoclasts produces an osteopenic phenotype in the Trem2-/- mice, similar to 
NHD patients [108].  How are TREM2 and DAP12 activated by M-CSF signaling? A separate 
study showed M-CSF stimulation resulted in DAP12 phosphorylation by Src kinases activated 
by CSF-1R [110]. This mechanism suggests these receptor pairs are in close physical 
proximity; however, a direct interaction between TREM2 and CSF-1R has not been reported 
(Fig. 2C). Very recently, a study using mouse microglia confirmed a role for TREM2 in Wnt/b-
catenin signaling in these cells. Trem2-/- microglia had suppressed b-catenin signaling and 
suffered G1/S cell cycle arrest [111], as predicted from the studies in osteoclast precursors. 
This results in fewer microglia and impaired microgliosis. 
3. TREM2 Ligands.
TREM2 binds anionic bacterial ligands 
Bacteria and poly-anionic molecules were the first potential ligands identified for TREM2 
[112]. TREM2 interacted with Gram-positive and Gram-negative bacteria in direct binding and 
signaling studies. In another study, CHO cells transfected with a chimeric TREM2-DAP12 
construct became competant to phagocytose bacteria [113]. Phagocytosis was dependent on 
Syk activation and the activity of the Rho GTPases Rac and Cdc42. Additional studies 
confirmed TREM2 can bind E. coli, but not Salmonella [66]. TREM2 also interacts with an 
unknown ligand in C. jejuni, a gram-negative bacteria which is a causative agent for food 
poisening [114]. 
The study by Daws et al. also found that anionic bacterial carbohydrates, particularly 
dextran sulfate, LPS, and LTA, but not chondroitin sulfate (CS), could block TREM2 binding to 
bacteria. Dextran sulfate could also activate TREM2 reporter cell lines similarly to E. coli [112]. 
Another study found that TREM2 can directly bind lipooligosaccharides (LOS) from N. 
gonococcus. Enzymatic removal of the acyl chains reduced binding, suggesting the lipidic acyl 
chains mediate binding to TREM2. SPR experiments were used to quantify the interaction (Kd  ≈ 
350 nM) [115]. 
TREM2 binds myeloid and non-myeloid mammalian cells 
Because myeloid cells have TREM2-dependent phenotypes when cultured without other 
cell types, it was hypothesized they would express a TREM2 ligand. Indeed, TREM2 can bind 
primary macrophages [89] and DCs [91]. With DCs, stimulation with LPS, CpG DNA, or 
Zymosan did not alter staining levels. However, TREM2 staining of THP-1 monocytes was 
shown to be ablated when cells were pre-treated with PMA+ionomycin [26], the first time a 
cellular TREM2 ligand was shown to be regulated in viable cells. These findings suggest a 
ligand that interacts with TREM2 in cis, perhaps to provide tonic signals or to function as a co-
receptor with TREM2 to recognize ligands in trans from extracellular stimuli. Importantly, the 
AD-risk mutations R47H and R62H had decreased binding to this cell-surface ligand, while a 
T96K variant had enhanced binding. This last variant has unclear disease risk, but may be 
protective. If these mutations affect binding to a cis ligand required for signaling, it will be 
important to experimentally distinguish deficits in ligand binding from signaling. 
Given the role of TREM2 in CNS homeostasis, several studies have also investigated 
the potential for a direct interaction between TREM2 on microglia and the other cells of the 
CNS, namely astrocytes and neurons. The first report of TREM2 ligands used Fc-TREM2 
proteins to bind a variety of astrocyte lines [112]. Binding could be blocked by competition with 
LPS or LTA, showing a role for anionic recognition in the cell-surface TREM2 ligand. Other 
groups have also shown TREM2 binds primary cultured rat astrocytes [116], and astrocytes can 
activate TREM2 reporter cells [117]. In addition to astrocytes, cytochemistry and reporter cell 
activation demonstrated the presence of a TREM2 ligand on cultured neurons [37], and flow 
cytometry experiments confirmed Neuro2A cells express a TREM2-specific ligand, as other 
TREM family proteins (TREML2 and TREML4) had minimal binding [26]. 
In addition to binding viable neurons, Fc-TREM2 staining of Neuro2A and other cell lines 
increased when the cells were apoptotic [37] and TREM2 staining of neurons was increased 
following iscemic attack [39]. Apoptotic neurons [37] and thymocytes [30] have also been shown 
to stimulate TREM2 signaling, suggesting a common ligand on apoptotic cells. It is unclear 
whether this increased binding to apoptotic cells is from increased exposure of one ligand or 
nascent exposure of an additional ligand. Functionally, downregulating Trem2 by shRNA in BV2 
microglial cells reduced phagocytosis of apoptotic neurons, and transfecting CHO cells with 
TREM2 made the cells competant to phagocytose apoptotic cells [37].  Altogether, these studies 
have identified TREM2 interactions with mammalian cells that do and do not express TREM2. 
TREM2 binds anionic ligands on mammalian cells 
TREM2 has been shown to bind a number of anionic molecules from mammalian cells. 
Cannon et al. performed the first demonstration of TREM2 proteins binding to phospholipids. 
Solid-state lipid ELISAs using a variety of plated phospholipids showed TREM2 binding was 
strongest with phosphatidylethanolamine (PE), phosphatidylserine (PS), and cardiolipin (CL), 
while phosphatidylcholine (PC) or sphingomyelin (SM) displayed greatly diminished binding 
[118]. Two other groups have obtained similar results showing strong binding to anionic lipids 
such as phosphatidic acid (PA) and PS using dot blots [119] or ELISA and liposome 
sedimentation [26]. Unlike assays with CD300 or [118,	120] or TIM [121,	122] family proteins, 
additon of calcium or magnesium did not enhance TREM2 binding, suggesting a different mode 
of recognition [26, 118]. The TREM2 crystal structure also showed that TREM2 does not contain 
structural features associated with selective phospholipid binding by other Ig domains [26]. 
Studies using TREM2 reporter cells also support the concept of phospholipids as 
TREM2 ligands. Plated sulfatide, PC, and SM all strongly stimulated mTREM2 [53] and similar 
results were obtained with hTREM2 [30]. However, the recognition profile is different than what 
has been observed in direct binding assays, where PC has minimal binding and anionic 
moieties have higher binding [26, 118, 119]. The R47H variant had minimal signaling to lipids 
other than PC and SM [30]. In a followup study with other TREM2 variants, R62H behaved 
similarly to R47H, while D87N and T96K increased signaling in response to PS and Sulfatide, 
but not PC [123]. These findings further support the hypothesis that TREM2 variants alter ligand 
binding and, hence, signaling. 
While TREM2 certainly binds phospholipids in the context of solid-state ELISA and 
liposome assays, and phospholipids can stimulate signaling in reporter cells, they are unlikely to 
represent the complete TREM2 ligand. In one study, apoptotic Jurkat cells (which expose PS on 
the cell surface) did not bind Fc-TREM2 [119]. This suggests that phospholipids are not 
sufficient for TREM2-cell binding and may need co-presentation with other molecules. Second, 
while results in our lab showed TREM2 binding to phospholipids by ELISA and liposome 
sedimentation, the disease variants R47H, R62H, and T96K did not grossly alter phospholipid 
binding [26]. Therefore, it will be important to understand how multiple interactions may 
influence TREM2 to recognize ligands and facilitate signaling. 
In addition to phospholipids, nucleic acids released by damaged cells are a possible 
TREM2 ligand. TREM2 can IP nucleotides from the supernatant of ischemic brains and purified 
DNA activated TREM2 reporter cells [39]. Given the common anionic theme for TREM2 ligands, 
it would not be surprising that nucleotides released from damaged cells in the brain could 
stimulate TREM2. 
Finally, by using enzymes that selectively cleave either heparan sulfates (HS) or CS, it 
was shown that TREM2 binds cell-surface proteoglycans and these are a major component of 
the cell-surface ligand [26]. Staining to THP-1 and Neuro2A cells was largely ablated by pre-
treating the cells with heparan sulfatases, but not chondroitinase. This selectivity for HS over CS 
is consistent with the earlier studies showing heparin (but not CS) could block TREM2 binding to 
bacteria [112]. In addition, proteoglycan binding would explain why TREM2 can bind such a 
wide range of cells. The AD disease risk variants lose binding to these cells while the T96K 
variant gained binding, suggesting proteoglycans are an important TREM2 ligand. Future work 
will be needed to address whether HS is a tonic or activating ligand, whether it is required for 
presenting another ligand, or whether it is necessary to orient TREM2 to signal upon ligation of 
an activating ligand such as phospholipids. 
TREM2 binds cellular mammalian proteins 
Beyond the anionic biomolecules, TREM2 has been linked to other mammalian proteins. 
Pulldown experiments of surface-biotinylated neurons identified the cytosolic chaperone protein 
HSP60 [116]. ELISA assays demonstrated a direct interaction between these proteins with a 
low micromolar affinity. While it is counter-intuitive for an intracellular chaperone to mediate 
extracellular signals, there is a body of research characterizing the role of various heat-shock 
chaperones as alarmins for the innate immune system [124]. 
Additionally, as discussed above, the receptor Plexin-A1 interacts with TREM2 as part of 
a signaling complex. These proteins were co-immunoprecipitated and the interaction was 
ablated by deleting certain domains in Plexin-A1 [104]. In addition to Plexin-A1, TREML1s co-
IPs with TREM2. The structural basis for these interactions are not known, and they may be 
indirect through association with signaling complexes [87]. 
TREM2 binds lipoproteins 
In 2015, two groups independently identified a direct interaction between TREM2 and 
apolipoproteins, including ApoE.  APOE and APOA were identified in protein bands precipitated 
from CSF by TREM2 [119] and interaction was verified by co-IP, ELISA, and dot blots [119, 
125]. Both groups found that TREM2 binds all ApoE isoforms, lipidated and non-lipidated, and 
that the R47H variant reduced binding to ApoE. A separate study used a protein microarray to 
identify ligands for TREM2 from a library of extracellular and secreted proteins and investigated 
potential hits with bio-layer interferometry (BLI) [126]. TREM2 bound apolipoproteins, including 
APOA, APOB, APOE, CLU, and LDL. In contrast to the other reports, non-lipidated proteins had 
reduced binding as assessed by the response amplitude. The kinetics of these responses were 
not quantified, so it is unclear if the differences are reduced affinity or because the lower 
molecular weight non-lipidated proteins produce a smaller signal by BLI. The R47H, R62H, and 
D87N variants had reduced signal compared to WT. Functionally, ectopic expression of TREM2 
in 293T cells enabled phagocytosis of APOE and Ab that was bound to APOE [126]. Finally, in a 
study with reporter cells, TREM2 signaled in response to LDL and HDL [123]. However, in 
contrast with the BLI data, the D87N had about three-fold increase in signaling. 
The link between APOE and TREM2 connects these two key AD-risk proteins. The risk 
associated with TREM2 variants is comparable with the APOE4 allele. Other evidence 
suggested TREM2 and APOE could have overlapping areas of function. TREM2 has been 
linked to lipid metabolism: Trem2 transgenic mice gain more weight on a high fat diet [127], and 
expression analysis connected Trem2 to lipid metabolic pathways [29, 53]. Furthermore, APOE 
interacts with Ab, lipids, and heparan sulfates [128], and is important for microglial functions 
including phagocytosis, inflammation, and cell health [129, 130]. Lipoproteins are highly 
abundant in serum, and the presence and role of lipoproteins will need to be considered in 
cellular experiments with TREM2. 
4. TREM2 function and model for ligand engagement.
To conclude, we summarize the reported TREM2 functions and try to arrange them 
through the context of various ligands. The reported ligands for TREM2 are broad and include 
ligands that could be thought to represent steady-state tonic stimuli or disease-specific stimuli. 
Therefore, the functions of TREM2 signaling could range from specific responses such as 
phagocytosis, cell activation, or collaboration with other signaling pathways to maintain cell 
survival and proliferation (Fig. 3). These possibilities are not mutually exclusive; on the contrary, 
it may be useful to conceptualize the different ligands as either tonic, homeostatic signals or 
damage-associated signals which produce different kinds or strengths of stimuli in order to 
accomplish the wide variety of functions reported for TREM2. 
TREM2 functions from endogenous signals maintain myeloid cell homeostasis, regulate 
inflammation, and enable phagocytosis. 
During development and homeostatic conditions, TREM2 is important for myeloid cell survival, 
proliferation, and maturation. TREM2 signals ensure myeloid cells remain ready and competent 
to respond to damage and disease. 
1. TREM2 responds to tonic stimuli as a receptor and/or co-receptor for myeloid
survival and maturation
This is an attractive, but still undefined mechanism where TREM2 signaling sustains myeloid 
cell survival and proliferation in order that the myeloid cells can respond to other stimuli in a 
condition-specific manner. One possible mechanism is a role for TREM2 in b-catenin activation 
[111], which probably involves interactions with M-CSF signals [108]. Another possibility is 
TREM2 is not engaging an activating ligand, but is preferentially associating with DAP12 to 
localize it at the cell surface where it can be phosphorylated by Src or other kinases activated by 
CSF-1 or other survival pathways (Fig. 3A). 
2. TREM2 signals are important for myeloid cell maturation
Studies using human monocytes from NHD patients with mutations in TREM2 observed 
decreased capacity to mature into osteoclasts and DCs [10, 80]. Similar to collaboration with M-
CSF, TREM2 connects Plexin-A1 to DAP12 for osteoclastogenesis [104]. Therefore, TREM2 
plays a role in the ability of myeloid cells to mature following stimulation by cytokines (Fig. 3B). 
3. TREM2 responds to tonic stimuli to regulate inflammation
TREM2 and DAP12 reduce inflammatory TLR signals [89, 90] in cultured BMDMs. This role did 
not require stimulation with an exogenous ligand, suggesting it is mediated by a ligand on the 
BMDMs or perhaps from the culture media. This function likely also involves co-regulation of 
adaptor proteins that dampen TLR signaling (Fig. 3C). 
Which ligands could be important for these functions? Many of these in vitro results did 
not require antibody stimulation of TREM2, suggesting a ligand present on the myeloid cells or 
readily available in culture. Phospholipids, proteoglycans, or lipoproteins make attractive 
candidates as these ligands would be ubiquitous. For example, APOE is highly abundant in 
serum and CSF, with concentrations in the µg/mL range [131]. However, because these ligands 
are so ubiquitous, understanding how signaling could be regulated is a challenge. 
TREM2 functions during disease 
In addition to its role as a tonic receptor, TREM2 recognizes a variety of ligands associated with 
damage, disease, and infection. These ligands may mimic tonic stimuli or instead may produce 
an activating signal above the tonic threshold. 
1. TREM2 responds to damage stimuli to drive survival and activation of myeloid
cells.
During disease, TREM2 responds to DAMPs such as ligands exposed on apoptotic 
membranes, myelin lipids, DNA exposed by necrotic cells, ligands presented by Ab plaques, or 
perhaps lipoparticles enriched in apoptotic phospholipids. TREM2 stimulation by these ligands 
could be important for TREM2 function under the additional stress from damage. In this 
scenario, TREM2 signaling licenses the response to pathogens and other damage. This cellular 
activation program can take a number of forms, including sustaining cell survival, regulating 
cytokine production, and/or permitting phagocytosis by other receptor pathways. For example, 
TREM2 was required for full phagocytic capacity of antibody-Ab complexes (which are 
recognized by FcR for phagocytosis), showing TREM2 enables the phagocytic functions of 
other receptors [132]. TREM2 inhibits inflammatory cytokine production in cultured microglia 
following exposure to apoptotic neurons [133], and Trem2-deficient and haploinsufficient 
microglia have impaired microgliosis and don’t properly respond to plaques [30, 42, 45, 47, 134] 
(Fig. 3D). 
2. TREM2 directly binds DAMPs/PAMPs for phagocytosis
While the primary role of TREM2 may not be phagocytosis, there have been reports of TREM2-
mediated phagocytosis of a direct ligand, including phagocytosis of apoptotic neurons that 
express a TREM2 ligand [37, 116, 133], and bacteria [113] likely through recognition of anionic 
bacterial components [112]. These examples did not require TREM2 stimulation by antibodies 
or separate ligands. Instead, cross-linking by bacterial carbohydrates or apoptotic membrane-
exposed ligands activate TREM2 signaling, resulting in microtubule mobilization and 
phagocytosis (Fig. 3E). 
Phagocytosis is a good example for how different types of TREM2 signaling and ligands 
may induce different functions. Studies generally ascribe a pro-phagocytic role for TREM2. For 
example, some studies have shown ectopic expression of TREM2 is sufficient to promote 
phagocytosis in non-myeloid cells [25, 113]. However a most interesting study from Knapp and 
	colleagues demonstrated Trem2 deficiency had opposite effects on phagocytosis by bone 
marrow and alveolar macrophages [135]. In the context of neurodegenerative disease, it has 
often been assumed that TREM2 has a major role in phagocytosis of debris. However, given 
that studies have observed increased [30], unchanged [136], and decreased [31] levels of Ab 
plaque levels in Trem2-deficient mice, phagocytosis may not be the principal role of TREM2 in 
AD. Indeed, despite the defect in microgliosis and an apparent role for the plaques in stimulating 
TREM2 [45], Trem2-haploinsufficient mice did not have a phagocytic deficit. Trem2 deficient 
microglia display impaired phagocytosis, but this may be an indirect result of even more severe 
deficits in microglia activation [42, 45]. Another study noted that phagocytosis of Ab is increased 
in Trem2-transduced microglia isolated from 7-month-old, but not 18-month-old 
APPswe/PS1dE9 mice [137], suggesting that TREM2 itself is not sufficient for phagocytosis if 
other factors lost with age are not present. 
The TREM2 crystal structure provides insights into ligand engagement 
The human TREM2 Ig domain crystal structure provides some clues as to how TREM2 
may interact with various ligands. TREM2 has a pronounced basic patch on its surface that is 
involved in the recognition of cell-surface proteoglycans and is most likely important in the 
recognition of additional anionic ligands [26]. The major AD-risk variants (R47H, R62H) are 
contained in this surface and additional mutations that increase the basic surface (T96K) 
increase binding to ligands while other R to D mutations in the basic surface decrease cellular 
binding. Therefore, this surface is involved in recognition of cell-surface proteoglycans. 
Furthermore, this surface is not observed on TREM1 or the other TREM family crystal 
structures. Also noteworthy is that circular dichroism spectroscopy studies revealed a subtle 
conformation change for the R47H variant, but not the R62H or T96K variant. The portion of the 
CD spectra altered is associated with tryptophan residues within Ig folds. Therefore, it is 
possible that the R47H variant specifically disrupts another part of the protein structure whereas 
the other residues likely only impact the basic patch. There is also a hydrophobic surface on the 
protein that may be involved with recognizing lipidous ligands. In particular, cell-surface 
proteoglycans on myeloid cells may act in cis as a tonic ligand for TREM2 while simultaneously 
orienting or clustering the protein to receive activating signals from other ligands. These signals 
may be induced through interactions with other surfaces on TREM2 or may result by “hand-off” 
from GAGs to a higher-affinity ligand that recognizes the basic surface (Fig. 4). There are 
several precedents for receptor-GAG interactions mediating immune signaling, such as CD14-
TLR4 [138], CXCL12 chemokine [139], and acetylcholine receptors [140]. To answer these 
questions, experiments must be performed with the different TREM2 ligands to dissect their 
effect on the different modules of TREM2 signaling and interplay with other pathways. Epitope-
mapping experiments will be needed to confirm binding sites between TREM2 and ligands to 
understand overlap in TREM2 ligands and also to understand how different ligands interact with 
TREM2 to result in inhibitory or activating signals. Given that different TREM2 variants produce 
different results on protein structure and function [25, 26, 28], it will be also important to conduct 
studies using knock-in models of the mutant proteins. Finally, it is important to consider the role 
of sTREM2 in disease and to identify its signaling receptors. 
Future perspectives: Outstanding questions regarding TREM2 
1. Is there a role for TREM2 in regulating C1q and complement expression in microglia?
TREM2 was reported to inhibit expression of C1q in alveolar macrophages [141] and
C1q is expressed by microglia during development and improperly during AD to prune
neuronal synapses [142].
2. Is surplus TREM2 signaling harmful? The T96K variant has been shown in two studies
to have increased ligand binding or signaling [26, 123], but this variant has not been
robustly linked to disease. If gain-of-function TREM2 variants are indeed disease-risk, it
would mean therapies that stimulate TREM2 must be carefully assessed.
3. When is TREM2 function most critical during disease and when could TREM2 agonists
or antagonists have the most benefit? TREM2 deficiency is reported to have opposing
effects on Ab levels and disease pathology during early and late disease [43].
4. What is the role of sTREM2 in AD, and can it be exploited therapeutically? A decoy
function would make stimulation of transmembrane TREM2 more difficult. However, if
sTREM2 has a beneficial function as a signaling molecule, recombinant sTREM2 could
be considered as a therapeutic.
5. How do culturing conditions influence the interpretation of cellular assays? TREM2 is
likely to be highly influenced by cell density, health of neighboring cells, and perhaps
most importantly, the concentration and activity of lipoparticles.
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Table 1 – Summary of TREM2 links to human disease and animal models of disease 
Disease Observation or 
model 
Phenotype Possible role of 
TREM2 
Reference: 
Neurodegenerative disease 
Nasu-Hakola 
Disease 
NHD patient TREM2 mutations co-
segregate with NHD 
TREM2 mutations 
cause NHD 
[7] 
Osteoclast 
maturation from 
PBMCs 
Monocytes from NHD 
TREM2 carriers have 
impaired osteoclast 
differentiation.  
TREM2 involved in 
myeloid maturation 
[10, 80] 
Osteopenic mice Reduced proliferation of 
osteoclast precursors, 
accelerated osteoclast 
maturation and apoptosis. 
Myeloid proliferation 
and survival 
[108] 
Alzheimer’s 
disease 
Genetic links 
Sequencing & 
GWAS studies 
First two studies to identify 
a link between TREM2 
variants and AD 
R47H is a risk variant. 
Others possible.  
[4, 5] 
TREM2 R47H correlated 
with CSF tau and p-tau 
R47H is an AD risk 
variant  
[18] 
R47H did not fully explain 
TREM2 disease risk 
R62H is an AD risk 
variant 
[3] 
Alzheimer’s 
disease 
Ab Models 
APPPS1 mice Decreased number and 
size of plaque-associated 
microglia in Trem2 
heterozygotes. No change 
in total Ab. 
Microgliosis [47] 
5XFAD mice Trem2-/- mice have 
Increased Ab and impaired 
microglial response at  
8mo. Decreased microglial 
survival. 
Microglia survival, 
microgliosis.  
Protective in Ab 
[30] 
5XFAD, APPPS1 
mice 
5XFAD Trem2-/- mice have 
fewer microglia (8mo) and 
less plaque clustering 
(4,8mo), producing diffuse 
plaque morphology and 
increased neuronal 
pathology. No change in 
total Ab.  
Microgliosis, microglial 
proliferaction.  
Protective in Ab 
[42] 
APPPS1 mice Trem2-/- mice have 
reduced Ab plaque burden 
at 4mo. Decreased plaque 
clustering of Iba1+ cells.  
Plaque response. 
Possible role in 
proliferation, survival, 
and/or trafficking 
Detrimental in Ab 
[31] 
5XFAD, CRND8, 
PS/APP  
Human R47H carrier 
samples 
TREM2 is required for 
microglial barrier function 
around Ab plaques. Human 
R47H carriers mirror 
Trem2 haploinsufficient 
mice. 
Microgliosis and 
protective plaque 
response 
[45] 
APPPS1 mice TREM2 increases amyloid 
burden early, but reduces 
Ab burden late in disease. 
Microglial/myeloid 
proliferation, 
inflammation, and 
plaque response 
[43] 
APPswe/PS1dE9 
mice 
In vivo overexpression 
reduced plaque load and 
inflammation.  
Anti-inflammatory, 
Phagocytosis of Ab 
[32]
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APPswe/PS1dE9 
mice 
Overexpressing Trem2 in 
old mice (18mo) had no 
effect on AD pathology. 
Age-restricted 
protective role 
[137] 
Alzheimer’s 
disease 
Tau models 
P301S mice Trem2 overexpression 
ameliorated tau pathology. 
Protective, anti-
inflammatory 
[50] 
P301S mice Lentiviral knockdown 
increased tau pathology. 
Protective, anti-
inflammatory 
[51] 
Multiple Sclerosis Cuprizone TREM2 sustains microglia 
during aging and cuprizone 
challenge. Reduces myelin 
debris. 
Microglial survival and 
proliferation during 
aging myelin response 
[53] 
Cuprizone Trem2-/- mice have 
increased myelin debris, 
decreased microglial 
proliferation and activation. 
Microgliosis and 
proliferation 
[52] 
EAE Antibody blockade of 
TREM2 signaling 
exacerbates symptoms. 
Beneficial in MS [117] 
EAE EAE symptoms were 
reduced by Trem2-
transduced macrophages.  
Anti-inflammatory, 
protective 
[143] 
Prion Pathogenesis Prion infection No effect on prion 
pathogenesis, but reduced 
microglial activation. 
Microgliosis and 
proliferation 
[54] 
Cardiovascular disease 
Stroke Experimental 
Ischemia 
Trem2-/- mice had 
increased infarction, 
decreased microglia 
activation, and fewer 
phagocytic microglia. 
Microgliosis and 
phagocytosis 
Protective following 
stoke 
[39] 
Experimental 
Ischemia 
Trem2-/- mice have fewer 
microglia at glial scars and 
decreased microglial 
activation. No change in 
scar size.  
Microgliosis [55] 
Chronic pulmonary disease 
Viral-induced 
COPD 
SeV-induced chronic 
airway disease  
Trem2-/- mice have 
reduced macrophage 
expansion which reduced 
chronic disease. IL-13 
stimulation produces 
sTREM2 which prevents 
macrophage apoptosis.  
Survival and 
proliferation. 
sTREM2 prevents 
macrophage 
apoptosis, allowing 
conversion to 
alternatively activated 
macrophages, which 
promote airway 
disease 
[62] 
Wound Healing 
Colon injury Chemical colon injury Trem2-/- mice had reduced 
inflammation and wound 
damage.  
Inflammatory, bacterial 
killing. 
[64] 
Biopsy injury TREM2 required for wound 
healing and promotes M2 
phenotype 
Promote anti-
inflammatory M2 
phenotype 
[63] 
Infection 
Animal 
infection 
E. coli endotoximia. TREM2 was protective in 
sepsis infection.  
Phagocytic, anti-
inflammatory 
[144] 
LPS and E. coli 
endotoximia. 
Trem2-/- mice had 
increased early 
inflammation and faster 
resolution. 
Phagocytic. Anti-
inflammatory.  
[145]
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P. aeruginosa TREM2 activated PI3K/Akt 
pathway to control 
inflammation. 
Anti-inflammatory [146] 
S. pneumoniae TREM2 decreased C1q 
expression in alveolar 
macrophages and TREM2 
was detrimental to survival 
in intranasal challenge. 
Anti-phagocytotic, pro-
inflammatory in AMs. 
Opposite results in 
BMDMs 
[141] 
In vitro cellular 
infection 
P. aeruginosa TREM2 increased ROS 
production through 
Akt/PI3K pathway. No 
change in phagocytosis. 
Bacterial killing [67] 
S. Typhimurium TREM2/DAP12 required 
for ROS response following 
Salmonella infection. 
Bacterial killing [66] 
B. abortus TREM2 inhibited NO 
production and increased 
bacterial load. 
Promotes bacterial 
growth  
[68]
Table 2. Reported TREM2 ligands 
Ligand Techniques Variants Ref 
Bacteria/bacterial 
components 
Whole Bacteria CS, P, FC, RC, CB, E [66, 112, 113] 
C. jejuni lysate E, RC [114] 
N. gonococcus
lipooligosaccharides E, SPR, RC [115] 
Anionic Bacterial Carbohydrates CB [112] 
Cholora toxin B E, RC [147] 
Mammalian Cells 
THP-1 monocytes FC [26] 
BMDMs FC [89] 
BMDCs FC [91] 
Astrocytes RC, CS [112, 116, 117] 
Neuronal Cells CS, RC, FC [26, 37, 39, 116] 
Apoptotic cells FC, RC, P [30, 37] 
Anionic molecules 
Phospholipids & 
Sulfolipids E, DB, RC, LB 
R47H, R62H ↓ D87N, 
T96K ↑ 
[26, 30, 53, 118, 
119, 123, 148] 
DNA IP, RC [39] 
Sulfated proteoglycans FC [26] 
Mammalian proteins 
HSP60 E, CS. [116] 
Plexin-A1 FRET, IP [104] 
TREML1 (short transcript) IP [87] 
Apolipoproteins (A,B,E,J) DB, P, IP, E, BLI, PM 
R47H ↓[119, 125] 
R47H, R62H, 
D87N↓[126] 
[119, 125, 126] 
Lipoparticles BLI, RC, PM R47H, R62H ↓ D87N↑↓, T96K ↑ [123, 126] 
Negative results 
Certain Mammalian Cells CS [112] 
Apoptotic Jurkat cells FC [119] 
Key: E = ELISA, RC = reporter cell, FC = flow cytometry P = phagocytosis/cellular uptake, IP = Co-immunoprecipitation, 
CB = 5	 competitive binding, CS = cell staining, LB = liposome binding, BLI = biolayer interferometry, PM = protein
microarray, SPR = 6	 surface plasmon resonance. 
Figure Legends 
Figure 1. TREM2 signaling mechanisms. 
A) Canonical TREM2 signaling occurs following cross-linking of TREM2. Src phosphorylates the
DAP12 ITAM. This recruits and activates Syk. Syk activity leads the phosphorylation and 
activation of downstream effectors including PI3K, PLCγ, LAB or LAT, Cbl, Grb2, and Vav. 
DAP10 also recruits PI3K. The end result of these pathways is Akt activation, calcium flux, 
ERK/MAPK activity, and actin mobilization. B) TREM2 signaling is inhibited through multiple 
mechanisms. TREML1 associates with TREM2 signaling complexes and recruits SHP-1 through 
its ITIM. The scaffolding protein LAB recruits the E3 ubiquitin ligase Cbl, which downregulates 
Src and Syk. Incomplete DAP12 phosphorylation results in a “hidden ITIM” which can recruit 
SHIP-1. C) The most prevalent model for multifaceted TREM2 signaling is activating vs tonic 
receptor engagement by multivalent, high-affinity ligands vs low affinity, monovalent ligands. D) 
Soluble TREM2 is produced by proteolytic cleavage and may have signaling functions separate 
from transmembrane TREM2. 
Figure 2. Role for TREM2 in regulating other signal pathways. 
A) TREM2 inhibits TLR responses through the recruitment of DOK3 to the DAP12 ITAM at the
plasma membrane and potentially by sequestering signaling intermediates such as ERK or 
creating a less activating environment with scaffolding proteins such as LAB. (Structures PDBs: 
TREM2 5ELI [26] and 3FXI [149] - signaling complex of TLR4 (dark and light red), MD2 (cyans) 
complexed with LPS). B) TREM2 is required for the Plexin-A1 response to Sema6D. Two 
molecules of Plexin-A1 dimerize upon binding to a dimer of Sema6D. The Ig-like domains of 
Plexin-A1 colored in magenta were required for the interaction with TREM2. Structure PDBs: 
TREM2 5ELI, Plexin-A4 dimer 5L5K [150] - (Blue and cyan with magenta highlights) 
superimposed on Sema6D (greens, 3OKY, [151]). C) TREM2 signaling is required for b-catenin 
	activation during M-CSF/CSF-1R signaling. (Structure PDB: 4WRM [152] - CSF-1R orange and 
M-CSF cyan with signaling dimer shown in lighter shading).
Figure 3. Possible roles for TREM2 resulting from different ligands. 
A-C) During normal conditions, TREM2 signaling from endogenous ligands permits a number of
functions. A) TREM2 is a co-receptor or co-stimulatory molecule for signaling pathways involved 
in myeloid maturation, proliferation, and survival. B) TREM2 signals (perhaps independently of 
co-receptors) are important for maturation. C) TREM2 regulates inflammatory responses by 
influencing TLR and other activating networks to maintain homeostasis.  D-E) TREM2 
recognizes additional ligands associated with disease. D) These signals may increase activation 
and survival so that myeloid cells can respond in a context-dependent manner. E) TREM2 can 
induce phagocytosis of certain ligands, such as bacteria. 
Figure 4. Model for TREM2 signal by WT and variant proteins. 
A) TREM2 has a pronounced basic patch, and the disease variants R47 and R62 are part of
this surface. TREM2 also has separate surfaces that are potentially involved in ligand binding, 
such as a hydrophobic surface above the basic patch. Note that residues involved in recognition 
and binding of specific phospholipids in other Ig domain proteins are not present in TREM2. B) 
Role of GAGs in TREM2 signaling. Heparan sulfate proteoglycans interact with TREM2, likely in 
cis on TREM2-expressing cells. These may function to orient and cluster TREM2 to receive 
activating signals such as phospholipids or APOE. C) The R47H and R62H variant have 
reduced binding to cell-surface proteoglycans and have reduced signaling to phospholipids and 
lipoparticles. The decreased affinity for GAG may impair the ability of these variants to 
recognize and/or signal in response to these ligands. 
Figure 1. Kober and Brett 
Figure 2 Kober and Brett
Figure 3 Kober and Brett 
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Background: The function of MAGP2 was studied by inactivating its gene (Mfap5!/!) in mice.
Results: Mfap5!/! mice have a neutrophil deficiency and other phenotypes that are different from MAGP1- and fibrillin-
deficient animals.
Conclusion:MAGP2 has functional roles in hematopoiesis and in vessel wall maintenance.
Significance: Characterization of MAGP2 function is crucial to the identification and treatment of microfibril-related disease.
Microfibril-associated glycoprotein (MAGP) 1 and 2 are evo-
lutionarily related but structurally divergent proteins that are
components of microfibrils of the extracellular matrix. Using
micewith a targeted inactivation ofMfap5, the gene forMAGP2
protein, we demonstrate that MAGPs have shared as well as
unique functions in vivo.Mfap5!/!mice appear grossly normal,
are fertile, and have no reduction in life span. Cardiopulmonary
development is typical. The animals are normotensive and have
vascular compliance comparable with age-matched wild-type
mice, which is indicative of normal, functional elastic fibers.
Loss of MAGP2 alone does not significantly alter bone mass or
architecture, and loss ofMAGP2 in tandemwith loss ofMAGP1
does not exacerbate MAGP1-dependent osteopenia. MAGP2-
deficient mice are neutropenic, which contrasts with mono-
cytopenia described inMAGP1-deficient animals. This suggests
thatMAGP1andMAGP2have discrete functions in hematopoi-
esis. In the cardiovascular system, MAGP1;MAGP2 double
knockoutmice (Mfap2!/!;Mfap5!/!) showage-dependent aor-
tic dilation. These findings indicate that MAGPs have shared
primary functions in maintaining large vessel integrity. In solid
phase binding assays,MAGP2 binds active TGF"1, TGF"2, and
BMP2. Together, these data demonstrate that loss of MAGP2
expression in vivo has pleiotropic effects potentially related to
the ability ofMAGP2 to regulate growth factors or participate in
cell signaling.
The ECM2 is a complex biopolymer that provides strength to
tissues and plays instructive roles in organogenesis and tissue
homeostasis (1). An abundant component of the ECM is the
microfibril, which imparts limited elasticity to tissues, acts as a
template for elastin deposition, and is a regulator of signaling
events. Microfibrils are 10- to 12-nm fibers built upon a back-
bone of fibrillin and decorated with function-modifying acces-
sory proteins that include growth factor complexes, fibulins,
emilins, andMAGPs (2, 3). Mutations in the genes for microfi-
bril components have varied systemic effects that are not always
apparent with in vitro experimentation (3–5). The complexity
of microfibril structure necessitates in vivo manipulation of
proteins for an accurate understanding of microfibril function
and identification of microfibril-related disease.
MAGP1 (the protein product of themicrofibrillar-associated
protein 2 (Mfap2) gene) and MAGP2 (the protein product of
theMfap5 gene and also known as MP-25) are a two-member
family of small microfibril-associated proteins"31 kDa and 25
kDa in size, respectively (6, 7). Both proteins are found only in
vertebrates, and phylogenetic studies suggest that MAGP2
arose from MAGP1 through gene duplication early in verte-
brate evolution (8). The two MAGPs share a functional C-ter-
minal matrix-binding domain that is characterized by con-
served cysteine residues (9, 10). MAGP2 has a conserved
proprotein convertase cleavage site within this domain that
makes MAGP2 a substrate for multiple proprotein convertase
family members (11). Also unique to MAGP2 is an RGD integ-
rin-binding motif located at the N terminus.
Amino acid sequences in the N-terminal regions of MAGP1
and MAGP2 are dissimilar, but both are enriched in acidic
amino acids. MAGP1 contains two consensus sequences forO-
but not N-glycosylation (12), whereas MAGP2 contains five
conserved, predicted O-linked glycosylation sequences. Func-
tional studies with MAGP1 show that the acidic N terminus
contains a growth factor interaction motif capable of binding
active TGF! and bone morphogenic protein (BMP) (13).
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MAGP1 is associated with all microfibrils except those
directly adjacent to the plasma membrane of aortic endothelial
cells and those at the junction of the zonule of the eye (14–16).
AlthoughMAGP2 has been localized to both elastin-associated
microfibrils and elastin-freemicrofibrils in a number of tissues,
the protein exhibits patterns of tissue localization and develop-
mental expression that are more restricted than those of
MAGP1 (7, 17). The association of MAGP1 and MAGP2 with
other microfibrillar proteins is covalent, requiring reducing
agents for their extraction (18).
Genetic deletion of extracellular MAGP1 in mice results in
an array of phenotypes, including a bleeding diathesis, obesity,
and osteopenia (13, 19, 20). MAGP1-deficient animals also
have a pronounced deficiency in circulating and tissue mono-
cytes. Here we report the generation and initial characteriza-
tion of mice with null alleles of the MAGP2 gene (Mfap5) and
both MAGP1 and MAGP2 (Mfap2!/!;Mfap5!/!) (DKO)
genes.We find thatMfap5!/! (2KO) phenotypes are non-over-
lapping with mice lacking MAGP1 (1KO). However, the
absence of both MAGPs causes changes in large vessel archi-
tecture. Biochemical studies show that MAGP2 protein binds
active TGF!1, TGF!2, and BMP2. Taken together, these data
show thatMAGP2 has unique,MAGP1-independent functions
in hematopoiesis and thatMAGPs have redundant functions in
large vessels.
EXPERIMENTAL PROCEDURES
Generation and Breeding of MAGP2-deficient and MAGP1-
MAGP2-deficientMice—Homologous recombinationwas used
to insert a gene-targeting cassette containing the coding
sequence for neomycin resistance into the exon 9 region of the
Mfap5 gene in murine ES cells. G418-resistant ES cell colonies
were screened by Southern blot analysis, and ES cell clones,
positive for recombination, were injected into C57Bl/6 blasto-
cysts. Chimeric mice were bred for germ line transmission.
Genotype analysis was performed on genomic DNA isolated
from tail tissue using primers listed in supplemental Table 1.
Generation of mice deficient in bothMAGP1 andMAGP2 was
achieved by breeding MAGP2 mutant mice with previously
generated animals deficient in MAGP1 (13). Mice used for
these studies were maintained on a mixed-strain background,
and wild-type controls were generated from the same parental
stock as MAGP-deficient animals. Animals were housed in a
pathogen-free facility, and the Washington University Animal
Studies Committee approved all procedures.
Genomic DNA Isolation and Sequencing—Genomic DNA
isolated from adult mouse tail tissue was used with primers
listed in supplemental Table 1 to confirm the location and ori-
entation of the targeting construct within the Mfap5 gene
locus. For all sequencing reactions, bands were extracted from
agarose gel, and PCR products were isolated using a QIAquick
gel extraction kit according to the protocol of themanufacturer
(Qiagen Inc., Valencia, CA). Amplicons were then ligated into
the pGEM-T vector using the rapid DNA ligation kit according
to the protocol of themanufacturer (RocheDiagnostics,Mann-
heim, Germany) and introduced into DH5# Escherichia coli
(Promega Corp., Madison,WI). The growthmediumwas inoc-
ulated with ampicillin-resistant, color-selected colonies, and
plasmid products were isolated using QIAprep Spin Miniprep
kits according to the instructions of themanufacturer (Qiagen).
The Protein and Nucleic Acid Chemistry Laboratory (Wash-
ington University, Saint Louis, MO) performed DNA sequenc-
ing. All DNA alignments were performed using DNASTAR
Lasergene 9 software.
Total RNA Isolation and in Situ Hybridization—Total RNA
was isolated from adult mouse lung, kidney, and heart using
TRIzol reagent, and reverse transcription cDNA amplification
was performed using 1 "g of RNA and SuperScript III first-
strand synthesis system with oligo(dT) according to the speci-
fications of the manufacturer (Invitrogen). Complement DNA
was amplified using primers listed in supplemental Table 1.
Ethidium bromide gels for nonsense-mediated decay studies
were imaged with the ChemiDoc MP system and Image Lab
version 4.0 software using identical exposure and filter settings
(Bio-Rad). For sequencing, PCR band excision and sequencing
were performed according to methods detailed previously.
RNA probe generation and in situ hybridization for Mfap5,
Mfap2, and collagen1#1 (Col1a1) was performed as described
previously using mRNA isolated from adult mouse heart and
primers listed in supplemental Table 1 (21–23). RNA probes
were 806 bp in length forMfap5, 802 bp forMfap2, and 846 bp
for Col1a1.
Antibodies, Western Blotting, and Immunohistochemistry—
Rabbit polyclonal antibodies against mouse MAGP2 (24) and
MAGP1 (13) have been described previously. ForWestern blot
analysis of serially extracted mouse tissue lysates, adult mouse
lung was homogenized in 990 "l of PBS (pH7.4) and 10 "l of
protease inhibitor mixture (catalog no. P8340, Sigma Aldrich,
Saint Louis, MO) and extracted 24 h at 4 °C. The samples were
pelleted by centrifugation at 16,000# g or 20 min at 4 °C. The
liquid portion of the sample was removed forWestern blotting,
and the pellet was resuspended in 1 MNaCl and protease inhib-
itors and extracted for 24 h. The process was repeated using 8 M
urea, PBS, and 20 mM DTT (seen in Fig. 5C,D), and 8 M urea$
DTT. Western blotting was performed using standard proce-
dures. Samples were run on 7.5% or 12% SDS-PAGE gels and
transferred to nitrocellulose membranes. Ponceau S stain was
applied for 5 min and removed using 0.1 M NaOH. All blocking
steps were performed with blocking buffer containing 5%
casein, 0.1% coldwater fish skin gelatin, and 0.01% Tween 20 in
TBS. Primary antibodies were applied overnight at 4 °C at a
dilution of 1:10,000 for MAGP2 (in 5% BSA) or 1:1000 for
MAGP1 (in 5% BSA). Secondary antibodies were applied at
1:4000 in casein block and incubated for 1 h at room tempera-
ture. ECL reagents were used for detection of horseradish per-
oxidase, and chemiluminescence was read using the ChemiDoc
MP system and Image Lab version 4.0 software (GE Health-
care). Immunohistochemistry for paraffin sections was per-
formed using the ultrasensitive ABC peroxidase rabbit IgG
staining kit (Fisher Scientific, Pittsburgh, PA) according to the
instructions of the manufacturer, with the following modifica-
tions for MAGP2 detection. After peroxidase quenching, the
sectionswerewashed in 0.1%BSA inTBS.Hyaluronidase diges-
tion solution (1 mg/ml hyaluronidase in 0.1 M sodium acetate
buffer (pH5.5) containing 0.85% NaCl) was applied, and the
sections were incubated in a humid chamber for 30 min at
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37 °C. The sections were washed in BSA/TBS three times for 5
min. A guanidine/DTT solution was applied to the sections for
15 min. The sections were washed with BSA/TBS three times
for 5 min before incubation with iodoacetamide solution for 15
min. The sections underwent a final BSA/TBS wash before
application of ultra-sensitive staining kit block solution. Pri-
mary anti-MAGP2 antibody was diluted 1:8000 in blocking
solution and applied to the sections overnight at 4 °C. Second-
ary antibody solution was made using 2.25 "l/ml of secondary
antibody. Horseradish peroxidase reactivity was visualized
using the metal enhanced DAB substrate kit (Fisher). Imaging
was performed on a Zeiss Axioskop using identical exposure
and filter settings. Image processing was performed using
Adobe Photoshop CS5 software.
Flow Cytometry—Monoclonal antibodies used for flow
cytometry were as follows: phycoerythrin-conjugated hamster
anti-mouse CD3e (BD Biosciences), FITC rat anti-mouse
CD335 (NKp46, eBioscience, San Diego, CA), FITC rat anti-
mouse Ly-6G (eBioscience), phycoerythrin rat anti-mouse
CD115 (eBioscience), allophycocyanin rat F4/80 (Abcam,Cam-
bridge, MA). Phycoerythrin hamster IgG1, FITC rat IgG2a,
FITC rat IgG2b, phycoerythrin rat IgG2a control, and allophy-
cocyanin rat IgG2b isotype controls were utilized according to
the suggestions of the manufacturer. Mice were killed by CO2
narcosis, and the chest and abdominal cavity were exposed to
reveal the heart, dorsal aorta, and spleen. Whole blood was
collected from the dorsal aorta in a heparinized syringe. Red
cells were lysed with NH4Cl buffer for 10 min at room temper-
ature andwashed twicewith FACs buffer (1#PBS and 2%FBS).
After blocking with mouse Fc Block (BD Biosciences) for 20
min, 2# 105 cells were incubated with antigen-specific or iso-
type control antibodies for 30 min at 4 °C. Cells were washed
twicewith FACs buffer and fixedwith 4%paraformaldehyde for
15 min, washed twice, and stored overnight. Spleens were
removed, and splenocytes were isolated after passage through a
70-"m nylon mesh filter. Lysis, blocking, incubation, and fixa-
tion were identical to the white blood cell treatment above.
Cells were sorted on a FACSCalibur machine (BD Biosciences)
with Cell-Quest software (BD Biosciences). The percentage of
positive cells for each cell type was determined by gating on
isotype control, nonspecific labeling (percentage of positive
cells within gate % 5% for control), followed by subtraction of
background percentage from antibody-specific results. A min-
imum of 105 live cell events were recorded for each analysis.
Experiments were performed with at least five animals of each
genotype (n $ 5), and experiments were repeated at least two
times with mice 2 and 6 months of age.
Microcomputed Tomography ("CT)—Microcomputed
tomography analysis of left tibias from 6-month-old mice was
performed as described previously (19), with the exception that
the tibias were not frozen. The tibias were embedded in 2%
agarose and scanned using a Scanco "CT 40 (Scanco Medical
AG, Zurich, Switzerland). For trabecular bone measurements,
the growth plate was excluded and 30 # 16-"m sections were
contoured. For cortical bone, the sections were analyzed just
above the tibiofibular junction, and three sections per tibiawere
analyzed. Contouring and analysis were performed by the
Washington University Musculoskeletal Research Facility
using Scanco MicroCT software. Identical contouring and
analysis parameters were used for all tibias. The tibias from at
least five male mice of each genotype (n $ 5) were used for
analysis.
BloodPressure andMechanical Properties of AscendingAorta
and Left Carotid Artery—Six-month-old male mice were
weighed and then anesthetized using 1.5% isoflurane, keeping
the body temperature constant. A solid-state catheter was
inserted into the right common carotid artery, isoflurane was
reduced to 0.5%, and blood pressure measurements were
recorded (25, 26). The heartswere excised andweighed, and the
aortas and left carotid arteries were removed for mechanical
testing as reported previously (25). At least 12malemice of each
genotype (n$ 12) were used for analysis.
Recombinant MAGP2 and MAGP1 Proteins and Biolayer
Interferometry (BLI)—The coding sequence formouseMAGP2
protein, excluding the N-terminal signal sequence, was cloned
into pET23b as a tagless construct. This plasmid was trans-
formed into Rosetta 2(DE3) E. coli cells for protein expression.
MAGP2 proteins were purified from inclusion bodies, followed
by oxidative refolding as described previously (27). Recombi-
nant His6-tagged MAGP1, used for Western blotting, was
expressed and isolated as described previously for this protein
(13).
Native MAGP2 protein was expressed in mammalian cells
and purified as follows. Full-length mature-form MAGP2,
without the endogenous signal sequence, was cloned into the
pHL-Avitag3 vector (28) containing an optimized signal
sequence at the N terminus as well as a BirA biotin ligase rec-
ognition sequence and hexahistidine (His6) tag at the C termi-
nus. Protein was expressed by large-scale transient transfection
of FreeStyle 293F cells cultured in serum-free Freestyle 293
medium (Life Tech.). Culture supernatants were collected 72 h
post-transfection, and protein was purified to homogeneity
using nickel affinity chromatography. Purity was assessed by
SDS-PAGE. Site-specific biotinylation of the C-terminal tags
were carried out using E. coli BirA biotin ligase.
All surface plasmon resonance binding was performed on a
Reichert SR7000 surface plasmon resonance system. To bind
MAGP2 protein to the carboxymethyl dextran (CM-5) chip,
the chipwas preactivatedwith amixture of 200mM1-ethyl-3(3-
dimethylaminopropyl)carbodiimide hydrochloride and 50 mM
N-hydroxysuccinimide, and then 100"l MAGP2was diluted in
5 mM acetate buffer (pH 4.5) and injected with a flow rate of 10
"l/min at a concentration of 20 "M. This resulted in "1300
resonance units of MAGP2 protein coupled to the chip. Excess
reactive sites on the chip were then quenched with a 70-"l
injection of 0.5 M ethanolamine (pH 8). To measure MAGP2
binding to active TGF!1, carrier-free active human TGF!1
(R&D Systems, Minneapolis, MN) was diluted in surface plas-
mon resonance running buffer (10 mM HEPES, 150 mM NaCl,
0.05% Triton X-100 (pH 7.4)) and injected for 100 s at a flow
rate of 50 "l/min. The dissociation was monitored for 300 s.
The chip was recycled with 0.2 M glycine (pH 2.3) before sub-
sequent injections. The concentrations of TGF!1 injectedwere
100, 50, 50, 25, 25, and 12.5 nM. Background subtraction and
calculation of the dissociation constant for individual curves
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was calculated using Scrubber2 software (Center for Biolmo-
lecular Interaction Analysis, University of Utah).
The Octet system for Biolayer interferometry (Pall Life Sci-
ences, Ann Arbor, MI) was also used to assess MAGP2 binding
to active TGF!1 as well as TGF!2 and BMP2. Streptavidin-
coated biosensors from ForteBio were used to capture biotin-
ylated MAGP2 onto the surface of the sensor. After reaching
base line, sensors were moved to the association step contain-
ing 1000, 500, 250, 125, 62.5, 31.3, 15.6, and 7.8 nM activemouse
TGF!1, TGF!2, or BMP2 for 300 s and then dissociated for
300 s. A buffer-only reference was subtracted from all curves.
The running buffer consisted of 10 mM HEPES (pH 7.4), 150
mM NaCl, 3.4 mM EDTA, 1% BSA, 0.01% azide, 0.05% Tween,
and 0.005%TritonX-100. Affinities were estimated from global
kinetic analysis.
Statistical Analysis—Statistical significance was determined
by Student’s t test. Data are reported as a mean& S.D.
RESULTS
MAGP2 Gene Targeting—Homologous recombination was
used to disrupt the MAGP2 gene (Mfap5) by replacing exon 9
with a neomycin resistance cassette (Neo), causing a down-
stream frameshift. Our attempts to target exon 1 and the
upstream promoter sequence were unsuccessful. Exon 9
encodes the matrix-binding domain. If expressed, the mutant
protein lacking this domain would be incapable of binding to
fibrillin and, hence, would be a functional null.
PCR primers flanking each exon from 2–10, as well as within
the Neo cassette itself, were used to walk along the targeted
Mfap5 gene and confirm localization of the Neo cassette to
exon 9. Genomic DNA (gDNA) isolated from WT and
Mfap5!/! mice yielded identical amplicons using primers
flanking exons 2–8 of the Mfap5 gene (Fig. 1, A and B, and
supplemental Table 1). An exon 9 ampliconwas generated from
WT but not 2KO genomic DNA, and a forward primer to the
Neo sequence and a reverse primer at exon 9 produced an
amplicon from2KOand notWTgDNA (Fig. 1,A andC). These
PCR bands were gel-extracted and sequenced, confirming that
the Neo sequence was introduced at exon 9 of theMfap5 gene
(supplemental Fig. S1).
To generate DKO animals, 2KO mice were bred with 1KO
mice generated in a previous study (13). Fig. 4B confirms the
genotype of the DKO animals. The exon 9 forward primer, Neo
primer, and reverse exon 9 primer described above were used
forMfap5 genotyping reactions (Figs. 1 and 4B).
The Mfap5-targeted Allele (2'9) Is Transcribed, but the
Mutant mRNA Is Degraded—RT-PCR amplification was used
to determine whether mRNA is transcribed from the mutated
Mfap5 gene in 2KO mice. PCR products representing the
Mfap5 exon 2–10 sequence were amplified from bothWT and
2KO cDNA. However, the 2KO amplicon is 74 bp smaller than
the WT product (Fig. 2, A and B). DNA sequencing revealed
that the 2KO product is a transcript with exon 9 and the Neo
cassette spliced out (2'9) (supplemental Fig. S2 and Fig. 2C).
This sequence does not occur as a natural splice variant,
although we did identify a naturally occurring WT transcript
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FIGURE 1. Schematic of Mfap5 gene targeting. A, schematic of the Mfap5
gene with numbered bars representing exons (gray, non-coding; black, cod-
ing). Agene-targetingcassette containing thecoding sequence forneomycin
resistance was introduced by homologous recombination into the murine
Mfap5 gene. Lettered arrows represent primer pairs used for PCR. B and C,
gDNA from one WT and two 2KO mice was subjected to PCR. Lettered lines
refer to primer pairs indicated in A. A PCR amplicon is produced from theWT
and not the 2KO template because of the presence of the targeting construct
(boxed region, C, g). Primers to the targeting construct and Mfap5 sequence
produce a PCR product from the 2KO and not the WT gDNA template (boxed
region, C, h). PCR primers to Neo produce a product only from 2KO gDNA
(boxed region, C, j).
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of the Mfap5 mRNA transcript, with shaded rectangles representing exons.
PCR primer pairs directed against an exon and an exon/intron junction are
labeled, and the amplicon is depicted by shaded lines. B, RT-PCR was per-
formedusing themRNA template from twoWTand two2KOmice. No reverse
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the PCR reactions. Shaded lines refer to primer pairs illustrated in A. PCR prod-
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lacking exon 6 in one of fourWT animals tested (supplemental
Fig. S3 and Fig. 2C).
Because of a frameshift at the atypical exon 8–10 splice junc-
tion, there is a serine-to-arginine substitution and then a pre-
mature stop codon after domain 8 of the 2'9 transcript when
translated (Fig. 3,A and B). Premature termination codons that
occur upstream of an exon-exon junction frequently elicit non-
sense-mediated decay, a RNA surveillance mechanism that
degrades mutant transcripts (29). To determine whether non-
sense-mediated decay affects the stability of the 2'9 transcript,
RT-PCR was used to amplify 2'9 or WT mRNA isolated from
the heart, lung, and kidney. After 27 cycles of PCR, there were
only trace amounts of 2'9 PCR product compared with an
abundantWTmessage in all three tissues (Fig. 4). These results
indicate that little 2'9 mRNA escapes nonsense-mediated
decay in 2KO animals. Similar results were found for MAGP1-
MAGP2 double knockout animals (Fig. 4).
An antibody to MAGP2 was used to confirm loss of MAGP2
protein expression in 2KO and DKO animals. This antibody
reacts specifically withMAGP2 protein and does not recognize
MAGP1 (Fig. 5A). Immunohistochemistry onmouse aorta sec-
tions shows MAGP2 labeling in the intimal layer as well as
throughout the adventitia (Fig. 5B). This expression pattern
agrees with previous reports forMAGP2 expression in fetal calf
aortic tissue and supports the specificity of the MAGP2 anti-
body (7). MAGP2-reactive bands are present in Western blot
analyses using sequentially extracted lung tissue from WT
mice, whereas 2KO andDKO lung tissue lacksMAGP2 protein
(Fig. 5C). Also, WT and 2KO mouse lungs are positive for
MAGP1, whereas DKOmice lack this protein (Fig. 5D). Taken
together, these data demonstrate that the gene targeting strat-
egy was successful in preventingMAGP2 protein expression in
2KO and DKO animals and that DKO animals lack both
MAGP2 and MAGP1.
MAGP2 Deficiency Results in Decreased Levels of Circulating
Neutrophils but Normal Monocyte Counts—2KO and DKO
mice are viable and fertile with no gross abnormalities in
appearance or behavior. This contrasts with 1KO mice, which
have complex phenotypes, including hematopoietic defects,
obesity, and abnormal bone homeostasis (13, 19, 20). To inves-
tigate whether 2KO mice have defects in hematopoiesis, anti-
body labeling and flow cytometry were used to assess the com-
plement of hematopoietic cells in the peripheral blood
circulation or in spleen tissue. An average of 3330& 672 white
cells/ml of blood were collected. There was no statistical differ-
ence in total white blood cells per mouse among genotypes.
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Using GR1 positivity as an antibody marker, our results show
thatWTmice have neutrophil counts of 12.5% and 8.8% of total
peripheral blood and spleen cells, respectively. Similarly, 1KO
mice have neutrophil counts of 13.4% of total peripheral blood
(data not shown). In contrast, 2KO mice have significantly
decreased neutrophils (5.6% blood and 5.1% spleen) compared
with age-matched WT controls (Fig. 6). Likewise, DKO mice
also exhibit neutropenia, with 6.4% of total cells in peripheral
blood and 5.7% in the spleen. These findings indicate that loss
of MAGP2 causes a neutrophil deficiency in 2KO mice that is
not seen in 1KO animals and is not altered by loss ofMAGP1 in
DKO animals.
We have shown that mice deficient in MAGP1 are monocy-
topenic with fewer circulating monocytes and fewer tissue
macrophages.3 2KOmice, in contrast, have CD115$monocyte
numbers comparable with WT controls (4.5% versus 4.4%
blood and 0.7% versus 0.8% spleen, respectively) (Fig. 6). DKO
animals have reduced monocytes as a fraction of peripheral
blood (3.6% blood and 0.7% spleen), as would be expected for
1KO animals. F4/80 antibody reactivity was used as a marker
for macrophages in spleen tissue. 2KO and DKO mice had
macrophage numbers comparable with WT controls. These
data show that loss ofMAGP2 does not impactmonocyte num-
ber alone or in conjunction with loss of MAGP1. This demon-
strates that both 1KO and 2KOmice have unique alterations in
the myeloid cell lineage.
CD3 reactivity was used to assess lymphocytes in WT, 2KO,
and DKO mice. All three genotypes have equivalent lympho-
cyte numbers as a percentage of peripheral blood (Fig. 6). Sim-
ilar resultswere shown for 1KOanimals.3 Taken together, these
data show that loss of MAGP2 causes neutropenia in vivo and
demonstrate that this hematopoietic defect is MAGP1-inde-
pendent. Further, loss of MAGP2 on a 1KO background does
not impact the monocytopenia phenotype observed in 1KO
animals. Thus, MAGP1 andMAGP2 have discrete functions in
hematopoiesis.
Loss ofMAGP2Alone Does Not Significantly Alter BoneMass
or Architecture—Mice lacking MAGP1 are osteopenic by 6
months of age, with a high incidence of spontaneous fractures
(13, 20). Spontaneous fractures are not observed in 2KO or
DKO mice, and the skeleton appears grossly normal. "CT of
left tibias in 6-month-old 2KOmice shows trabecular and cor-3 R. P. Mecham, unpublished results.
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FIGURE 4. Absence of MAGP2#9 mRNA confirms functional knockout of
MAGP2. A, polyadenylated mRNA from the heart, lung, and kidney of two
DKO, 2KO, andWT animals eachwas reverse-transcribed and subjected to 27
rounds of PCR amplification with primers specific for the Mfap5 message.
Arrows indicateWT and 2'9 amplicons (2KO). Reactionswith primers to!-ac-
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FIGURE 5.2KOandDKOmice lackMAGP2protein.A, Western blot analyses
showing that anti-MAGP2 and anti-MAGP1 antibodies are specific for their
respective recombinant murine proteins (rMAGP2 and rMAGP1). B, immuno-
histochemistry on WT and 2KO sections demonstrates MAGP2 reactivity at
the intima (arrow) and adventitia (arrowhead) of WTmouse aorta. NoMAGP2
reactivity is seen in the 2KO aorta section. Scale bar ( 100 "m. C, Western
blotting of sequentially extracted (20 mM DTT fraction) mouse whole lung
lysateswith anti-MAGP2antibodydemonstrating the absenceofMAGP2pro-
tein in 2KO andDKO animal tissue. Two animals of each genotypewere used,
and an arrow indicates the MAGP2 protein band. Mammalian MAGP2 from
tissue lysate runs as a larger protein than bacterially expressed rMAGP2
because of posttranslational modifications. D, Western blotting of sequen-
tially extractedmousewhole lung lysateswith anti-MAGP1 antibody demon-
strating the absence of MAGP1 protein in DKO animals only. Two animals of
each genotype were used, and arrows indicate MAGP1 protein bands. The
major rMAGP1 band runs as a larger protein because of the His6 tag. Tissue
lysates were run with bacterially expressed rMAGP2 or His6-tagged rMAGP1
and shown on the same blot. However, the recombinant protein section of
the blot is shown at a shorter exposure interval, as indicated by a black line.
Bands above the indicated MAGP proteins represent nonspecific antibody
reactivity (NS). I( intima;M(media; A( adventitia.
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tical bone to be comparable in all aspectswith age-matchedWT
controls (Fig. 7). Further, loss ofMAGP2 on a 1KO background
(DKO) does not exacerbate changes in bonemass and architec-
ture associated withMAGP1 loss of function (Fig. 7). It is inter-
esting to note that DKOmice share the abnormal cortical bone
morphology of 1KO mice characterized by a smaller marrow
cavity, ormedullary area, thanWTor 2KOmice and, therefore,
have an increased bone volume fraction (Fig. 7B). These data
demonstrate that loss of MAGP2 by itself has a minimal effect
on bone character and suggest that, unlike MAGP1, MAGP2
has little or no role in normal bone homeostasis.
MAGP1 andMAGP2Double-null (DKO)MiceHave a Larger
Aorta at Physiological Pressures—In vitro studies suggest
MAGP2 expression may be necessary for normal elastic fiber
assembly (30). This idea is supported by the expression pattern
of MAGP2 in elastin-rich structures such as the aorta, aortic
root, atrialis of the mitral valve, bronchioles of the lung, large
vessels of the heart, lung, and kidney, as well as skin (Figs. 8 and
5B) (7). Previous work determined that 1KO mice are normo-
tensive with normal aortic and left carotid pressure outer diam-
eter curves at 14 weeks of age (13). The cardiopulmonary sys-
tem in 2KO, 1KO, and DKO mice appears grossly normal.
These mice are normotensive with systolic, diastolic, andmean
blood pressures comparable with age-matched WT animals
(Fig. 9A). However, compliance studies show that the diameter
of the ascending aorta in 6-month-old DKO mice is signifi-
cantly increased compared with WT controls, 1KO, and 2KO
mice at physiologic pressures of 75–125millimeters ofmercury
(Fig. 9B). Pressuremeasurements of the outer diameter taken at
4 months of age indicate that the ascending aorta outer diame-
ter is not significantly different from theWT at this time point
(data not shown). These data show that, in DKO animals, the
loss of MAGP1 and MAGP2 have a combinatorial effect in
increasing the aorta outer diameter at physiologic pressures
and that this change in tissue architecture becomes apparent
with increasing age.
To determine whether changes in the outer diameter of aor-
tic vessels could be explained by changes in heart size, heart
weight to body weight ratios were calculated and found to be
comparable among all genotypes (Fig. 9, C and D). Taken
together, these data demonstrate that loss of bothMAGP1 and
MAGP2 expression increases aortic vessel diameter in vivo.
These changes are age-dependent and not secondary to
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changes in body size, composition, or heart size. This suggests
that MAGP1 and MAGP2 have shared primary functions in
maintaining large vessel integrity.
MAGP2ProteinBindsActiveTGF!andBMPGrowthFactors—
MAGP1 has an acidic TGF!-binding domain located in the N
terminus of the protein, and loss of MAGP1 increases TGF!
signaling in multiple tissues (13, 19, 31). Although the amino-
terminal sequences are different in MAGP1 andMAGP2, both
regions are highly acidic (Fig. 3, A, C, and D), suggesting that
MAGP2 may have the ability to bind TGF! family ligands (8).
Surface plasmon resonance and BLI were performed with
immobilized MAGP2 and active TGF!1, TGF!2, or BMP2 in
solution. TGF!1, TGF!2, and BMP2 bound reversibly to
MAGP2 (Fig. 10, A–C). Steady-state analysis of BMP2 binding
to bacterially expressed and refolded or nativemammalian cell-
secretedMAGP2 showed similar kinetics. The equilibrium dis-
sociation constant (KD) for BMP2 binding of refolded, bacteri-
ally expressedMAGP2 is 210 nM, whereas theKD for binding to
mammalian MAGP2 is 190 nM. These data demonstrate that
MAGP2 binds active TGF! superfamily members and suggests
that these interactions may have biological relevance.
DISCUSSION
MAGP2 is a protein component of fibrillin-containing
microfibrils where it partners with MAGP1 and other microfi-
bril-associated proteins to define microfibril function (18).
Mutations in fibrillin lead to Marfan syndrome, characterized
by long bone overgrowth and abnormalities in the cardiovascu-
lar and pulmonary systems (3). It is interesting that none of
those changes are evident in MAGP2-deficient mice. MAGP2
deficiency also shows little overlap with phenotypes found in
mice lackingMAGP1, which supports unique functions for the
individual proteins and agrees with the more limited distribu-
tion of MAGP2 compared with MAGP1.
Microfibrils serve to regulate growth factor availability, par-
ticularly the activity of TGF!, BMP, andNotch familymembers
(32–34). Because these growth factors are produced by and sig-
nal to many cell types, signaling must be tightly regulated. The
fibrillins sequester the TGF! large latent complex in the ECM,
where it can be activated when needed. Mutations in fibrillin
lead to elevated active TGF! levels, which accounts for the phe-
notypes associated withMarfan syndrome. The role ofMAGPs
in growth factor signaling may be more complex in that they
may function to sequester ligands from, or present them to,
signaling receptors in a tissue-specific manner (33, 34).
FIGURE 8. Mfap5 mRNA is expressed by cells of the aorta, mitral valve,
coronary vessels, kidney, lung, and pinnae. In situ hybridization to detect
Mfap5 (A and D–I), Mfap2 (B), and Col1a1 (C), expression was performed on
14-"m sections from 4-month-old wild-type mice. A and A), arrows demon-
strate digoxigenin-labeled mRNA (blue) localized to the intima (arrow) and
adventitia (arrowhead) of the aorta. A) is a magnification of the boxed region
in A. B, Mfap2 mRNA is expressed throughout the aorta (arrow). C, Col1a1
mRNA is heavily expressed in the aortic adventitia (arrow).D andD),Mfap5 is
expressed in the atrialis of the mitral valve (MV, arrow). E, Mfap5 mRNA
is found in the coronary vessel (CV, arrow). F, significant Mfap5 expression is
localized to the aortic root (AR, arrow). G and G), large airways and arterioles
(G), arrow) are positive for Mfap5 expression. H, large vessels of the kidney
express Mfap5 (arrow). J, J), and K, no nonspecific reactivity is detected in
Mfap5 sense control sections. Scale bar ( 300 "m. Micrographs were taken
using identical camera settings and image processing.
1000
1400
1800
2200
WT
1KO
1000
1400
1800
2200
WT
DKO
Pressure-outer diameter
m
ic
ro
m
et
er
s
Aorta WT and 2KO Aorta WT and 1KO
Aorta WT and DKO
0 25 50 75 100125150
1000
1400
1800
2200
WT
2KO+
+
+
+
+
* *
* *
1000
1400
1800
2200
WT
2KO
1KO
DKO
Aorta all genotypes
0
50
100
150
WT
2KO
1KO
DKO
W
T
2K
O
1K
O
DK
O
0.0000
0.0025
0.0050
W
T
2K
O
1K
O
DK
O
0
20
40
Blood pressure
Heart weight:body weight Body weight
m
m
H
g
gr
am
s
B
A
C D
Mean        Systolic        Diastolic
m
ic
ro
m
et
er
s
Pressure Pressure
0 25 50 75 100125150
0 25 50 75 100 125 1500 25 50 75 100 125 150
FIGURE 9. The outer diameter of aortic vessels is increased at physiolog-
ical pressures in DKOmice. A, histogram of mean blood pressure measure-
ments. B, pressure myography performed on aortae from 6-month-old male
mice.A significant increase inaortic outerdiameter atphysiologicpressures is
seen in DKO animals. C, graph indicating mean body weight of mice at the
timeof sacrifice.D, graphdepictingmeanheartweight to bodyweight ratios.
*, p% 0.01;$, p( 0.02.
MAGP2 Loss of Function Has Pleiotropic Effects in Vivo
28876 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 288•NUMBER 40•OCTOBER 4, 2013
 at W
ashington University on August 18, 2014
http://www.jbc.org/
Downloaded from 
MAGP1 binds TGF!s, BMPs, and Notch receptors and
ligands (13, 33). Much like the classical fibrillinopathies,
MAGP1 loss of function leads to increased TGF! signaling and
subsequent disease in some tissues (4, 13, 19, 20). LikeMAGP1,
MAGP2 also binds TGF! superfamily members as well as
Notch receptors and ligands. This suggests that MAGP2 may
regulate these growth factors in vivo. Interestingly, proper lev-
els of Notch signaling are required for definitive hematopoiesis,
whereas TGF! and BMP are master regulators of hematopoi-
etic stem cell quiescence and osteoblastic niche size, respec-
tively (35–37). TGF! signaling can differentially affect most
hematopoietic stem cell types according to signal strength, sig-
nal localization, and differentiation state of the target cell (36).
Thus,misregulation ofNotch, TGF!, or BMP signaling because
of loss of MAGPs is consistent with alterations in cells of the
myeloid lineage. Both MAGP1 and MAGP2 are expressed in
trabecular bone, consistent with a potential role for these pro-
teins in hematopoiesis (16). Differences in MAGP1 and
MAGP2 expression patterns and growth factor binding affini-
ties may explain the neutropenia in 2KO mice and monocyto-
penia in 1KO animals. Interestingly, loss of MAGP2 function
does not modify the monocytopenia seen in MAGP1-deficient
mice because DKO animals exhibit both neutropenia and
reduced monocyte cell numbers.
In addition to influencing cells within the bone marrow,
TGF!/BMP signaling coordinates bone anabolism (via osteo-
blast activation) with bone catabolism (via differentiation of
osteoclasts from hematopoietic stem cell precursors) (38–41).
MAGP1-deficient mice develop osteopenia with age because of
increased osteoclast number (20). A study of these animals
revealed increased circulating levels of the osteoclast differen-
tiation factor receptor activator of NF&B ligand (RANKL) (19).
Treatment of cultured MAGP1-deficient osteoblasts with TGF!
neutralizing antibodies reducedRANKLproduction by these cells
tobase-line levels, suggesting increasedTGF! signalingbecauseof
loss ofMAGP1 function as the primary defect in bone homeosta-
sis. The studies detailed here indicate that, unlikeMAGP1, loss of
MAGP2 function does not negatively affect bonemineral density.
Furthermore, DKO mice do not develop spontaneous fractures
and lack severe osteopenia associated with MAGP1 deficiency.
This suggests that loss ofMAGP2 in tandemwith loss ofMAGP1
restores bonemineral density.
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An explanation for why loss of MAGP2 is protective against
bone loss may lie in the ability of MAGP2 to manipulate Notch
signaling. MAGP1 and MAGP2 both have the ability to bind
Notch1, Jagged1, Jagged2, andDelta1 (33). Both proteinsmedi-
ate ectodomain shedding of Notch1 and activate the Notch
intracellular domain.MAGP2, however, has the added ability to
activate Notch signaling through release of Jagged1 from the
cell surface (42). The activated Notch intracellular domain
inhibits osteoclast differentiation both from hematopoietic
precursors and from preosteoclasts (43). Jagged1/Notch intra-
cellular domain signaling also impedes osteoclast formation by
inhibiting RANKL expression in mature osteoblasts (43). Inhi-
bition of Notch signaling in the context of bone formation
increases osteoblast differentiation, thereby increasing bone
formation (43). The studies detailed here indicate that loss of
MAGP2 alone has a slight net anabolic effect on bone mass.
Thus, changes in Notch signaling associated with MAGP2
deficiency may provide a mechanistic explanation for why
MAGP1-induced increases in osteoclastogenesis are not as
prominent in DKO animals.
Previous work demonstrates that fibrillin-1 deficiency leads
to increased aortic diameter pressure curves, hypotension, frag-
mentation of elastin, and changes in aortic compliance that
becomes apparent with age (44, 45). Our findings also show
increases in aortic diameter pressure curves in 6-month-old
MAGP DKOmice but not in the single knockouts. As with the
fibrillinopathies, changes in large vessel architecture and func-
tion in DKO animalsmay occur because of several contributing
factors. Firstly, changes in MAGP expression may cause devel-
opmental changes in ECM architecture that become more
apparent with age. This idea is supported by studies in
zebrafish, where loss of MAGP1 causes distension and loss of
vessel integrity in cranial and caudal blood vessels during devel-
opment (46, 47). Secondly, ECM remodeling and homeostasis
may be altered by loss of MAGPs. Increased TGF! signaling in
aortic tissue occurswith loss of growth factor binding bymicro-
fibril proteins (3, 44, 48). This leads to extensive pathological
remodeling, loss of vessel integrity, and, ultimately, aortic dis-
section in mice and humans in vivo (3, 48, 49). Loss of MAGP
results in a similar, albeit blunted pattern of pathologic remod-
eling, leading to loss of vessel integrity but not aortic dissection.
Because MAGPs are highly expressed in large vessels and bind
active TGF! ligands, it is possible that loss of MAGPs causes
small changes in TGF! signaling that, over time, produce a
fibrillinopathy-like phenotype in large vessels (7, 13).
An Arg-Gly-Asp (RGD)-containing sequence in fibrillin-1,
when applied to cells, was found to increase the expression of
matrix metalloproteinases 1 and 3 (50). Increased proteolytic
activity by matrix metalloproteinases is a characteristic feature
of fibrillinopathies such asMarfan syndrome (51).MAGP2 also
contains an RGD sequence that binds #v!3 integrins, although
the function of this domain in MAGP2 is not understood (52).
Because RGD-containing sequences can be important regula-
tors of proteolytic activity, cell adhesion, and growth factor
presentation to cells, one must consider mutations in fibrillins
or MAGPs that impair MAGP-fibrillin interaction as poten-
tially important. As stated previously, MAGPs covalently bind
fibrillins on themicrofibril. Disease-causingmutations in fibril-
lin-1 in mice are associated with increases in MAGP2 expres-
sion in vivo, suggesting a regulatory link between these micro-
fibrillar proteins (24, 53, 54). Increased gene expression and/or
mutations in MAGPs or fibrillins may result in unbound
MAGPs in the ECM with unknown effects on growth factor
signaling and matrix metalloproteinases expression. When
taken together, these data demonstrate that loss of MAGPs
shares pathological features of fibrillinopathies and raise the
question as to how much of the pathology attributed to loss of
fibrillin function is directly linked to loss of MAGP-fibrillin
interaction and subsequent MAGP-dependent ECM changes.
Interestingly, MAGP2 expression is negatively correlated
with patient survival from advanced-stage ovarian cancer (55).
Mok et al. (55) suggest thatMAGP2-dependent changes in can-
cer cell biologymay be conferred viamultiplemechanisms. The
authors correlate MAGP2-mediated #v!3 integrin interaction
with chemotherapy resistance and cell survival (55). Also inte-
gral to tumor survival is development of a blood supply through
angiogenesis. MAGP2 negatively regulates Notch signaling in
endothelial tip cells and promotes angiogenic sprouting, poten-
tially providing another mechanism for MAGP2-mediated
tumor growth and survival (34). Previous studies demonstrate
a high metastatic potential in human melanoma cell clones
with expression of peanut agglutinin-reactive glycosylation
on MAGP1 and MAGP2 (56). Analysis of MAGP proteins
with the NetOGlyc server demonstrates two highly con-
served and one non-conserved predicted O-linked glycosyl-
ation site in the N terminus of MAGP1 (12). MAGP2 has five
highly conserved and one non-conserved O-linked carbohy-
drate site, all within the amino-terminal portion of the mol-
ecule (Fig. 3B). Additional glycosylation domains onMAGP2
suggest evolutionary acquisition of unique protein-protein
interactions. It is currently known that protein glycosylation
patterns change in the context of cancer, with the net effect
of altering cell signaling and nutrient availability (57, 58).
Moreover, MAGP2 physically interacts with active TGF!s,
BMPs, and Notch receptors and ligands. It is not difficult to
imagine that MAGP2 expression may allow transformed
cells to harness several powerful mechanisms to promote
tumor growth, metastasis, and chemotherapy resistance.
Research directed at uncovering the molecular mechanisms
by which MAGP2 promotes tumor growth and metastasis is
clinically important.
These studies demonstrate that MAGP2 plays a role in the
biology of the hematopoietic and vascular systems and suggest
thatMAGP2 is capable of regulating growth factor bioavailabil-
ity.Work by other authors also linksMAGP2 expression status
to cancer outcome (34). Clearly, further understanding of
MAGP2 function not only increases our understanding of ECM
biology but has the potential to significantly impact human
health.
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A critical step toward improved diagnosis and 
treatment of chronic inflammatory diseases de-
pends on defining the immune mechanisms for 
the persistent accumulation of activated im-
mune cells in the target tissue. In the case of the 
lung, clinical evidence suggests that acute in-
fection with a respiratory virus might lead to 
chronic lung diseases such as asthma and COPD 
(Holtzman, 2012). To determine precisely how 
acute infection causes chronic lung disease, we 
developed a high-fidelity mouse model of this 
process. In this model, mouse parainfluenza virus 
(also known as Sendai virus, SeV) is substituted 
for the related human pathogen to achieve more 
efficient viral replication and thereby produce 
the severe acute illness and subsequent chronic 
respiratory disease that is typical of the pathol-
ogy found in humans (Walter et al., 2002). Using 
this model system, we determined that postviral 
lung disease depends on airway progenitor 
epithelial cell (APEC) production of IL-33 to 
drive invariant NK T cells (iNKT cells) and lung 
macrophages toward IL-13 production (Kim 
et al., 2008; Byers et al., 2013). The result is 
IL-13–dependent inflammation (signified by 
type 2 activation and accumulation of lung mac-
rophages) and airway mucus production (signi-
fied by MUC5AC mucin gene expression). This 
innate epithelial to immune cell loop also ap-
pears relevant to human disease because increased 
numbers of IL-33–expressing APECs are found 
in association with an IL-13 gene expression 
signature (including increased MUC5AC mRNA 
and protein) in the lungs of humans with severe 
chronic obstructive pulmonary disease (COPD; 
Kim et al., 2008; Agapov et al., 2009; Alevy et al., 
2012; Byers et al., 2013).
In our previous work, we recognized that 
the APEC population was capable of self-renewal 
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Viral infections and type 2 immune responses are thought to be critical for the development 
of chronic respiratory disease, but the link between these events needs to be better defined. 
Here, we study a mouse model in which infection with a mouse parainfluenza virus known as 
Sendai virus (SeV) leads to long-term activation of innate immune cells that drive IL-13–
dependent lung disease. We find that chronic postviral disease (signified by formation of 
excess airway mucus and accumulation of M2-differentiating lung macrophages) requires 
macrophage expression of triggering receptor expressed on myeloid cells-2 (TREM-2). Analy-
sis of mechanism shows that viral replication increases lung macrophage levels of intracellular 
and cell surface TREM-2, and this action prevents macrophage apoptosis that would other-
wise occur during the acute illness (5–12 d after inoculation). However, the largest increases 
in TREM-2 levels are found as the soluble form (sTREM-2) long after clearance of infection 
(49 d after inoculation). At this time, IL-13 and the adapter protein DAP12 promote TREM-2 
cleavage to sTREM-2 that is unexpectedly active in preventing macrophage apoptosis. The 
results thereby define an unprecedented mechanism for a feed-forward expansion of lung 
macrophages (with IL-13 production and consequent M2 differentiation) that further  
explains how acute infection leads to chronic inflammatory disease.
© 2015 Wu et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
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titers, and pattern of tissue inflammation in wt/wt and wt/opT 
mice (not depicted).
In contrast to the similarities in acute illness in wt/wt and 
wt/opT mice, we found marked differences in the development 
of chronic lung disease that develops after clearance of infec-
tious virus and is fully manifest at 49 dpi (Walter et al., 2002; 
Kim et al., 2008; Byers et al., 2013). Under these chronic con-
ditions, we observed that the increases in each lung monocyte–
macrophage population at 49 dpi in wt/wt mice were all markedly 
attenuated in wt/opT mice (Fig. 1 B). Tissue monocytes, which 
were the most abundant monocyte–macrophage population 
in the lung, exhibited no increase in wt/opT mice at 49 dpi. 
In concert with the decreased lung monocyte–macrophage 
levels in wt/opT mice, we also found that induction of 
IL-13 expression and mucous cell metaplasia in wt/wt mice was 
markedly inhibited in wt/opT mice at 49 dpi (Fig. 1 C). Simi-
larly, the postviral increases in lung levels of Il13 mRNA 
and downstream Muc5ac mRNA and type 2 macrophage 
(M2) markers Arg1 and Chitinase 3–like-3 (Chi3l3) mRNA in 
wt/wt mice were completely blocked in wt/opT mice at 49 dpi 
(Fig. 1 D). These findings are consistent with our previous 
work showing that lung macrophages are critical for IL-13 
production, and in turn, that IL-13 is required to drive mucus 
production and M2 differentiation in our postviral mouse model 
of lung disease (Tyner et al., 2006; Kim et al., 2008; Byers et al., 
2013). The results also provide a basis for next determining 
what factors might regulate the expansion of disease-producing 
lung macrophages under these conditions.
TREM-2 control of postviral disease
Based on the association of TREM-2 with M2 differentiation 
(Turnbull et al., 2006), we investigated the role of TREM-2 
in macrophage-dependent postviral lung disease. In that con-
text, we found that the development of this type of lung dis-
ease was associated with increased lung Trem2 (but not other 
Trem) mRNA levels based on gene expression microarray 
and real-time qPCR assay (Fig. 2, A and B; and Table S1). 
Moreover, the development of postviral lung disease at 49 dpi 
in WT mice was markedly attenuated in Trem2?/? mice. 
Thus, Trem2?/? mice showed marked decreases in lung in-
flammation and airway mucus production based on tissue stain-
ing (Fig. 2 C) as well as significantly decreased lung levels 
of the key cytokine Il13 mRNA, the predominant mucin 
Muc5ac mRNA, and the M2 markers Arg1 and Chi3l3 mRNA 
based on real-time qPCR assay (Fig. 2 D). Dap12?/? mice 
exhibited a similar inhibition of postviral disease (Fig. 2, C and D), 
consistent with the association of TREM-2 and DAP12 
phenotype in other systems (Bouchon et al., 2000; Kaifu et al., 
2003; Turnbull et al., 2006). In contrast, Trem1/3?/? mice 
manifested no significant difference in the development of 
chronic postviral disease (Fig. 2, C and D), perhaps diver-
gent from the pro-inflammatory role of TREM-1 in other 
disease models (Bouchon et al., 2001a; Schenk et al., 2007; 
Klesney-Tait et al., 2013).
The distinct nature of TREM-2 actions in postviral lung 
disease prompted a further examination of mechanism. We 
and inducible release of IL-33 to sustain ongoing activation 
of the innate immune system (Holtzman et al., 2014). How-
ever, the existing data did not explain the selective activation 
of the lung macrophage population and the special domi-
nance of type 2 (M2) macrophages as a downstream part of 
the disease process. In the present study, we therefore aimed 
to better understand how the lung macrophage component 
of this disease process is triggered by acute infection and then 
is manifest for months. We reasoned that triggering receptor 
expressed on myeloid cells 2 (TREM-2) might contribute 
to this process because M2 polarization is associated with 
TREM-2 expression in isolated macrophages (Turnbull et al., 
2006). In pursuing this possibility, we found that the soluble 
form of TREM-2 (sTREM-2) was linked to the develop-
ment of chronic postviral lung disease and was active in pro-
moting macrophage survival. The data stand in contrast to 
the conventional view that cleavage of cell surface TREM-2 
to sTREM-2 results in an inactive end product. The results 
thereby provide for a previously unrecognized control over 
macrophage survival and a consequent type 2 immune re-
sponse that can serve both as a pathogenic mechanism and as 
a therapeutic target and accompanying biomarker for chronic 
inflammatory disease.
RESULTS
Macrophage control of postviral disease
To further define the role of macrophages in our postviral 
mouse model of chronic lung disease (Walter et al., 2002), 
we first assessed the impact of a new strategy for macrophage 
deficiency. We previously showed that mice that were treated 
with clodronate or mice that were homozygous for the op 
mutation in the Csf1 gene (Csf1op/op) led to marked macro-
phage depletion and blockade of postviral lung disease, but 
both pharmacologic and genetic approaches to depletion led to 
mice that were also more susceptible to viral infection (Tyner 
et al., 2005; Kim et al., 2008). In the present case, we started 
with Csf1op/opT (op/opT) mice, which carry an osteocalcin-
driven Csf1 transgene (T) that rescues the osteopetrotic, but 
not the macrophage defect, in op/op mice (Abboud et al., 
2002). We then used these mice to generate heterozygous 
Csf1wt/opT (wt/opT) mice with a subtler defect in macrophage 
level and perhaps function. Of note, we still found that the 
increase in lung levels of tissue monocytes (SSClowLy6G–F4/
80+CD11b+) and interstitial macrophages (SSChighCD11c–
Ly6G–Siglec-F–F4/80+CD11b+) that occurs in WT (wt/wt) 
mice at 5 d post-inoculation (dpi) with Sendai virus (SeV) 
was significantly attenuated in wt/opT mice (Fig. 1 A and 
Fig. S1). We observed no increase (and instead found a signifi-
cant decrease) in alveolar macrophages (SSChighCD11c+Ly6G– 
Siglec-F+F4/80+CD11b–) in wt/wt and wt/opT mice at 5 dpi, 
reflecting a predominant effect of Csf1 deficiency on tissue 
monocytes and interstitial macrophages during acute infection. 
Despite these differences in lung monocyte–macrophage lev-
els, we found the same degree of acute illness (0–12 dpi) as 
signified by essentially identical body weight changes, viral 
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Figure 1. Effect of macrophage deficiency on postviral lung disease. (A) Lung levels of total cells, tissue monocytes (tissue monos), interstitial 
macrophages (interstitial macs), and alveolar macrophages (alveolar macs) for wt/wt and wt/opT mice at 5 dpi with SeV or UV-inactivated SeV (SeV-UV) 
determined by flow cytometry staining with fluorescent bead-based quantitation. (B) For conditions in (A), corresponding values for 49 dpi. (C) Represen-
tative photomicrographs of lung sections stained with PAS plus hematoxylin, immunostained for MUC5AC and counterstained with hematoxylin, or  
immunostained for IL-13 and counterstained with DAPI. Bars, 200 µm. (D) Lung levels of Il13, Muc5ac, Arg1, and Chi3l3 mRNA in wt/wt and wt/opT mice 
at 49 dpi with SeV or SeV-UV. For A, B, and D, * represents a significant increase from SeV-UV, and ** represents a significant decrease from correspond-
ing wt/wt control value. All experimental data were verified in at least three independent experiments.
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Figure 2. Induction and function of Trem2 gene expression during postviral lung disease. (A) Gene expression microarray analysis of mRNA from 
lungs of mice at 3 and 49 dpi with SeV (105 pfu) or SeV-UV. Scatter plot depicts log2 normalized gene expression. Each symbol represents the expression 
value for an individual gene with the top 20 differentially expressed genes colored red and annotated in black, and others colored gray. Genes encoding 
Trem family members and Dap12 are colored red if significantly increased, blue if decreased, or white if unchanged, and are annotated in red. (B) Lung 
levels of Trem1, Trem2, and Il13 mRNA at indicated dpi with SeV. * represents a significant increase from (–) SeV control value. Values at 0 dpi were no 
different than those for SeV-UV 0–49 dpi. (C) Representative photomicrographs of PAS and Muc5ac staining of lung sections from WT, Trem2?/?, 
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WT mice at 49 dpi (Fig. 4 B). Here, we show that this ex-
pansion is markedly down-regulated in Trem2?/? mice based 
on tissue immunostaining (Fig. 4 B). In addition, FACS-based 
separation of lung macrophage populations revealed that tis-
sue monocytes and interstitial macrophages exhibited a marked 
increase in Il13, Arg1, and Chi3l3 mRNA levels with the 
development of postviral disease at 49 dpi in WT mice, and 
this postviral induction was markedly attenuated in Trem2?/? 
mice (Fig. 4 C). In contrast, alveolar macrophages showed 
no induction of Il13 mRNA but nonetheless still manifested 
a slight increase in Arg1 mRNA and a marked increase in 
Chi3l3 mRNA at 49 dpi in WT mice. The observed levels of 
Il13, Arg1, and Chi3l3 mRNA in alveolar macrophages from 
WT mice were nearly identical to those in Trem2?/? mice 
(Fig. 4 C). This subset profile might again reflect a predominant 
first established that there was no significant difference in acute 
illness among Trem2?/?, Dap12?/?, and Trem1/3?/? mice as 
signified by similarities in body weight change, viral titer and 
tissue distribution, and pattern of tissue inflammation (Fig. 3, 
A–D). Therefore, we returned to our interest in the role of 
TREM-2 in modifying long-term macrophage function. We 
first found that TREM-2 expression at 49 dpi was specific to 
lung tissue macrophages based on co-localization with mac-
rophage markers F4/80 and Mac-3 in tissue immunostaining 
(Fig. 4 A). Similarly, TREM-2 expression was found in lung 
macrophages (CD45+F4/80+) and not stromal cells, e.g., epi-
thelial cells (CD45–EpCAM+), based on flow cytometry stain-
ing (unpublished data).
As demonstrated previously (Kim et al., 2008), we also 
found a marked expansion of IL-13+ lung macrophages in 
Dap12?/?, and Trem1/3?/? mice at SeV p.i. day 49. Bar, 200 µm. (D) Corresponding lung levels of Il13, Muc5ac, Arg1, and Chi3l3 mRNA for conditions in 
(A). * represents a significant increase from SeV-UV mice and ** a significant decrease from corresponding WT control mice. All experimental data were 
verified in at least three independent experiments.
Figure 3. Similarity of acute illness  
after viral infection in WT and knockout 
mice. (A) Body weights in WT, Trem2?/?, 
Dap12?/?, and Trem1/3?/? mice at the indi-
cated dpi. (B) Viral titers assessed by real-
time qPCR assay for SeV N gene RNA in 
lungs of indicated mouse strains at 5 and  
8 dpi. For A and B, values represent mean ± 
SEM for 4–7 mice. (C) Representative photo-
micrographs SeV immunostaining in lung 
sections from WT and Trem2?/? mice at  
0–8 dpi. (D) Representative photomicrographs 
of hematoxylin and eosin staining of lung 
sections from indicated mouse strains at  
5 dpi. Each section contains an area of bron-
chiolitis with inflammatory cells surrounding 
an airway and adjacent blood vessel. Bar, 
200 µm. All experimental data were verified 
in at least three independent experiments.
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(Fig. 5 A). Moreover, flow cytometry staining for TREM-2 
was found exclusively on CD11b+CD11c– lung cells at 5 dpi 
(Fig. S2), which is consistent with localization to tissue mono-
cytes and interstitial macrophages and not to alveolar macro-
phages or dendritic cells. Postviral induction of cell surface 
TREM-2 was found only at 2–8 dpi (Fig. 5, A and B) and 
was therefore similar to induction for lung levels of SeV, sug-
gesting that SeV replication might increase cell surface TREM-2 
on macrophages. To follow up this possibility, we studied 
BMDMs infected with GFP-labeled SeV and showed an in-
crease in cell surface staining for TREM-2 that correlated closely 
with viral titer (Fig. 5, C and D). Moreover, SeV infection 
caused a dose-dependent increase in cell surface TREM-2 lev-
els on BMDMs that was reproduced using poly(IC) treatment, 
effect of TREM-2 deficiency on tissue monocytes and inter-
stitial macrophages. Given the predominance of the tissue 
monocyte population, these findings were consistent with 
the decrease in whole lung levels of Il13, Arg1, and Chi3l3 
mRNA found in Trem2?/? mice.
Cell surface TREM-2 expression and function
We next assessed the regulation of TREM-2 expression and 
function under the current paradigm that TREM-2 expressed 
on the cell surface works in coordination with its adapter 
protein DAP12 to signal for macrophage activation (Turnbull 
et al., 2006). In the present model, cell surface expression of 
TREM-2 on lung macrophages was detected on tissue mono-
cytes and interstitial macrophages but not alveolar macrophages 
Figure 4. Induction and function of TREM-2 in lung macrophages during postviral lung disease. (A) Representative photomicrographs of TREM-2 
plus F4/80 or Mac-3 immunostaining of lung sections from WT mice at 49 dpi with SeV or SeV-UV. Bar, 200 µm. (B) Representative photomicrographs of 
F4/80 plus IL-13 immunostaining of lung sections from WT and Trem2?/? mice at 49 dpi with SeV-UV or SeV. Bar, 200 µm. (C) Levels of Il13, Arg1, and Chi3l3 
mRNA in FACS-purified tissue monos, interstitial macs, and alveolar macs from WT and Trem2?/? mice at 49 dpi with SeV or SeV-UV. Each value represents 
mean ± SEM for five mice and is representative of three experiments. * represents a significant increase from corresponding SeV-UV in WT value, and 
** represents a significant decrease from corresponding SeV in WT value. All experimental data were verified in at least three independent experiments.
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Figure 5. Regulation of cell surface and intracellular TREM-2 levels during viral replication and postviral lung disease. (A) Representative histograms from 
FACS analysis of TREM-2 immunostaining for tissue monos, interstitial macs, and alveolar macs from lungs of mice at 5 or 49 dpi with SeV-UV or SeV. (B) Corresponding 
MFI values for cell surface TREM-2 levels on tissue monos at the indicated dpi based on analysis conditions in A. (C) Representative cytograms from flow cytometry analysis 
of cell surface TREM-2 immunostaining for BMDMs at 0–3 dpi with GFP-expressing SeV (SeV-GFP). (D) Corresponding MFI values for cell surface TREM-2 and SeV-GFP for 
conditions in C. (E) Representative histograms for flow cytometry analysis of cell surface and intracellular TREM-2 immunostaining for BMDMs with indicated conditions. 
(F) Western blotting of TREM-2 in BMDMs at 2 dpi with SeV (MOI 0–10). (G) ELISA of cellular TREM-2 and sTREM-2 in BMDMs at 2 dpi with SeV for indicated MOI or with
SeV at MOI 10 for 0–3 dpi. * represents a significant increase from corresponding control at MOI 0 and 0 dpi and Ø represents an undetectable level of sTREM-2. (H) Trem2
mRNA level in BMDMs with SeV at MOI 1 and 10 for 0–1 dpi. All experimental data verified in at least three independent experiments.
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additional effects at later time points that influenced long-term 
disease outcome.
sTREM-2 expression and function
To pursue the possible chronic actions of TREM-2 in the 
postviral model, we first determined whether there was long-
term production of TREM-2 protein in the lung in this model. 
Indeed, we found a marked increase in lung levels of TREM-2 
at 49 dpi compared with baseline or to the relatively small in-
crease found at 5 dpi (Fig. 7 A). Given the absence of detectable 
cell surface TREM-2 at 49 dpi and the relatively small in-
crease in intracellular TREM-2 at either 5 or 49 dpi (Fig. 5 A), 
this late increase in TREM-2 levels at 49 dpi was likely a marker 
of sTREM-2 formation in the diseased lung. Since IL-13 pro-
duction was also markedly increased at 49 dpi, we questioned 
whether IL-13 might promote TREM-2 cleavage at the cell 
surface and consequent formation of sTREM-2. In support of 
this possibility, we found that IL-13 administration caused 
a time-dependent loss of cell surface levels of TREM-2 in 
BMDMs (Fig. 7 B). The effect of IL-13 was specific for the 
IL-13 receptor since the same effect was found for IL-4 (that 
also activates this receptor) but was not detectable for other 
type 2 cytokines (IL-5 and IL-9; Fig. 7 C). Treatment with 
IL-13 also resulted in a time-dependent increase in cellular 
TREM-2 levels in BMDMs, as expected for M2 differentia-
tion, but caused an even greater increase in sTREM-2 levels 
released from BMDMs (Fig. 7 D). The increases in cellular 
TREM-2, especially the even greater increases in sTREM-2 
production, were attenuated in BMDMs from Dap12?/? 
mice (Fig. 7 D). Moreover, the expected increase in sTREM-
2 levels was not found during postviral disease in Dap12?/? 
mice (Fig. 7 E). Together, these findings indicated that both 
IL-13 and DAP12 were contributing to sTREM-2 forma-
tion and any consequent function of sTREM-2 in chronic 
postviral disease.
To pursue a possible role for sTREM-2 in postviral disease, 
we analyzed the effect of recombinant sTREM-2 (amino acids 
19–136) on macrophage function. Immunostaining of BMDMs 
incubated with sTREM-2 showed that the protein was local-
ized to the cell cytoplasm and not the cell surface and was 
thereby accessible to intracellular proteins (Fig. 8 A). In that 
context, we found that sTREM-2 administration to BMDMs 
caused a significant increase in Arg1 mRNA levels (as a sign of 
M2 differentiation), but the increase was not preserved for 
other M2 markers (e.g., Chi3l3 mRNA) and was not nearly as 
effective as IL-13 for driving these responses (Fig. 8 B). Thus, 
the direct effect of sTREM-2 on M2 differentiation was rela-
tively small and was therefore unlikely to contribute to biolog-
ical function or postviral disease. However, in the process of 
conducting these experiments, we recognized that sTREM-2 
treatment of BMDMs resulted in marked protection against the 
usual progression to cell death in this culture system, and this 
protective effect resulted in expanded numbers of BMDMs from 
both WT and Trem2?/? mice (Fig. 8 C). Similarly, sTREM-2 
treatment caused a dose-dependent expansion of BMDMs 
from WT, Trem2?/?, and Dap12?/? mice (Fig. 8 D). Here again, 
and this increase was unaffected by DAP12, TLR3, or PKR 
deficiency (Fig. 5 E). In addition to the increase in surface 
TREM-2 levels, we also found that SeV infection caused a 
smaller but sustained increase in intracellular levels of TREM-2 
in BM-derived macrophages (BMDMs) unaccompanied by 
any detectable production of sTREM-2 or any increases in 
Trem2 mRNA (Fig. 5, F–H). A similar increase in intra-
cellular TREM-2 level was found in vivo at 5 and 49 dpi. 
Together, the results suggest that SeV promotes an increase 
in surface TREM-2 levels based on increased TREM-2 for-
mation and either transport to or retention at the cell sur-
face with relatively little if any TREM-2 cleavage from the 
cell surface.
The relatively transient increase in cell surface TREM-2 
levels suggested an acute effect on macrophage function after 
viral infection. Consistent with this idea, we found that the 
increase in the number of tissue monocytes (and interstitial 
macrophages but not neutrophils) at 5 dpi in WT mice was 
attenuated in Trem2?/? mice (Fig. 6 A and not depicted). This 
attenuation was not accompanied by decreases in monocyte 
chemokine production based on lung levels of Ccl2 and 
Cx3cl1 mRNA at 3–5 dpi (Fig. 6 B) or decreases in mono-
cyte influx into the lung based on tracking CD45.2 trans-
ferred monocytes by flow cytometry at 5 dpi (Fig. 6 C). 
However, we did detect increased macrophage apoptosis in 
Trem2?/? mice compared with WT mice based on immuno-
staining for active caspase-3 and Mac-3 at 5–12 dpi (Fig. 6, 
D and E), suggesting a role for TREM-2 in specifically pro-
moting macrophage survival after viral infection. Cells that 
were active caspase-3+ were not also SeV+ (Fig. 6 F), suggest-
ing that TREM-2 antiapoptotic actions were independent 
of viral cytopathic effect. In addition, the timing of apoptosis 
corresponded to a relative decrease in Csf1 mRNA and CSF-1 
protein levels in the lung (Fig. 6, G and H), consistent with 
the link between CSF-1 and macrophage survival via DAP12 
signaling (Otero et al., 2009). Moreover, we detected no defect in 
CSF-1 production in Trem2?/? mice suggesting that the CSF-1 
survival signal required downstream activation of TREM-2 to 
prevent apoptosis. Indeed, we found a marked increase in 
apoptosis with CSF-1 withdrawal in BMDMs from Trem2?/? 
mice compared with WT control mice based on propidium 
iodide staining, Annexin V staining, and active Caspase-3 
immunoblotting (Fig. 6, I–K). We detected a slight increase in 
apoptosis in BMDMs from Trem2?/? mice even in cultures 
with CSF-1, but this effect was also attributable to CSF-1 
withdrawal because CSF-1 was added only once at the start 
of the 2-d culture period and was therefore being consumed 
and depleted from the culture medium. This condition there-
fore represents a partial degree of CSF-1 withdrawal and 
a consequent loss of the CSF-1 to TREM-2 survival signal in 
Trem2?/? cells. Together, our results suggested that cell sur-
face TREM-2 might preserve macrophage survival and pro-
mote macrophage accumulation after viral infection and 
thereby lead to long-term macrophage-dependent disease. 
However, the relatively transient effect of TREM-2 during 
acute infection also raised the possibility that TREM-2 had 
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Figure 6. Effect of cellular TREM-2 on macrophage apoptosis during acute viral infection. (A) Flow cytometry analysis of lung levels of total 
cells, tissue monos, and neutrophils (SSChighLy6G+) for WT and Trem2?/? mice at 0–5 dpi with SeV. (B) Ccl2 and Cx3cl1 mRNA levels in WT and Trem2?/? 
mice at 0–5 dpi. For A and B, values represent mean ± SEM for 5 mice, and * represents a significant increase from 0 dpi and ** a significant decrease 
from corresponding WT mice. (C) Representative cytograms for flow cytometry analysis of levels of CD45.2+ tissue monos in WT and Trem2?/? mice at  
3 dpi after CD45.2 WT and Trem2?/? BMDMs were introduced into CD45.1 WT mice at 0 dpi. (D) Representative photomicrographs of active caspase-3 and 
Mac-3 immunostaining of lung sections from WT and Trem2?/? mice at 8 dpi. Arrows indicate cells with double-positive immunostaining. Bar, 200 µm. 
(E) Quantification of analysis in (D). Values represent mean ± SEM for 12 randomly selected fields of lung sections from 3 mice, and ** represents a sig-
nificant increase from corresponding WT mice. (F) Representative photomicrographs of active caspase-3 and SeV immunostaining of lung sections from
WT and Trem2?/? mice at 5 dpi. Arrows indicate cells with active caspase-3+ immunostaining. Bar, 200 µm. (G) Lung levels of Csf1 mRNA for WT and
Trem2?/? mice at indicated dpi. (H) Corresponding lung levels of CSF-1 for conditions in (G). For G and H, values represent mean ± SEM for 5 mice, and
* represents a significant increase from 0 dpi. (I) Flow cytometry analysis of propidium iodide staining of BMDMs from WT and Trem2?/? mice cultured
with or without CSF-1 for 1 d. (J) Levels of Annexin V immunostaining in PI– cells for culture conditions in (I). Values represent mean ± SEM for 6 ran-
domly selected fields of replicate wells, and * represents a significant increase from (+) CSF-1, and ** a significant increase from corresponding WT mice.
(K) Western blot levels of active caspase-3 for culture conditions in I. All experimental data were verified in at least three independent experiments.
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the increased levels of apoptosis under these conditions in 
Trem2?/? and Dap12?/? macrophages that are unable to gen-
erate sTREM-2.
Given the difficulties in monitoring apoptosis in vivo (e.g., 
we detected no active caspase-3 tissue staining at 49 dpi; un-
published data) we sought additional markers of sTREM-2 
action during postviral lung disease. In that regard, we were 
able to establish that sTREM-2 treatment resulted in a time-
dependent and selective increase in molecular pathways con-
nected to cell survival and proliferation, e.g., ERK1/2 and 
MAPK14 phosphorylation but not AKT phosphorylation or 
BCL-2 induction (Fig. 9 A). The effect of sTREM-2 on phospho-
ERK1/2 and phospho-MAPK formation was more pro-
nounced in BMDMs from Trem2?/? mice compared with 
WT mice (Fig. 9 A), consistent with the enhanced effect of 
sTREM-2 on viability of BMDMs from Trem-2?/? compared 
with WT mice based on fold-change (Fig. 8 D). In translating 
these findings to the postviral model in vivo, we found that 
phospho-ERK1/2 immunostaining was markedly increased 
and co-localized to lung macrophages at 49 dpi compared with 
5 dpi or SeV-UV control conditions in WT mice (Fig. 9 B). 
Moreover, the increase in phospho-ERK1/2 immunostaining 
was not detected at 49 dpi in Trem2?/? mice (Fig. 9 B). These 
results were consistent with increases in the numbers of total 
the baseline numbers of BMDMs were increased in WT mice 
compared with Trem2?/?, and Dap12?/? mice under these 
culture conditions, but this difference was corrected in re-
sponse to sTREM-2 treatment (Fig. 8 D). The protective ef-
fect was specific for active sTREM-2 because it was lost with 
heat inactivation (Fig. 8 E). Flow cytometry analysis with 
propidium iodide staining indicated that sTREM-2 admin-
istration resulted in attenuation of apoptosis due to CSF-1 
withdrawal in BMDMs from WT mice, as well as Trem2?/? 
and Dap12?/? mice (Fig. 8 F). As expected, the level of apop-
tosis with CSF-1 withdrawal in BMDMs from WT mice 
was markedly increased in Trem2?/? and Dap12?/? mice, 
but this effect was also fully preventable and dose-dependent 
with sTREM-2 administration (Fig. 8 F). Treatment with 
sTREM-2 also reversed the increase in activate caspase-3 
levels that develops with CSF-1 withdrawal, confirming an 
effect on apoptosis (Fig. 8 G). In contrast, sTREM-2 had no 
effect on cellular proliferation based on BrdU incorporation 
(Fig. 8 H), as expected for cell cultures deprived of CSF-1 stimu-
lation. This result is also consistent with the absence of signifi-
cant cell proliferation in the lung in vivo when disease becomes 
manifest (Tyner et al., 2006). Together, these findings support 
a role for sTREM-2 in protection against macrophage apop-
tosis under low CSF-1 conditions, and thereby explained 
Figure 7. Effect of IL-13 on production of sTREM-2. (A) Lung levels of TREM-2 determined by ELISA at 5 or 49 dpi with SeV or SeV-UV. Values 
represent mean ± SEM for 5 mice, and * represents a significant increase from corresponding SeV-UV mice. (B) Representative histograms from flow 
cytometry analysis of cell surface TREM-2 on BMDMs treated with or without IL-13 (20 ng/ml) or IgG control for 1–3 d. (C) Representative histograms 
from flow cytometry analysis of cell surface TREM-2 on BMDMs treated with or without IL-13, IL-4, IL-5, or IL-9 (20 ng/ml) or IgG control for 1 d.  
(D) Levels of cellular and sTREM-2 in BMDMs obtained from WT and Dap12?/? mice and cultured with IL-13 for 1–3 d post-administration (dpa) as in B.
Values represent mean ± SEM for 3 replicate wells, and * represents a significant increase from 0 dpa and ** a significant decrease from corresponding WT
cells. (E) Lung levels of TREM-2 in WT and Dap12?/? mice at 49 dpi. Values represent mean ± SEM for 5 mice, and * represents a significant increase from
SeV-UV and ** a significant decrease from corresponding WT mice. All experimental data were verified in at least three independent experiments.
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provide for a crucial regulatory role of TREM-2 in a feed-
forward pathway that expands the M2 macrophage population 
and thereby promotes IL-13–dependent chronic lung disease.
immune cells and macrophages in the lung at 49 dpi in WT 
mice, as well as marked inhibition of this cellular response at 
49 dpi in Trem2?/? mice (Fig. 9 C). Together, these findings 
Figure 8. Effect of sTREM-2 on macro-
phage apoptosis. (A) Representative photo-
micrographs of immunostaining for 
recombinant sTREM-2 after incubation with 
BMDMs for 30 min with and without cell 
permeabilization with saponin. Bar, 100 µm. 
(B) Levels of Arg1 and Chi3l3 mRNA in BM-
DMs obtained from Trem2?/? and WT mice
and then cultured with sTREM-2 (0–200 ng/ml)
or IL-13 (20 ng/ml) for 1 d. Values represent
mean ± SEM for 3 replicate wells, and * repre-
sents a significant increase from no treatment
control (0 ng/ml). (C) Representative photomi-
crographs of sTREM-2–treated BMDMs cul-
tured in 15% L-cell conditioned medium for
7 d. Bar = 200 µm. (D) XTT assay for BMDMs
obtained from WT, Trem2?/?, and Dap12?/?
mice and then cultured with sTREM-2
(0–200 ng/ml) for 2 d after CSF-1 withdrawal.
Values represent mean ± SEM for 3 replicate
wells, and * represents a significant increase
from corresponding untreated control cells.
(E) XTT assay of BMDMs from WT mice cultured
with native (unheated) or denatured (heated)
sTREM-2 (0–200 ng/ml) with culture condi-
tions in D. * represents a significant increase
from corresponding untreated control cells.
(F) Flow cytometry analysis of propidium
iodide staining of BMDMs obtained from WT,
Trem2?/?, and Dap12?/? mice and cultured
with sTREM-2 (0–200 ng/ml) with or without
CSF-1 for 1 d. (G) Western blot levels of active
caspase-3 for culture conditions in F. (H) Flow
cytometry analysis of BrdU-labeling of BMDMs
from Trem2?/? mice for culture conditions in F.
All experimental data were verified in at least
three independent experiments.
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in the lung. In the context of our previous work, the in-
creased number of macrophages would be available to inter-
act with iNKT cells and drive further IL-13 production 
thereby resulting in IL-13–dependent differentiation of the 
macrophage population toward an M2 pattern of gene ex-
pression (including Arg1 and Chi3l3) and differentiation of 
an airway progenitor epithelial cell (APEC) niche to airway 
mucous cells (AMCs) as signatures of chronic lung disease (as 
diagrammed in Fig. 10). The scheme is consistent with our 
observation that TREM-2–deficient mice are markedly pro-
tected from the development of chronic lung disease as a long-
term consequence of viral infection.
The role of TREM-2 in chronic disease described in this 
study provides for at least four major and unexpected insights. 
First, TREM-2 signaling was often portrayed as antiinflam-
matory and reparative, whereas increased TREM-1 signals 
DISCUSSION
This report identifies TREM-2 as a key component of an in-
nate immune pathway for the pathogenesis of chronic lung 
disease. We use a postviral mouse model of this type of dis-
ease to show that: (1) during acute illness, viral replication 
increases lung macrophage levels of intracellular and cell sur-
face TREM-2, and this action mediates a CSF-1–dependent 
cell survival signal that prevents macrophage apoptosis; (2) 
during chronic postviral disease, IL-13 and DAP12 signals 
promote increased expression and cleavage of TREM-2 from 
the cell surface to form sTREM-2 at increased levels in the 
lung; and (3) sTREM-2 is not inactive as previously thought, 
but is instead capable of promoting macrophage survival via 
antiapoptotic signals such as ERK1/2 activation. Together, 
these events allow for TREM-2 to participate in a feed for-
ward mechanism to amplify the accumulation of macrophages 
Figure 9. Effect of TREM-2 deficiency on apoptosis signaling pathway. (A) Western blot levels of indicated cell survival proteins in BMDMs  
cultured from WT and Trem22/2 mice after treatment with mouse sTREM-2 (200 ng/ml) for 0–24 h. (B) Representative photomicrographs of phospho-
ERK1/2 (p-ERK) and Mac-3 immunostaining with DAPI counterstaining of lung sections from WT and Trem22/2 mice at 5 or 49 dpi with SeV or SeV-UV. 
Arrows indicate cells with double-positive immunostaining. Bar, 200 µm. (C) Flow cytometry analysis of lung levels of total cells and tissue monos for WT 
and Trem22/2 mice at 0 and 49 dpi. Values represent mean ± SEM for 5 mice, and * represents a significant increase from 0 dpi and ** a significant de-
crease from corresponding WT mice. Values at 0 dpi were no different than those for SeV-UV (49 dpi). All experimental data were verified in at least three 
independent experiments.
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levels were found long after clearance of infectious virus and 
were manifest as marked increases in sTREM-2 that had been 
cleaved from the cell surface. These circumstances led to the 
unexpected function of sTREM-2 as a potent antiapoptotic 
factor for macrophages. Our data suggests that sTREM-2 acts 
as an intracellular messenger to trigger the activation of ki-
nases (e.g., ERK1/2) that promote cell survival. However, ad-
ditional work will need to define the precise molecular pathway 
downstream of sTREM-2 actions, including those proposed 
for TREM-2–DAP12 signaling for cell survival (Otero et al., 
2009, 2012). Meanwhile, however, our results may also help 
to explain the proposed benefit of sTREM-2 cleavage in 
neurodegenerative disease, where decreased sTREM-2 cleav-
age caused by mutation may be associated with impaired macro-
phage (i.e., microglial) function in the CNS (Kleinberger 
et al., 2014).
A third unanticipated result of our study was the potent 
role of DAP12 and IL-13 in regulating TREM-2 cleavage and 
sTREM-2 formation. Similar to signaling function of cell 
surface TREM-2, the formation of sTREM-2 and any con-
sequent downstream action of sTREM-2 was still dependent 
on DAP12. This new connection between sTREM-2 and 
DAP12 could help explain how distinct TREM signals are 
transduced into different downstream effects on cell behavior. 
Thus, both TREM-1 and TREM-2 on the cell surface are 
proposed to signal via DAP12, and this adaptor has only a sin-
gle immunoreceptor tyrosine-based activation motif (ITAM) 
for subsequent signal transduction. It has been proposed that 
the avidity of TREM (or other receptor) interaction with 
DAP12 might dictate a positive versus negative signal from 
this ITAM to the downstream kinase (Turnbull and Colonna, 
2007). In the present experiments, we find that TREM-2 
function is linked to DAP12 by a protein maturation process 
that appears distinct from TREM-1–DAP12 and TREM-2–
DAP12 signaling. Similarly, IL-13 also contributed to the 
TREM-2 cleavage process in what appears to be a novel role 
for IL-13. In both cases, additional work is needed to define 
the molecular mechanism for TREM-2 cleavage. This type of 
were thought to be proinflammatory and destructive in 
models of intestinal and CNS disease (Schenk et al., 2007; 
Takahashi et al., 2007; Seno et al., 2009). This view is con-
sistent with studies showing that engagement of TREM-1 
promotes secretion of proinflammatory cytokines (including 
IL-6 and TNF) and increases the inflammatory responses 
downstream of TLR and NLR engagement (Bouchon et al., 
2000, 2001a; Bleharski et al., 2003; Netea et al., 2006; Fortin 
et al., 2007; Schenk et al., 2007). Meanwhile, similar approaches 
showed that TREM-2 activation generally antagonized acti-
vation signals for inflammation (Daws et al., 2001; Colonna, 
2003; Hamerman et al., 2006; Turnbull et al., 2006). In con-
trast, the present results provide for a paradigm in which 
TREM-2 activation promotes the development of chronic 
inflammatory disease. This model is consistent with reports for 
up-regulation of M2 gene expression (including TREM2) in 
macrophages isolated from cigarette smokers with and without 
COPD (Shaykhiev et al., 2009; Koth et al., 2010). However, 
these previous studies as well as others that assess association 
with disease cannot determine cause and effect actions of TREM 
signaling in the development of disease. Moreover, the pres-
ent application of new tools to separately study both TREM-1 
and TREM-2 deficiency in vivo and in vitro in the same model 
system was critical to dissect any differences in TREM family 
member function.
A second unexpected aspect of the present findings is the 
biological activity of sTREM-2. In fact, we initially approached 
the issue of TREM-2 activity as being a function of TREM-2 
localization to the cell surface, where it could presumably 
bind to an as yet poorly defined ligand, and in association 
with DAP12, initiate a signaling pathway for cell survival 
(Otero et al., 2009). Indeed, we were able to secure evidence 
for this mechanism in the setting of acute infection, wherein 
viral replication increases TREM-2 on the surface of infected 
macrophages. However, this relatively transient effect on 
macrophage survival did not appear to explain the long-term 
effect of TREM-2 on postviral lung disease. We therefore 
pursued evidence that the greatest increases in TREM-2 lung 
Figure 10. Scheme for regulation and function of TREM-2 in chronic postviral lung disease. Major steps include: (1) early activation of lung 
macrophages in which viral replication increases TREM-2 at the cell surface; (2) cleavage of TREM-2 from the cell surface to form sTREM-2 in a process 
that is up-regulated by IL-13 and DAP12; (3) sTREM-2 actions to prevent apoptosis in association with increased ERK1/2 activation and thereby allow for 
amplified macrophage interaction with iNKT cells and consequent IL-13 production; and (4) IL-13–dependent differentiation of the macrophage popula-
tion toward an M2 pattern of gene expression (including Arg1 and Chi3l3) and differentiation of an airway progenitor epithelial cell (APEC) niche to air-
way mucous cells (AMCs) as signatures of chronic lung disease.
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sTREM-2 formation or action. Initial studies already suggest 
an increase in TREM-2 expression in concert with excess 
levels of airway mucus and M2 macrophages in human lung 
disease (Byers and Holtzman, 2011; Byers et al. 2013. Inter-
national Meeting of the American Thoracic Society. Abstr. 
A141.). The present findings justify further validation of these 
observations in humans with chronic lung disease and addi-
tional work to correct any abnormalities in TREM-2 action 
in this type of disease and other diseases that implicate a role 
for TREM-2 in regulating macrophage survival.
MATERIALS AND METHODS
Mice. WT C57BL/6J mice were obtained from The Jackson Laboratory. 
The op/opT mice were generated as described previously (Abboud et al., 
2002) and were provided by N. Ghosh-Choudhury (University of Texas, 
San Antonio). These mice were crossed to WT mice to generate heterozy-
gous wt/opT mice and littermate wt/wt control mice. Dap12?/? mice were 
provided by T. Takai (Tohoku University, Sendai, Japan). Trem2?/? mice 
were generated as described previously (Turnbull et al., 2006). Trem1/3?/? 
mice were generated as described previously and were backcrossed to 
C57BL/6 mice until >99% of the loci were derived from this strain. Tlr3?/? 
mice were generated as described previously (Alexopoulou et al., 2001). 
Pkr?/? mice were generated as described previously (Yang et al., 1995) and 
rederived from frozen embryos obtained from M. White and H. Virgin IV 
(Washington University, St. Louis, MO). All mice were maintained on a 
C57BL/6 genetic background and were used in protocols approved by Ani-
mal Studies Committee of Washington University School of Medicine in 
accordance with National Institutes of Health guidelines.
Viral inoculation and monitoring. Mice were inoculated with SeV (105 
pfu), an equivalent amount of UV-inactivated SeV (SeV-UV), or PBS as de-
scribed previously (Kim et al., 2008). SeV-UV and PBS inoculations gave 
identical results, and therefore are treated interchangeably as controls. Viral 
titers for stock solutions and lung infections were monitored by plaque-
forming and real-time PCR assays as described previously (Kim et al., 2008).
Analysis of mRNA. For gene expression microarrays, RNA was iso-
lated and analyzed using Illumina Mouse-WG6 v2 BeadChips (Illumina) as 
described previously (Byers et al., 2013). Visualization and plotting was 
performed using DecisionSite for Functional Genomics (TIBCO Spotfire). 
Microarray data were deposited in the National Center for Biotechnology 
Information (NCBI) Gene Expression Omnibus (GEO) under series acces-
sion nos. GSE49603 and GSE61437. For real-time qPCR assays, RNA was 
purified from lung homogenate using TRIzol (Invitrogen) and was con-
verted to cDNA using the High-Capacity cDNA Archive kit (Applied Bio-
systems). Target mRNA was quantified by real-time PCR assay using specific 
fluorogenic probes and primer sets and the Fast Universal PCR Master 
Mix system (Applied Biosystems). Primer-probe sets for mouse Ccl2 (Mcp-1; 
Mm00441242_m1), Cx3cr1l (Mm00436454_m1), Trem1 (Mm00451738_m1), 
Trem2 (Mm00451744_m1), Chi3l3 (Mm00657889_mH), Arg1 (Mm00475988_
m1), and Dap12 (Mm00449152_m1) were obtained from Applied Biosys-
tems. The forward and reverse primers and probes for mouse Il13 were 
5?-GGTGCCAAGATCTGTGTCTC-3?, 5?-CCACACTCCATACCAT-
GCTG-3?, and 5?-AAGACCAGACTCCCCTGTGCAAC-3?; for Muc5ac 
were 5?-TACCACTCCCTGCTTCTGCAGCGTGTCA-3?, 5?-ATAG-
TAACAGTGGCCATCAAGGTCTGTCT-3?, and 5?-TATACCCCT-
TGGGATCCATCATCTACA-3?; for Csf1 were 5?-CTTCATGCCA-
GATTGCCTTTG-3?, 5?-CGCATGGTCTCATCTATTATGTCT-3?, 
5?-CAGCTGGATGATCCTGTTTGCTACCT-3?; and for mouse Gapdh 
were 5?-AAGGTGAAGGTCGGAGTCA-3?, 5?-CATGTAAACCATG-
TAGTTGAGGT-3?, and 5?-CGGATTTGGTCGTATTGGGCGC-3?. All 
insight could provide a useful target for antiinflammatory 
therapy by inhibiting cleavage and a consequent excess of 
sTREM-2 formation.
A fourth issue that is distinct for our results relates to the 
view of M2 macrophages and macrophage subsets in mediat-
ing inflammatory disease. For example, other disease models 
such as allergen challenge concentrate on blocking the mac-
rophage response to IL-13 and conclude that there is no role 
for M2 macrophages in the disease process (Nieuwenhuizen 
et al., 2012). In contrast, our model focuses on the role of 
macrophages in IL-13 production as the fundamental step in 
producing disease, so it is this step that needs to be targeted 
for disruption. Notably, however, allergen-challenge models 
may depend on recruited monocytes but not resident alveolar 
macrophages for the development of lung disease (Zasłona 
et al., 2014). Similarly, we found differences in tissue mono-
cyte and interstitial macrophage versus alveolar macrophage 
characteristics (e.g., level of Il13 mRNA induction and sensitiv-
ity to TREM-2 regulation) during the development of postviral 
disease. These results also support the paradigm of inflamma-
tory monocyte recruitment and subsequent differentiation 
into disease-producing macrophages and provide a basis for 
assessing these events in situ with reporter labeling and intra-
vital imaging in the future.
Our study focused on the role of TREM-2 in macrophage 
function based on evidence that macrophages are key to the 
development of postviral disease. However, we recognize 
that myeloid (conventional) DCs may contribute to postviral 
disease at least in the first few weeks after viral inoculation 
(Grayson et al., 2007) and may express TREM-2 at least 
in vitro (Bouchon et al., 2001b; Ito and Hamerman, 2012). We 
found TREM-2 expression on CD11b+CD11c– cells (i.e., 
monocytes and macrophages) and not on CD11b+CD11c+ 
cells (i.e., DCs) at 5 dpi with virus using FACS, but we can-
not yet exclude expression on DCs at 49 dpi given the low 
levels of cellular expression of TREM-2 and the low num-
bers of DCs at this later time point. Thus, further studies with 
different technologies will be needed to determine any role 
for DC-expressed TREM-2 after viral infection.
In sum, we have defined a novel role for TREM-2 in the 
development of chronic lung disease using a postviral mouse 
model of this process. Our previous work led to a new consid-
eration of the role of innate immune activation of macrophages 
in this type of disease. However, there was little subsequent 
progress toward further understanding and thereby specifi-
cally blocking the macrophage component of postviral dis-
ease in experimental models or humans. Herein, we describe 
an unanticipated mechanism whereby TREM-2 allows for 
macrophages to accumulate in the lung and thereby amplify 
disease-promoting IL-13 production. In this setting, TREM-2 
appears to affect the chronic disease process without influenc-
ing acute viral illness, thereby creating an opportunity to in-
hibit excessive TREM-2 action without compromising host 
defense. The findings thereby provide an opportunity to down-
regulate the type 2 immune response and prevent the develop-
ment of this type of immune-mediated disease by interrupting 
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mAb at 4°C. We used the following antibodies: rat anti-mCD11b (clone 
M1/70; eBioscience), anti-Ly6C (clone al-21; BD), anti-Ly6G (clone 1a8; 
BD), anti-mouse F4/80 (clone BM8; eBioscience), anti-mouse TREM-1 (clone 
174031; R&D Systems), anti-m/hTREM-2 (clone 237920; R&D Systems), 
anti–mouse CD11c (clone HL3; BD), anti–mouse CD45.2 (clone 104; eBio-
science), and anti–mouse Siglec-F (clone E50-2440; BD). We used flow cytom-
etry and FACS to identify and purify specific cell populations in mouse lungs 
using the following gates: tissue monocytes as SSClowLy6G–F4/80+CD11b+, 
interstitial macrophages as SSChighCD11c–Ly6G–Siglec-F–F4/80+CD11b+, 
alveolar macrophages as SSChighCD11c+Ly6G–Siglec-F+F4/80+CD11b–, and 
neutrophil gate as SSChighLy6G+ (Fig. S1). Analysis was performed using 
Moflo (DAKO-Cytomation) and FlowJo software (Tree Star). Cells were 
counted using flow cytometry and fluorescent counting beads (CountBright; 
Life Technologies).
Cell culture. Bone marrow cells were flushed from femurs and differenti-
ated in 150 × 15 mm Petri dishes in DMEM medium containing 0.29 g/liter 
l-glutamine, 1 mM sodium pyruvate, 10% FBS, and 30% L929 fibroblast-
conditioned medium as a source of CSF-1. At day 6 or indicated times,
BMDMs were resuspended by incubation in 1 mM EDTA in PBS for
10 min on ice, washed twice with PBS and plated into tissue culture plates.
In some experiments, BMDMs were incubated with poly(IC) (Sigma-Aldrich)
or mouse IL-13 (R&D Systems). For cell viability assays, BMDMs were
seeded into 96-well tissue culture plates at 5 × 104 cells per well and were
assessed for viability using the Cell Proliferation kit (XTT) from Roche. For
cell proliferation assays, BMDMs were seeded into 6-well tissue culture
plates, labeled for 18 h with BrdU (10 µM), and then assessed using flow cy-
tometry with the FITC BrdU Flow kit (BD).
Apoptosis assays. For propidium iodide (PI) assay, BMDMs were cultured 
in L cell–conditioned medium for 5 d and deprived of CSF-1 for 1 d to induce 
apoptosis (Otero et al., 2009). Cells were detached using EDTA (1 mM) in 
PBS, washed, fixed with 70% ethanol, and incubated with PI (50 µg/ml) and 
RNase (40 µg/ml) for 1 h. Samples were analyzed for DNA content using a 
FACScan (BD). For Annexin V assay, BMDMs were differentiated in L 
cell–conditioned medium for 5 d, detached with EDTA, seeded onto the 
poly-D-Lysine-coated coverslips (BD) placed in a 24-well plate, and cul-
tured in medium without CSF-1 for 1 d. PI and Annexin V immunostaining 
was performed according to the manufacture’s protocol (Invitrogen). Annexin 
V–positive, PI-negative staining cells were quantified using microscopy, and 
values were expressed as the percentage of apoptotic cells (Annexin V posi-
tive, PI negative) relative to the total number of cells in 6 randomly selected 
fields of the two wells.
Monocyte influx. For analysis of monocyte influx into the lung, BMMs 
were purified from CD45.2 WT and Trem2?/? mice using negative selec-
tion with the EasySep Mouse Monocyte Enrichment kit (StemCell Tech-
nologies). Purified monocytes were then introduced into CD45.1 WT mice 
(3 × 106 cells per mouse via tail vein injection) at 0 dpi with SeV, and the 
number of CD45.2+ cells in the lung was determined 3 or 5 d later using 
FACS and fluorescent counting beads.
ELISA. For lung tissue samples, lung tissue was minced and then homog-
enized in PBS containing protease inhibitor cocktail (cOmplete; Roche) 
using a rotor-type homogenizer (Tissue-Tearor; Biospec Products). For 
cell supernatant and lysate samples, BMDM (2 × 106 cells in 2 ml of com-
plete DMEM containing 15% L cell–conditioned medium) were seeded 
into 12-well tissue plates, treated with or without IL-13 (20 ng/ml) or SeV 
(MOI 1 and 10). Cell supernatants were collected, and cells were washed 
twice with chilled PBS and then lysed in radio-immunoprecipitation assay 
(RIPA) buffer (Sigma-Aldrich) containing protease inhibitors. Levels of 
CSF-1 were determined using a Duoset ELISA kit (R&D Systems) and 
levels of cellular TREM-2 and sTREM-2 with a TREM-2 ELISA kit 
(Antibodies-online.com).
probes were designed to span introns and did not react with genomic DNA. 
Samples were assayed on the 7500 Fast Real-Time PCR System and ana-
lyzed using the 7500 Fast System Software (Applied Biosystems). Levels of 
specific gene expression were normalized to Gapdh mRNA levels.
Western blotting. For TREM-2 expression, BMDMs were seeded in 
6-well tissue culture plates and were infected with SeV at MOI 1 and 10 for
48 h. For caspase-3 expression, BMDMs were seeded in 6-well tissue culture
plates and were cultured in the presence or absence of L cell-conditioned
medium for 16 h. Cells were lysed and boiled in reducing SDS-PAGE sample
buffer containing 100 mM Tris, pH 6.8, 4% SDS, 5% ?-mercaptoethanol,
20% glycerol and 0.2% bromophenol blue. Lysates was subjected to 4–15%
gradient gel electrophoresis (Bio-Rad Laboratories) and transferred to PVDF
membrane (Millipore) in 10% methanol, 25 mM Tris and 192 mM glycine,
pH 8.3. Anti-Caspase-3 Ab was from Cell Signaling Technology. Rat anti–
mouse TREM-2 mAb (clone 178.9.4) was generated as described previously
(Turnbull et al., 2006). Antibody binding was detected using the enhanced
chemiluminescence (ECL) system (GE Healthcare). Molecular weight stan-
dards were run on each blot to validate that each of the indicated bands cor-
responded to the appropriate molecular weight.
Recombinant protein expression and purification. The mouse TREM-2 
Ig domain (amino acid residues 19–136) tagged with 6X His (sTREM-2-his) 
was expressed, secreted, and purified from mammalian cell culture as previ-
ously described (Kober et al., 2014). Precautions were taken to prevent in-
troduction of endotoxin either by using either new, sterile plasticware or by 
soaking glassware overnight in 0.5 M NaOH. The final purified protein was 
exchanged in PBS using a microconcentrator (Sartorius). For heat inactiva-
tion, sTREM-2-his was boiled at 100°C for 1 h.
Microscopy. Tissues were fixed with 10% formalin, embedded in paraffin, 
cut into 5-µm sections, and adhered to charged slides. Sections were deparaf-
finized in Citrosolv (Fisherbrand), hydrated, and in the case of immunofluor-
escence microscopy, treated with heat-activated antigen unmasking solution 
(Vector Laboratories). Immunostaining of mouse tissue was performed using 
anti-MUC5AC mAb (Thermo Fisher Scientific; clone 45M1), anti–Mac-3 
mAb (BD; clone M3/84), anti–Caspase-3 mAb (clone 5A1E; Cell Signal-
ing Technology), anti–mouse TREM-2 (R&D Systems), anti–mouse F4/80 
mAb (clone CI:A3-1; Abcam), anti–mouse phospho-ERK1/2 (clone D13.14.4E, 
Cell Signaling Technology), anti–mouse IL-13 mAb (R&D Systems), and 
anti-SeV antibody (SPAFAS, Inc.). Antibody binding was visualized using 
Alexa Fluor 488 or 594 fluorochromes (Invitrogen). Slides were counter-
stained with DAPI-containing mounting media (Vector Laboratories).
For sTREM-2 immunostaining, BMDMs were seeded into 2-well 
chamber slide (Nalge Nunc International) at 2 × 105 cell per well. For sur-
face sTREM-2 immunostaining, BMDMs were incubated with sTREM2-
his (10 µg/ml) for 30 min on ice and then washed four times with chilled 
PBS and incubated with mouse anti-6X His tag antibody (Abcam; clone His.
H8) followed by Alexa Fluor 488–conjugated anti–mouse IgG (Invitrogen) 
and fixation with 4% PFA. For intracellular sTREM-2 immunostaining, 
cells were incubated with sTREM-2-his for 30 min at 37°C, washed with 
PBS, fixed with 4% PFA, and then permeabilized with 0.2% Saponin, 2% 
BSA in PBS for 30 min before incubation with anti-6X His tag antibody 
and Alexa Fluor 488–conjugated anti–mouse IgG. All microscopy was per-
formed using an Olympus BX51 microscope and a Retiga-2000R camera 
system (QImaging).
Flow cytometry and FACS. Single-cell lung suspensions were made from 
minced lung tissue subjected to collagenase (Liberase Blendzyme III; Roche), 
hyaluronidase (Sigma-Aldrich), and DNase I (grade II; Roche) digestion for 
45 min at 37°C and then treated with ACK buffer to remove red blood cells. 
Cell percentages were unchanged if lungs were perfused before digestion (sug-
gesting that intravascular cells did not contribute significantly to the analy-
sis), so unperfused lungs were used for all experiments. Staining of surface 
markers was performed using FcR blockade and fluorochrome-conjugated 
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Background: P38 MAP kinases are centrally involved in mediating extracellular signaling in various diseases.
While much attention has previously been focused on the ubiquitously expressed family member MAPK14
(p38α), recent studies indicate that family members such as MAPK13 (p38δ) display a more selective cellular
and tissue expression and might therefore represent a specific kinase to target in certain diseases.
Methods: To facilitate the design of potent and specific inhibitors, we present here the structural, biophysical, and
functional characterization of two newMAPK13-inhibitor complexes, aswell as thefirst comprehensive structur-
al, biophysical, and functional analysis of MAPK13 complexes with four different inhibitor compounds of greatly
varying potency.
Results: These inhibitors display IC50 values either in the nanomolar range or micromolar range (N800-fold
range). The nanomolar inhibitors exhibit much longer ligand-enzyme complex half-lives compared to themicro-
molar inhibitors as measured by biolayer interferometry. Crystal structures of the MAPK13 inhibitor complexes
reveal that the nanomolar inhibitors engageMAPK13 in the DFG-out bindingmode, while themicromolar inhib-
itors are in the DFG-inmode. Detailed structural and computational docking analyses suggest that this difference
in bindingmode engagement is driven by conformational restraints imposed by the chemical structure of the in-
hibitors, and may be fortified by an additional hydrogen bond to MAPK13 in the nanomolar inhibitors.
Conclusions: These studies provide a structural basis for understanding the differences in potency exhibited by
these inhibitors.
General significance: They also provide the groundwork for future studies to improve specificity, potency, phar-
macodynamics, and pharmacokinetic properties.
© 2016 Elsevier B.V. All rights reserved.
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1. Introduction
The mitogen activated protein kinase (MAPK) p38α (MAPK14) is the
founding and most studied member of the p38 MAPK family. MAPK14 is
ubiquitously expressed and centrally involved in pro-inflammatory sig-
naling; it has thus been the focus of numerous drug-development pro-
jects for several diseases involving chronic inflammation, including
rheumatoid arthritis and inflammatory bowel disease [1–4]. Recent
breakthroughs in structure-based drug design have resulted in highly
specific and potent inhibitors to MAPK14 [5–7], but there are remaining
concerns as to the practicality of targeting this enzyme, since knockout
of this gene in mice results in embryonic lethality [8–10], and efforts to
develop MAPK14 inhibitors have ended in failed drug trials, usually due
to toxicity [11]. In contrast to MAPK14, other members of the p38
MAPK family display restricted tissue and cellular expression, and there-
fore may represent viable targets for specific diseases. Along these lines,
MAPK11 (p38β) is highly similar to MAPK14 (75% sequence identity),
whereasMAPK12 (p38γ) andMAPK13 (p38δ) aremore sequence diverse
(62% and 61% identical to MAPK14, respectively). Also, the MAPK12/
MAPK13 double knockout mouse displays no detrimental phenotypes,
only reduced innate inflammatory responses induced by lipopolysaccha-
ride (LPS) [12].
MAPK13 has recently emerged as a disease-specific p38 MAPK drug
target. Compared to MAPK14, MAPK13 displays more tissue-specific
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expression patterns, and therefore contributes to more restricted func-
tions [13,14]. This restricted expression pattern suggests that this kinase
may be targeted in specific biological pathways. For example, MAPK13
regulates insulin secretion and survival of pancreatic β-cells, and
MAPK13-deficient mice are protected against insulin resistance induced
by a high-fat diet and oxidative stress-mediatedβ-cell failure, suggesting
a role in diabetes [15]. MAPK13 is also pivotal in neutrophil chemotaxis
pathways, where it contributes to acute respiratory distress syndrome
(ARDS) [16]. In addition, studies in knockout mice indicate that
MAPK13 contributes to pathways activated in chronic inflammatory
conditions [12], is centrally involved in tumorogenesis in both colitis-
associated colon cancer [17] and squamous cell carcinoma models [18],
and is crucial for development of arthritis in certain models [19]. Finally,
MAPK13 activation is required for IL-13-dependent airway mucus over-
productionwhich is a characteristic feature of chronic inflammatory lung
disease [20].
Given the role of MAPK13 in chronic lung disease (and possibly
other diseases),we initiated the first structure-based drug project to de-
velop inhibitors targeting MAPK13 [20]. This work also presented the
first structures of MAPK13 complexes with inhibitors, and for any p38
MAPK family member other than MAPK14. As noted above, MAPK14
has been the subject of intense structure-based drug design efforts,
and numerous structural and biophysical studies of MAPK14-inhibitor
complexes have been reported (N170 structures in the PDB as of
October 2015). Thus, much is known about the structural requirements
forMAPK14 inhibition [21]. To develop amore complete understanding
of the structural basis for activation of MAPK13, we developed
methods to produce both unphosphorylated (inactive) and dually-
phosphorylated (active) MAPK13 in quantities for structural and bio-
physical studies and used these proteins to study complexeswith inhib-
itors for the purposes of targeting this kinase through structure-based
drug design [20,22]. Herewe present a complete functional, biophysical,
and structural characterization of two new MAPK13-inhibitor com-
plexes, new biophysical data on two previously reported complexes,
and the first comprehensive analysis of MAPK13 in complex with all
four structurally characterized inhibitors, which display greatly varying
potency. These studies reveal the structural basis for differences in po-
tency for this set of inhibitors.
2. Materials and methods
2.1. Materials
All inhibitors were synthesized at Washington University as de-
scribed previously [20].
2.2. Expression constructs
Full-length human MAPK13 is 365 amino acids and contains sev-
eral basic residues at the C-terminus. For crystallization, a slightly
truncated MAPK13 construct (1–352) was designed and cloned
into pET28a as a N-terminal 6-His-tagged construct using the NdeI
and XhoI restriction endonuclease sites. A full-length human
MAPK13 construct was prepared similarly to produce protein for en-
zyme inhibition and biophysical studies [20]. The construct was con-
firmed by sequencing. A pET28a construct of N-terminal-6-His-
tagged lambda-phosphatase was a kind gift from Dima Klenchin
(University of Wisconsin, Madison, WI).
2.3. Protein expression and purification
Constructs were transformed into Rosetta2 (DE3) Escherichia coli
(Stratagene) and colonies were grown on a plate with kanamycin selec-
tion (50 μg/ml). Cultures for protein expression were grown in Luria
broth (LB) media using chloramphenicol (40 μg/ml) and kanamycin
(50 μg/ml) selection. Both the MAPK13 crystallization construct (1–352)
and full-length protein (1–365) were expressed and purified in a similar
manner, as outlined here. Protein expression was induced at 30 °C by
addition of 0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) and
each 1 L of media was enriched with 10 ml of saturated glucose solution
during protein expression. Protein expression was carried out at 30 °C
for 4 h.
Cell pellets were harvested by centrifugation and suspended in lysis
buffer suitable for nickel-nitrilotriacetic acid (Ni-NTA) gravity chroma-
tography (50 mM K2HPO4 pH 8.0, 300 mM NaCl, 10 mM imidazole,
10% glycerol, 10 mM 2-mercaptoethanol). Cells were lysed by addition
of 0.5 mg/ml lysozyme and DNAse I followed by sonication. Clarified ly-
sate was passed over Ni-NTA superflow resin (Qiagen), whichwas then
washedwith lysis buffer containing 20mM imidazole and then proteins
were eluted with 250 mM imidazole. The protein was further purified
by gel filtration chromatography (Superdex 200) in a buffer consisting
of 20mMHEPES pH 7.5, 150mMNaCl, 0.001%NaN3, 5 mM dithiotreitol
(DTT), and 10% glycerol. The protein eluted as a single peak correlating
to a monomeric molecular weight [22]. This peak was harvested and
then dephosphorylated in vitro by addition of lambda phosphatase
(0.1 mg/ml) and 5 mMMnCl2 at room temperature for 30 min, which
was then quenched with 5 mM EDTA. This treatment was not very effi-
cient and only increased the amount of dephosphorylated MAPK13 by
about 10% [22]. Following dialysis against a buffer consisting of 20 mM
Tris pH 8.0, 10 mM NaCl, 1 mM DTT, and 10% glycerol (buffer A) at
4 °C overnight, the protein was then subjected to anion exchange chro-
matography using a MonoQ column (GE Lifesciences). Protein was
injected onto the column using buffer A and then eluted off using a gra-
dient from 0 to 60% of buffer B (20mMTris pH 8.0, 1MNaCl, 1mMDTT,
and 10% glycerol) over 40 column volumes. This resulted in separation
of unphosphorylated and phosphorylated MAPK13 [22]. The
unphosphorylated MAPK13 peak was harvested and used for structural
studies with inhibitors. Full-length MAPK13 for enzyme inhibition and
biophysical assays was expressed and purified similarly.
2.4. Preparation of MAPK13-inhibitor co-crystals
Crystals of non-phosphorylated MAPK13 were obtained by mixing
protein solution (at 10 mg/ml) with reservoir solution (50 mM ammo-
nium tartrate, 18% PEG 3350) in a 4:1 (protein: reservoir) ratio, similar
to as previously described by us [20]. Co-crystal complexes with inhib-
itor compounds 58 and 117 were prepared by soaking, similar to our
previous work. Inhibitor compound stocks were prepared in DMSO at
100 mM and then added to crystal-containing drops at 1:10 volume,
for a final inhibitor concentration of 10 mM in the drop. Crystals were
allowed to soak for 10min to 4 h before cryoprotection inmother liquor
supplemented with 25% ethylene glycol, followed by flash-freezing at
−160 °C in a chilled nitrogen stream.
2.5. Data collection, reduction and structure determination
X-ray diffraction data were collected at either the Advanced Photon
Source (beamline 19-ID) or theAdvanced Light Source (beamline 4.2.2).
Data were indexed and processed with HKL2000 [23]. The phase prob-
lem was solved by isostructural replacement using the apo form of
MAPK13 (PDB ID: 4YNO) [20] in an initial round of rigid body refine-
ment. Compoundswere clearly visible in FO – FC differencemaps follow-
ing rigid body refinement (see Fig. 3). Model rebuilding and compound
fitting to electron density maps was performed manually using Coot
[24] and refinement was carried out in PHENIX [25]. Structural analysis
of MAPK13-inhibitor contacts was performed in LigPlot+ [26]. All mo-
lecular graphics figures were produced using PyMOL [27]. All crystallo-
graphic software were obtained and maintained by the SBGrid
distribution [28]. Diffraction images were deposited with the Structural
Biology Data Grid [29]. Data collection and refinement statistics are
summarized in Table 1.
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2.6. Differential scanning fluorimetry
Melting temperature of MAPK13 and MAPK14 was measured in the
presence of inhibitors (58, 61, 117, 124) using a Protein Thermal Shift
Dye Kit (Life Technologies, CA) according to manufacturer's specifica-
tions. This assayusedboth theunphosphorylated and thephosphorylat-
ed forms of MAPK13 and unphosphorylated MAPK14 at a final
concentration of 0.15 mg/ml in the reaction mixture. A titration experi-
ment was carried out first to demonstrate specificity and establish dy-
namic range. Based on this, single point experiments were carried out
on all kinases using a final inhibitor concentration of 25 μM. Each condi-
tion was replicated five times. The experiment was carried out on a
7500 Fast Real-Time PCR System (Life Technologies, CA) using the
melt curve template. The initial incubation step at 25 °C was modified
to be 30 min to ensure complex formation between the inhibitors and
the proteins. Data were analyzed using Protein Thermal Shift Software
v1.1 (Life Technologies). Additional statistical analysis was carried out
in Prismv5.0c. Results are summarized in Fig. 6 and Table 3 andpresent-
ed asmean±S.E.M. Replicate experimentswere carried out using three
different protein preps on different days to obtain mean ± S.E.M.
2.7. MAPK13 inhibition assay
Compounds were assayed for inhibition of MAPK13 kinase activity
using an immobilized metal affinity polarization (IMAP) as previously
described [20]. Briefly, the assay contained activated (phosphorylated)
MAPK13, a FITC-labeled substrate, and the test compound. Experiments
were carried out at concentrations in the linear phase of the rate kinet-
ics. Assay reactions contained 0–100 μM test compound, 5–35 nM
(EC80) activated MAPK13, 3 μM (Km,app) ATP, and 100 nM FITC-labeled
EGFR peptide substrate (FITC-KRELVERLTPSGEAPNQALLR-NH2). The
IC50 values for each compound were determined from the compound
concentration versus fluorescence polarization (mP) plot using nonlin-
ear curve fitting.
2.8. Inhibitor binding kinetics measured by biolayer interferometry
Kinetics of MAPK13 binding to small molecules was assessed using
bio-layer interferometry with an Octet (ForteBio, Menlo Park, CA) as de-
scribed previously [20]. MAPK13 was randomly biotinylated in vitro
using EZ-link NHS-PEG4-Biotin (Thermo Scientific) at a 1:2 molar ratio
(protein: reagent). Super-streptavidin-coated biosensors from ForteBio
were used to capture biotinylatedMAPK13 onto the surface of the sensor.
After reaching baseline, sensors were moved to association step for 300 s
and then dissociation for 300 s. Curves were corrected by a double-
referencing technique using both biotin-coated pins dipped into the ex-
perimentalwells and abuffer-only reference. Thebindingbuffer consisted
of 20 mMHEPES pH 7.5, 150 mMNaCl, 0.005% Tween 20, and 5% DMSO.
Fig. 1. Schematic of MAPK13 inhibitors and their IC50 values. (a) Schematic of MAPK13
inhibitor compounds characterized in this manuscript. (b) Data and curve fit used to
determine IC50 values for compounds 58 and 117. Values represent mean and error bars
are SEM. (c) IC50 values, 95% confidence range, and coefficients of determination (R2). *
denotes values were previously reported [20].
Table 1
Crystallographic statistics for MAPK13 complexes with inhibitor compounds.
Compound 58 117
Data collection statistics
Space group P212121 P212121
Unit cell (Å) a = 61.0
b = 70.2
c = 92.9
a = 61.3
b = 69.7
c = 93.1
Source ALS 4.2.2 APS 19-ID
Wavelength (Å) 1.0000 0.9790
Resolution (Å) 50.0–2.60 (2.69-) 50.0–2.00 (2.07-)
Rsym (%) 9.1 (50.8) 5.5 (36.9)
Completeness (%) 88.5 (100) 81.2 (87.8)
Redundancy 7.0 (7.3) 4.6 (4.4)
I/σ (I) 20.6 (3.6) 21.6 (2.5)
Refinement statistics
Rwork (%) 21.8 20.0
Rfree (%) 27.3 24.1
Amino acid residues (#) 340 340
Waters (#) 23 213
RMSD bond length (Å)/angles (°) 0.003/0.667 0.004/0.904
Wilson B (Å2) 48.4 31.3
Ave B. protein 52.2 37.0
Ave. B inhibitor 40.5 31.3
Ave. B water 48.1 42.7
Ramachandran
%Favored 87.4 95.3
%Allowed 12.0 4.4
%Outliers 0.6 0.3
Poor rotamers (no./%) 12/3.99% 5/1.6%
Clashscore (score/percentile) 6.72/99th 6.10/95th
Molprobity (score/percentile) 2.16/94th 1.83/85th
Luzzati error 0.35 0.24
PDB ID 5EKN 5EKO
Values in parenthesis are for the highest-resolution shell.
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Fig. 3. Structures of MAPK13 complexes with inhibitors. (a) Ribbon diagram of MAPK13 (grey) with DFG-out inhibitors 58 and 61. Hinge and activation loop are both colored red.
(b) Ribbon diagram of MAPK13 (grey) with DFG-in inhibitors 117 and 124. Hinge and activation loop are both colored red. (c) Crystal structure of compound 58 (green) in complex
with MAPK13 in DFG-out mode. Omit Fo – Fc electron density contoured at 3.0 σ is shown for the compound and 2Fo – Fc electron density contoured at 2.0 σ is shown for Phe169.
(d) Our previously reported crystal structure of compound 61 (cyan) in complex with MAPK13 in DFG-out mode for comparison (4EYJ). (e) Crystal structure of compound 117
(yellow) in complex with MAPK13 in DFG-in mode. Omit Fo – Fc electron density contoured at 3.0 σ is shown for the compound and 2Fo – Fc electron density contoured at 2.0 σ is
shown for Phe169. (f) Our previously reported crystal structure of compound 124 (magenta) in complex with MAPK13 in DFG-in mode for comparison (4EYM). The dynamic
positioning of Phe169 of the DFG motif is shown in all complexes.
Fig. 2. Biolayer interferometry analysis of MAPK13 binding to inhibitors. (a–b) Biolayer interferometry sensorgrams for (a) compound 58 and (b) compound 117. Processed data are shown
as black lineswith global kineticfits overlaid as red lines. (c) Table ofMAPK13-inhibitor complexhalf-lives derived from theglobal kineticfits of kassociation and kdissociation (t1/2= ln2/kdissociation).
* denotes values were previously reported [20].
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MAPK13-inhibitor complex half-lives were calculated from dissociation
constants determined from global kinetic analysis (t1/2 = ln2/kdissociation).
2.9. Computational docking
In silico docking studies were carried out in GLIDE from the
Schrodinger Suite [30,31]. All inhibitorswere treated as ligands and pre-
pared from their SMILES strings using LigPrep without changing ioniza-
tion states. Protein coordinates were imported from pdb files and
processed using the Protein Preparation Wizard (PDB ID 4MP9 for
MAPK13 DFG-out; 4MP5 for MAPK13 DFG-in; 1KV2 for MAPK14 DFG-
out; 1P38 for MAPK14 DFG-in). A rigid grid of 36 Å was generated cen-
tered on the DFG residues. Ligands were docked flexibly into the grid in
Standard Precision (SP) mode. After the docking simulation was com-
pleted, the protein was overlapped with the coordinates from the co-
crystal structures. RMSD between the docked coordinates and the
crystal coordinates for the inhibitor was calculated using a command-
line script, rmsd.py (available from http://www.schrodinger.com/
scriptcenter/14). Results are summarized in Table 4.
3. Results and discussion
3.1. A series of inhibitors with greatly varied potencies for MAPK13
Here we report the steady-state, biophysical, and structural eval-
uation of a set of MAPK13 inhibitors. The inhibitor design was in-
spired by analyzing potent MAPK14-inhibitor complex structures,
superposing on our unphosphorylated (apo) MAPK13 structure,
and realizing smaller substituents in the ATP-binding pocket would
be required for optimal binding [20]. Specifically, we focused on
BIRB-796, which binds to MAPK14 in DFG-out mode and exhibits
an IC50 of 4 nM, and inhibits other p38 isoforms, but at much lower
potencies (IC50 = 520 nM for MAPK13) [32]. Superposition of
BIRB-796 into MAPK13 indicated it could sterically clash with the
gatekeeper residue, so we designed inhibitors with smaller substitu-
ents at this position that we hypothesized would bind in DFG-out
mode [20]. We began by determining the IC50 values in a steady-
state enzyme inhibition assay. These values for 1-(3-tert-butyl-1-
methyl-1H-pryzol-5-yl)-3-[4-(pyridin-4-yloxy)phenyl]urea (com-
pound 61) and 2-(morpholin-4-yl)-N-[4-(pyridin-4-yloxy)phenyl]
pyridine-4-carboxamide (compound 124) were reported previously
[20]. Here we determine the IC50 values for 1-(3-tert-butyl-1-
Fig. 4.MAPK13 binding pockets for inhibitor compounds. Binding pockets for (a) compound 58, (b) compound 61, (d) compound 117, and (e) compound 124. All residues thatmake van
der Waals or polar contacts are shown. Hydrogen bonds are shown as thin black lines. One hydrogen bond that is unique to compounds 58 and 61 as compared to 117 and 124 is
highlighted with the red arrow. (c) Table of polar and non-polar contacts each compound makes with MAPK13. (f–h) Overlay comparison showing hinge interactions with the
pyridinyl rings of (f) compounds 58 and 61, (g) compounds 117 and 124, and (h) compounds 58 and 124. Note in (h) that there is a displacement of 0.5 Å for the pyridinyl nitrogen in
comparing 58 and 124.
Table 2
Backbone torsion angles that define the conformation of the MAPK13 DFG motif.
Compound DFG
conformation
Leu 167 Asp 168 Phe 169
φ (°) ψ (°) φ (°) ψ (°) φ (°) ψ (°)
58 DFG-out −124.5 170.8 −154.0 150.4
61 DFG-out −119.6 169.4 −144.7 93.6 −66.0 −22.9
117 DFG-in −107.8 156.4 62.5 37.1 −82.5 150.0
124 DFG-in −111.3 160.9 55.5 39.7 −81.9 162.6
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methyl-1H-pyrazol-5-yl)-3-[4-(pyridin-4-ylsulfanyl)phenyl]urea
(compound 58) and 3-(4-methyl-1H-imidazol-1-yl)-N-[4-(pyridin-
4-xyloxy) phenyl] benzamide (compound 117) (Fig. 1a). Surprising-
ly, the IC50 values varied over a wide range; while compounds 58 and
61 displayed IC50 values in the nanomolar range, compounds 117
and 124 displayed IC50 values in the micromolar range, over 800-
fold less potent (Fig. 1b and c).
3.2. Kinetic and binding analysis of inhibitors with MAPK13
Inhibitor binding kinetics has become an important drug design
criteria. In particular, slow dissociation rates have been associated
with improved inhibitor activities due to prolonged target engagement
in vivo [33]. Tounderstandwhether inhibitor binding kinetics correlated
with potency, we analyzed this property using biolayer interferometry
(BLI), in a manner similar to that for compounds 61 and 124 reported
previously [20]. In these assays, biotinylated MAPK13 was immobilized
on the streptavidin-coated BLI pin and association and dissociation ki-
netics were analyzed. The two compounds that displayed IC50 values
in the nanomolar range displayed slower association and dissociation
rates with around 100-fold longer complex half-lives (t1/2 = 111 to
137 s) as compared to inhibitor compounds with micromolar IC50
values (t1/2 = 1 to 3 s) (Fig. 2a–c). These kinetic constants are of similar
magnitude as those for MAPK14 complexes with inhibitors measured
by surface plasmon resonance (SPR) [34].Wehypothesized that this dif-
ference could correlatewith different bindingmodes or binding pockets
utilized by the inhibitors.
3.3. MAPK13 inhibitors display two different binding modes
In order to elucidate how our novel inhibitors bound toMAPK13,we
determined the X-ray crystal structures of the complexes (Table 1). We
had noticed during our structural analysis of the inactive (MAPK13) and
dually-phosphorylated active (MAPK13/pTpY) forms of the protein [22]
that a significant portion of the activation loop (residues 173–180),
which is ordered in the dual-phosphorylated protein, is not visible in
our high resolution electron density maps of the unphosphorylated
form. We therefore reasoned that we should be able to obtain inhibitor
complexes with MAPK13 via soaking inhibitors into crystals of the
unphosphorylated form, and indeed we were able to demonstrate the
validity of this method previously with the crystal structures of
MAPK13 in complex with compounds 61 (PDB ID: 4EYJ) and 124
(4EYM). We observed a strong difference electron density for the two
new compounds using this method (Fig. 3c & e). We found that the
compounds displaying nanomolar IC50 values all bound similarly and
occupied the ATP binding pocket, as well as an adjacent pocket usually
occupied by Phe169 (of the DFG motif), displacing it from this pocket
(Fig. 3a, c–d, and Table 2). This mode of binding has been termed as
“DFG-out” and was first observed in the complexes of c-Abl with
Gleevac [35] and MAPK14 with BIRB-796 [36]. In contrast, compounds
displaying micromolar IC50 values bound in a similar manner, but did
not displace Phe169 from the pocket (Fig. 3b, e, f), binding to MAPK13
in what is known as “DFG-in” mode (Table 2). Thus, in the case of the
MAPK13 inhibitors presented here, it appears that bindingmode creates
amarked difference in potency. However, it should be noted that highly
potent inhibitors that bind to MAPK14 in DFG-in mode have been iden-
tified (e.g., skepinone-L [5] and SB203580 [37]), so binding mode does
not always dictate efficacy.
3.4. Analysis of binding pocket interactions of inhibitors in complex with
MAPK13
To understand the structural basis for the observed binding modes
exhibited by the different MAPK13-inhibitor complexes, we performed
a comprehensive analysis of the binding pockets occupied by each in-
hibitor. The inhibitors analyzed here have similar designs, consisting
of a heterocyclic ring that interacts with the hinge region of MAPK13,
a central aromatic that occupies the ATP-binding site, and a bulky
(mostly hydrophobic) group, with these units spanned with by various
polar linkers (Fig. 1a). The binding pockets were very similar, with sim-
ilar numbers of van Der Waals contacts and hydrogen bonds to
MAPK13. We found that, compared to the micromolar inhibitors, the
nanomolar inhibitors engaged in one additional hydrogen bond with
MAPK13 (3 versus 4) (Fig. 4c). All inhibitors engaged in hydrogen
bonds with the backbone amide nitrogens of Met110 (in the hinge)
and Asp168 (in the DFG motif) (Fig. 4a, b, d, e). The main difference
was seen in interactions involving the side-chain carboxylic acid of
Glu72. This side-chain engages in a hydrogen bond with the linker be-
tween central aromatic and bulky hydrophobic groups in these inhibi-
tors. The nanomolar inhibitors all contain urea linkers whereas the
micromolar inhibitors both contain amide linkers. The second hydrogen
bondmade possible with the urea linkages (red arrow, Fig. 4a, b) assists
to lock the bulky hydrophobic groups in relative conformations that re-
quire the moieties to bind to the Phe pocket, thus making these inhibi-
tors selective for the DFG-out conformation of the kinase. In addition,
the extra atom in the urea versus amide linkage likely assists in optimal
positioning of terminal hydrophobic groups to access the allosteric
Phe169 pocket. Analysis of the hinge hydrogen bond with the pyridine
moieties found in each of these inhibitors showed that in the DFG-in in-
hibitors (compounds 58 and 61) this hydrogen bond is about 2.5 Å
(Fig. 4f, h), whereas this distance is about 3.0 Å in theDFG-out inhibitors
(117 and 124) (Fig. 4g, h). Thus it appears that the shorter linkage
(amide versus urea) also impacts inhibitor potency by lowering the
strength of the hinge hydrogen bond interaction in an attempt to opti-
mally bind the hydrophobic pockets on the opposite end of the mole-
cule. Therefore, it appears from analysis of these compounds in
complex with MAPK13 that not only does the urea linkage provide ad-
ditional hydrogen bonding abilitywithMAPK13, it also assists in provid-
ing optimal spacing of large ring groups to optimally bind to respective
pockets, including the allosteric Phe169 pocket. However, it should be
noted that biphenyl amide inhibitors similar to compounds 117 and
124 have previously been observed to bind to both DFG-in and DFG-
out conformations of MAPK14 and bind in similar modes to those ob-
served in our MAPK13 structures [34], thus the inclusion of such groups
does not dictate that these inhibitors can only bind in DFG-in modes.
3.5. Sequence comparison of inhibitor binding pockets in mammalian
MAPK13 proteins
Given that numerous animal systems are used for in vitro studies, we
carried out analysis of MAPK13 sequences from higher mammals to ex-
aminewhether therewere any gross differences in theMAPK13 binding
pockets for the inhibitors characterized here. The MAPK13 sequences
for the species analyzed here averaged N90% identity (Fig. 5). Of the nu-
merous residues lining the binding pocket for the inhibitors, only one
displayed a very conservative variation. Residue Phe109 (in the hinge
region) is a Tyr in chicken MAPK13 (Fig. 5). Structure-based analysis
of the inhibitor binding pocket sequence conservation would suggest
Fig. 5. Sequence alignment of MAPK13 from relevant disease model mammals. Invariant and conserved residues are highlighted with magenta and yellow backgrounds, respectively.
Secondary structure of human MAPK13 is shown above the alignment. The hinge region, DFG motif, gatekeeper (G), dual phosphorylation site (P), and activation loop are shown.
Residues that form the binding pockets for inhibitor compounds are marked (black I). Figure was generated using ESPript3.0 [43].
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that the inhibitors analyzed here should bind similarly to MAPK13 pro-
teins in common animal models.
3.6. Thermodynamic stability of MAPK13 complexes with inhibitors
Previous studies have demonstrated the use of differential scanning
fluorimetry as a method for identifying potential kinase inhibitors
based on the enhanced thermal stability upon complexation [38,39]. A
general observation has been that more potent kinase inhibitors lend
greater thermal stability to the protein [40]. We decided to analyze our
diverse potency inhibitors using this method. We carried out experi-
ments with both the inactive (unphosphorylated) MAPK13 and active
(dually-phosphorylated) MAPK13/pTpY, as well as with MAPK14. First,
we carried out a titration on MAPK13 to establish a dynamic range for
the inhibitors (Fig. 6). Based on this result, we carried out subsequent ex-
perimentswith 25 μM inhibitor. The differences inmelting temperatures
using the two forms of MAPK13 were similar, indicating that the inhibi-
tors effectively bound both forms of the protein (Table 3). The melting
point shifts were about a degree higher for MAPK13/pTpY, likely due to
the fact that this form is stabilized by contacts involving the phosphory-
lated activation loop, [22] which would be dislodged by the DFG-out in-
hibitors. We found that the micromolar inhibitors (compounds 117 and
124) induced small increases in melting temperatures of MAPK13 (1–
2 °C). In contrast, the nanomolar inhibitors all induced large shifts in
melting temperatures of MAPK13 (7–8 °C). In addition, we found that
our inhibitors induced larger Tm shifts in MAPK13 than MAPK14 (by a
difference of 2–3 °C). For comparison, we also ran the DSF experiments
with the potent MAPK14 inhibitor BIRB-796, which is optimized for
MAPK14 (IC50 [MAPK14] = 4 nM; IC50 [MAPK13] = 520 nM) [32]. We
found that the melting point shifts corresponded with the known differ-
ences in potencies (DTm [MAPK14] = 13.7 °C; [MAPK13] = 5.9 °C).
Taken together, these results suggest our best inhibitors characterized
here display slight selectivity forMAPK13 versusMAPK14, which should
improve with optimization. Thus, the inhibitors which displayed the
greatest potency and longest complex half-lives induced the greatest
shift in thermal stability, indicating that this could be a robust screening
method to presage inhibitor potency for MAPK13, and selectivity versus
MAPK14.
3.7. Computational analysis of inhibitor complexes
Wecarried out computational docking studies to gain further insight
into why subsets of inhibitors bind to the DFG-in conformation versus
the DFG-out conformation of MAPK13. In these calculations, the inhibi-
tors were introduced as SMILES strings (with no predefined conforma-
tion) and were flexible during docking. The inhibitors were docked to
MAPK13 coordinates in both the DFG-in and DFG-out mode. For com-
pounds 58 and 61, which bind in the DFG-out mode, the calculations
reproduced the crystal structures extremely accurately when docked
to the MAPK13 DFG-out coordinates (Table 4). However, they showed
high variation and poor docking scores when docked to MAPK13 in
DFG-in coordinates. In contrast, for compounds 117 and 124, which
bind in DFG-inmode, the calculations accurately reproduced the crystal
structure coordinates for the inhibitors regardless of whether MAPK13
was in DFG-in or DFG-out mode (Table 4). In other words, regardless
of whether or not the Phe pocket was available for inhibitor moiety
binding, the DFG-in inhibitors preferred to bind to the same pockets
as observed in the crystal structure. These calculations indicate that
this set of inhibitor structures can be predicted fairly accurately using
GLIDE, and imply that part of the selective driving force is goodness of
fit to the available pockets and the inherent structure preferred by in-
hibitor. To analyze this further, we carried out the same calculation
using MAPK14 in both DFG-in and DFG-out mode as the receptor for
these inhibitors. With the MAPK14 structures, we obtained similar re-
sults as with MAPK13, and the simulations reproduced inhibitors bind-
ing configurations observed in the MAPK13 co-crystal structures. Thus,
regardless of the receiver kinase, the inhibitors take on configurations
observed in the crystal structures, indicating that the major driving
forces for this set of inhibitors is chemically-encoded structural con-
straints of the compound and shape complementarity to available
pockets.
4. Conclusions
Here we present the functional, biophysical, and structural charac-
terization of two new inhibitor complexes with MAPK13, as well as
the first comprehensive functional, biophysical, and structural analysis
of all four of our inhibitor complexes, including the first use of thermo-
dynamic and computational methods to study these complexes. These
represent the only four MAPK13 inhibitor complexes structurally char-
acterized to date, and are thus extremely valuable to drug design efforts
that target this emerging molecular target. The inhibitors examined
here displayed widely varying potencies, with IC50 values in either the
nanomolar range, or, N800-fold less potent, in the micromolar range.
These potencies correlated well with small-molecule binding kinetics
measured by BLI. The nanomolar-potency inhibitors displayed complex
half-lives about 100 times longer than those of the micromolar inhibi-
tors. It should be noted that the half-lives measured here using BLI are
comparable to those of MAPK14-inhibitor interactions measured by
the comparable flow-based method of SPR [34]. Co-crystal structures
of MAPK13 in complex with each of the four inhibitors revealed that
the high potency inhibitors all bound to the kinase in DFG-out configu-
ration, whereas the lower potency inhibitors both bound in DFG-in
Table 3
Inhibitor-induced thermal stability shifts measured by differential scanning fluorimetry
(DSF).
Compound ΔTm-MAPK13
(°C)a
ΔTm-MAPK13/pTpY
(°C)a
ΔTm-MAPK14
(°C)a
Kd (μM)b
58 8.1 ± 0.3 9.0 ± 0.4 5.2 ± 0.3 1.9 ± 0.3
61 7.2 ± 0.3 7.8 ± 0.4 5.1 ± 0.3 2.6 ± 0.5
117 1.8 ± 0.4 2.0 ± 0.5 −1.4 ± 0.4 N.D.c
124 1.1 ± 0.3 1.2 ± 0.5 −0.8 ± 0.3 N.D.
BIRB-796 5.9 ± 0.2 13.7 ± 0.3
a ΔTm are reported at inhibitor concentrations of 25 μM and kinase concentrations
at 2.5 μM.
b Derived from titrations shown in Fig. 6.
c Not determined.
Fig. 6. Changes in MAPK13 melting temperatures (ΔTm) induced by binding inhibitors as
measured by DSF. Titration of inhibitors is shown while MAPK13 concentration was held
at 0.15 mg/ml. The point at each concentration is an average of three replicate
experiments conducted with different protein preps. Error bars are SEM. Curve fitting
done in PRISM 5 using the one site total binding equation for nonlinear regression.
Calculated Kd's listed in Table 3.
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configuration. This is worth noting, since high potency inhibitors can be
developed for either mode, for example skepinone-L [5] and SB203580
[37] are highly potent MAPK14 inhibitors that bind in DFG-in mode.
Slow inhibitor dissociation rates have emerged as an important param-
eter for sustained efficacy of kinase inhibitors. In general, slower kinetics
have been observed for inhibitors binding to the DFG-out mode of ki-
nases, possibly due to kinetic constraints caused by the necessary struc-
tural reconfiguration [36,41]. However, the structural mechanisms that
influence inhibitor binding kinetics are poorly understood, thus com-
prehensive structural and kinetic studies such as those presented here
are quite valuable in creating these correlations. It can be noted that
the structures for the inhibitor complexes were derived by soaking in-
hibitors into already formed crystals, and thus, may not be reflective
of solution structure. However, given the correlation between the
solid state observation of bindingmodes and the solution state biophys-
ical data (binding thermodynamics, kinetics, and IC50 values) and com-
putational predictions, we believe this is highly unlikely.
Detailed analysis of the binding pockets for the inhibitors revealed
that all inhibitors, regardless of potency, interacted with MAPK13 in a
very similar fashion, forming hydrogen bonds with the same residues
in all four structures. The high potency inhibitors all engaged in one ad-
ditional hydrogen bond, but computational docking and chemical rea-
soning indicate that this is mostly driven by the preferred lowest
energy configuration of the inhibitor, which is intrinsic to its structure,
and the goodness of fit of that conformation to the available pockets.
It is worth noting that one of the development points of the GLIDE soft-
ware has been to predict accurate kinase complexes with inhibitors
[42]. The complexes withMAPK13 characterized here were readily pre-
dicted and suggest that this software approach could be used effectively
for in silico screening to identify new chemical families with the poten-
tial to bind MAPK13.
DSF has been shownpreviously to be an effectivemethod for screen-
ing for potential binders and inhibitors of kinases, and the thermalmelt-
ing shifts usually correlate well with affinity [40]. We found this to be
the case with the set of inhibitors here, with the thermal shifts also cor-
relating with binding mode (DFG-in versus DFG-out). These thermal
shifts appear to correlate with binding affinities of the inhibitors, as ob-
served in our titration experiments. These experiments do suggest,
however, that this method could be utilized effectively to identify new
inhibitors for MAPK13 by screening and to prioritize ranking based on
magnitude of melting point stabilization. These experiments also sug-
gest this method could be used to screen for inhibitors that selectively
target MAPK13 versus MAPK14. The inhibitors analyzed here have not
been optimized yet for potency or selectivity, yet they do display
some preference for bindingMAPK13 in our DSF experiments. Combin-
ing our structural studies of inhibitor binding done here with sequence
comparison of MAP13 versus MAPK14 [22], the most sequence diver-
gent area that contacts the inhibitors is in the hinge region, thus this
will be focus of our future iterations of inhibitor design.
Recent studies of diseasemodels in MAPK13 knockoutmice and cel-
lular studies have highlighted the importance that signaling pathways
relying onMAPK13may contribute to several diseases, including certain
types of asthma, arthritis, cancer, and diabetes [15,17–20]. Altogether,
the functional, structural, and biophysical characterizations presented
here provide the first comprehensive analysis of this type for inhibitor
complexes with MAPK13, elucidating the structural basis for their
mechanism of action, thus providing a knowledge base for the
structure-based development of potent, and eventually specific,
inhibitors.
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